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Abstract 
Down syndrome (DS) is a genetic condition caused by the triplication of chromosome 21 (HSA21). 
DS has a worldwide incidence of 1:700-1000 live births. The most invalidating feature of DS is 
intellectual disability (ID). ID, that lifelong affects DS individual, is mainly due to neurodevelopment 
alterations, characterized by reduced neurogenesis and defects in neuron maturation. These defects 
are already present during early fetal life stages. The molecular mechanisms that are at the basis of 
these phenotypic alterations of DS have not been fully understood so far, due to the extremely 
complicated genetic imbalance of trisomy 21. In the last decade, scientists have exploited DS mouse 
models in order to clarify the molecular mechanisms whereby gene triplication leads to the trisomy-
linked brain phenotype and design possible interventions. The most studied DS model is the Ts65Dn 
mouse whose phenotype largely mimics the human condition. However, despite intense efforts of 
scientific community, there are currently no therapies for DS. Considering the time course of brain 
development, pharmacotherapies should be carried as early as possible during the lifespan. But is it 
possible to pharmacologically rescue the neurodevelopmental defects of DS? Our group has recently 
found that neonatal treatment with fluoxetine, an antidepressant belonging to the selective serotonin 
reuptake inhibitor class, resulted in the restoration of neurogenesis and behavioral deficits in Ts65Dn 
mice. These results showed for the first time that the trisomy-linked brain defects are reversible, 
provided that therapy is administered very early during the lifespan. Clinical trials are necessary in 
order to establish whether fluoxetine has the same positive impact in children with DS as in neonate 
Ts65Dn mice. Since we cannot take for granted that a molecule that is effective in mouse models is 
similarly effective in humans, it is important to establish whether there are other molecules that are 
as effective as fluoxetine. Such an extensive approach would increase the probability to discover 
therapies that are effective in humans too. Based on these premises, the overall goal of this project 
was to establish whether neonatal treatment with “unexplored” molecules restores the major 
neurodevelopmental defects and cognitive performance in the Ts65Dn mouse model and 
whether their effect is retained after treatment cessation. In this study, I have explored the effects 
of three different molecules administered to Ts65Dn mice during the neonatal period. 1) ELND006, 
a selective inhibitor of APP γ-secratase. ELND006 blocks the formation of a small APP-derived 
peptide, AICD, which inhibits the activity of the mitogenic SHH pathway, thereby reducing 
neurogenesis. 2) Epigallocatechin-3-gallate (EGCG), a natural inhibitor of the kinase DYRK1A, 
whose overactivity in the DS brain negatively affects neurogenesis. 3) 7,8-dihydroxyflavone (7,8-
DHF), a natural mimetic of BDNF that by activating the TRKB receptor may compensate for the 
reduced levels of BDNF in the DS brain and, thus, the lack of the pro-neurogenic actions of BDNF. 
Neonatal treatment with ELND006 restored neurogenesis and neuron number in the dentate gyrus 
(DG) and synaptic development in the hippocampal formation of Ts65Dn mice. Most of these effects 
were retained at one month after treatment cessation and were accompanied by restoration of the 
synaptic function at the synapse between DG granule cells and field CA3 pyramidal neurons. 
However, ELND006 treatment caused some adverse effects. In Ts65Dn mice neonatally treated with 
EGCG, we found full restoration of hippocampal neurogenesis, neuron number and synapse 
development. At one month after treatment cessation, however, these effects had disappeared and 
there were no signs of behavioral improvement. 7,8-DHF, administered in neonate Ts65Dn mice, 
caused restoration of neurogenesis, DG granule cell number, and dendritic spine density. Mice that 
were treated with 7,8-DHF from postnatal day 3 to adolescence exhibited restoration of learning and 
memory, indicating that the recovery of the hippocampal anatomy translated into a functional rescue. 
No adverse effects were observed on the general health and growth of mice. A comparison of the 
three therapies used in this study indicates that although all are able to rescue neurogenesis, targeting 
the BDNF/TRKB pathway with 7,8-DHF may represent the treatment with the highest translational 
impact for children with DS because it is effective and appears to have a high safety profile. 
Demonstration that it is possible to pharmacologically prevent brain developmental alterations in a 
mouse model of DS with a variety of agents may stimulate the design of clinical trials with the 
molecule/s with the highest efficacy and the safest profile. This is the challenge that faces the 
community of preclinical researchers interested in DS: to transform a dream into reality. 
 Abstract (italiano) 
La sindrome di Down (SD) è una condizione genetica dovuta alla triplicazione del cromosoma 21. 
La SD ha una incidenza a livello mondiale di 1:700-1000 nati vivi. L’aspetto più invalidante della SD 
è la disabilità intellettiva (DI). La DI, che colpisce gli individui con la SD durante tutta la vita, è 
principalmente dovuta ad alterazioni del neurosviluppo, caratterizzate a loro volta da riduzioni dei 
processi di neurogenesi e maturazione neuronale. Questi difetti sono già presenti durante le prime fasi 
dello sviluppo fetale. Ad oggi, i meccanismi molecolari che sono alla base delle alterazioni 
fenotipiche della SD non sono stati compresi completamente, a causa dello sbilanciamento genico 
estremamente complesso della trisomia 21. Negli ultimi 10 anni, la comunità scientifica si è avvalsa 
di modelli murini di SD per comprendere più approfonditamente i meccanismi molecolari che portano 
al fenotipo cerebrale legato alla trisomia e, di conseguenza, sviluppare possibili strategie terapeutiche. 
Il modello murino di SD più studiato è il topo Ts65Dn, che mima in modo dettagliato la condizione 
umana. Nonostante gli intensi sforzi profusi dalla comunità scientifica, al momento non esistono 
terapie per la SD. Tenendo in considerazione l’andamento dello sviluppo cerebrale, un approccio 
farmacologico dovrebbe essere effettuato il prima possibile durante la vita degli individui. Ma è 
possibile ripristinare farmacologicamente i difetti del neurosviluppo tipici della SD? Il nostro gruppo 
ha recentemente effettuato un trattamento neonatale nel topo Ts65Dn con fluoxetina, un 
antidepressivo appartenente alla classe degli inibitori selettivi della ricaptazione della serotonina. Il 
trattamento è stato in grado di ripristinare la neurogenesi e le funzioni cognitive nei topi Ts65Dn. 
Questi risultati hanno mostrato, per la prima volta, che i difetti cerebrali legati alla trisomia sono 
reversibili, a patto che la terapia sia somministrata nelle fasi precoci della vita. Trials clinici saranno 
necessari per stabilire se la fluoxetina abbia nei bambini con SD lo stesso impatto positivo che ha 
avuto nei topi neonati. Non si può dare per scontato cha gli effetti positivi di una molecola osservati 
in un modello di topo siano riscontrabili anche nell’uomo; pertanto, è di estrema importanza stabilire 
se ci siano altre molecole efficaci quanto la fluoxetina. Sulla base di queste premesse, l’obiettivo 
generale di questo progetto è stato quello di stabilire se un trattamento neonatale con molecole 
“inesplorate” fosse in grado di ripristinare i principali difetti del neurosviluppo e cognitivi nel 
topo Ts65Dn, e se gli effetti fossero mantenuti dopo la cessazione del trattamento. In questo 
studio, ho valutato gli effetti di tre molecole differenti somministrate al topo Ts65Dn durante il 
periodo neonatale. 1) ELND006, un inibitore selettivo della γ-secratasi. ELND006 blocca la 
formazione di un piccolo peptide derivante da APP, AICD, che inibisce a sua volta l’attività 
mitogenica della via di segnalazione SHH, provocando quindi una riduzione del processo di 
neurogenesi. 2) Epigallocatechina-3-gallato (EGCG), un inibitore naturale della chinasi DYRK1A, 
la cui iper-attivazione nel cervello SD influenza negativamente il processo di neurogenesi. 3) 7,8-
diidrossiflavone (7,8-DHF), una molecola naturale che mima l’attività del BDNF tramite 
l’attivazione del recettore TRKB. 7,8-DHF potrebbe compensare la scarsa produzione di BDNF (e 
quindi riduzione del processo di neurogenesis) nel cervello SD. Il trattamento neonatale con 
ELND006 ha ripristinato la neurogenesi nel giro dentato (DG) e lo sviluppo sinaptico nella 
formazione ippocampica del topo Ts65Dn. Molti di questi effetti si sono mantenuti un mese dopo 
cessazione del trattamento e sono stati accompagnati dal ripristino delle funzioni sinaptiche nel 
circuito “granuli del DG e neuroni piramidali del campo CA3”. Il trattamento con ELND006 ha però 
causato qualche effetto collaterale. Nei topi Ts65Dn trattati neonatalmente con EGCG abbiamo 
osservato un completo ripristino della neurogenesi ippocampale e dello sviluppo sinaptico. Un mese 
dopo la cessazione del trattamento, però, questi effetti scomparivano e non vi erano segni di 
miglioramento comportamentale. 7,8-DHF, somministrato in topi Ts65Dn neonati, ha portato ad un 
ripristino della neurogenesi e della densità di spine dendritiche. I topi Ts65Dn trattati dal giorno post-
natale 3 fino all’adolescenza hanno esibito un ripristino della memoria e dell’apprendimento, 
 suggerendo che il recupero dell’anatomia ippocampale si traduceva in un recupero funzionale. Non 
sono stati osservati affetti collaterali sulla salute generale e sulla crescita dei topi. Un confronto delle 
tre molecole utilizzate in questo studio indica che, sebbene tutte siano in grado di ripristinare il 
processo di neurogenesi, il 7,8-DHF potrebbe avere il più alto impatto traslazionale nei bambini con 
SD. Questo perché non solo è efficace, ma non causa alcun effetto collaterale. La dimostrazione che 
sia possibile prevenire farmcologicamente le alterazioni dello sviluppo cerebrale in un modello di 
topo di SD con diverse molecole potrebbe stimolare l’ideazione di trials clinici con la/le molecola/e 
con la più alta efficacia e sicurezza. Questa è la sfida con cui si confronta la comunità di ricercatori 
preclinici coinvolti nello studio della SD: trasformare il sogno in realtà. 
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7,8-DHF = 7,8-dihydroxyflavone 
Ach = Acetylcholine 
AchE = Acetylcholine esterase 
AD = Alzheimer’s disease 
AICD = Amiloyd intracellular domain 
ANOVA = Analysis of variance 
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Aβ = Amyloid β  
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BDNF = Brain derived neurotropic factor 
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Gli1/2 = Glioma-associated oncogene 1/2 
GRIK1 = Glutamate ionotropic receptor kainate type subunit 1 
GSK3β = Glycogen synthase kinase 3β 
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ID = Intellectual disability 
IFNs = Interleukins and interferons 
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1. RATIONALE AND GOAL OF THE STUDY 
 
Down syndrome (DS) is a relatively high-incidence (1:700-1000) genetic condition due to triplication 
of chromosome 21. Individuals with DS may have various medical problems but intellectual disability 
is the common hallmark of this pathology. Furthermore, individuals with DS are bound to develop 
Alzheimer’s-like pathology after 40 years of age, with consequent development of dementia (Hartley 
et al., 2015). The intellectual disability that characterizes DS is mainly due to alteration of brain 
development that can be traced back to fetal life statges. In particular, the DS brain is characterized 
by a widespread impairment in the processes of neurogenesis that involves the ventricular and 
subventricular zones (the germinal niches of most of the brain neurons), the hippocampal dentate 
gyrus and the cerebellum (Contestabile et al., 2007, Guidi et al., 2008, Guidi et al., 2011a). The 
dendritic tree of the DS neurons exhibits a reduction both in total length and density of dendritic 
spines (Takashima et al., 1981, Becker et al., 1986, Vuksic et al., 2002), implying that the reduction 
of neurogenesis is worsend by impairment in dendritic development. The outcome of all these 
defects is a reduction in the complexity of brain wiring, which explains the impairment in several 
cognitive domains that characterizes DS. 
Mouse models that accurately mirror human pathologies are essential tools in order to comprehend 
deeply the mechanisms that underlie a given pathology and to evaluate the outcome of targeted 
therapies. The most used and best-characterized model of DS is the Ts65Dn mouse, that recapitulates 
many aspects of the human condition, including reduced neurogenesis, defects in neuronal 
maturation, impaired long-term learning and memory, and the tendency to develop Alzheimer’s-like 
pathology (Choong et al., 2015). Many molecular mechanisms have been proposed to underlie 
neurodevelopmental defects of DS. Indeed, numerous studies report that abnormal activity of the 
products of some triplicated genes, such as APP, DYRK1A, and RCAN1, may be implicated, directly 
or indirectly, in the alterations of neurogenesis, neuronal maturation, imbalance of 
excitation/inhibition, and the early onset of Alzheimer’s-like pathology in DS. Due to the complexity 
2 
of the outcome of gene imbalance, the mechanisms whereby gene triplication impairs brain 
development in DS have not been fully clarified. Yet, knowledge gained during the past few years 
regarding perturbed pathways may provide a rational basis to attempt targeted therapies in DS mouse 
models. A variety of pharmacological approaches has been used so far in the Ts65Dn mouse model 
and some of them translated into an improvement in hippocampus-dependent learning (see (Stagni et 
al., 2015a)). However, when some of them (for instance, memantine, a drug prescribed for treatment 
of Alzheimer’s disease, or folinic acid) were used for clinical trials in individuals with DS, they failed 
to replicate the good results obtained in mice. It must be enphasized that most of the brain neurons 
are born prenatally and their maturation takes place in the perinatal period. Therefore, it is not 
unexpected that clinical trials in individuals with DS at adult life stages may not translate into a 
behavioral benefit because the optimum time windows for the rescue of neurogenesis and 
dendritogenesis are are well over. Thus, there are currently no therapies for DS.  
Since neurodevelopmental defects are present from early fetal life stages in DS, the better strategy to 
“heal” individuals with DS should be based on pharmacologycal interventions carried out as early as 
possible. This idea can be summarized in four words:”The sooner, the better”. Indeed, recent work 
has shown that prenatal therapy with fluoxetine restores overall brain development and cognitive 
performance in the Ts65Dn mouse model (Guidi et al., 2014) and that neonatal therapy restores 
hippocampal development and hippocampus-dependent behavior (Bianchi et al., 2010b, Guidi et al., 
2013, Stagni et al., 2013, Stagni et al., 2015b). These promising results show for the first time that 
the trisomy-linked brain defects are reversible, provided that therapy is administered very early during 
the life span. Clinical trials are necessary in order to establish whether fluoxetine has the same positive 
impact in children with DS as in neonate Ts65Dn mice. If so, this may prompt clinical trials during 
pregnancy. It must be noted that an unavoidable problem with clinical trials concerns the time that 
intervenes between proposal and acceptance of the protocol and, given that the protocol is approved, 
the actual execution of the clinical trial. It has been estimated that eight years represent the mean time 
neecessary for the whole process. This means that a very long time will elapse before knowing 
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whether a drug that is effective in the mouse model is equally effective in individuals with DS. This 
time will be wasted if the attempted therapy will prove to be ineffective. For this reason, it is important 
to “gain time” and expedite the discovery of several different treatments in mouse models. This will 
offer to the community of clinicians a panel of drugs that may be worthwhile testing in different 
clinical trials, which, of course, may increase the probability to discover treatments that are effective 
in humans too. Such an approach will meet the needs of the families of children with DS and open a 
breakthough for the “cure” of intellectual disability.  
The overall goal of this project was to establish whether neonatal treatment with new “unexplored” 
molecules restores the major neurodevelopmental defects and cognitive performnce in the Ts65Dn 
mouse model and whether their effect is retained after treatment cessation. In this study, I have 
explored the effects of three different molecules in the Ts65Dn mouse model of DS, based on the 
rational basis described below. 
ELND006, a selective inhibitor of the γ-secratase. ELND006 blocks the formation of AICD, a small 
peptide derived from the processing of APP, that triggers the transcription of PTCH1, the inhibitor of 
the SHH mitogenic pathway. Since APP is triplicated in DS and in Ts65Dn mice, we hypothesized 
that accumulation of AICD may cause overexpression of PTCH1, thereby reducing neurogenesis. If 
so, inhibition of AICD production in the early neonatal period may revert the trisomy-linked 
neurogenesis defects.  
Epigallocatechin-3-gallate (EGCG), a flavonoid present in green tea extracts, is an inhibitor of 
DYRK1A. DYRK1A is a kinase that derives from a triplicated gene in individuals with DS and 
Ts65Dn mice. It has been proposed that DYRK1A is a candidate gene closely implicated in various 
DS phenotypes, including neurogenesis impairment. Thus, inhibition of DYRK1A with EGCG in the 
early neonatal phases may have a positive effect on neurogenesis.  
7,8-dihydroxiflavone (7,8-DHF), a natural flavone present in several plants, is a mimetic of BDNF 
and activates the TRKB receptor. The BDNF/TRKB signaling pathway plays a key role in 
neurodevelopment by stimulating neuronal maturation and neurogenesis. There is evidence that the 
4 
BDNF/TRKB system is deregulated in DS, suggesting that this deregulation may contribute to 
neurogenesis impairment. Thus, restoration of BDNF/TRKB signaling through 7,8-DHF may have a 
positive impact on neurogenesis. 
The results of this study are described in Section 3.1 (ELND006), Section 3.2 (EGCG) and Section 
3.3 (7,8-DHF). The outcome of individual treatments is discussed in the corresponding section. A 
comparison of the advantages and disadvantages of these selected molecules is reported in the section 
“General Discussion”. 
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2. INTRODUCTION 
 
2.1 Down syndrome 
Down syndrome (DS, OMIM 190685), also known as trisomy 21, is the most frequently survivable 
occurring chromosomal disorder due to aneuploidy in humans and is the most commonly known 
disorder of intellectual disability (Kazemi et al., 2016, Antonarakis, 2017). About 95% of affected 
individuals have the full/free trisomy of human chromosome 21 (HSA21) i.e. an extra copy of 
HSA21, and their chromosome count is 47. The leading cause of trisomy is attributed to meiotic non-
disjunction, which occurs mainly in the ovum, although the reason for this phenomenon is not 
completely clear. Indeed, the maternal origin for trisomy of HSA21 is prevailing, the cases of paternal 
origin being less than 10%, and the maternal age is a major risk factor for the onset of DS [see (Vacca 
et al., 2016)]. The incidence of DS in the United States is ~1 per 700 live births, and the worldwide 
incidence is ~1 per 1000 live births. Disease prevalence varies among countries because of 
sociocultural and economic variables, including average maternal age at conception as well as 
prenatal screening and abortion opportunities (Coppede, 2016, Hefti and Blanco, 2017). Individuals 
with DS now live longer than they used to, thanks to improvements in health care and in care for 
people with disabilities. DS subjects have many physical and neurological problems such as 
congenital heart disease, Alzheimer’s disease (AD), low IQ average (range 30–70) leukemia, 
hypotonia and motor disorders [see (Bartesaghi et al., 2011)]. 
 
2.2 History 
In 1959, Jerome Lejeune, working with Gautier and Turpin at Necker Hospital in Paris, France, 
described DS, as we currently know it (Fig. 2.1A). Although they discovered the trisomy of HSA21, 
the path that brought to this finding started more than a century before. In a very interesting report 
for the 50th anniversary of the Lejeune’s discovery, Giovanni Neri and John Opitz retraced all the 
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events that allowed Lejeune and colleagues to discover trisomy 21. Almost 100 years elapsed before 
the real cause of DS was correctly identified. The first description of what is now called DS was by 
Edouard Onesimus Seguin (1812–1880), a student of Jean Marc Gaspard Itard (the founding father 
of the special pedagogy), and founder, in France and the United States, of methods and systems for 
educating those with mental retardation. John H. Langdon Down in 1866 gave the next description 
of DS. In his paper, “Observations on an Ethnic Classification of Idiots”, Down made a classification 
of patients with mental retardation based on ethnic characteristics (Fig. 2.1B). Down mixed visionary 
concepts, and old prejudice, such as that of parental degeneracy, and his language is all but politically 
correct in describing the different types of idiocy according to ethnic varieties. In 1923 T. Halbertsma 
of Haarlem, had a great intuition. He argued that DS was of germinal origin. He did so on the basis 
of twin data, 15 cases of dizygotic twins always being discordantly affected, and the two pairs of 
presumed monozygotic twins being concordantly affected. Then, in 1932, long before the discovery 
of the human karyotype, Waardenburg predicted that DS was probably caused by a chromosomal 
aberration. This thesis was sustained by two pediatricians, Adrien Bleyer of St. Louis, and Guido 
Fanconi of Zurich. A large and important work on DS was made by Penrose in 1939, who 
demonstrated that maternal age correlates with the occurrence of DS. Then came 1959, when Lejeune 
et al. discovered that a triplication of HSA21 is the cause of DS (Neri and Opitz, 2009).  
 
2.3 Etiology 
All the defective features that characterize DS are due to the triplication of HSA21. In Genetics, the 
presence of a normal set of chromosomes is called euploidy, while aneuploidy indicates the presence 
of an abnormal number of chromosomes. Among chromosomal aberration, DS is the most widespread 
aneuploid condition (Driscoll et al., 2009). It occurs during cell division when chromosomes do not 
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Figure 2.1. A bit of history. A: a picture of Jerome Lejeune (1926-1994) [top, image taken from (Neri and 
Opitz, 2009)] and the first page of the historic paper by Lejeune, Gautier, and Turpin [bottom, image taken 
from (Neri and Opitz, 2009)] published at the Rendering of the Academy of Sciences January 26 of 1959. B: 
a portrait of John Langdon Haydon Down, (1828-1896) (top, image taken from 
http://en.wikipedia.org/wiki/Image:JLHdown.jpg) and the first page (bottom, image taken from 
http://www.neonatology.org/classics/down.html) of the original paper “Observations on an Ethnic 
Classification of Idiots” by J. Langdon H. Down, M.D., London, London Hospital Reports, 3:259-262, 1866. 
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separate well between the two cells. In more than 90% of cases, DS occurs when maternal meiotic 
nondisjunction results in trisomy 21. Other chromosomal abnormalities that may result in DS include 
Robertsonian translocations (2–4 % of the cases), a structural chromosomal abnormality resulting 
from a trisomic dose of the long arm of HSA21 attached to chromosomes 14, 21, or 22 (also called 
isochromosomes); partial trisomy of HSA21 (mosaicism, 2–4 %), a condition in which individuals 
have both trisomic and euploid cell lines; and ring chromosomes (chromosomes whose arms have 
fused together to form a ring) (Papavassiliou et al., 2009). 
 
2.4 Human Chromosome 21 
HSA21 is the smallest human chromosome and represents about 1.5% of the total DNA of cells (Fig. 
2.2A). Owing to its role in DS and its small size (̴ 46 Mb), HSA21 is the most-studied human 
chromosome [see (Antonarakis, 2017)]. Sequencing of HSA21 was completed in 2000 within the 
Human Genome Project (Hattori et al., 2000). HSA21 was the second human chromosome to be fully 
sequenced after HSA22. So far, prediction of the number of genes set on HAS21 was estimated 
between 738-756 (data updated to January 2017; NCBI Map Viewer; Vega Genome Browser 54) and 
it has an average of 15 genes per Mb. Among these, 233 are protein coding genes (226 known 
proteins; 5 novel proteins, 2 putative proteins), 306 processed transcripts genes, i.e. long non-coding 
RNA (299 lncRNAs; 7 unclassified processed transcripts), 182 pseudogenes (141 processed 
pseudogenes; 32 unprocessed pseudogenes; 6 transcribed processed pseudogenes; 1 transcribed 
unprocessed pseudogenes), 1 IG (immunoglobulin) gene and 16 TEC (to be experimentally 
confirmed) genes (Fig 2.2B). All this genomic elements are spread on the entire length of the long 
arm of HSA21; the exact sequences of the short arm of HSA21 have not yet been completely 
elucidated. Looking at numbers reported above, it appears that HSA21 is among the poorest 
chromosomes in terms of functional DNA elements per Mb [see (Antonarakis, 2017)]; this could be 
the reason why triplication of this chromosome deals with life after birth. However, there are two rich 
regions of G-negative bands (thus, rich of structural genes) on the distal half of the HSA21q (21q22) 
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(Shapiro, 1997). Among the proteins known to be encoded by HSA21, 23 proteins are involved in 
signal transduction and 31 proteins are transcription factors that may influence the expression of other 
genes in the genome. Although proteins have a pivotal role in regulating gene activity, other central 
characters of the puzzle are ncRNA (non-coding RNA), which are likely to disturb several cellular 
functions and developmental processes. This further leads to a high phenotypic variability and 
heterogeneity in the DS population, highlighting the importance for understanding how over-
expression of HSA21 proteins and RNA may influence the transcriptome of the entire genome. 
Summarizing, the phenotypic heterogeneity and variability in DS is primarily due to: i) the three 
copies of functional genomic elements on HSA21; ii) the genetic variation of HSA21; iii) the genetic 
variation on non-HSA21 loci. 
Important advances have been made in understanding the phenotypic impact of the over-expression 
of some HSA21 genes. In particular, the molecular basis of the early onset AD, that is seen in DS, 
the molecular basis of the leukaemias that frequently occur in DS and the identification of genomic 
regions of HSA21 that harbor functional elements or causative genetic variation for certain 
phenotypes, such as congenital heart defects [see (Antonarakis, 2017)].  
 
2.4.1 Most studied genes involved in DS phenotype 
As deepened in the previous paragraph, many actors interact and bring to DS phenotype. Among 
them, in the last years some genes (and their products) were deeply studied because of either their 
overall influence on the genome or the role they hold in development of other pathologies (also 
present in DS), such as AD or leukaemia. As reported in EXaC database 
(http://exac.broadinstitute.org/), HSA21 genes may be divided based on haploinsufficiency 
(intolerability of loss-of-function variants). It has been argued that haploinsufficient genes are also 
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Figure 2.2. Chromosomic overview of Down syndrome. A: chromosomic pattern of an individual with 
trisomy 21 (image modified from https://www.huffingtonpost.com/lisa-pullen-kent/rockin-the-socks-for-
worl_b_9513440.html). B: the pie chart indicates the gene content of HSA21 [see (Antonarakis, 2017)]. C: 
human chromosome 21 (HSA21). In the image are highlighted some genes that, when triplicated, play a key 
role in the phenotypic feature of DS [modified from (Rachidi and Lopes, 2008)]. D: some of heatlh problem 
due to the triplication of HSA21 that may affect individuals with Down syndrome (image taken from 
https://commons.wikimedia.org/wiki/File:Human_chromosome_21_from_Gene_Gateway_with_label.png). 
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sensitive to three copies and are thus good candidates for contributing to some of the phenotypes in 
full or partial trisomies. Genes with the highest haploinsufficiency index are most likely to contribute 
to a DS phenotype, whereas those with the lowest haploinsufficiency index are least likely to 
contribute to a DS phenotype [see (Antonarakis, 2017)]. Accordingly, some of the principal genes 
involved in DS phenotype that deserve a citation [see also (Rozier et al., 2003)] are SIM2, DYRK1A, 
DSCAM, GRIK1, APP, S100β, SOD1, RCAN1, KCNJ6, OLIG1, SYNJ1 (Fig. 2.2C). Some 
characteristics of these gene products are briefly highlighted below. 
SIM2. Single-minded homolog 2. SIM2 is a transcription factor that is a master regulator of 
neurogenesis. It binds aryl hydrocarbon receptor nuclear translocator (ARNT) and together 
translocate into the nucleus stimulating gene expression (Chatterjee et al., 2013). It regulates many 
genes, thus resulting in some of the DS phenotypes [see (Antonarakis, 2017)]. 
DYRK1A. Dual-specific tyrosine-(Y)-phosphorylation Regulated Kinase 1A. DYRK1A is a kinase 
that plays a significant role in a signalling pathway regulating cell proliferation and may be involved 
in brain development. DYRK1A was proposed to be one of the potent candidate genes closely 
implicated in various DS phenotypes. Down syndrome patient-derived fibroblasts exhibit impaired 
proliferation due to elongation of the G1 phase of the cell cycle and the extended G1 duration is 
restored by knocking down DYRK1A [see (Stagni et al., 2017)]. This evidence strongly suggests a 
key role of DYRK1A in the regulation of proliferation and differentiation of trisomic neural 
progenitor cells (Stagni et al., 2017).  
DSCAM. Down Syndrome Cell Adhesion Molecule. DSCAM, which acts as an adhesion molecule, 
is expressed in the developing nervous system, where it intervenes in various stages of neuronal 
development. For instance, it has important functions in early development (neuronal proliferation, 
maturation, and synaptogenesis) and in formation of neuronal networks (Perez-Nunez et al., 2016). 
Therefore, the over-expression of this protein in DS patients may be related to cellular dysfunctions 
that affect the development of the Central Nervous System (CNS), and/or favour AD-related dementia 
in adulthood (Perez-Nunez et al., 2016). 
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GRIK1. Glutamate Ionotropic Receptor Kainate type subunit 1. GRIK1 is a subunit of the kainate 
family of glutamate receptors, which are composed of four subunits and function as ligand-activated 
ion channels. GRIK1 forms heteromeric ligand-activated ion channels with other kainate receptor 
subunits (GRIKs 2,3 and KA 1,2). Altering proportions of the subunits may alter overall channel 
composition and biochemical properties [see (Gardiner and Costa, 2006)]. This receptor is involved 
in pain sensitivity which may explain evidence that individuals with DS express pain or discomfort 
more slowly and less precisely than the general population [see (Gardiner and Costa, 2006)].   
APP. Amyloid beta (A4) Precursor Protein. APP is a transmembrane protein involved in the 
regulation of synapse formation, neural plasticity and iron export (Turner et al., 2003, Priller et al., 
2006). APP is the precursor of the β-amyloid peptide, created by two successive proteolytic cut made 
by β- and γ-secretases. Accumulation of β-amyloid leads to the formation of amyloid plaques, one of 
the main actor involved in AD onset in the general population. Furthermore, it is one of the triplicated 
gene that is thought to play a key role in neurodevelopmental alterations in DS and to underlie 
development of Alzheimer’s-like pathology in adults with DS [see (Stagni et al., 2017)].  
S100β. S100 calcium Binding protein beta. S100β is a cytoplasmic glial-specific protein and is 
expressed preferentially by astrocytes. It is involved in a number of cellular processes (cell cycle 
progression; differentiation) acting as a neurotropic and protective factor. Otherwise, it can contribute 
to neuroinflammation and cellular loss when its production and release increase in aging. So far, it 
seems to be involved in development of AD and it could be used as a prediction factor for the onset 
of the pathology [see (Lott, 2012)]. 
SOD1. Superoxide Dismutase 1. SOD1 is one of the three copper-zinc superoxide dismutases 
expressed in humans and localizes on the outer mitochondrial membrane. SOD1 is a main element of 
the respiratory chain and its role is to convert superoxide anions into molecular oxygen and hydrogen 
peroxide (H2O2), having an antioxidant function. Dysfunctions of this enzyme provokes oxidative 
stress, in turn leading to inflammation and favouring some pathologies like amyotrophic lateral 
sclerosis or ischemic heart diseases. In DS, triplication of SOD1 causes an accumulation of H2O2 
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(until 50% higher than normal in a variety of DS cells and tissues). This could imply a risk factor for 
subsequent neurodegeneration in aged DS patients [see (Perluigi and Butterfield, 2011)]. 
RCAN1. Regulator of Calcineurin 1. RCAN1 is a protein involved in numerous processes, included 
the regulation of neural proliferation and maturation. The protein encoded by this gene interacts with 
Calcineurin A and inhibits Calcineurin-dependent signalling pathways. Calcineurin is a calcium and 
calmodulin-dependent serine/threonine protein phosphatase. Calcineurin activates the nuclear factor 
of activated T cell cytoplasmic (NFATc; a transcription factor) by dephosphorylating it. The activated 
NFATc is then translocated into the nucleus, where it up-regulates the expression of interleukin 2 
(IL-2), which, in turn, stimulates the growth and differentiation of T cell response [see (Stagni et al., 
2017)]. RCAN1 was seen to be over-expressed in the DS fetal brain and in DS mouse models and 
this deregulation may contribute to neurodevelopmental alteration typical of DS. 
KCNJ6. Potassium voltage-gated Channel subfamily J member 6. KCNJ6, which encodes GIRK 
subunit 2 (GIRK2) of the G-protein coupled inward rectifying K+ channel (GIRK), is located on 
human HSA21 (Hattori et al., 2000) and within triplicated segments of mouse chromosome 16 in 
mouse models of DS (Best et al., 2007). GABAB receptors are metabotropic G-protein coupled 
receptors that are thought to release Gβγ subunits that activate K+ channels, causing neuron 
hyperpolarization (Chalifoux and Carter, 2011). This hyperpolarization decreases neuron excitability 
and enhances Mg2+ blockade of NMDA receptors to reduce their overall current and thus Ca2+ influx. 
This influx is fundamental for initiating the physiological changes that occur during synaptic 
plasticity. It has been shown that up-regulation of GIRK2 protein in the Ts65Dn mouse model of DS 
results in a larger slow inhibitory postsynaptic current (IPSC) mediated by GABAB receptors (Siarey 
et al., 1999). Moreover, evidence in Ts65Dn mice shows that GIRK2 is over-expressed in various 
brain regions, and that this leads to an exaggerated GABAB receptor-mediated inhibitory response in 
neurons from the hippocampus (Harashima et al., 2006). 
OLIG1/2. Oligodendrocyte transcription factor 1 and 2. OLIG1/2 are transcription factors that 
promote formation and maturation of oligodendrocytes, especially within the brain and that cooperate 
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during neural tube formation. OLIG2 mis-expression impairs cortical progenitor proliferation, causes 
precocious cell cycle exit, massive neuronal cell death, downregulation of neuronal specification 
factors including NGN1, NGN2 and PAX6, and a defect in cortical neurogenesis [see (Stagni et al., 
2017)]. It must be observed that during embryonic development neural precursors in the medial 
ganglionic eminence (MGE) of the Ts65Dn mouse exhibit a faster proliferation rate. This feature is 
abrogated by deletion of an allele of Olig1 and Olig2 (Chakrabarti et al., 2010). This suggests that 
OLIG1 and OLIG2 may play a differential role in the modulation of neurogenesis according to brain 
region and developmental time. 
SYNJ1. Synoptojanin 1. This gene encodes a phosphoinositide phosphatase that regulates levels of 
membrane phosphatidylinositol-4,5-bisphosphate. The synaptojanin family comprises proteins that 
are key players in synaptic vesicle recovery at the synapse. As such, expression of this enzyme may 
affect synaptic transmission and membrane trafficking. There is evidence that over-expression of 
SYNJ1 in DS is functionally linked to the enlargement of early endosomes, that in turn provokes 
disruption of synaptic vesicle transportation (Cossec et al., 2012). 
 
2.5 Typical features of individuals with DS 
DS patients are characterized by numerous phenotypic defects and medical problems caused by the 
triplication of HSA21 (Fig. 2.2D). The most invalidating aspect of the DS condition is intellectual 
disability that is the unavoidable hallmark of DS and has a heavy impact on public health. In addition, 
DS is coupled with congenital heart defects, gastrointestinal anomalies, hypotonia, craniofacial 
abnormalities, audiovestibular and visual impairment and hematopoietic disorders. Furthermore, 
people with DS tend to develop leukemia, thyroid disorders, and AD like pathology with age [see 
(Kazemi et al., 2016)]. 
Congenital heart defects (CHD). The incidence of CHD in newborn babies with DS is up to 50% 
[see (Asim et al., 2015)]. The most common form of CHD in the DS population are atrioventricular 
canal/septal defects (AVSDs), which affects up to ~40% of the patients. Of all the heart defects, 
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AVSDs is the most serious and has an adverse impact on survival. Ventricular septal defects (VSD) 
are also present in DS and affect up to 35% of patients [see (Noble, 2008, Asim et al., 2015)]. AVSDs 
are characterized by the presence of a common atrioventricular junction with an ovoid shape, and 
defects of the muscular and membranous atrioventricular septum. There is disproportion of outlet and 
inlet dimensions of the left ventricle. These features possibly lead to a blood travelling from the left 
side (venous blood) of the heart to the right side of the heart (arteriosus blood), or the other way 
around. In case of VSD, the defect lies in ventricular septum of the heart due to which some of the 
blood from the left ventricle leaks into the right ventricle leading to pulmonary hypertension.  
Although with minor incidence, abnormalities such as isolated secundum atrial septal defects (8%), 
isolated tetralogy of Fallot (4%) and isolated patent ductus arteriosus are present in DS patients 
(Freeman et al., 1998). Importantly, most of the anomalies in infants with DS are suitable for complete 
surgical correction, with single ventricle palliation recommended for children with complex cardiac 
anomalies [see (Arumugam et al., 2016)]. 
Gastrointestinal anomalies. DS patients present a large number of gastrointestinal defects. These 
defects, which could affect up to 7-12% of children with DS (Freeman et al., 2009, Bull and 
Committee on, 2011), are duodenal stenosis/atresia (3.9%), anal stenosis/atresia (1.0%), esophageal 
atresia with or without tracheoesophageal fistula (0.4%), pyloric stenosis (0.3%) and Hirschsprung 
disease (0.8%) [see (Arumugam et al., 2016)]. DS patients constitute ~12% of all cases of 
Hirschsprung disease (HD). HD is a form of low intestinal obstruction caused by the absence of 
normal myenteric ganglion cells in a segment of the colon (Amiel et al., 2008). In HD children, the 
absence of ganglion cells results in the failure of the distal intestine to relax normally, encouraging 
chronic constipation, poor weight gain, vomiting and swollen abdomen. 
Hypotonia. Almost all children with DS suffer from muscle hypotonia (MH), a state of reduced 
muscle tone, usually related to the skeletal muscles. MH usually leads to numerous problems, as a 
delay in developmental milestones, mastication problems (due to poor neuromuscular control), 
muscular weakness and dental anomalies (Dey et al., 2013). MH in people with DS has been related 
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to a dysregulation of the expression of the α1 and α2 chains of type VI collagen (COL6A1 and 
COL6A2 respectively), that are located on the long arm of HSA21. Type VI collagen has a crucial 
role in the function and stability of skeletal and cardiac muscle (Dey et al., 2013). 
 
2.5.1 Other medical problems associated with DS 
Leukemia. Children with DS tend to develop leukemia, even though they develop solid tumors in 
lower rate in comparison with general population. The risk of developing acute megakaryoblastic 
leukemia (AMKL), a rare subtype of acute myeloid leukemia (AML), is increased 500-times in 
children with DS, and risk of acute lymphoblastic leukemia (ALL) is 20-fold greater in children with 
DS (Xavier and Taub, 2010). Although in childhood ALL is significantly more common than AML, 
for children with DS under 15 years of age the ratio of ALL to AML is 1.7. For the general population 
of non-DS children, the equivalent ratio is 6.5 (Xavier and Taub, 2010). 
Thyroid disorders. Individuals with DS are at an increased risk of developing thyroid disease, with a 
lifetime prevalence ranging from 13% to 63% [see (Hardy et al., 2004)]. Furthermore, congenital 
hypothyroidism is about 28 times more common in infants with DS than in the general population 
with an incidence of 1%, detected by newborn screening (Forth 1984). Hypothyroidism in DS could 
contributes to intellectual disability. After the newborn period, TSH values in DS increase and they 
have been reported to be as high as 85% of euploid infants under the age of 12 months [see (Hardy et 
al., 2004)]. Thyroid dysfunction, expressed as a high TSH concentration, is associated with growth 
retardation in children with DS who are younger than 4 years. Unfortunately, there are very few 
studies systematically examining the frequency of thyroid disease in infants with DS.  
Epilepsy. 5–13% of children with DS display seizures [see (Arya et al., 2011)]. The occurrence is 
bimodal with 40% having seizures before 1 year of age and with 40% developing seizures after thirty 
years, with generally tonic–clonic or myoclonic in manifestation [see (Lott, 2012)]. Infantile spasms 
are associated with electroencephalographic (EEG) characteristics. It appears that children with DS 
have better seizure control compared to other patients with symptomatic infantile spasms, and early 
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initiation of appropriate treatment may contribute to the prevention of late seizure development and 
better developmental outcome [see (Arya et al., 2011)]. 
 
2.6 Neurological defects in DS 
The most common feature of DS is intellectual disability that affects almost 100% of people with this 
pathology. DS individuals typically display an average Intelligence Quotient (IQ) of 50 (30-70) and 
mental age is rarely over 8 years. Children with DS show a delay in cognitive development [see (Lott 
and Dierssen, 2010, Bartesaghi et al., 2011, Rueda et al., 2012)]. There is, however, a great inter-
individual variability in the intensity of DS phenotype. Indeed, a few individuals with DS have been 
reported to have a normal IQ value. The IQ in DS is not constant over a lifetime, but it progressively 
decreases with age. The first deceleration occurs early, between the age of 6 months and 2 years, with 
a further decline in adolescents (Rachidi and Lopes, 2008). DS cognitive defects emerge in infancy 
and accumulates in early childhood, with impairment of speech, language, motor skills, cognition, 
adaptive behavior and a higher risk of psychopathology. Infants with DS are unable to roll until the 
sixth month and are unable to sit independently until between 8.5 and 11.7 months. The delay is 
greater for later developing motor skills: DS infants crawl on their hands and knees between 12.2 and 
17.3 months of age and walk between 15 and 74 months (Vicari, 2006). During infancy, children with 
DS exhibit a slower transition from babbling to speech and a delay in expressive lexicon and syntax, 
although no difference in vocalization types are present. Adolescents and young adults with DS 
usually have very poor linguistic capacities and a longer period of phonological errors and poorer 
intelligibility, although language comprehension is relatively more advanced than syntax (Dykens et 
al., 1994, Chapman and Hesketh, 2000, Vicari, 2006). Individuals with DS perform visual-perceptual 
and imagery material processing in a significantly poorer way than mental age-matched individuals 
do. However, when the task involves the processing of spatial data, performance of DS individuals is 
similar to that of controls. Many individuals with DS exhibit impairment in verbal short-term and 
working memory [see (Vicari, 2006)]. Children with DS have normal learning ability for tasks 
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requiring implicit memory but exhibit selective impairment of explicit memory, with poor 
information encoding, impaired retrieval abilities and attention deficits (Carlesimo et al., 1997, Vicari 
et al., 2000). When tested for learning tasks that specifically assess the state of function of the 
hippocampal and prefrontal systems infants and adults with DS show severe impairment [see (Nadel, 
2003)].  
 
2.6.1 Alzheimer’s-like pathology in DS 
DS is characterized by a high incidence of early onset Alzheimer’s disease (AD). Indeed, signs of 
AD-like pathology are found in the brains of virtually all people with DS by 35-40 years of age (Fig. 
2.3A). The prevalence of dementia increases with age above 45 years, with the majority of people 
with DS developing dementia by the age of 65 [see (Lott, 2012, Ruparelia et al., 2013)]. Since AD 
develops only in some individuals of the general population but it is almost an invariable hallmark of 
DS (although not all individuals develop dementia, even by 70 years of age), this implies that trisomic 
genes play a paramount role in the development of the disease [see (Ruparelia et al., 2013, Choong 
et al., 2015)]. This condition makes DS an excellent natural genetic model for the study of AD-like 
biological mechanisms and identification of potential biomarkers. The progressive accumulation of 
AD pathology suggests that there is a preclinical phase in DS-AD with a delay of at least 10 years 
between the onset of AD pathology and dementia diagnosis, similar to what is described for AD in 
the general population, which provides a window for intervention [see (Hamlett et al., 2016)]. 
Biological mechanisms involved in DS-AD include extracellular amyloid β protein (Aβ) 
accumulation (Fig. 2.3B), intraneuronal neurofibrillary tangles (NFTs) deposition (Fig. 2.3B), BFCN 
(basal forebrain cholinergic neurons) loss, neuron loss in the locus coeruleus, hippocampal 
abnormalities, imbalance of neurotrophic factors, alterations in long-term potentiation, abnormal 
endosomal signaling, presence of neuroinflammation, and oxidative stress [see (Hartley et al., 2015, 
Hamlett et al., 2016)]. In DS there is an over-expression of the gene for APP from which the amyloid-
β-protein is derived [see (Lott, 2012, Hartley et al., 2015)]. It has been suggested that an abnormal 
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APP metabolism initiates AD pathogenesis by triggering a set of events that result in Aβ aggregation, 
particularly of the Aβ42 peptide, in the extracellular plaques [see (Choong et al., 2015, Hartley et al., 
2015)]. Evidence in favor of this hypothesis comes from rare families with early onset AD who have 
small internal duplications of HSA21 that include APP, and tends to be present with cerebral amyloid 
angiopathy [see (Ruparelia et al., 2013, Hamlett et al., 2016)]. Conversely, although very rare, partial 
trisomy 21 excluding APP (i.e., with two “doses” of APP) does not appear to lead to AD [see (Choong 
et al., 2015)]. According to recent evidence, in addition to over-expression of APP, other triplicated 
genes may be involved in the development of AD and contribute to excessive tau phosphorylation in 
DS. They are DYRK1A, RCAN1, SOD1, ETS-2, BACE2, and S100β [see (Lott, 2012, Hartley et al., 
2015)]. The prevalence and time-course of AD in DS suggests that interventions may be attempted 
in young adults with DS in order to prevent the onset of AD. However, due to the difficulty in 
obtaining clinically and pathologically well-characterized human DS brain tissue, the need to develop 
and investigate animal models of this disorder is critical. 
 
2.6.2 Cognitive reserve paradigm 
The concept of “reserve” tries to explain how individual differences in susceptibility to age-related 
brain changes or Alzheimer's disease-related pathology originate. Cognitive reserve (CR) refers to 
individual differences in how tasks are performed that may allow some people to be more resilient 
than others. This theory considers two types of reserve: brain reserve, which refers to actual 
differences in the brain itself (for example more neurons or synapses to lose) that may increase 
tolerance for a given pathology, and CR. The idea of brain reserve is supported by studies that suggest 
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Figure 2.3. Alzheimer’s disease in Down syndrome. A: A chemical marker that binds to plaques and tangles 
allows their detection in the brains of individuals with Down syndrome or Alzheimer’s disease. The blue color 
corresponds to lower amounts of plaques and tangles, while yellow and green represent higher amounts (Lott, 
2012). B: Aβ deposition in the brain of an infant with Down syndrome (Lott, 2012). C: Immunolabelling with 
anti-amyloid-β of the midfrontal cortex of a 46-year-old person with Down syndrome (Lott and Dierssen, 
2010). Abbreviations: Aβ, β-amyloid; DS, Down syndrome; y, years. 
.
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that prevalence or incidence of dementia is lower in individuals with larger brains. In contrast, the 
concept of CR suggests that the brain actively attempts to cope with brain damage by using pre-
existing cognitive processing approaches or by enlisting compensatory approaches. This would allow 
individuals with high CR to better counteract the brain damage than individuals with lower CR. Thus, 
the CR concept is an active form of reserve in that, the same amount of pathology will have different 
effects on different people, even when the brain size is held constant. There are recent suggestions 
that life experience may act to prevent or minimize pathology. For example stimulating environments 
upregulate BDNF expression that in turn fosters the growth of new neurons and stimulates neural 
plasticity. There are other suggestions that cognitively stimulating activities may slow the rate of 
hippocampal atrophy in normal aging, and perhaps even prevent accumulation of amyloid plaques. 
Although individuals with a higher CR can tolerate more pathology than those with a lower CR, it 
must be noted that there is common point in all people where the pathology is so severe that function 
cannot be maintained. Given these assumptions, individuals with higher CR will begin their cognitive 
decline when pathology is more advanced and thus have less time until they reach the point where 
pathology overwhelms function. This results in a more rapid rate of decline once it begins. Thus, it 
becomes extremely important to find a way to prevent this rapid decline, possibly by acting 
pharmacologically or by environmental stimuli very early (before the first symptoms of the pathology 
begin) in the life of an individual [all the information about cognitive reserve are based on the review 
by (Stern, 2012)].  
Individuals with DS are bound to develop AD. Thus, the theory of cognitive reserve may also be valid 
for DS. In the last decade, many attempts have been made by the scientific community in order to 
find pharmacotherapies effective on brain development in DS. The discovery of pharmacological 
treatments that are able to foster neurogenesis and, thus, increase the cognitive reserve could be a 
useful tool for the “cure” of DS as well as prevention of AD in DS. 
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2.7 DS mouse models: tools for the understanding of DS pathology and therapy 
design 
Mouse models that accurately mirror human pathologies are essential tools in order to comprehend 
deeply the mechanisms that underlie a given pathology and to evaluate the outcome of targeted 
therapies. So far, a number of DS mouse models carrying trisomy for different sets of HSA21 
orthologous genes have been created with different methods [see (Bartesaghi et al., 2011)]. These 
models are briefly described hereafter. The difficulty for making a “perfect” model for DS lies in the 
fact that the ~160 HSA21 protein-coding genes are scattered among three mouse chromosomes: ~100 
map to the telomeric segment of mouse chromosome 16 (MMU16); ~20 map of MMU17; ~40 to 
internal segments of MMU10 [see (Gardiner, 2015, Antonarakis, 2017)].  
Model with triplication of the whole MMU16. The first mouse model of trisomy 21, generated by 
spontaneous Robertsonian translocations of MMU16, was labelled Ts16 (Fig.2.4A) (Gropp et al., 
1975). Ts16 and DS share a common genetic defect because the distal portion of mouse chromosome 
16 is syntenic with most of the distal portion of human chromosome 21 (Holtzman et al., 1992). The 
value of this model, however, is limited because the Ts16 embryos die in utero.  
Segmental trisomic mice. The most used and best-characterized model of DS is the Ts65Dn mouse 
that was created approximately 25 years ago (Davisson et al., 1993). The Ts65Dn mouse is trisomic 
for at least 55 % of HSA21 orthologous protein-coding genes, but it lacks the remaining ~45% (Fig. 
2.4A). Moreover, it bears 50 protein-coding genes that are not orthologs for HSA21 genes, a segment 
that is an artefact of the method used in its construction (Duchon et al., 2011). These features may 
confound phenotypic consequences seen in this model. Although the Ts65Dn mouse shows genetic 
limitations, it is still the most popular choice among DS models because it recapitulates many aspects 
of the human condition, including, cytoarchitectural abnormalities in many brain regions and deficits 
in learning and memory [see (Bartesaghi et al., 2011, Rueda et al., 2012, Gardiner, 2015, Stagni et 
al., 2017)]. Ts65Dn mice have reduced dimension in comparison with euploid mice (Fig.2.4B). 
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Another characteristic of the Ts65Dn is to develop, like humans with DS, Alzheimer’s-like pathology 
with age. 
The Ts1Cje is trisomic for 81 genes located in the region of MMU16 that extend from Sod1 to Znf295 
(Fig. 2.4A) (Sago et al., 1998). Ts1Cje mice show reduced cerebellar volume and abnormalities in 
craniofacial development similarly to Ts65Dn mice, but generally less severe. Ts2Cje model carries 
the same segment of MMU16 triplicated in the Ts65Dn mouse (Fig. 2.4A) but is translocated to 
chromosome 12 (Villar et al., 2005). 
The Ms1Ts65 mouse model has a partial trisomy that starts from App to Sod1 and includes about 33 
genes (Fig. 2.4A). The chromosomal region between App-Sod1 is present in the Ts65Dn model and 
it lacks in the Ts1Cje model. This allows comparisons among the trisomies and permits to assess the 
contributions of the phenotype of Ts65Dn mice of genes proximal to App up to Sod1 regarding the 
learning and behavioural phenotype (Sago et al., 2000). 
The Ts1Rhr mouse model, which is trisomic for the Cbr1-Orf9 genetic interval (DSCR) that includes 
33 genes (Fig. 2.4A) (Olson et al., 2004), shows a reduction in the volume of the brain but not of the 
cerebellum and hippocampus (Aldridge et al., 2007). Moreover, the Ts1Rhr model displays 
derangement in the spatial organization of subcortical structures (Aldridge et al., 2007). This mouse 
became of particular interest because it demonstrated that trisomy of this region (the DSCR) was not 
sufficient to replicate all structural and functional abnormalities of DS. 
The Ms1Rhr mouse model combines the deletion of the Cbr1-Orf9 region with the Ts65Dn trisomy 
region (Fig. 2.4A). Ms1Rhr model shows a reduced volume, height, width, and length of the brain, 
reduced volume of the hippocampus at two and three months of age, but an increase in the volume of 
the cerebellum (Aldridge et al., 2007, Olson et al., 2007).  
Models with triplication of MMU16, MMU17 and/or MMU10. Two models, which are trisomic for 
a segmental region of MMU17, have been recently created. The Ts1Yah mouse, which is trisomic 
for 12 genes in the MMU17 region, syntenic to the sub-telomeric region of HSA21, displays deficits 
in novel object recognition, similarly to other DS models, but no impairments in hippocampus-
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dependent spatial memory. The Ts(1617)43H(Ts43H) mouse, which is trisomic for 30 Mb of 
proximal MMU17, exhibits spatial learning deficits analogous to those observed in Ts65Dn mice 
(Vacik et al., 2005). Differences between these models reveals the complexity of the genetic code 
that modulates different aspects of behaviour in DS patients. 
The Dp(16)Yey mouse is a more recently created DS model (Li et al., 2007). It is trisomic for all 
MMU16 region orthologous to HSA21 and not for the non-HSA21 orthologs (Fig. 2.4A). Although 
the Dp(16) mouse still needs to be fully characterized, the few available studies indicate that it 
exhibits various brain dysmorphologies (Starbuck et al., 2014), is impaired in several tests of learning 
and memory (Goodliffe et al., 2016), and shows defects in long-term potentiation (Yu et al., 2010b). 
Other two models with a partial triplication of MMUs for the entire regions that are orthologous with 
HSA21 were developed. They are: the Dp(10)Yey mouse, with a partial triplication of MMU10 (Fig. 
2.4A), that does not show cognitive impairment; the Dp(17)Yey, with a partial triplication of MMU17 
(Fig. 2.4A), that shows abnormal hippocampal long-term potentiation (Yu et al., 2010b). 
An attempt to create a “full-trisomic” mouse was made successfully by Yu et al (Yu et al., 2010a). 
They produced a triple transgenic mouse that carries triplications spanning the entire HSA21 syntenic 
regions on all MMU10, MMU16 and MMU17 mouse chromosomes 
(Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+) (deriving from a consecutive breeding of models 
Dp(16)1Yey, Dp(17)1Yey and Dp(10)1Yey) (Fig. 2.4A). This model showed learning and memory 
deficits and LTP impairment. However, because of viability issues, time, and expense, this mouse 
has not been extensively studied yet [see (Gardiner, 2015)]. 
Models with insertion of HSA21. An alternative model is provided by “transchromosomic” (trans-
species aneuploidy) mouse strains in which mice carry an extra human chromosome and are thus 
trisomic only for the genes on this chromosome. The Tc1 mouse is unique in that it is a 
transchromosomic line that carries a freely segregating and almost complete copy of HSA21 (Fig. 
2.4A) (Wiseman et al., 2009). Consistent with the impact of HSA21 trisomy in humans, Tc1 mice 
show reduced long-term potentiation (LTP) in the hippocampal dentate gyrus (DG) region (O'Doherty 
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et al., 2005) and impaired performance in tasks such as object recognition memory. However, the 
random loss of this human chromosomal fragment during mouse development resulted in variable 
levels of mosaicism of the extra chromosome in different tissues, confounding the analysis of the 
phenotypic consequences. 
Transgenic mouse models. In order to evaluate the involvement of single triplicated genes in DS 
features, several transgenic mouse models with one orthologous HSA21 gene were created (TgSod1, 
TgApp, TgEts2, TgS100β, TgDyrk1a, TgDscr1, TgSim2, TgBace2, TgSynj1 and TgPfk1). The 
transgenic mouse for Sod1 gene for example, showed decreased cell number in several brain areas 
and decreased LTP in the hippocampal field Cornu Ammonis 1 (CA1) (Rachidi and Lopes, 2008). 
The transgenic mouse TgS100β showed dendritic abnormalities similar to those in the fetal DS brain 
and astrocytosis, while transgenic mice TgApp exhibited over-expression of APP protein in the 
neocortex and hippocampus region and mimicked features of DS (Rachidi and Lopes, 2008). Recent 
work focused on the role of Dyrk1a triplication in the cognitive deficit of DS, showing that transgenic 
mice (TgDyrk1a) exhibit various but not all learning defects of Ts65Dn mice (Altafaj et al., 2001, 
Ortiz-Abalia et al., 2008).  
 
2.8 Neurodevelopmental alterations in DS 
Intellectual disability (ID) is the most invalidating feature of DS. ID, that lifelong affects DS 
individuals, is mainly due to brain hypotrophy. Several lines of evidence show that neurogenesis 
reduction and dendritic hypotrophy are the two major determinants of brain hypotrophy in DS. These 
defects starts at early fetal life stages and continues in the postnatal life.  
This section provides comparative information on neuroanatomical defects and neurogenesis 
alterations in the fetal/neonatal DS brain and in mouse models of DS during early developmental 
stages and adulthood. In particular, evidence will be summarized regarding brain gross anatomy, 
cytoarchitecture, proliferation potency, phenotype acquisition, neuron maturation, and some 
molecular mechanism that could underlie neurodevelopmental defects in DS. 
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Figure 2.4. Mouse models of Down syndrome. A: Schematic representation of HSA21 and syntenic regions 
of MMU16, MMU17, and MMU10 and different mouse models trisomic for different sets of genes orthologous 
to those of HSA21. B: Ts65Dn mouse model of Down syndrome. The Ts65Dn mouse is the most popular 
choice among DS models because it recapitulates many aspects of the human condition, including, 
cytoarchitectural abnormalities in many brain regions and deficits in learning and memory. Image on the left 
is taken from (Kuehn, 2016); image on the right was modified from 
https://www.slideshare.net/plus15campaign/dsrtf-webinar-dr-h-craig-heller-stanford-university. 
Abbreviations: HSA21, human chromosome 21; Mmu, mus musculus chromosome.
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2.8.1 Anatomy of the DS brain: humans with DS 
Individuals with DS have an overall reduced brain volume and numerous brain regions appear to be 
smaller in comparison with controls (Weis et al., 1991, Kesslak et al., 1994, Raz et al., 1995, Pinter 
et al., 2001b, Teipel and Hampel, 2006). Volume reduction is particularly prominent for the 
cerebellum and brainstem (Jernigan et al., 1993, Raz et al., 1995, Aylward et al., 1997), and for the 
hippocampus (Aylward et al., 1999). The brain hypotrophy that characterizes DS is already present 
in neonates and can be traced back to prenatal life stages (Fig. 2.5). 
GROSS ANATOMY 
Fetuses. A pioneering study in fetuses aged 15-22 weeks (Schmidt-Sidor et al., 1990) found no gross 
differences in brain shape, weight or fronto-occipital length. Neither were any differences in the 
cerebellum or hippocampus. This is in contrast with the hypotrophy found by other studies regarding 
the DS fetal brain. The absence of differences in Schmidt-Sidor’s study may be attributable to the 
fact that fetuses were not stratified by age, which, may obscure differences between DS and non-DS 
fetuses. However, the evaluation of the brain of fetuses with DS during relatively restricted time 
windows of gestation shows that fetuses with DS exhibit reduced brain weight (Guihard-Costa et al., 
2006) and volume reduction in various hippocampal structures (Guidi et al., 2008) and in the 
cerebellum (Guidi et al., 2011b). In addition to weight and volume differences, the fetal DS brain 
exhibits distinctive shape alterations. It is markedly brachycephalic due to a reduction in the length 
of the frontal lobe, with an increase in the transparietal length (Guihard-Costa et al., 2006). A 
pioneering study showed that the hippocampus of fetuses with DS is less well-formed in comparison 
with control fetuses (Sylvester, 1983). This evidence has been substantiated by a following study 
showing numerous neuroanatomical defects in the DG and hippocampus of DS fetuses (Fig. 2.5) 
(Guidi et al., 2008). A typical feature of DS fetuses is a notable reduction in the transcerebellar 
diameter (Rotmensch et al., 1997, Winter et al., 2000, Guihard-Costa et al., 2006). Moreover, the 
cerebellum has an abnormal shape, due to shorter lobes and shallower fissures (Fig. 2.5) (Guidi et al., 
2011b).  
28 
 
 
Figure 2.5. Brain hypotrophy in Down syndrome fetuses. Examples of the brain (scale bar 1 cm), 
hippocampus (scale bar 1 mm) and cerebellum (scale bar 2 mm) of a diploid (left) and a DS fetus (17–21 GW) 
(right). Images were taken from (Guidi et al., 2008, Guidi et al., 2011b, Stagni et al., 2017). Abbreviation: DS, 
Down syndrome. 
29 
Infants and children. The brains of infants and children with DS have a reduced volume in 
comparison with normal children due to a reduction in the volume of both the grey and white matter 
(Pinter et al., 2001b, Kates et al., 2002, Smigielska-Kuzia et al., 2011). In addition, save for the 
occipital lobes, all brain lobes have a reduced size (Pinter et al., 2001b, Kates et al., 2002, Smigielska-
Kuzia et al., 2011). Volume reduction is also present in the hippocampus (Pinter et al., 2001b, 
Smigielska-Kuzia et al., 2011), cerebellum (Pinter et al., 2001b) and amygdala (Smigielska-Kuzia et 
al., 2011). Pinter et al. found no difference in the volume of the superior temporal gyrus (Pinter et al., 
2001a) nor, at variance with the study by Smigielska-Kuzia et al., in the volume of the amygdala 
(Pinter et al., 2001a). The absence of differences in the volume of the amygdala may be related to the 
older age of children in Pinter’s study (11.3 vs. 6.7 years). DS children exhibit a significant reduction 
in the volume of the gray matter in the posterior lobe of the cerebellum, cingulate gyri, 
parahippocampal gyri and hippocampi, and in the volume of the white matter in the left 
posterior/anterior lobes of the cerebellum, left brainstem and frontal and parietal lobes, and sub-lobar 
region (Carducci et al., 2013). In contrast, significant preservation in the volume of gray matter is 
present in the left middle temporal lobe, the right sub-lobar region (lentiform nucleus) and in the 
parietal lobes (Carducci et al., 2013). The shape alterations present at fetal life stages are retained in 
the brain of infants and children with DS. At 3-5 months, the fronto-occipital length is shortened 
(secondary to reduction of frontal lobe growth), the occipital poles are flattened, the superior temporal 
gyri are narrower and the brain stem and cerebellum are smaller (Schmidt-Sidor et al., 1990). A study 
in children with DS from birth to five years of age reports a reduction in the fronto-occipital 
circumferences (Wisniewski, 1990).  
CYTOARCHITECTURE 
Fetuses. By 40 weeks of gestation, the cellular distribution of the layers of the visual cortex appear 
to be scarcely defined in DS fetuses in comparison with control fetuses (Becker, 1991). Lamination 
of the temporal neocortex of fetuses with DS is both delayed and disorganized (Golden and Hyman, 
1994). In the brain of fetuses with DS [Gestational Week (GW) 19.8±2.2] brain neuron density 
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appears normal (Weitzdoerfer et al., 2001), although stereological quantification of total cell number 
in the neocortex showed that fetuses with DS at GW 19 have notably fewer cells than control fetuses 
(Larsen et al., 2008). Moreover, fetuses with DS (GW 17-21) have fewer cells than controls in the 
hippocampus and parahippocampal gyrus (Guidi et al., 2008). In addition, the cellular layers of the 
cerebellum have a reduced thickness and a prominent hypocellularity (Guidi et al., 2011b). 
Infants and children. DS neonates have fewer cells in the primary visual cortex and this difference 
persists during infancy (Wisniewski, 1990). In the brain of children with DS, areas 3, 4, 17 and 41 
are characterized by architectonic abnormalities and a significant poverty of granular cells. Likewise, 
extracortical structures, such as the ventral cochlear nucleus, exhibit a greatly reduced number of 
neurons and a low cell packing density (Gandolfi et al., 1981). The reduced granule cell density 
(Baxter et al., 2000) observed in the cerebellum of fetuses with DS is retained in children. In addition 
to brain hypocellularity, children with DS exhibit remarkable abnormalities in the size of cortical 
minicolums in the superior temporal gyrus (Buxhoeveden et al., 2002), indicating gross defects in the 
architecture of the functional units of the neocortex.  
 
2.8.2 Anatomy of the DS brain: DS mouse models 
GROSS ANATOMY 
Embryonic period. There are relatively scarce data regarding brain development of DS mouse models 
at embryonic life stages. At embryonic day (E) 13.5, E14.5 and E16.5 the Ts65Dn mouse shows a 
smaller medial-lateral length of the telencephalon and a reduction in the wet brain weight at E13.5 
and E18.5 in comparison with euploid mice. Surprisingly, at E18.5 the Ts65Dn mouse recovers both 
the brain weight and the telencephalon gross size, indicating a probable early delay during brain 
growth (Chakrabarti et al., 2007). In the embryonic period E13.5-18.5, the Dp(16) model does not 
show any defect in forebrain growth. Its brain hemispheres are comparable to the euploid littermates 
along both the medial–lateral and rostro-caudal axes (Goodliffe et al., 2016). Brain development has 
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also been shown to be disrupted in Ts1Cje and Ts2Cje mice and at E14.5 their brain are smaller 
when compared with their euploid counterparts (Ishihara et al., 2010). 
Early postnatal period. Data about differences between euploid and Ts65Dn mice in brain weight in 
the early post-natal period are inconsistent. According to some studies the Ts65Dn mouse has a 
reduced brain weight at P2 (Guidi et al., 2014) and P15 (Stagni et al., 2016), but other studies do not 
reports differences at P8, P15 and P22 (Belichenko et al., 2004, Chakrabarti et al., 2007, Bianchi et 
al., 2010b). While some studies show that the Ts65Dn mouse has no volume defects in the DG of the 
hippocampus, cortex, striatum and cerebellum at P2, P6, P10 and P22 (Holtzman et al., 1996, 
Belichenko et al., 2004, Lorenzi and Reeves, 2006), other studies report differences in the volume of 
the DG at P2 and P15 (Contestabile et al., 2009) and in the size of cerebellum at P2, P6 and P14 
(Roper and Reeves, 2006, Contestabile et al., 2007). Ts1Cje mice at P12 show no reduction in brain 
weight and no modifications of overall brain volume compared with euploid mice (Ishihara et al., 
2010). 
Adolescence/adulthood. At P45 Ts65Dn mice have a reduced brain weight when compared with 
controls (Bianchi et al., 2010b). Accordingly, also the volume of the neocortex, cerebellum and 
hippocampus (DG, CA1 and CA3) is compromised at this age (Bianchi et al., 2010b, Guidi et al., 
2014). Three month-old Ts65Dn mice exhibit a reduction of the DG volume (Lorenzi and Reeves, 
2006, Stagni et al., 2015b), of cerebellar volume (Aldridge et al., 2007, Necchi et al., 2008), but a 
normal brain weight (Holtzman et al., 1996, Belichenko and Kleschevnikov, 2011, Stagni et al., 
2015b) and normal volume of the brain and of the hippocampus (Aldridge et al., 2007, Olson et al., 
2007). Ts65Dn mice aged 20-28 weeks showed a volume reduction in the CA2 field, but a normal 
volume in the other regions of the hippocampus (Insausti et al., 1998). In Ts1Rhr mice aged 3 months 
the volume of the brain but not of the cerebellum and hippocampus is reduced in comparison with 
euploid mice (Aldridge et al., 2007). Moreover, the Ts1Rhr model displays derangement in the spatial 
organization of subcortical structures (Aldridge et al., 2007). While at three months of age Ts1Rhr 
mice have a reduced volume of the cerebrum and cerebellum, at 7.5 months they have a brain weight 
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and volume of the posterior hippocampus that are larger than euploid mice (Belichenko et al., 2009). 
The Ms1Rhr mouse has a reduced volume, height, width, and length of the brain, reduced volume of 
the hippocampus at two and three months of age, but an increase in the volume of the cerebellum 
when compared to their euploid counterparts (Aldridge et al., 2007, Olson et al., 2007). At 10-16 
weeks, the Ts1Cje mouse exhibits a reduction in the cerebellar volume (Olson et al., 2004). Similarly 
to earlier life stages, at 3 month the Ts1Cje mouse has no difference in brain weight and volume 
(Hewitt et al., 2010, Ishihara et al., 2010). No differences in brain weight have been also found in 
Ts1Cje mice aged 6-6.5, 7-7.5 and 9-10 months (Belichenko et al., 2007). Likewise, the area of the 
hippocampus shows no difference between Ts1Cje mice aged 18 months and their euploid 
counterparts (Belichenko et al., 2007). Dp(16) mice aged 3 months show a reduction of cerebellum 
cross-sectional area in comparison with euploid mice (Starbuck et al., 2014). The 
Dp(16)/Dp(17)/Dp(10) mouse model at 3 months has hydrocephalus, with lateral ventricles of the 
brains abnormally dilated (Yu et al., 2010a). 
CYTOARCHITECTURE  
Embryonic period. In the period E13.5-E18.5, the Ts65Dn mouse shows a thickness reduction in the 
inner zone (IZ) and sub-plate/cortical plate (SP/CP), with no differences in the thicknesses of the 
ventricular zone (VZ) and subventricular zone (SVZ). By E18.5 to birth, all layers of the neocortical 
wall have the same dimension in Ts65Dn mice as in euploid mice (Chakrabarti et al., 2007). The 
Ts65Dn model during the embryonic period displays a reduction in the size of the pyramidal cell 
layer of the CA1 region (Chakrabarti et al., 2007). Both Ts1Cje and Ts2Cje mice exhibit a reduction 
in cortical thickness at E14.5 when compared with their euploid counterparts (Ishihara et al., 2010). 
The Dp(16) mouse, in contrast with the Ts65Dn and the Ts1Cje/Ts2Cje models, does not exhibit 
prenatal forebrain growth alterations. At E13.5–E18.5, Dp16 mice do not show differences in the 
thicknesses of the VZ/SVZ, IZ, CP, and overall thickness of neocortical and hippocampal layers 
(Goodliffe et al., 2016).  
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Early postnatal period. At P2, Ts65Dn mice exhibit a reduced cellularity in the neocortex, DG, 
hippocampus, striatum, thalamus, hypothalamus mesencephalon, and cerebellum (Contestabile et al., 
2007, Guidi et al., 2014). Hypocellularity in the DG has also been documented at P6 (Lorenzi and 
Reeves, 2006) and P15 (Bianchi et al., 2010b). At P8 and P15, Ts65Dn mice exhibit a reduction in 
the number of glutamatergic neurons in the neocortex and a concomitant increase in the number of 
inhibitory interneurons both in the neocortex and field CA1 (Chakrabarti et al., 2010). While at P0 
Ts65Dn mice exhibit a similar number of cerebellar granule cell precursors as euploid mice in the 
external granular layer of the cerebellum (Roper and Reeves, 2006), at P2 there is a reduction in cell 
density in the external granular layer, internal granular layer, and Purkinje cell layer (Roper et al., 
2006, Roper and Reeves, 2006, Contestabile et al., 2008, Guidi et al., 2014). The reduced thickness 
of the internal granular layer lasts until adulthood (Roper and Reeves, 2006). At variance with other 
brain regions, no differences were reported in either the number or size of basal forebrain cholinergic 
neurons in P2, P10 and P22 Ts65Dn and age-matched euploid mice (Holtzman et al., 1996). Dp(16) 
mice, at P15, show a reduced number of both excitatory and inhibitory neurons in the somatosensory 
cortex (Goodliffe et al., 2016). Tc1 and Ts1Rhr mice show neither abnormal distribution of neurons 
nor differences in neuron polarity and orientation over the cortex at P21 (Haas et al., 2013). 
Adolescence/adulthood. The defects in cytoarchitecture displayed by Ts65Dn pups are retained in 
adolescent mice. At P45 the Ts65Dn mouse shows reduced cell density, fewer granule neurons in the 
DG and a reduced thickness of the terminal field of the mossy fibers in the CA3 field in comparison 
with euploid mice (Bianchi et al., 2010b, Stagni et al., 2013). Accordingly, at 3 months of age, there 
is a reduction in cell density and total granule cell number in the DG of Ts65Dn mice, but no 
significant differences in cell number in the CA1 and CA3 fields were detected (Lorenzi and Reeves, 
2006, Stagni et al., 2015b). A reduction in total granule cell number has been also detected in Ts65Dn 
mice aged 20-28 weeks (Insausti et al., 1998). Recent evidence shows that that perhirinal cortex of 
P15 Ts65Dn mice exhibits a reduced cellularity. in comparison with age-matched euploid mice. The 
same defect was present in 1.5-4.5 months old Ts65Dn mice, that display a significant cellularity 
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reduction in layers V (-25%) and VI (-23%) (Roncace et al., 2017). The cerebellum exhibits a normal 
cortical layering, but a reduction in the thickness of the molecular layer and granule cell layer of the 
vermis and in the density of the granule cells and Purkinje cells (Olson et al., 2007, Necchi et al., 
2008). At 8-10 weeks, the Ts1Rhr mouse does not have a cell density reduction in both the internal 
granule cell layer and Purkinje cell layer. Ts1Rhr mice aged 7.5 months shows a greater thickness of 
the motor cortex in comparison with euploid mice (Belichenko et al., 2009). The Ms1Rhr mouse 
exhibits a higher density and number of both granule cells and Purkinje cells in comparison with 
euploid mice (Olson et al., 2007). A reduction in granule cell and Purkinje cell density was observed 
at three months of age in the Dp(16) mouse (Starbuck et al., 2014). Finally, the Ts1Cje mouse differs 
from its euploid counterpart in granule cell density, but not in Purkinje cell density (Olson et al., 
2004) and at 18 months it has a thickness of the granule cell layer and molecular layer of the DG that 
is similar to that of controls (Belichenko et al., 2007). Data focusing on subcortical structures are also 
available for adult Ts65Dn mice. It has been shown that Ts65Dn mice aged 3 months exhibit no 
differences in i) the number of cholinergic cells in the medial septum-diagonal band of Broca and 
distribution of AchE fibers in the hippocampus; ii) the shape and distribution of tyrosine hydroxylase 
positive neurons in the substantia nigra and locus coeruleus; iii) the distribution of serotonin-positive 
neurons along the midline of Raphe nuclei (Megias et al., 1997). In 5-8 month-old Ts65Dn mice there 
is a reduction in the number of BFCN in the medial septum, consistently with evidence at earlier life 
stages (Cooper et al., 2001, Contestabile et al., 2006, Ash et al., 2014, Kelley et al., 2014). Ts65Dn 
mice aged 6-8 months and 14-18 months exhibit a reduction in acetylcholine transferase 
immunoreactivity in the hippocampus in comparison with euploid mice, suggesting a reduction in the 
cholinergic innervation originated in the medial septum (Kelley et al., 2016). 
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2.8.3 Proliferation potency in DS 
2.8.3.1 Humans with DS 
Differentiation of the neural tube into an outer mantle layer and an inner proliferative zone has 
occurred by gestational week six and some neurons have already been born. At week 7 of gestation, 
the germinal matrix can be divided into a VZ and an overlying SVZ. Neurons migrate out of these 
germinal zones giving origin to the cortical plate (Chan et al., 2002). In the human forebrain, 
neocortical neurons are generated during a restricted period that begins at approximately GW 6 and 
is largely completed by GW 18 (Stiles and Jernigan, 2010). By week 24 of gestation, the size of the 
VZ and SVZ is considerably reduced and there is a marked decrease in proliferative activity (Chan et 
al., 2002). There is a more prolonged period of neurogenesis in the human DG and cerebellum in 
comparison with the other brain regions. In the DG, neurogenesis begins at approximately GW 12 
and is almost accomplished within the first postnatal year (Seress et al., 2001, Rice and Barone, 2010). 
Production of cerebellar granule cells starts at GW 12 (Abraham et al., 2011) and continues in the 
first few postnatal months (ten Donkelaar et al., 2003). The reduced cellularity in the brain of fetuses 
with DS suggests a reduction in proliferation potency starting from the earliest periods of 
neurogenesis. Due to the obvious difficulties in obtaining fetal material, very little information is 
available concerning neurogenesis in the fetal DS brain. By exploiting immunostaining for Ki-67 (a 
protein expressed during all phases of the cell cycle) evidence was obtained that in fetuses with DS 
(GW 17-23) the number of proliferating cells was notably reduced in the hippocampal DG, germinal 
zones of the hippocampus proper and parahippocampal gyrus, and in the germinal matrix of the 
inferior horn of the lateral ventricle (Contestabile et al., 2007, Guidi et al., 2008). In addition, the 
number of proliferating cells was notably reduced in the external granular layer of the cerebellum, 
and in a region of the fifth cerebellar lobe that is the remnant of the cerebellar VZ (Guidi et al., 2011b). 
A notable reduction in cell proliferation, as assessed by the cell cycle marker Ki-67 and the M-phase 
marker phospho-histone H3 (PH3) immunostaining, was also found along the VZ and SVZ of the 
frontal cortex of DS fetuses (GW 18) (Lu et al., 2012). A corresponding decline in proliferation was 
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also discovered in vitro in neurospheres generated from the frontal cortex of DS fetuses (Lu et al., 
2012). This evidence shows a widespread reduction in the number of actively dividing cells in 
numerous brain regions of fetuses with DS, clearly indicating that alterations in proliferation rate are 
present at the very beginning of the process of neurogenesis.  
 
2.8.3.2 DS Mouse models 
By exploiting DS mouse models it has been possible to better elucidate the spatio-temporal 
distribution of the proliferation defects in the trisomic brain. In mice, similarly to humans, the bulk 
of brain neurons derive from the VZ and SVZ and are generated before birth. In contrast, in the 
subgranular zone (SGZ) of the hippocampal DG, a neurogenic niche that produces neurons destined 
to the DG, the bulk of neurogenesis takes place during the first two postnatal weeks, continues in a 
relatively substantial manner until young adulthood, and thereafter decreases with age (Altman and 
Bayer, 1975, Altman and Bayer, 1990a, c). A second important postnatal neurogenic niche is the SVZ 
of the lateral ventricle that gives rise to cells (most likely astrocytes and oligodendrocites) destined 
for the neocortex in the first few postnatal days (Brazel et al., 2003) and, subsequently, gives origin 
to granule neurons destined for the olfactory bulb. In the mouse cerebellum, granule cell production 
begins at approximately E15 but continues up to the second postnatal week (Sillitoe and Joyner, 2007, 
Sudarov and Joyner, 2007). Table 4 summarizes data obtained from the literature regarding 
proliferation rate in DS mouse models at different life stages. Regarding the magnitude of the 
differences in comparison with their euploid counterparts, they are in the range from -4 to -64% 
(average 33.7) in the Ts65Dn model, -25 to -60% (average 31.8) in the Ts1Cje model, and -30 to -
51% (average 41.8) in the Ts2Cje model. 
Embryonic period. There might be different causes regarding brain development alteration during 
fetal stages, such as (i) a smaller progenitor cell population at the beginning of neuronogenesis, (ii) 
altered kinetics of neuroblast proliferation, or (iii) increased death of either progenitors or postmitotic 
neurons (discussed below). The Ts65Dn model shows an overall reduction of BrdU-positive cells in 
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the pallium during embryonic developmental stages due to delayed exit from the cell cycle 
(Chakrabarti et al., 2007). Another deficit regards a poor generation of neurons by the germinal zone 
and abnormal migration of newly generated neurons into the SP/CP (Chakrabarti et al., 2007). In 
agreement with no detectable differences in prenatal brain development, the Dp(16) model does not 
show any variations in the size of actively dividing cell population across genotypes from E13.5 to 
E18.5 in either the neocortex or the MGE (Goodliffe et al., 2016). Both Ts1Cje and Ts2Cje mice 
show an overall reduction in the number of BrdU-positive cells in the period E13.5-E14.5 throughout 
the dorsal pallium. In particular, there are fewer BrdU-positive cells in VZ, SVZ, IZ, SP and CP in 
comparison with their euploid counterparts (Ishihara et al., 2010). Furthermore, they exhibit a 
reduction in the number of Ki67-positive cells. Taken together, these findings indicate that the pool 
of neural progenitor cells is highly compromised in these models (Ishihara et al., 2010). 
Early postnatal period. In mice, the SGZ of the DG and the SVZ continue to proliferate during the 
entire lifespan (as in human beings), while in the cerebellum the production of granule neurons lasts 
from birth to the second postnatal week (Altman, 1982). At P0, the Ts65Dn mouse shows a strong 
decrease in the mitotic potency of the cerebellar granule neuron precursors (CGP) of the cerebellum 
and, at P2, it has fewer BrdU-positive cells in the EGL in comparison with euploid mice (Roper and 
Reeves, 2006, Contestabile et al., 2009, Guidi et al., 2014). This defect does not ameliorate at P6 and 
it translates into a reduction of CGP population at P30 (Roper and Reeves, 2006, Contestabile et al., 
2009). An explanation of these defects could be the elongation of the cell cycle, with the G1 and G2 
phases being those mainly impaired (Contestabile et al., 2009). At P2, the Ts65Dn mouse also shows 
fewer BrdU-positive cells in the SVZ, DG, neocortex, striatum, thalamus, hypothalamus, 
mesencephalon and pons (Contestabile et al., 2009, Guidi et al., 2014). Proliferation deficits have 
been observed at P15 in the striatum, neocortex, SVZ and DG and at P6, P15 and P30 in the DG 
(Lorenzi and Reeves, 2006, Contestabile et al., 2007, Bianchi et al., 2010a).  
Adolescence/adulthood. During pre- and early-postnatal developmental stages, the number of 
proliferating cells in the Ts65Dn model is strongly affected. This defect is retained at further life 
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stages. In particular, at P30 and P45 the Ts65Dn mouse has a reduced number of BrdU- and Ki-67-
positive cells in both SGZ of the DG and SVZ (Bianchi et al., 2010b, Chakrabarti et al., 2011, Guidi 
et al., 2014). Defects in the number of granule cells of the DG are still present when Ts65Dn mice 
reach adulthood (Insausti et al., 1998). A region that does not have proliferation defects at P45 is the 
olfactory epithelium, were PCNA-positive cells are equal between genotypes (Bianchi et al., 2014). 
In Ts65Dn mice aged 2-3 months there is a significant decrease in the density of BrdU-positive cells 
and Ki-67-positive cells in the motor cortex, in the DG and in the SVZ, but not in the corpus callosum 
(Belichenko and Kleschevnikov, 2011, Stagni et al., 2015b). The proliferation potency and cellularity 
defects in the hippocampus and SVZ of Ts65Dn mice persist when they reach 5 months of age or 
later ages (Corrales et al., 2013, Martinez-Cue et al., 2013, Lopez-Hidalgo et al., 2016). Ts65Dn mice 
aged 14 months show a reduction in the number of BrdU-positive cells in the SVZ and rostral 
migratory stream, indicating that defects present in earlier life stages in these zones persist during the 
life span (Guidi et al., 2016). At 3 months both Ts1Cje and Ts2Cje mice show a reduction in the 
number of proliferating cells in the DG and SVZ (Ishihara et al., 2010). 
 
2.8.4 Mechanisms underlying proliferation potency impairment  
The reduced proliferation potency that characterizes DS is due to a complex interaction between 
different molecular mechanisms, in which both triplicated and non-triplicated genes are involved.  
Progression through the cell cycle is regulated by cyclin-dependent kinases (CDKs), and their 
interactions with cyclins and CDK inhibitors (CKIs). CDKs bound to their cognate cyclins drive 
transition phases of the cell cycle. Regulation of G1 is crucial for the balance between maintenance 
of the progenitor pool and generation of differentiated neurons, and inhibition of positive regulators 
of cell cycle progression enhances differentiation and reduces the size of the pool of neural 
stem/progenitor cells (Hindley and Philpott, 2012). The activity of D-type cyclins is necessary for 
progression through the G1 phase of the cell cycle. In the Ts65Dn mouse model of DS neural 
progenitor cells of the embryonic VZ of the lateral ventricle and hippocampus exhibit an elongation 
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of the S-phase as well as total length of the cell cycle (Chakrabarti et al., 2007). In the cerebellum of 
neonate Ts65Dn mice, granule cell precursors exhibit cell cycle elongation due to an increase in the 
length of the G1 and G2 phases of the cell cycle (Contestabile et al., 2009). This evidence in a DS 
model suggests that a reduction in the proliferation rate may be one of the determinants of the reduced 
proliferation potency in DS. Data obtained in the hippocampal DG and ventricular germinal matrix 
of fetuses with DS, suggests that neural progenitors exhibit an elongation of the G2 phase of the cell 
cycle cell and, possibly, an overall cell cycle elongation (Contestabile et al., 2007). Altered 
proliferation dynamics has been shown in fibroblast from DS patients (Kimura et al., 2005). More 
recently, it has been shown that DS patient-derived fibroblasts have an extended G1 duration (Chen 
et al., 2013). Elongation of the G1 obviously implies an overall increase in the duration of the cell 
cycle and, thus, a reduction in proliferation rate. It is important to observe that the G1 phase of the 
cell cycle is considered to be the critical window during which cells decide to proliferate, assume a 
reversible arrest (G0), or begin a path towards terminal differentiation or senescence. The available 
evidence suggests that the reduction in the number of cycling cells in the trisomic brain may be 
accounted for by reduction in proliferation rate (increase in the cell cycle length) as well as by a 
precocious exit from the cell cycle. Although various triplicated genes are likely to be involved in 
cell cycle alteration, the evidence reported below strongly suggests that Dual specificity tyrosine-
phosphorylation-regulated kinase 1A (DYRK1A) (Fig. 2.6A) and Amyloid precursor protein (APP) 
may play a particularly prominent role (Fig. 2.6B). 
DYRK1A. DYRK1A was proposed to be one of key candidate genes closely implicated in various DS 
phenotypes. There is evidence that triplication of DYRK1A leads to over-expression of DYRK1A in 
the brain of fetuses and adults with DS (Lockstone et al., 2007, El Hajj et al., 2016) and in DS-human 
pluripotent stem cells (iPSC)-derived NPCs (Hibaoui et al., 2014). Knocking down DYRK1A in Down 
syndrome patient-derived fibroblasts restored the impaired proliferation (Chen et al., 2013). This 
effect has been attributed to restoration of the G1 phase. This evidence strongly suggests a key role 
of DYRK1A in the regulation of proliferation and differentiation of trisomic neural progenitor cells. 
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One of the targets of DYRK1A is cyclin D1, an important cell cycle protein that promotes G1-to-S 
phase transition and is required for cell proliferation (Hindley and Philpott, 2012, Chen et al., 2013). 
DYRK1A phosphorylates cyclin D1 at Thr286 (Chen et al., 2013), causing its nuclear export, 
followed by degradation by an ubiquitin-dependent mechanism (Soppa et al., 2014). There is 
evidence that DYRK1A increases G1 duration in a dose-dependent manner reducing cyclin D1 levels 
(Chen et al., 2013). Consistently with DYRK1A over-expression in DS, cyclin D1 levels are reduced 
in the frontal lobe of fetuses with DS (Bernert et al., 1996) and in fibroblasts of DS patients (Chen et 
al., 2013). This evidence suggests that DYRK1A/Cyclin D1 may be one of the mechanism underlying 
the reduced proliferation potency of the DS. Alteration of DYRK1A and cyclin D1 expression similar 
to those found in humans have also been observed in the Ts65Dn mouse. Embryonic cortical stem 
cells in the dorsal VZ of Ts65Dn embryos contains 1.5-fold more DYRK1A protein than euploid 
embryos and have reduced cyclin D1 levels with a consequent lengthening of the G1 cell cycle phase 
and a reduction in the number of divisions producing neurons (Najas et al., 2015). The resulting deficit 
in cortical neurons persists at postnatal life stages. Genetic normalization of Dyrk1a dosage in the 
Ts65Dn embryos restores cyclin D1 to normal levels and this effect is accompanied by a restoration 
of the number of cortical neurons at postnatal life stages (Najas et al., 2015). This evidence suggests 
that DYRK1A-mediated degradation of cyclin D1 may underlie the reduction of progenitor 
neurogenic potential. It has been shown that NPCs from Ts65Dn mice exhibit a premature neuronal 
differentiation that is prevented by normalization of DYRK1A activity with harmine (Mazur-Kolecka 
et al., 2012), suggesting that DYRK1A over-expression in DS leads to premature neuronal 
differentiation. In addition to reduce nuclear levels of Cyclin D1, over-expression of DYRK1A has 
been shown to increase the transcriptional levels of the antiproliferative cyclin-dependent kinase 
inhibitor p27KIP1 (CDKN1B) (Hammerle et al., 2011) and also its stability by phosphorylating it on 
Ser10 (Soppa et al., 2014). It is well-established that DYRK1A phosphorylates p53 and that 
DYRK1A-induced p53 phosphorylation leads to induction of p53 target genes and impaired G1/G0-
S phase transition, resulting in attenuated proliferation. p21CIP1, also known as cyclin-dependent 
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kinase inhibitor 1, represents a major target of p53 that promotes its transcription (Park et al., 2010). 
Accordingly, brains from embryonic Dyrk1a transgenic mice exhibit elevated levels of DYRK1A, 
phosphorylated p53, and p21CIP1 as well as impaired neuronal proliferation (Park et al., 2010). 
Increased levels of DYRK1A, p53 and p21CIP1 have been observed in the frontal cortex of fetuses and 
adults with DS (Park et al., 2010). Excessive p21CIP1 levels have also been found in the hippocampus 
of young Ts65Dn mice (Stagni et al., 2015b). This evidence strongly suggests that DYRK1A may 
also hamper proliferation by increasing p21CIP1 levels. 
APP. APP is one of the triplicated gene that is thought to play a key role in neurodevelopmental 
alterations in DS and to underlie development of Alzheimer’s-like pathology in adults with DS. 
Although in whole brain homogenates of fetuses with DS no significant differences in APP levels 
have been detected (Ferrando-Miguel et al., 2003), we found increased levels of APP protein in 
homogenates from the basal ganglia of fetuses with DS (Guidi et al., 2017). Moreover, increased APP 
levels have been detected in brains of fetuses with DS at the protein level (Tanzi et al., 1987). 
Consistently with increased APP expression, increased levels of APP carboxy-terminal fragments 
have been found in the brain of fetuses with DS (Russo et al., 2001). In addition, increased APP levels 
have been detected in cultures of cortical neurons from fetuses with DS (Busciglio et al., 2002). 
Consistently with evidence in DS brain tissue, increased levels of APP and of its derivatives were 
found in NPCs from SVZ of P2 Ts65Dn mice and cerebellar samples form P2 mice (Contestabile and 
Ciani, 2008, Trazzi et al., 2011, Trazzi et al., 2013). Over-expression of APP in HEK293 cells has 
been shown to inhibit cell proliferation. Consistently with this observation, gene expression profiling 
of HEK 293 cells overexpressing APP reveals an alteration of a set of genes involved in G1/S 
checkpoint regulation, cell proliferation and p53 signaling. This evidence, in conjunction with the 
higher expression levels of APP starting from the earliest phases of brain development, suggests that 
this gene may play a prominent role in neurogenesis alterations in DS. Processing of APP gives origin 
to various derivatives including AICD (amyloid precursor protein intracellular domain). Excessive 
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AICD levels appear to affect cell proliferation by interacting with glycogen synthase kinase 3-β 
(GSK3β) signaling and the Sonic Hedgehog (SHH) signaling pathway. 
GSK3β is a constitutively active kinase that is inhibited by an increase in its phosphorylation (on 
ser9). Increased activity of its dephosphorylated form causes adverse effects, such as a reduction in 
neurogenesis and impairment of synapse development (Eldar-Finkelman and Martinez, 2011, Kim 
and Snider, 2011), and altered GSK3β activity appears to be involved in neurodegenerative and 
neurological disturbances (Eldar-Finkelman and Martinez, 2011). Reduced phosphorylation levels 
(on ser9) of GSK3β has been found in NPCs from Ts65Dn mice (Trazzi et al., 2014) and in the 
hippocampal DG and VZ of the hippocampus of fetuses with DS (Trazzi et al., 2014). More recently, 
a reduction in pSer9 of GSK3β have been observed in hippocampal homogenates of Ts65Dn mice 
aged 3 and 7 months (Kazim et al., 2017). The latter evidence suggests that early alterations in GSK3β 
activity may significantly contribute to impair proliferation of NPCs during brain development. 
Compelling evidence suggests that excessive levels of AICD prevent GSK3β phosphorylation (on 
ser9) thereby increasing its activity (Trazzi et al., 2014). Recent evidence shows that GSK3β 
phosphorylates cyclin D1 at Thr286 (Takahashi-Yanaga and Sasaguri, 2008). Therefore, the 
increased activity of GSK3β in trisomic cells may increase the phosphorylation of cyclin D1 and its 
nuclear export and degradation. GSK3β regulates the WNT/beta-catenin signaling pathway. 
Increased GSK3β activity increases beta-catenin phosphorylation and retains it in the cytoplasmic 
compartment, favoring ubiquitin-proteasome system beta-catenin degradation. On the contrary, non-
phosphorylated beta-catenin escapes degradation, and translocates into the nucleus where it induces 
the expression of downstream target genes including cyclin Dl. In trisomic cells, increased activity 
of GSK3β reduces beta-catenin nuclear translocation and, consequently, the expression of cyclin D1 
(Takahashi-Yanaga and Sasaguri, 2008). The fact that GSK3β regulates the levels of cyclin D1 in 
two different manners suggests that this kinase may play a prominent role in deregulation of cell 
proliferation in DS. AICD, in addition to interacting with GSK3β, increases the transcription of the 
Patched 1 (PTCH1) protein in trisomic NPCs (Trazzi et al., 2011). PTCH1 is an SHH receptor that 
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keeps the mitogenic SHH pathway repressed by inhibiting the 7-pass transmembrane protein 
Smoothened (SMO), thereby hampering proliferation. Consistently with the increased APP/AICD 
levels, PTCH1 is overexpressed in fetuses with DS and in the Ts65Dn mouse model (Trazzi et al., 
2011), indicating that this deregulation is likely to play an important role in neurogenesis alterations 
in DS. Consistently with this idea, restoration of PTCH1 levels restores the proliferation defects of 
trisomic NPCs (Trazzi et al., 2011). There is evidence that activation of the SHH pathway induces 
sustained activity of the G1 cyclin-Rb axis by enhancing the expression of cyclin D1, cyclin D2, and 
cyclin E (Kenney and Rowitch, 2000). This suggests that increased PTCH1 levels in trisomic cells 
may hamper cell cycle progression by reducing the expression of cyclin D1 (and cyclin D2, cyclin 
E). Thus, increased AICD levels hamper the activity of the SHH pathway at two different levels: 1) 
because they increase PTCH1 expression and 2) because they increase GSK3 activity which, in turn, 
contributes to hamper translocation of the effectors of the SHH pathway to the nucleus.  
GSK3β signaling activates the β-site APP cleaving enzyme 1 (BACE1) gene expression, resulting in 
enhanced β-secretase processing of APP and Aβ production (Ly et al., 2013). Since Aβ derives from 
the cleavage of the APP beta-carboxyterminal fragment that is composed by Aβ plus AICD, the 
observed increase in Aβ should be paralleled by an increase in AICD levels. This evidence suggests 
that overactivity of GSK3β in DS may potentiate the production of AICD and the detrimental effects 
described above. It is of interest to observe that DYRK1A-mediated APP phosphorylation at the 
Thr668 residue enhances the formation of Aβ (Park et al., 2007) suggesting enhanced formation of 
AICD may also be mediated by DYRK1A over-expression.  
Evidence in Ts65Dn mice showed reduction in cyclin B1 and SKP2 levels and a larger number of 
dividing cells in the G2 phase and a prolonged G2 phase (Contestabile et al., 2009). Cyclin B1 is the 
regulatory subunit of CDK1, the key controller of mitosis entry (Takizawa and Morgan, 2000). 
Hence, downregulation of cyclin B1 is expected to induce a lengthening of the G2 phase. In addition, 
the cytoplasmic/nuclear subcellular localization of cyclin B1 has been shown to be regulated by the 
SHH pathway. Indeed, PTCH1 interacts with cyclin B1 and hampers its nuclear transfer 
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Figure 2.6. Mechanisms underlying impairment of proliferation potency in DS. The mechanisms whereby 
overexpression of the triplicated genes DYRK1A (A), APP (B) impair proliferation of NPCs in DS are 
schematically illustrated [modified from (Stagni et al., 2017)]. Abbreviation: nuc, nuclear. 
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(Barnes et al., 2001), indicating that PTCH1 also participates in the regulation of G2/M checkpoint 
(Adolphe et al., 2006). 
 
2.8.5 Phenotype acquisition 
2.8.5.1 Humans with DS 
Various studies show that the reduced proliferation potency of the trisomic brain is worsened by 
reduction in the acquisition of a neuronal phenotype accompanied by an increase in the acquisition 
of an astrocytic phenotype. This defect is already present during the earliest phases of neurogenesis 
because quantification of the number of mature neurons (NeuN-positive cells) and astrocytes (GFAP-
positive cells) in the hippocampal and parahippocampal region showed that in all these regions fetuses 
with DS have proportionally fewer neurons and a larger number of astrocytes compared with normal 
fetuses (Guidi et al., 2008). Consistently with this evidence, in neonates with DS the interlaminar 
glial palisade, composed by astroglial cells, appears to be altered by the first year of age (Colombo et 
al., 2005). Astrocytic hypertrophy and an increase in astrocyte number are present in the fetal DS 
brain and this defect is retained in adulthood (Mito and Becker, 1993, Griffin et al., 1998). Likewise, 
quantification of cells immunopositive for the astrocytic markers S100β and GFAP showed that 
children with DS have a notably larger number of astrocytes then controls in the hippocampus and 
frontal and occipital lobes (Becker, 1991). Results obtained in fetal tissue were confirmed in cortical 
neuronal cultures derived from fetuses with DS or from fibroblast-derived iPSCs from patients with 
DS. Human DS iPSC lines generated from second trimester amniotic fluid exhibit a reduction in the 
acquisition of a neuronal phenotype (Lu et al., 2013). Cell cultures derived from the cortex of fetuses 
with DS exhibit a reduced number of cells that differentiate into neurons (β III-Tubulin-positive cells; 
7%) in comparison with control cultures (56%). Moreover, DS neurons exhibit a notable reduction in 
neurite length (Bahn et al., 2002). This study, however, did not show a difference between euploid 
and DS cultures in the number of cells differentiated into astrocytes (GFAP-positive cells) (Bahn et 
al., 2002). iPSC-derived NPCs from DS patients maintained under spontaneous differentiation 
46 
condition were shown to give rise to fewer neurons (β III-Tubulin-positive cells) and more astrocytes 
(S100β-positive cells) (19.7±0.9% and 78.2±0.7%, respectively) in comparison with control cultures 
(33.4±2.0% and 60.9±2.0%, respectively) (Chen et al., 2014). In addition, DS neurons generated 
under spontaneous differentiation conditions exhibited decreased neurite length compared with 
control neurons. iPSCs derived from monozygotic twins discordant for trisomy 21 show that DS 
iPSCs exhibit an abnormal neural differentiation. In particular, DS-cells exhibit decreased expression 
of neuronal markers (β III-Tubulin and MAP2) and an increase in astrocytic markers (GFAP, 
VIMENTIN, S100β, OLIG1 and OLIG2) consistent with a shift from neuronal to astroglial and 
oligodendroglial phenotypes (Hibaoui et al., 2014). Moreover, neurons derived from Twin-DS-iPSCs 
exhibited a reduced number and length of neuritis. 
 
2.8.5.2 DS mouse models 
DS mouse models show abnormalities in phenotype acquisition similar to those found in individuals 
with DS. A reduction in the number of cells differentiated into neurons and an increase in number of 
cells with an astrocytic phenotype has been found in cultures of NPCs from the SVZ of neonate 
Ts65Dn mice (Trazzi et al., 2011, Trazzi et al., 2013). Likewise, in the DG and cerebellum of young 
adult Ts65Dn mice the total number of new cells with a neuronal phenotype is significantly reduced 
and the number of new cells with an astrocytic phenotype is larger than in euploid mice (Contestabile 
et al., 2007, Contestabile et al., 2009, Bianchi et al., 2010b, Ishihara et al., 2010, Chakrabarti et al., 
2011, Guidi et al., 2014). Although in absolute terms Ts65Dn mice may have a similar number of 
astrocytes as euploid mice, they have a higher ratio of astrocytes over total cell number due to their 
reduced number of new neurons (Guidi et al., 2014). Consistently with the enhancement in astrocytic 
phenotype acquisition, a higher number of astrocytes has been found in the hippocampus of Ts65Dn 
mice in comparison with euploid mice, although the difference did not reach significance (Holtzman 
et al., 1996, Guidi et al., 2014). In contrast to this evidence, a recent study shows that 4 month-old 
Ts65Dn mice have a lower percentage of BrdU/GFAP-positive cell in the DG in comparison with 
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euploid nice (Lopez-Hidalgo et al., 2016). Four- to five month-old Ts65Dn mice display higher 
density of total inhibitory neurons in the somatosensory cortex than in their euploid littermates, and, 
in particular of Calretinin-positive cells (Perez-Cremades et al., 2010). Cultures of NPCs from the 
SVZ of Ts1Cje mice exhibit a reduction in the number of cells differentiated into neurons and an 
increase in new astrocytes with no differences in the number of new oligodendrocytes (Moldrich et 
al., 2009, Hewitt et al., 2010, Kurabayashi et al., 2015). Impairment of neuronogenesis has been also 
found in the SVZ and DG of Ts1Cje mice aged 3 months (Ishihara et al., 2010). Much less information 
is available regarding the olygodendrocytic lineage in DS. Regarding the acquisition of an 
oligodendrocytic phenotype, the available evidence suggests no patent alterations in this process. 
Unlike NPCs, which are reduced in number in Ts65Dn mice, the number of oligodendrocyte 
precursor cells (OLIG2+NG2-positive cells) in P7-P60 Ts65Dn mice is similar to that of euploid mice 
(Olmos-Serrano et al., 2016). Moreover, an analysis of oligodendrocyte precursor cells isolated from 
the cortex of P7 mice showed no differences between euploid and trisomic cultures. However, cell 
culture experiments show that Ts65Dn oligodendrocytes exhibit cell-autonomous impairment in 
oligodendrocyte maturation and viability (Olmos-Serrano et al., 2016). This difference is consistent 
with the reduced myelination observed in fetuses and children with DS (Wisniewski and Schmidt-
Sidor, 1989, Becker, 1991, Abraham et al., 2011) and in the Ts65Dn mouse model (Meraviglia et al., 
2016, Olmos-Serrano et al., 2016).  
 
2.8.6 Mechanisms underlying impairment of phenotype acquisition 
As described above, acquisition of a neuronal phenotype is impaired in DS, and trisomic NPCs exhibit 
a shift towards the acquisition of an astrocytic phenotype. The Janus kinase-signal transducer and 
activator of transcription JAK-STAT pathway is one of the most crucial pathway for the 
astrogliogenic differentiation machinery in neural progenitor cells (Bonni et al., 1997). Ligands as 
interleukins and interferons (IFNs) family bind to their corresponding receptors. Binding to these 
receptors activates JAKs, which can activate the transcription factors STATs. STATs migrate from 
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the cytoplasm to the nucleus to bind the promoters of target genes and initiate transcription. Among 
STATs transcription factors, STAT3 specifies glial cell fate by transcriptional activation of astrocytic 
genes, such as GFAP and S100β. The increase in the acquisition of an astrocytic phenotype in the DS 
brain may be attributable to over-expression of ligands and receptors that activate the JAK-STAT 
signaling pathway. In this connection, it is important to note that on HSA21 there are several genes 
encoding receptors both for interferons (IFNAR1, IFNAR2, IFNGR2) and IL10RB and therefore 
responsible for activating JAK-STAT signaling cascades (Fig. 2.7). Consistently with triplication of 
these genes, a significant increase of IFNAR2 proteins has been found in the cerebral cortex of DS 
fetuses at 19–21 weeks of gestational age (Ferrando-Miguel et al., 2003). In addition, over-expression 
of the triplicated genes Ifnar1, Ifnar2, and Il10rb has been found at the RNA level in the brain of 
neonate Ts1Cje mice (Amano et al., 2004). The fact that IFNR genes are triplicated and upregulated 
in DS individuals and DS mouse models may predispose the DS brain to greater IFNs sensitivity. 
Interestingly, serum levels of IL-6 are increased in DS children (Corsi et al., 2006), which is consistent 
with the hypothesis of overactivation of the JAK-STAT signaling cascade in DS. Taken together, 
these data suggest that overstimulation of the JAK-STAT signaling pathway due to over-expression 
of IFNRs starting from early phases of brain development may promote neural progenitor cell fate 
toward astrogliogenic pathways in the DS brain. Overstimulation of JAK-STAT signaling pathway 
can also be linked to over-expression of two other triplicated genes, APP and DYRK1A. There is 
evidence that soluble secreted APP (sAPP) enhances the activity of the JAK-STAT signaling cascade, 
suggesting that increased levels of sAPP may enhance the process of astrogliognesis in DS (Trazzi et 
al., 2013). Indeed, NPCs from Ts65Dn mice exhibit enhanced expression of JAK1 and GFAP that is 
restored by treatment with an antibody that recognizes the N-terminal region of APP (sAPP). In line 
with data obtained in trisomic NPC cultures, upregulation of JAK1 and STAT3 has been detected in 
the hippocampus of neonate Ts65Dn mice. Taken together these results strongly suggest that in 
trisomic NPCs high levels of sAPP may activate the JAK/STAT signaling pathway, thus promoting 
the expression of GFAP (Fig. 2.7).   
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As mentioned above, increased levels of the APP-derived peptide AICD enhances Ptch1 expression, 
which keeps the SHH pathway repressed. Consequently, in trisomic NPCs the levels of Gli1 and Gli2 
transcription factors, the mediators of SHH signaling, are down regulated. Gli2 induces 
neuronogenesis in neuronal stem cells by positively regulating the expression of neurogenic basic 
helix-loop-helix genes, such as Mash1. Mash1 was found to be downregulated in trisomic NPCs and 
restoration of the activity of the SHH pathway restored its levels (Trazzi et al., 2013). Thus, the 
triplicated APP may account for enhancement of astrogliogenesis, through the JAK-STAT signaling 
cascade, and reduction of neurogenesis, through the APP/AICD system (Fig. 2.7).  
Over-expression of DYRK1A in wild-type cortical progenitors increases STAT3 phosphorylation at 
Ser(727) (Fig. 2.7), a regulatory site that enhances the transcriptional activity of STAT3 (Kurabayashi 
et al., 2015), suggesting that the increased propensity of Ts1Cje neocortical progenitors to 
differentiate into astrocytes may be due to increased dosage of DYRK1A. Indeed, in Ts1Cje cortical 
progenitors STAT3 Ser(727) phosphorylation and STAT activity are elevated in a DYRK1A-
dependent manner and reducing DYRK1A level attenuates deregulation of STAT (Kurabayashi et 
al., 2015). These findings strongly suggest that DYRK1A-dependent potentiation of STAT signaling 
pathway may contribute to the aberrant astrogliogenesis in DS. Consistently with this idea, targeting 
DYRK1A pharmacologically or by shRNA in iPSCs derived from monozygotic twins discordant for 
trisomy 21 resulted in a considerable correction in the acquisition of a neuronal phenotype in Twin-
DS-iPSCs (Hibaoui et al., 2014).   
 
2.8.7 Dendritic hypotrophy  
Dendritic pathology is a typical feature of the DS brain and appears to correlate to some extent with 
the cognitive profile. 
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Figure 2.7. Mechanisms underlying impairment of phenotype acquisition in DS. Overexpression of the 
indicated triplicated genes enhances the activity of the JAK-STAT pathway which leads to increased 
expression of GFAP and S100β and, consequently, to the enhancement of astrogliogenesis [image modified 
from (Stagni et al., 2017)]. 
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2.8.7.1 Humans with DS 
Dendrites. It has been argued that DS persons start their lives with an apparently normal neuronal 
architecture that progressively degenerates. Thus, normal or even increased branching in the DS fetus 
and newborn contrasts with dendritic hypotrophy in older children with DS. Becker et al. showed that 
dendritic branching and length in both apical and basilar dendrites were greater in infants with DS 
younger than 6 months than in normal infants (Becker et al., 1986). During the peak period of 
dendritic growth and differentiation, quantitative analysis of dendrites showed no significant 
differences in dendritic differentiation of pyramidal neurons of prefrontal cortex of the brains of 2.5-
month-old DS infants (Vuksic et al., 2002). In contrast, the pyramidal neurons of the visual cortex of 
newborns older than 4 months have shorter basilar dendrites (Takashima et al., 1981). Subsequent to 
2.5-month of age, children with DS exhibit a steady decrease in dendritic length, especially in apical 
dendrites. Dendritic hypotrophy is also present in pyramidal neurons of the parietal cortex of children 
with DS (Schulz and Scholz, 1992). The dendritic hypotrophy seen in childhood continues into 
adulthood, with a marked decrease in dendritic branching and dendritic length in elderly adults with 
DS (Takashima et al., 1989). This evidence shows that in DS brains the dendritic tree begins to be 
atrophic in early infancy without a recovery at subsequent life stages. In agreement with the 
deteriorated dendritic development, down-regulation of various proteins forming neuron 
cytoscheleton or associated with the endoplasmic reticulum takes place in the DS brain. All these 
changes may be involved in the deteriorated neuritic outgrowth and arborization of DS neurons.  
Spines. Spine counts (basilar dendrites) in the visual cortex of fetuses with DS are similar to those of 
control fetuses. After birth, infants with DS have a reduced number of spines, that show also an altered 
morphology (Takashima et al., 1981). While in normal subjects, spine density on the basal dendrites 
of cortical pyramidal neurons increases until 15 years of age and gradually decrease after 20 years, in 
subjects with DS spine density poorly increases in children and rapidly decreases in adults (Suetsugu 
and Mehraein, 1980, Takashima et al., 1989). A reduced spine density has been found in the apical 
dendrites of pyramidal neurons of the hippocampus and cingulate cortex and in both the apical and 
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basilar dendritic arbors of CA1 and CA2-3 pyramidal neurons in patients with DS when compared to 
age-matched controls (Suetsugu and Mehraein, 1980, Takashima et al., 1989). The dendritic spines 
of the DS brain exhibit also aberrant morphology. Indeed, starting from infancy, spines are small, 
have short stalks and are intermingled with unusually long spines (Marin-Padilla, 1976). Drebrin A, 
a neuron-specific F-actin binding proteins, regulates dendritic spine morphology, size and density, 
and is manifold decreased in brains of fetuses and adults with DS (Shim and Lubec, 2002). Over-
expression of drebrin A favors excitation in mature hippocampal neurons (Ivanov et al., 2009). Since 
drebrin expression is reduced in DS individuals (Shim and Lubec, 2002), a reduced excitatory-
inhibitory ratio is expected in DS individuals.  
 
2.8.7.2 Mouse models of DS 
Dendrites. Similarly to humans, mouse models of DS exhibit defects in their dendritic arborisation. 
In Ts65Dn mice aged 45 days, the granule cells of the DG show a reduction in total dendritic length, 
branch number and mean length of each branch (Guidi et al., 2013, Guidi et al., 2014). These defects 
are still present when mice become young adults (3 months of age) or aged adults (13-17 months of 
age) (Velazquez et al., 2013, Dang et al., 2014, Stagni et al., 2015b). Defects in the dendritic pattern 
were also found in neocortical pyramidal cells of Ts65Dn mice aged 10 weeks (Benavides-Piccione 
et al., 2004). In the brain of neonate Ts65Dn mice the levels of MAP2, an early marker of the 
dendrites, are significantly increased compared to littermate controls (Pollonini et al., 2008). The 
levels of MAP2 in hippocampal extracts of adult (4 months) Ts65Dn mice are similar to those of 
littermate controls, while in middle-aged (9-15 months old) Ts65Dn mice hippocampal MAP2 levels 
undergo a decrease vs. controls (Granholm et al., 2003), suggesting an age-related dendritic 
deterioration.  
Spines. In Ts65Dn mice the basal dendrites of neocortical pyramidal cells exhibit a reduced spine 
density (Dierssen et al., 2003). A spine density reduction is also present in the granule cells of the 
DG, accompanied by a reorganization of inhibitory inputs, with a relative decrease in inputs to the 
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dendritic shafts and an increase in inputs to the necks of spines (Belichenko et al., 2004, Popov et al., 
2011, Stagni et al., 2013). The thorny excrescences of CA3 pyramidal neurons (the site of termination 
of the axons of the granule cells) also exhibit a large decrease in the number of thorns (Popov et al., 
2011, Stagni et al., 2013). The spines of Ts65Dn mice not only exhibit a density reduction, but also 
show an aberrant morphology. Indeed, the spines of young (21 days) and adult Ts65Dn mice have a 
larger volume in comparison with euploid mice in the DG, field CA1, motor, somatosensory and 
entorhinal cortices, and medial septum (Belichenko et al., 2004). Defects in spine density and spine 
shape, with a reorganization of inhibitory inputs were also detected in the granule cells of Ts1Cje 
and Ts2Cje mice, although these changes are less severe than in Ts65Dn mice (Villar et al., 2005, 
Belichenko et al., 2007). Similarly to other mouse models, the granule cells of Ts1Rhr mice exhibit 
a reduced spine density and a significant increase in the size of spine heads. In contrast, spine density 
is not reduced in pyramidal neurons of the motor cortex (Belichenko et al., 2009).  
 
2.8.8 Synaptic density, excitatory vs. inhibitory synapses, and synaptic proteins  
2.8.8.1 Humans with DS 
The synapses of the DS brain exhibit various alterations in the expression of synaptic proteins. 
Synapsin I (a pre-synaptic protein which binds synaptic vesicles to the cytoskeleton and regulates 
synaptic vesicle release) is expressed at lower levels in neurospheres from human embryonic tissue 
(Bahn et al., 2002). Since this protein plays a role in the regulation of transmitter release, its down 
regulation may compromise synaptic function. Synaptojanin, a synaptic protein thought to be 
involved in clathrin mediated synaptic vesicle endocytosis, is mapped on HSA21q22.2. Consistent 
with HSA21 triplication, excessive expression of synaptojanin has been demonstrated in the cerebrum 
of individuals with DS from fetal life stages to adulthood (Arai et al., 2002). In addition to changes 
in the expression of synaptic proteins, synapses of individuals with DS show abnormalities in synaptic 
length and contact zones (Wisniewski, 1990).  
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2.8.8.2 Mouse models of DS 
The synaptic density and the synapse-to-neuron ratio are reduced in the DG and hippocampal fields 
CA3 and CA1 of adult Ts65Dn mice (Kurt et al., 2004), with a reduced ratio that is specific for 
asymmetric synapses (presumably excitatory), while symmetric synapses (presumably inhibitory) are 
unchanged. In aged Ts65Dn mice, the temporal cortex has a lower number (30%) of asymmetric 
synapses while the number of symmetric synapses is not different vs. controls ((Kurt et al., 2000). 
The reduced number of excitatory synapses in Ts65Dn mice seems in agreement with the reduced 
levels of excitatory aminoacids found in the parahippocampal gyrus of patients with DS (Risser et 
al., 1997). The increase in the number of GABAergic interneurons found in the primary 
somatosensory cortex of 4-5 month old Ts65Dn mice (Perez-Cremades et al., 2010) suggests that in 
some brain regions excessive inhibition may be due to an absolute increase in the number of inhibitory 
synapses. In the brains of neonate Ts65Dn mice, the levels of synaptophysin, synapsin, spinophilin 
(a scaffold protein that is involved in spine morphology and density regulation) are similar to those 
of littermate controls (Pollonini et al., 2008). In the neocortex and hippocampal field CA1 of Ts65Dn 
mice a reduction in synaptic density has been detected as early as P8 (Chakrabarti et al., 2007). 
Ts65Dn mice aged 45 days or 3 months had fewer SYN and PSD-95 immunoreactive puncta in the 
DG, field CA3 and neocortex, suggesting a reduced number of presynaptic and postsynaptic terminals 
(Fernandez et al., 2009). Moreover, no differences were detected in the levels of other presynaptic 
proteins, such as synapsin, synaptotagmin (a putative calcium sensor in the presynaptic terminal) and 
synaptophysin (Fernandez et al., 2009). In the somatosensory cortex of 4-5 month-old Ts65Dn mice, 
there is an increment of synaptophysin vs. euploid littermates (Perez-Cremades et al., 2010). In the 
hippocampus of adult (4 months) Ts65Dn mice, whereas synapsin, spinophilin and gephyrin are 
expressed at levels similar to those of controls, the expression levels of synaptophysin are 
significantly decreased (Pollonini et al., 2008).  
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2.8.9 Trisomic genes and dendritic/synaptic alterations  
The study of the mechanisms implicated in the regulation of neuronal morphology during 
development and maintenance of the adult CNS is object of intense research. 
It has been reported that DYRK1A not only influences neurogenesis but also dendritic development 
(Yang et al., 2001, Hammerle et al., 2003). DYRK1A regulates development of the dendritic trees of 
neurons and modulates the activity of the c-AMP response element-binding protein (CREB), which 
participates in signal transduction pathways involved in synaptic plasticity and neuronal 
differentiation. Moreover, DYRK1A may modulate dendritic development by regulating vesicle 
trafficking that is dependent on dynamin1 (Hammerle et al., 2003), a GTPase putative substrate of 
DYRK1A that plays a fundamental role in neurite outgrowth (Chan et al., 2002). Interestingly, mice 
with one functional copy of Dyrk1a (Dyrk1a+/- mutants) display a brain size 30% smaller than that of 
wild-type mice, considerably smaller and less branched cortical pyramidal cells and behavioral 
defects (Benavides-Piccione et al., 2004). In humans, DYRK1A has been proposed to be associated 
with microcephaly and mental retardation, given its localization to the minimal overlapping region 
observed in patients with partial monosomy 21 (Moller et al., 2008). Transgenic mice over-expressing 
Dyrk1a exhibit altered synaptic plasticity associated to learning and memory defects (Ahn et al., 
2006). The studies in humans and animal models that are monoallelic or triallelic for 
DYRK1A/Dyrk1a, indicate that this gene is important in neural plasticity and necessary for the normal 
size and development of the brain in a dosage-sensitive way. 
Neurotrophins are a small family of soluble factors that include nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF) and neurotrophin 3 and 4 (NT3 and NT4). There are two types 
of neurotrophin receptors, the tropomyosin-related kinase receptors (TRKs) and the p75 neurotrophin 
receptor (p75) [see (Gonzalez et al., 2016)]. By specifically binding to tropomyosin-related kinase 
receptor B (TRKB), BDNF plays a key role in brain plasticity (Haniu et al., 1997), such as axonal 
and dendritic growth, membrane trafficking and fusion, and synapse formation, function, and 
plasticity. BDNF and its receptor TRKB represent the most widely expressed and studied 
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neurotrophin signaling pathway in the brain, and their participation in learning and memory is well-
established (Minichiello, 2009). Upon BDNF binding, the TRKB receptor dimerizes and undergoes 
autophosphorylation in specific tyrosines of the intracellular domain. Activation of TRKs leads to the 
activation of different molecular pathways, such as mitogen-activated protein kinases (MAPKs), 
phosphatidylinositol-3-kinase (PI3K)-AKT, phospholipase-C (PLC)-g-Ca2+, cyclic AMP 
(cAMP)/PKA, and the small GTPases of the Rho family Cdc42/Rac/RhoA [see (Gonzalez et al., 
2016)]. In the plasma membrane, activated TRKB can be translocated into lipid rafts after BDNF 
stimulation, a step that may be required to induce dendritic branching and spine formation in cortical 
neurons (Suzuki et al., 2004). These lipid domains are the sites where the Ca2+/calmodulin-dependent 
protein kinase CLICK-III plays a critical role in BDNF-induced dendritogenesis [see (Gonzalez et 
al., 2016)]. As mentioned above, the signaling pathways that regulate dendritic branching and spine 
formation via BDNF/TRKB include the activation of the PI3K/AKT and ERK1/2 signaling pathways 
as well as the activation of local protein translation by the mTOR kinase and activation of the Rho 
GTPase family protein to regulate the actin cytoskeleton [see (Gonzalez et al., 2016)]. Several lines 
of evidence suggest that BDNF increases the local translation of a subset of mRNAs in dendrites, 
including proteins related to CNS plasticity. In addition, CREB is required for BDNF-induced 
dendritic branching and dendritic spines plasticity of hippocampal neurons (Kwon et al., 2011). 
Finsterwald and colleagues demonstrated that the BDNF-induced increase in dendritic length and 
branching of cultured cortical neurons depends on the activation of the ERK pathway and 
phosphorylation of CREB at serine-133 (Finsterwald et al., 2010). In the DS brain, BDNF levels are 
already reduced at fetal life stages (Guedj et al., 2009, Toiber et al., 2010) and reduced BDNF levels 
have been shown in various brain regions of the Ts65Dn mouse (Bimonte-Nelson et al., 2003, Bianchi 
et al., 2010a, Fukuda et al., 2010, Begenisic et al., 2015, Stagni et al., 2015b, Kazim et al., 2017, 
Villarroya et al., 2017). In view of the prominent role of the BDNF-TRKB system in dendritic 
morphogenesis, deregulation of this pathway is probably a key determinant of the alterations of 
dendritic development and spine formation in DS. 
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2.9 Behavior impairment in DS 
2.9.1 Humans with DS 
As summarized in the preceding sections, the DS brain is characterized by a constellation of 
neurodevelopmental defects. The functional consequence of these morphogenetic changes results in 
abnormal neuronal connectivity and limited processing of information. Although the precise effect of 
cyto-architectonic abnormalities on cognitive development in DS is not clear, it seems plausible that 
neuropsychological abnormalities in DS, such as impairment of attention, executive control, language 
learning, working memory, and emotional responses, may reflect dysfunction in the cerebellar–
cortical–limbic circuitry (Lott, 2012, Karmiloff-Smith et al., 2016). Although most individuals with 
DS have mild-moderate cognitive impairment [see (Hart et al., 2017)], certain cognitive domains such 
as language and memory appear to be affected disproportionately in comparison to other types of 
intellectual disability, resulting in a characteristic neurocognitive phenotype. People with DS have 
relative strengths in visuospatial processing and implicit long-term memory but more difficulty in 
working memory, episodic long-term memory, expressive language, and executive function (Liogier 
d'Ardhuy et al., 2015). Children with DS have relative strengths in social motivation and engagement, 
but they may struggle with social problem solving or decision making and higher order social 
cognition tasks [see (Hart et al., 2017)]. 
 
2.9.2 Mouse models of DS 
Behavioral analysis of different DS models may help to elucidate the contribution of different groups 
of triplicated genes to behavioral impairment. The Ts65Dn mouse, the best-characterized model for 
DS, shows significant hyperactivity in the dark and in other settings that provoke caution and lack of 
movement in normal animals, such as in open-field and plus-maze tests. In addition, the Ts65Dn 
model exhibits no deficits in sensory capabilities and coordinated behaviors such as olfactory 
sensitivity, visual abilities, orienting reactions, forelimb strength, postural skills, coordination, 
climbing, locomotion, and motor coordination and balance deficits (rotarod test). In contrast, Ts65Dn 
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mice display notably reduced levels of performance in tasks that require the integrity of the 
hippocampal system, such as spontaneous alternation (T-maze task), contextual memory (fear-
conditioning test), spatial learning, long-term memory and cognitive flexibility (Morris water maze 
test; radial arm maze test), non-spatial short- and long-term declarative memory (novel object 
recognition). Ts65Dn mice also show deficits in learning an operant conditioning paradigm [see 
(Bartesaghi et al., 2011, Rueda et al., 2012)]. This evidence indicates that in Ts65Dn mice declarative 
memory which, in rodents is delineated along spatial and recognition memory domains, is impaired, 
similarly to individuals with DS. It is important to note that, similarly to humans with DS, the Ts65Dn 
mouse show a cognitive decline with age, indicating a strong correlation with the onset of AD-like 
pathology.  
Ts1Cje mice do not show differences in spontaneous motility compared to controls. Similarly to 
Ts65Dn mice, they display poorer performance in the T-maze task and Morris water maze test 
(MWM). Ms1Ts65 mice do not show differences in spontaneous motility compared to controls. 
However, in the MWM test they exhibit impairment in learning but not memory, as assessed in the 
probe phase of the test. In a novel open field activity test, Ts1Rhr mice show no difference in 
comparison with controls. Ts1Rhr mice are significantly impaired in the T-maze task (TM) and in the 
long-term (but not short-term) memory in the NOR test but show no impairment in the MWM test 
[see (Bartesaghi et al., 2011, Rueda et al., 2012)]. Dp(16) mice show impaired performance in the 
Morris water maze and the contextual fear conditioning tests. Ts1Yah mice are impaired in the novel 
object recognition and Y-Maze (YM) test, but their performance in the MWM is enhanced. Dp(17) 
do not show alterations in the Morris water maze and in the contextual fear conditioning tests. The 
Dp(10)1Yey/+; Dp(16)1Yey/+; Dp(17)1Yey/+ mouse is impaired in the Morris water maze and in 
the contextual fear conditioning test. Finally, Tc1 mice show altered performance in the novel object 
recognition test but not in the TM [see (Bartesaghi et al., 2011, Rueda et al., 2012)].  
Taken together, these data show that impairment of memory functions is a feature shared by various 
mouse models for DS. Different models may exhibit a different degree of impairment. In this regard, 
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it is noteworthy that the Ts65Dn mouse model is presently the one that best recapitulates the human 
condition. 
 
2.10 Therapeutic approaches in DS 
The HSA21 is the smallest human chromosome. Despite the reduced dimension, its triplication means 
that over 500 genes (protein coding genes plus non-coding RNAs) are expressed in an abnormal way. 
In addition to problems deriving from triplicated genes on HSA21 themselves, it should be taken into 
account that every gene can interact with a number of other genes scattered along the genome. This 
implies that the genetic imbalance in trisomy 21 is extremely complicated, and attempts to design a 
therapeutic strategy to counteract this genetic condition may represent a real challenge. However, in 
the 16 years since HSA21 genome was sequences (Hattori et al., 2000), there has been considerable 
progress in understanding the phenotypic impact of the over-expression of some HSA21 genes. In 
addition, the development of several different mouse models of DS and the improvement in 
techniques that use iPSCs have facilitated our understanding of DS. Important advances have been 
also made in understanding the molecular basis of the early onset AD in DS, the molecular basis of 
the leukaemias that frequently occur in DS and the identification of genomic regions of HSA21 that 
harbour functional elements or causative genetic variation for certain phenotypes, such as congenital 
heart defects. Importantly, the past decade of research in the field of DS has generated a cautious 
enthusiasm for attempting to treat individuals with DS using drugs that appeared to be effective in 
DS mouse models (Antonarakis, 2017). 
 
2.10.1 Clinical trials in DS 
Clinical trials in individuals with DS were based on condition-specific aspects of neurobiology, 
neurochemistry, and neuroplasticity or connectivity within the brain (Lott, 2012, Esbensen et al., 
2017). Given the variability in the behavioral and cognitive phenotype associated with DS and the 
consequent difficulty to design a correct pharmacological approach, the National Institutes of Health 
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(NIH) has supported the development of clinical trials for DS through the Down Syndrome Research 
Plan (NICHD, 2014) and DS-Connect, a national registry to connect families with researchers 
conducting clinical trials and improve understanding of health in DS (DHHS, 2016). Between 1990 
and 2000, pre-clinical research exploiting the Ts65Dn mouse model and other translational research 
made it possible to target molecular mechanisms in the brain to address the cognitive and functional 
deficits associated with DS (Hart et al., 2017).  
 
2.10.1.1 Cholinergic system  
Acethylcoline (Ach) is a key neurotransmitter in the peripheral and central nervous system. Ach is 
synthesized in cholinergic neurons by the enzyme choline acetyl-transferase and is converted in the 
inactive form by Acethylcoline esterase (AchE). DS has been associated with abnormalities in 
peripheral and central cholinergic functions [see (Hart et al., 2017)] and with reduction in the number 
of cholinergic neurons, which may affect cortical neuronal connectivity and maturation during early 
development (Becker, 1991). Cholinesterase inhibitors have been used to investigate potential effects 
of enhancing cholinergic function on cognition. 
Donepezil, a reversible inhibitor of AchE approved for use in people with AD in the general 
population, was used in the earliest clinical trial of pharmaceutical interventions in DS (Kishnani et 
al., 1999). Several recently completed randomized double-blind, placebo-controlled trials showed 
that donepezil was generally safe and well-tolerated in children and adults with DS but gave no 
significant benefit as a cognitive enhancer (Kishnani et al., 2009, Kishnani et al., 2010). A recent 
review by the Cochrane Collaboration network (Livingstone et al., 2015) concluded that there was 
no difference in cognitive functioning or behavior between individuals with DS treated with donepezil 
and placebo, although the probability to undergo an adverse event was higher for individuals with DS 
on donepezil [see (Hart et al., 2017)].  
Rivastigmine, an inhibitor of AchE and butyrylcholinesterase (BChE), is approved for the treatment 
of mild to moderate AD and has been shown to have benefit on the cognitive, functional and 
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behavioral problems commonly associated with dementia in AD (Finkel, 2004). A randomized 
double-blind, placebo-controlled trial in children and adolescents with DS suggested an improvement 
in a subset of participants for expressive language, but overall there were no with significant effects 
on adaptive function, executive function, language or memory measures (Spiridigliozzi et al., 2016).  
Piracetam is a member of the class of drugs known as nootropics, which are generally thought to 
enhance cognitive function by influencing vascular and neuronal functions in instances of brain 
dysfunction (Winblad, 2005). A Phase II placebo-controlled, 2-period crossover study was performed 
by Lobaugh et al. (2001) on children with DS (ages 6–13) in order to evaluate the effect of piracetam 
on cognitive functions, such a as attention, learning and memory. The trial showed that therapy with 
piracetam did not significantly improve cognitive functions and, in 7 of the 18 children who 
completed the study, was associated with side effects of the central nervous system (Lobaugh et al., 
2001).  
 
2.10.1.2 Glutamatergic system 
Memantine, a low-affinity uncompetitive antagonist for glutamatergic NMDA receptors, is a drug 
approved for treatment of moderate-to-severe AD, and was tested in different clinical trials in 
individuals with DS (Boada et al., 2012, Hanney et al., 2012). Memantine has been shown to act 
indirectly on the cholinergic system (Aracava et al., 2005). In individuals aged 18-32 years, no 
differences were detected in the two primary measures, but a significant improvement was seen in 
hippocampus-dependent function (Boada et al., 2012). After 1-year treatment with memantine (at a 
dose of 10 mg/d) in adults with DS over age 40, no improvements were observed in primary or 
secondary measures of cognition or adaptive function (Hanney et al., 2012). An ongoing Phase II trial 
in young adults with DS aged 15–32 is trying to assess whether a 16-week treatment with memantine 
will have an effect on learning and memory (clinicaltrials.gov NCT02304302). 
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2.10.1.3 GABAergic system modulators 
Excessive GABA-mediated neurotransmission has been proposed as one of the underlying causes of 
the cognitive deficits in Ts65Dn mice (Belichenko et al., 2004, Fernandez et al., 2007). Thanks to 
pre-clinical studies showing improvements in learning and memory with a GABAA antagonist 
(Fernandez et al., 2007) and selective GABAA α5 negative allosteric modulator (Martinez-Cue et al., 
2013), recent clinical trials in DS have targeted the GABA system. 
Pentylenetetrazole (PTZ) is a GABAA antagonist that was previously approved by the FDA for 
treatment of various cognitive impairments. PTZ is currently under investigation for cognitive 
enhancement in individuals with DS. A placebo-controlled study with PTZ up to 12 weeks in 
adolescents and young adults (ages 13–35) with DS has investigated the pro-cognitive effects in the 
domains of language, executive function, and adaptive behavior (Australian New Zealand Clinical 
Trials Registry ID ACTRN12612000652875). Although the study has completed enrollment and 
follow-up assessments, results have not been published yet. 
Basmisanil (Hoffmann-La Roche Pharmaceuticals), a selective GABAA α5 negative allosteric 
modulator, has been used in two multi-centre, Phase II, randomized, double-blind, placebo-controlled 
studies in order to improve cognition in adolescents/adults (12–30 years old; CLEMATIS study, 
ClinicalTrials.gov identifier NCT02024789) and children (6-11 years old; ClinicalTrials.gov 
identifier NCT02484703) with DS in a 26-week treatment study. Unpublished results from the 
CLEMATIS study showed that Basmisanil was not associated with significant impacts on cognition 
or adaptive behavior in young adults and adolescents with DS, leading to early discontinuation of the 
study in the pediatric population [see (Hart et al., 2017)].  
 
2.10.1.4 Natural compounds 
Folinic acid is a vitamer of vitamin B9 (or folate). Several genes involved in folate metabolism are 
located on HSA21 and folate deficiency has been linked to intellectual disability. Thus, folinic acid 
has been investigated as a potential pharmacotherapy in DS in a randomized controlled trial of 
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antioxidants and folinic acid (0.1 mg/day). No effects of treatment on development or long-term 
communication abilities were found in infants with DS (Ellis et al., 2008). More recently, a double-
blind, placebo-controlled, single-center study in DS infants (3–30 month-old) revealed an 
improvement in global developmental age for toddlers taking 1.0 mg/kg/day of folinic acid (Blehaut 
et al., 2010). The differences in the outcome of these two clinical trials may be due to the different 
dose used in DS infants. An ongoing 4-arm, placebo-controlled trial with folinic acid and thyroid 
hormone in combination is aimed at evaluating improvement of psychomotor development in 6–18 
month-old DS toddlers (ClinicalTrials.gov identifier NCT01576705).  
Epigallo-catechin-3-gallate (EGCG) is a flavonoid derived from green tea leaves and a well-known 
DYRK1A inhibitor. A randomized, placebo-controlled pilot study tested the effects of EGCG in 
combination with other green tea extracts on cognition in adolescents with DS (De la Torre et al., 
2014). Three months of treatment with green tea extracts improved recognition and working memory. 
Another study by the same group (a Phase II clinical trial) revealed that in adolescents with DS, a 
combination of green tea extracts plus cognitive training for 12 months had positive effects on visual 
recognition memory, inhibitory control, and adaptive behavior (de la Torre et al., 2016). Phase III 
trials with a larger DS population will be needed to assess the long-term efficacy of green tea extracts 
and cognitive training. The specific contribution of EGCG and of the other constituents of green tea 
extracts on behavioural improvement remains to be established.  
 
2.10.1.5 Molecules targeting AD 
Interventions targeting AD pathogenesis are currently being explored in clinical trials for DS.  
ACI-24, a recent developed vaccine targeting Aβ protein, has been designed to stimulate the immune 
system in order to prevent accumulation of amyloid plaques and trigger their clearance. It has been 
validated in a Phase I/II double-blind, randomised, placebo-controlled, adaptive design study of the 
safety, tolerability, immunogenicity and efficacy in patients with mild to moderate AD (WHO.int, 
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ICRT portal identifier EUCTR2008-006257-40-FI). A Phase I study in people with DS is currently 
investigating the effects of ACI-24 (ClinialTrials.gov identifier NCT02738450).  
Intranasal glulisine, is a rapid-acting insulin. Due to the role of insulin signaling in Alzheimer’s 
pathogenesis, the effects of glulisine have been investigated in AD (see (Hart et al., 2017)). The 
effects of intranasal glulisine are currently investigated in adults with DS to determine safety, 
feasibility, and cognitive effect on memory measures (ClinicalTrials.gov identifier NCT02432716).  
The effects of transdermal nicotine are currently investigated as a treatment for cognitive decline in 
adults with DS with the aim to establish safety, tolerability and efficacy for cognitive performance 
(ClinicalTrials.gov identifier NCT01778946).  
ELND005, an amyloid anti-aggregation agent, has been proposed to be used in individuals with DS 
because it may prevent the accumulation of plaques that might contribute to AD like dementia and 
may improve working memory by regulating brain myo-inositol levels. A clinical trial with 
ELND005 in the general population with AD did not show any effect on cognition or adaptive 
function [see (Hart et al., 2017)]. A recent phase II study, conducted in non-demented young adults 
with DS, showed that ELND005 was safe and well-tolerated, and that there were no side effects (Rafii 
et al., 2017). Results revealed improvements in the Neuropsychiatric Inventory score (examination 
of 10 behavioral sub-domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, 
euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity, (Cummings et al., 
1994) in 7 of 8 subjects receiving 250 mg twice daily of ELND005. There were, however, no 
significant overall treatment group-related trends on cognitive or behavioral measures.  
 
2.10.2 Preclinical studies in DS mouse models 
The idea of therapy for DS was unimaginable until few years ago. However, the initial knowledge of 
the HSA21 transcriptome, the continuous efforts to understand the signaling and other metabolic and 
developmental pathways that are dysregulated in DS, the availability of mouse models, the generation 
of T21 iPSCs and their differentiation to various cell types and tissues, and the understanding of the 
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numerous neurodevelopmental alterations, now provide some enthusiasm for potential therapeutic 
modalities. In the last 10 years, there has been an increase in research efforts focused on therapeutic 
interventions to rescue the brain phenotype and improve learning and memory in mouse models of 
DS. These therapies, which have been selected according to different rationales, have been mainly 
used in the Ts65Dn model. Most of the pharmacotherapies were conducted in adult Ts65Dn mice, 
while fewer therapies were explored at earlier life stages (neonatally or prenatally). This section 
summarizes what we know about the effects of pharmacotherapies during different life stages in DS 
mouse models. The attempted therapies may be grouped into five major classes. A) Therapies targeted 
to transmitter systems: (i) Therapies enhancing cholinergic transmission; (ii) Therapies 
antagonizing GABAergic transmission; (iii) Therapies enhancing noradrenergic transmission; (iv) 
Therapies targeted to the glutamate NMDA receptor; (v) Therapies targeted to the serotonergic 
system; (vi) Therapies targeted to the endocannabinoid system. B) Therapies employing 
neuroprotective agents, antioxidants, and free radical scavengers. C) Therapies targeted to 
perturbed signaling pathways. D) Therapies to normalize the expression of proteins coded by 
triplicated genes. E) Therapies that are known to have a proneurogenic effect [see (Stagni et al., 
2015a)]. Table 2.10.1 and Table 2.10.2 summarize the outcomes of attempted therapies (divided by 
their classifications) in DS mouse models [see also (Stagni et al., 2015a)].  
 
2.10.2.1 Therapies targeted to transmitter systems (Class A) 
(i) Therapies enhancing cholinergic transmission  
The rational basis for the use of AchE inhibitors in DS has been reported in the 2.10.1.1 section 
(Cholinergic system inhibitors). In the Ts65Dn models, AchE inhibitors were used mainly for the 
potential prevention or reversion of the loss of functional markers in the BFCN. Results obtained in 
Ts65Dn mice with AchE inhibitors or with choline supplementation are summarized below. 
Donepezil, physostigmine and galantamine. These molecules are AchE inhibitors. Donepezil was 
administered for 8 weeks in 4 month-old Ts65Dn mice. Treatment did not improve sensorimotor 
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abilities, locomotor activity in the home cage and L/M, evaluated with the MWM test (Rueda et al., 
2008a). Physostigmine, administered acutely to male Ts65Dn mice aged 4 months, rescued 
impairment in the four-arm spontaneous alternation task, but failed when administered to older mice 
(10 and 16 months) [see (Gardiner, 2015)]. Galantamine has been shown to be effective in 3-6 month-
old Ts65Dn mice in an impaired olfactory test of learning and memory (L/M) when administered for 
10 consecutively days [see (Gardiner, 2015)]. 
Choline supplementation. Choline, a vitamin-like nutrient, is a precursor of Ach. In a series of 
studies started in 2010, Strupp and colleagues analyzed the effects of choline supplementation in the 
diet of pregnant Ts65Dn dams (from E1 and continuing during lactation until the pups were weaned 
at P21). Their hypothesis was that treatment could improve BFCNs may thereby preventing the 
defects related to their degeneration (Moon et al., 2010, Velazquez et al., 2013, Ash et al., 2014, 
Kelley et al., 2014, Kelley et al., 2016). Ts65Dn progeny (6 months of age) of supplemented mothers 
showed improvement in the five-choice visual discrimination task (Moon et al., 2010). Choline 
supplementation plus environmental enrichment, restored hippocampal neurogenesis, reduced loss of 
BFCNs in the medial septum and restored hippocampus-dependent spatial cognition, tested with the 
Radial Arm Water Maze, in 13-17 month-old Ts65Dn mice (Velazquez et al., 2013, Ash et al., 2014, 
Kelley et al., 2014). These findings indicate that embryonic/early post-natal choline supplementation 
has effects that extend to very advanced life stages. 
 
(ii) Therapies antagonizing GABAergic transmission  
A number of studies have shown electrophysiological abnormalities in the hippocampal function of 
Ts65Dn mice, with repressed LTP and enhanced LTD. An imbalance between excitatory and 
inhibitory neurotransmission, probably due to increased generation of forebrain GABAergic 
interneurons, has been proposed to contribute to impair synaptic function and, consequently, L/M in 
the Ts65Dn model. Based on these premises, various GABAA receptor (GABAAR) and some GABAB 
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receptor (GABABR) antagonists were tested in the Ts65Dn mouse in order to equilibrate the 
excitation/inhibition ratio.  
Pentylenetetrazole (PTZ). PTZ is a circulatory and respiratory stimulant and a GABAAR antagonist. 
Two weeks of treatment with PTZ in 3-4 month-old Ts65Dn mice rescued spontaneous alternation in 
the T-maze and performance in the NOR test. Importantly, at two months after treatment cessation 
treated Ts65Dn mice exhibited restoration of LTP in the DG and normalization of the NOR test and 
spontaneous alternation in the TM test (Fernandez et al., 2007). Seven weeks of treatment in 4 month-
old Ts65Dn mice rescued performance in the MWM test, but caused some side effects (Rueda et al., 
2008a). Recently, another study demonstrated that 2 weeks of PTZ treatment was effective in rescuing 
deficits in NOR in both younger (2–3 month-old) and older (12–15 month-old) male Ts65Dn mice 
(Colas et al., 2013). 
Bilobalide and picrotoxin. They are two non-competitive GABAA receptor antagonists. Ts65Dn 
mice aged 3-4 months that had received bilobalide for four weeks underwent rescue of memory 
assessed with the NOR test. 2 weeks of treatment with picrotoxin in 3-4 month-old Ts65Dn mice was 
also able to rescue performance in the NOR test. Treated Ts65Dn with either bilobalide or picrotoxin 
retained their improved performance when evaluated 2 weeks later (Fernandez et al., 2007). 
α5 inverse agonist (α5IA). GABAAR exhibit considerable heterogeneity in terms of their 
composition and functional properties because 19 different subunits are assembled as 
heteropentamers [see (Gardiner, 2015)]. The α5 subunit is mainly expressed in the DG of the 
hippocampus and is linked to long-term memory functions. In 3-month-old male Ts65Dn, a single 
injection of the α5 inverse agonist α5IA rescued performance in the NOR and in the learning phase 
of the MWM test, but not in the probe trial (Braudeau et al., 2011). 
RO4938581. It is an α5 inverse agonist. RO4938581 was administered for 6 weeks to 3-4 month-old 
male Ts65Dn mice. This treatment restored LTP, hippocampal neurogenesis, and L/M in the MWM 
test (Martinez-Cue et al., 2013). 
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Bumetanide. In a recent study, Deidda et al. showed that GABAAR signaling was excitatory rather 
than inhibitory in Ts65Dn mice (Deidda et al., 2015). This excitatory activity was accompanied by 
(i) a shift in the reversal potential for GABAAR-driven Cl
− currents (ECl) toward more positive 
potentials and (ii) increased hippocampal expression of the cation Cl− cotransporter NKCC1 in both 
Ts65Dn mice and individuals with DS. Based on the evidence, Ts65Dn aged 10-16 weeks were 
treated with Bumetanide (a diuretic drug that inhibits NKCC1 cotransporter) for either one week or 
four weeks. Both treatment schedules rescued long-term hippocampus-dependent explicit memory, 
as assessed with CFC and NOR tests, in Ts65Dn mice. In contrast, one month of treatment with 
Bumetanide did not restore LTP in slices from Ts65Dn, indicating that effects of bumetanide on 
memory are independent of neuronal-circuit rearrangement. Finally, positive effects of Bumetanide 
on behavior disappeared after one week of drug withdrawal (Deidda et al., 2015). 
Flumazenil. Flumazenil (FLUM) is a GABAAR antagonist that is in current clinical use as an antidote 
in the treatment of benzodiazepine overdoses. FLUM is of interest because, unlike PTZ that is a 
noncompetitive GABAAR antagonist, FLUM is a competitive antagonist acting at the benzodiazepine 
binding site. 2-3 month-old and 8-10 month-old Ts65Dn mice were treated with FLUM for two weeks 
and then tested with the NOR test one week after treatment cessation. FLUM restored NOR test 
performance in Ts65Dn mice (Colas et al., 2017). The positive effects of FLUM in the NOR test 
persisted one month after treatment cessation (Colas et al., 2017).  
CGP55845. KCNJ6, encodes an inwardly-rectifying K+ channel, G protein-coupled inwardly-
rectifying potassium channel (GIRK) 2, that couples to GABAB receptors. Levels of GIRK2 are 
elevated in the hippocampus, frontal cortex, substantia nigra, and perhirinal cortex (Harashima et al., 
2006, Roncace et al., 2017) of Ts65Dn mice and there is evidence that GABAB-induced potassium 
currents are elevated in these brain regions, suggesting that they may contribute to the imbalance 
between excitatory and inhibitory neurotransmission (Best et al., 2007, Best et al., 2012). CGP55845, 
a GABAB receptor antagonist, was administered to 2-3 month-old Ts65Dn mice for 3 weeks or 
acutely (2-3 h before testing). CGP55845 rescued memory deficits assessed with the TM, NOR and 
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CFC behavioral tests and restored LTP in hippocampal slices from Ts65Dn mice (Kleschevnikov et 
al., 2012). 
 
(iii) Therapies enhancing noradrenergic transmission  
The noradrenergic input from the Locus Coeruleus (LC) exerts a modulatory role on hippocampal 
neurons via β-adrenergic receptors and is essential for contextual learning [see (Bartesaghi et al., 
2011)]. Neurons of LC are affected in several neuropathologies, such as AD, Parkinson disease and 
Huntington disease. Middle-aged DS individuals show significant loss of cells from LC (Mann et al., 
1985) and the same defect is present in the Ts65Dn mouse model starting from 6 months of age 
(Salehi et al., 2009). Ts65Dn mice also displays a reduction of the amount of noradrenaline (NA) in 
the hippocampus. 
L-DOPS. It is a synthetic precursor of NA, metabolized into NA by cells. 6 month-old Ts65Dn male 
mice that were injected with L-DOPS during the CFC test underwent full restoration of performance 
(Salehi et al., 2009). 
Xamoterol. It is a β1-adrenergic receptor partial agonist. 6 month-old Ts65Dn male mice that were 
injected with xamoterol with the same schedule used for L-DOPS underwent full restoration of 
freezing in the CFC test (Salehi et al., 2009). In a subsequent study, xamoterol was acutely 
administered to 9-12 month-old Ts65Dn male mice. Treatment rescued behavioral defects in NOR, 
CFC, and TM tests (Faizi et al., 2011). 
Formoterol. Formoterol is a long-acting β2-adrenergic agonist that has been proposed as protective 
agent against cholinergic system degeneration (Antonarakis, 2017). In a recent study, formoterol was 
administered acutely (4 hours before behavior analyses) to 5-6 month-old Ts65Dn mice. Results 
showed that formoterol caused significant improvement in the cognitive function (CFC test) and was 
associated with a significant improvement in the density of synaptic terminals in the DG and increased 
the dendritic complexity of newly born granule neurons of the DG (Dang et al., 2014). 
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DREADDs. Designer receptors exclusively activated by designer drugs (DREADDs) are novel and 
powerful tools that can be used to enhance neuronal activity and investigate discrete neuronal 
populations in the brain (Vazey and Aston-Jones, 2014). 14 month-old Ts65Dn mice were treated 
acutely with a DREADD, hM3Dq, administered via adeno-associated virus into the LC under a 
synthetic promoter, PRSx8, to selectively stimulate LC neurons by exogenous administration of the 
inert DREADD ligand clozapine-N-oxide. This treatment enhanced performance in the NOR test and 
reduced hyperactivity in Ts65Dn mice (Fortress et al., 2015). 
 
(iv) Therapies targeted to the glutamate NMDA receptor  
Memantine. This molecule is an uncompetitive antagonist of the N-methyld-aspartate (NMDA) 
receptor that indirectly acts on the cholinergic system (see 2.10.1.1 paragraph). In a first study, Costa 
et al. showed that an acute treatment with memantine in both 4-6 and 10-14 month-old male Ts65Dn 
mice was able to rescue L/M deficits in the CFC test (Costa et al., 2008). In 9 month-old Ts65Dn 
mice, 9 weeks of memantine administration rescued impairments in the MWM test (Rueda et al., 
2010). When administered from 4 to 9.5 months of age, memantine improved performance of Ts65Dn 
mice on the WRAM and NOR tests (although memantine had negative effects in euploid mice). 
Importantly, one week after treatment cessation, the positive effects seen on cognition disappeared. 
Finally, hippocampal slices from Ts65Dn mice preincubated with memantine exhibited normal levels 
of LTD after exposure to NMDA (Scott-McKean and Costa, 2011). 
 
(v) Therapies targeted to the serotonergic system  
Serotonin (5-HT), one of the major neurotransmitters of the CNS, is essential for neurodevelopment 
starting from the earliest fetal stages. The serotonergic system, which is altered in DS, has been linked 
to neurogenesis defect and reduced dendritic spine size in individuals with DS and Ts65Dn mice. 
Both individuals with DS and Ts65Dn mice displays a reduced expression of the serotonin 5-HT1A 
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receptor in the hippocampus, suggesting that a pharmacotherapy targeted to the serotonergic system 
may be a good strategy to ameliorate neurodevelopmental defects in DS.  
Fluoxetine. Fluoxetine, also known by trade name Prozac, is an antidepressant belonging to the 
selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine works by delaying the reuptake of 5-
HT through the inhibition of serotonin transporter. This mechanism allows 5-HT to persist longer in 
the inter-synaptic cleft and, thus, to enhance its action on postsynaptic neurons. Based on evidence 
that antidepressants increase neurogenesis in the DG and SVZ of rodents, Clark et al tested the 
efficacy of fluoxetine administered for two weeks in Ts65Dn mice aged 2-5 months. The results of 
this study showed that treatment with fluoxetine rescued neurogenesis in the hippocampus of Ts65Dn 
mice (Clark et al., 2006). Based on these premises, our group investigated the effects of early 
treatment with fluoxetine on brain development and behavior in Ts65Dn mice (Bianchi et al., 2010b, 
Guidi et al., 2013, Stagni et al., 2013, Guidi et al., 2014, Stagni et al., 2015b). We administered 
fluoxetine neonatally (from P3 to P15) and we found that treatment restored hippocampal 
neurogenesis and total granule cell number (Bianchi et al., 2010b). Importantly, at one month after 
treatment cessation, treated Ts65Dn mice exhibited full restoration of granule cell number, granule 
cell dendritic pattern, hippocampal connectivity, signal transfer from the granule cells to CA3, and 
hippocampus-dependent memory (Bianchi et al., 2010b, Guidi et al., 2013, Stagni et al., 2013). In a 
subsequent study we examined the effects of neonatal treatment with fluoxetine when mice reached 
adulthood (3 months of age) and found that in neonatally-treated Ts65Dn mice hippocampal 
cellularity, dendritic architecture, spine density, and L/M functions were still fully rescued (Stagni et 
al., 2015b). Since serotonin is essential for neurogenesis and dendritic development from the earliest 
fetal life stages in humans (Faber and Haring, 1999, Whitaker-Azmitia, 2001), we hypothesized that 
treatment with fluoxetine during pregnancy could rescue most of the neurodevelopmental alterations 
that characterize the trisomic brain. Thus, we administered fluoxetine to pregnant Ts65Dn dams from 
E10 to birth, with the aim of restoring the bulk of neurogenesis in pups, and we analyzed the outcome 
of treatment when mice was P2. We found that fluoxetine restored neurogenesis and cell density 
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throughout the forebrain (SVZ, SGZ, neocortex, striatum, thalamus, hypothalamus), midbrain 
(mesencephalon) and hindbrain (cerebellum and pons). In addition, prenatal-treatment with 
fluoxetine had enduring effects on Ts65Dn mice aged 45 days. Indeed, neural precursor proliferation 
was still restored in SVZ and the DG of the hippocampus, the dendritic development of postnatally 
born granule neurons and pre- and post-synaptic terminals were normalized and there was restoration 
of cognitive performance (NOR and CFC tests). These results demonstrate, for the first time, that the 
neurodevelopmental defects that characterize DS are reversible. Heinen and colleagues treated 
Ts65Dn mice aged 5–7 months with ﬂuoxetine for a total of 6 weeks and found no improvement in 
the MWM test and no change in the BFCN levels of ChAT (Heinen et al., 2012). In addition, they 
reported a very high rate of seizures and death in treated Ts65Dn mice. It must be noted that these 
adverse effects are very likely due to the dose used in this study (8-fold higher than that used by our 
group) and treatment duration (6 weeks vs 13 days) (Heinen et al., 2012). A study by Begenesic et al. 
(Begenisic et al., 2014) 2 month-old male and female Ts65Dn mice were treated for two weeks with 
fluoxetine. Treatment restored performances in olfactory learning and spontaneous alternation in a 
four arm maze and normalized levels of LTP and GABA release from synaptosomes (Begenisic et 
al., 2014). 
The promising results obtained with fluoxetine in the Ts65Dn model have prompted the design of 
clinical trials for the DS population. In 2016 the University of Texas Southwestern Medical Center, 
proposed a pilot study to investigate the effects of prenatal treatment with fluoxetine in pregnant 
mothers with a fetal diagnosis of DS. Unfortunately, no official information about this clinical trial is 
reported in ClinicalTrials.gov. In the framework of a project entitled “Novel avenues for the rescue 
of intellectual disability in Down syndrome” and coordinated by our research group, the protocol for 
a Phase I clinical trial has been submitted to the Italian Authority regulating clinical trials (AIFA) by 
our collaborators at Federico II University (Naples, Italy). This is a prospective, single-center, not 
controlled, one-arm, open study aimed at evaluating the safety and tolerability of fluoxetine in a 
paediatric population with DS. We hope that this pilot study will start as soon as possible. 
73 
(vi) Therapies targeted to the endocannabinoid system 
JZL184. The most abundant endocannabinoid in the brain is 2-arachidonoylglycerol (2-AG). The 
principal hydrolytic enzyme responsible for the degradation of 2-AG is monoacylglycerol lipase (MAGL). 
JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL). Ts65Dn mice aged 9.5-11.4 
month were treated with JZL184 for 4 weeks, in order to evaluate its effects on behavior and synaptic 
function (Lysenko et al., 2014). Treatment with JZL184 appears to improve long-term memory (NOR 
test) and hippocampal LTP (in the CA1 field), but has no effects on short-term (NOR test) and 
working memory (YM test) (Lysenko et al., 2014). 
 
2.10.2.2 Therapies employing neuroprotective agents, antioxidants, and free radical scavengers 
(Class B) 
Neuroprotective agents 
Neuropeptides are small proteinaceous substances produced and released by neurons through the 
regulated secretory route and acting on neural substrates. Neuropeptides are the most diverse class of 
signaling molecules in the brain and are engaged in many physiological functions (Burbach, 2011). 
NAPVSIPQ (NAP) and SALLRSIPA (SAL). Glial cells release several survival-promoting factors, 
including the activity-dependent neuroprotective protein (ADNP) and the activity-dependent 
neurotrophic factor (ADNF) (Incerti et al., 2011). The active peptide fragments of these proteins, 
NAPVSIPQ (NAP) and SALLRSIPA (SAL), mimic the activity of their parent proteins, exerting a 
protective effect against oxidative stress, the severity of traumatic head injury, stroke, and toxicity 
associated with the Aβ peptide [see (Bartesaghi et al., 2011, Gardiner, 2015, Stagni et al., 2015a)]. 
Busciglio et al demonstrated that treatment of DS cultured cortical neurons with either NAP or SAL 
increased neuronal survival and reduced degenerative morphological changes (Busciglio et al., 2007). 
In a first study, Incerti et al. treated 10 month-old Ts65Dn mice with NAP/SAL for 9 days. During 
days 4-9 mice were subjected to the MWM test and showed rescued L/M functions (Incerti et al., 
2011). However, after a further 10 days with no additional treatment, treated Ts65Dn mice no longer 
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remembered the platform location (Incerti et al., 2011). In another study, conducted by the same 
group, pregnant Ts65Dn dams were injected with NAP/SAL from E8 to E12. At 8-10 months of age 
the treated offspring were evaluated in the MWM test. Treated Ts65Dn offspring exhibited improved 
learning abilities. Unfortunately, data regarding probe test that assesses memory are lacking (Incerti 
et al., 2012). 
Peptide 6. It is a derivative of the ciliary neurotrophic factor, which has been shown to enhance 
neurogenesis, dendritic and synaptic plasticity, and memory in rodents (Chohan et al., 2011). In a 
study by Blanchard et al. 11–15-month-old female Ts65Dn mice were treated for 1 month with 
peptide 6 (Blanchard et al., 2011). According to the authors, the performance in the MWM test was 
improved, although the reporetd data do not appear to completely support this conclusion [see 
(Gardiner, 2015)]. 
Peptide 021. Peptide 021 (P021) is a ciliary neurotrophic factor (CNTF) small-molecule mimetic. 2–
3-month-old pregnant Ts65Dn dams were treated with compound P021 in the feed from E8 until 
weaning of the pups on P21 (Kazim et al., 2017). Evaluation of developmental milestones from P1 
to P21 showed that treatment prevented the delay in neurobehavioral development in Ts65Dn pups. 
In addition, prenatally-neonatally treated 3 weeks-old Ts65Dn offspring displayed amelioration of a 
pre-synaptic protein (SYN) deficit, decrement of GSK3β activity, and an increment in the expression 
of synaptic plasticity markers (Kazim et al., 2017). Morever, authors demonstrated that this treatment 
schedule with P021 caused restoration of cognitive functions, assessed by MWM test, open field and 
one-trial object recognition/discrimination task when mice had 7 months of age (Kazim et al., 2017). 
Estrogen. The fact that women with DS have premature menopause and early onset cognitive decline 
prompted some studies with estrogen. In a study by Granholm et al., 11-14 month-old female Ts65Dn 
mice were treated with estrogen for two months. Estrogen significantly improved initial learning in 
the discriminating water T-maze. Estrogen also reversed the age-related loss of ChAT and NGF, two 
BFCN functional markers (Granholm et al., 2002). Another study in male Ts65Dn mice aged 6 
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months showed that estrogen treatment for 3 weeks failed to rescue the learning deficit in the WRAM 
(Hunter et al., 2004b). These results suggest sex differences in estrogen responses. 
Minocycline. Minocycline is an antibiotic (derivative of the tetracycline) that is of interest because 
it is considered to have neuroprotective effects. 3 months of treatment with minocycline in 10 month-
old male Ts65Dn mice improved performance in the WRAM (not to euploid levels) and rescued age-
related loss of ChAT in the BFCN (Hunter et al., 2004a). 
Nerve Growth Factor (NGF). With aging, Ts65Dn mice exhibitd reductions in BFCN size and 
number and regressive changes in the hippocampal terminal fields of these neurons. These changes 
are associated with significantly impaired retrograde transport of NGF from the hippocampus to the 
basal forebrain [see (Bartesaghi et al., 2011)]. In a study by Cooper et al., Ts65Dn mice aged 18 
months received NGF via a microosmotic pump implanted into the lateral ventricle for 12 weeks. 
Intracerebroventricular NGF infusion reversed abnormalities in BFCN size and number and restored 
the deficit in cholinergic innervation (Cooper et al., 2001). 
 
Antioxidants and free radical scavengers 
Oxidative stress and mitochondrial dysfunction are both considered hallmarks of DS tissues and 
contributors to neurological phenotypes across the DS lifespan. This oxidative stress, which damages 
mitochondrial membrane and lipids, occurs in DS during pre- and post-natal development and can 
modify critical processes of neurogenesis, differentiation, migration, and survival. Several HSA21 
genes, among them SOD1, BACH1, ETS2, and S100B, are known to contribute to the regulation of 
oxidative stress when overexpressed [see (Gardiner, 2015, Stagni et al., 2015a)]. Consistent with these 
observations, it was shown that levels of oxidative stress are elevated in the brains of adult Ts65Dn 
(Lockrow et al., 2009). 
α-tochopherol. This molecule is the most biologically active form of vitamin E. 4 month-old male 
Ts65Dn mice was fed with an α-tochopherol enriched diet for either 4 or 6 months. Treatment was 
found to reduce the levels of oxidative stress in Ts65Dn brains, to improve performance in the 
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WRAM at 8 and 10 months and prevent the loss of the TRKA receptor in the BFCN (Lockrow et al., 
2009). 
Vitamin E enriched diet was administered to pregnant Ts65Dn females from the day of conception 
throughout pregnancy and to their pups until 10 weeks of age. Supplementation of vitamin E was 
found to reduce lipid peroxidation products in the DG of adult Ts65Dn mice, to increase granule cell 
density, to ameliorate abnormal anxiety in the elevated plus maze test, and to improve spatial L/M in 
the MWM test (Shichiri et al., 2011).  
SGS-111. SOD1 over-expression in DS individuals causes a three- to four-fold increase in 
intracellular reactive oxygen species (ROS) [see (Stagni et al., 2015a)]. SGS-111 is an analog of 
piracetam with neuroprotective and nootropic properties. It was administered to pregnant Ts65Dn 
dams from the day of conception, throughout pregnancy, and to their pups during the following 5 
months. Treatment failed to improve L/M in the MWM test, although there was a reduced 
hyperactivity in Ts65Dn mice (Rueda et al., 2008b). 
Melatonin. Melatonin is an indole amine mainly synthesized and secreted by the pineal gland. Its 
exogenous administration has been demonstrated to induce neuroprotective effects by regulating anti- 
and pro-oxidant enzymes, acting as a potent ROS scavenger, and repairing molecules damaged by 
ROS overgeneration. Due to these effects, melatonin has been proposed as a powerful tool in the 
treatment of neuropathologies in which oxidative stress is enhanced, such as DS (Parisotto et al., 
2016). Melatonin, administered to 5 month-old male Ts65Dn mice in drinking water for 4 months 
plus another one-month (5 months in total) during behavioral testing was shown to rescue learning 
abilities tested with MWM test. In addition, melatonin increased the levels of ChAT in BFCNs 
(Corrales et al., 2013). In a subsequent study, administration of melatonin to 6 month-old Ts65Dn for 
5-6 months was found to rescue neurogenesis and LTP (Corrales et al., 2014). In a recent work, the 
same group showed that melatonin also reduces oxidative stress and decreases hippocampal 
senescence in the Ts65Dn model (Parisotto et al., 2016). 
 
77 
2.10.2.3 Therapies targeted to perturbed signaling pathways (Class C) 
Lithium. Lithium is largely used for the treatment of bipolar depression and was seen to have 
neuroprotective properties and to stimulate neurogenesis in the DG of rodents [see (Bartesaghi et al., 
2011)]. Although the molecular mechanisms underlying responses to lithium are not known yet, it 
has been shown that it can inhibit GSK3β and inositol phosphatases, compete with Mg2+ in protein 
binding and modulate the Wnt/β-catenin pathway [see (Gardiner, 2015)]. 12 month-old Ts65Dn mice 
treated for one month with lithium exhibited restoration of cell proliferation in the SVZ, rostral 
migratory stream and olfactory bulb, restoration of the size of the proliferating pool of precursor cells 
in the SVZ, and olfactory functions. However, no neurogenesis enhancement was seen in the SGZ of 
the DG (Bianchi et al., 2010a, Guidi et al., 2016). In contrast, 5 month-old Ts65Dn mice treated for 
one month with lithium showed a complete rescue of DG neurogenesis, hippocampal LTP and 
performance in the CFC, NOR, and OL tests (Contestabile et al., 2013). 
SAG 1.1. SHH signaling is extremely important for neuronal precursor proliferation. Roper et al. 
demonstrated that the reduced proliferation of cerebellar granule cell precursors from Ts65Dn mice 
is related to an attenuated response to SHH protein. SAG 1.1, a smoothened (SMO, the receptor of 
SHH) agonist, relieves the inhibitory effect of PTCH1 (the inhibitor of SHH pathway) on SMO. A 
single injection of SAG 1.1 in P0 Ts65Dn rescued at P6 the decreased cell number in the granule cell 
layer of the cerebellum (Roper and Reeves, 2006). Importantly, the positive effects of SAG1.1 on 
cerebellar cellularity lasted until 4 months of age. In addition, this treatment restored the MWM test 
performance and hippocampal LTP, but failed to improve cerebellar LTD and performance in the 
YM test (Das et al., 2013). 
 
2.10.2.4 Therapies to normalize the expression of proteins coded by triplicated genes (Class D) 
The role of DYRK1A in the neurodevelopmental alteration of DS has been highlighted in sections 
2.8.4; 2.8.6; 2.8.9. Due to the involvement of DYRK1A in the DS neurological phenotype, in the last 
few years various therapies has been attempted in DS mouse models aimed at normalizing its activity. 
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Epigallo-catechin 3 gallate (EGCG). EGCG is a flavonoid present in green tea extracts. In addition 
to its antioxidant activity, it is a non-selective but highly specific inhibitor of DYRK1A. The first 
study on the effects of EGCG in DS demonstrated that incubation with EGCG of hippocampal slices 
from Ts65Dn mice restored LTP at the Schaffer collateral-CA1 synapse (Xie et al., 2008). A 
subsequent study on transgenic YACtg152F7 mice (that over-express Dyrk1A) showed that chronic 
administration with a polyphenol based diet (that includes EGCG) from gestation to adulthood was 
able to correct brain morphogenesis alterations, and long-term memory assessed using the NOR test 
(Guedj et al., 2009). In addition, Dyrk1A transgenic mice treated with EGCG for one month starting 
from P21 undergo restoration of hippocampal neurogenesis (Pons-Espinal et al., 2013). In adult 
Dyrk1A transgenic mice, a 4–6 week administration of green tea extracts rescues defective long-term 
potentiation in the prefrontal cortex (Thomazeau et al., 2014). Finally, treatment with extracts 
containing EGCG in adult mBACtgDyrk1a mice restores components of GABAergic and 
glutamatergic pathways in the cortex and hippocampus, and improves behavioral deficits (Souchet et 
al., 2015). Recently, it has been reported that one month of treatment with EGCG in 3 month-old 
Ts65Dn male mice rescued their performance in the MWM test to the level of the euploid mice (De 
la Torre et al., 2014). In contrast, Stringer et al. demonstrated that pure EGCG administered to 
Ts65Dn mice from weaning for either three or 7 weeks (at a dose of 20.0 mg/kg/d), and 51 days (at a 
dose 100.0 mg/kg/d) did not improve performance in a battery of behavioral tasks (Stringer et al., 
2015a, Stringer et al., 2015b). Green tea extracts containing EGCG (45%) were also administered in 
combination with environmental enrichment for 30 days in 1-2 month-old Ts65Dn female mice. Co-
treatment restored cortico-hippocampal-dependent L/M (MWM, NOR tests), rescued dendritic spine 
density in field CA1 and normalized the proportion of excitatory and inhibitory synaptic markers in 
field CA1 and DG (Catuara-Solarz et al., 2016). There is evidence that incubation of NPCs isolated 
from the hippocampus of Ts65Dn mice with EGCG restores mitochondrial biogenesis and improves 
proliferation rate (Valenti et al., 2016). 
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ALGERNON (Altered generation of neurons). ALGERNON is a recenttly identified compound 
that inhibits DYRK1A and has been shown to rescue proliferative deficits in Ts65Dn-derived 
neurospheres and human neural stem cells derived from individuals with DS (Nakano-Kobayashi et 
al., 2017). ALGERNON was orally administered to pregnant Ts1Cje dams from E10 up to E15. Adult 
Ts1Cje mice that had been prenatally-treated with ALGERNON showed complete restoration of brain 
morphology, neurogenesis in the DG, and L/M functions (YM, Barnes Maze, CFC tests) (Nakano-
Kobayashi et al., 2017). 
DAPT (Class D). N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenyl glycine t-butyl ester is a γ-
secretase inhibitor developed in order to reduce Aβ deposition. Administration of DAPT to 4 month-
old Ts65Dn mice for 4 days was found to normalize Aβ levels and to improve L/M (Netzer et al., 
2010).  
 
2.10.2.5 Therapies that are known to have a proneurogenic effect (Class E) 
P7C3 (Class E). The aminopropyl carbazole P7C3 was discovered for its ability to enhance cell 
survival and decrease apoptosis, thereby preventing the neurogenic and cognitive decline seen in aged 
rats (Pieper et al., 2010) and rodent models of neurodegeneration (Tesla et al., 2012). In a recent 
study, 4-10 weeks-old Ts65Dn were chronically administered with P7C3 for 3 months. Evaluation of 
the brains at the end of treatment showed a complete restoration of neurogenesis (evaluated with 
immunohistochemistry for Ki-67, BrdU, DCX, and the apoptotic marker AC-3) in the DG (Latchney 
et al., 2015). 
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Table 2.10.1. Therapies administered at adult life stages in the Ts65Dn (and Ts1Cje) mouse 
model of DS. 
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The classes reported in the column “Treatment” correspond to those summarized in the section 2.10.2. The outcome “Rescued” 
means that in treated DS mouse models the examined phenotype became similar to that of untreated euploid mice. The outcome 
“Improved” means that in DS mouse models treatment ameliorated but did not rescue the examined phenotype. Abbreviations: 
ADNF, Activity Dependent Neurotrophic Factor; ADNP, Activity Dependent Neuroprotective Protein; BM, Barnes Maze; CFC, 
Contextual Fear Conditioning; CNTF, Ciliary Neurotrophic Factor; d, day; DG, dentate gyrus; m, month; MWM, Morris Water 
Maze; NA, not available; NOR, Novel Object Recognition; NPR, Novel Place Recognition; PM, Plus Maze; SA, Spontaneous 
Alternation Task; SVZ, subventricular zone; TM, T-Maze; w, week; WRAM, Water Radial Arm Maze; YM, Y-Maze. 
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Table 2.10.2. Therapies administered at neonatal and embryonic life stages in the Ts65Dn 
mouse model of DS. 
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The classes reported in the column “Treatment” correspond to those summarized in the section 2.10.2. The outcome “Rescued” means 
that in treated Ts65Dn mice the examined phenotype became similar to that of untreated euploid mice. The outcome “Improved” means 
that in Ts65Dn mice treatment ameliorated but did not rescue the examined phenotype. Abbreviations: CFC, Contextual Fear 
Conditioning; d, day; DG, dentate gyrus; E, embryonic; m, month; MWM, Morris Water Maze; NA, Not Available; NOR, Novel Object 
Recognition; PM, Plus Maze; TM, T-Maze; RAWM, Radial Arm Water Maze; SVZ, subventricular zone; w, week; YM, Y-Maze. 
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3. Results Sections 
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3.1 Section 1 
 
”Short- and long-term effects of the -secretase inhibitor 
ELND006 in the Ts65Dn mouse model of Down 
syndrome” 
 
Information reported in this section refers to:  
1) “Inhibition of APP γ-secretase restores Sonic Hedgehog signaling and neurogenesis in the 
Ts65Dn mouse model of Down syndrome”. Giacomini A, Stagni F, Trazzi S, Guidi S, Emili 
M, Brigham E, Ciani E, Bartesaghi R. Neurobiology of Disease 82 (2015) 385–396. 
2) “Long-term effect of neonatal inhibition of APP γ-secretase on hippocampal development in 
the Ts65Dn mouse model of Down syndrome”. Stagni F, Raspanti R, Giacomini A, Guidi S, 
Emili M, Ciani E, Giuliani A, Bighinati A, Calzà L, Magistretti J, Bartesaghi R. Stagni, 
Raspanti and Giacomini contributed equally to the article. Neurobiology of Disease 103 
(2017) 11–23. 
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3.1.1 Abstract 
 
Neurogenesis impairment is considered a major determinant of the intellectual disability that 
characterizes Down syndrome (DS). Excessive levels of AICD, a cleavage product of the trisomic 
gene APP, increase the transcription of PTCH1, a Sonic Hedgehog (SHH) receptor that keeps the 
mitogenic SHH pathway repressed. This suggests that excessive inhibition of the SHH pathway may 
concur to impair neurogenesis in DS. Since AICD results from APP cleavage by -secretase, the goal 
of the current study was to establish whether treatment with a -secretase inhibitor normalizes AICD 
levels and restores neurogenesis by restoring the functionality of the SHH pathway. To this purpose 
we exploited the Ts65Dn mouse, a widely used model of DS. We found that treatment with a selective 
-secretase inhibitor (ELND006) in Ts65Dn pups (postnatal period P3-P15) restored neurogenesis in 
the subventricular zone and hippocampus, hippocampal granule cell number and synapse 
development, indicating a positive impact of treatment on brain development. In the hippocampus of 
treated Ts65Dn mice there was a reduction in the expression levels of PTCH1, which is consistent 
with reduction of AICD formation due to ELND006-mediated inhibition of -secretase. In the 
framework of potential therapies for DS, it is extremely important to establish whether the positive 
effects of early intervention are retained after treatment cessation. A second goal of the study was to 
establish whether early treatment with ELND006 leaves an enduring trace in the brain of Ts65Dn 
mice. We found that in neonatally treated (postnatal period P3-P15) Ts65Dn mice the pool of 
proliferating cells in the hippocampal dentate gyrus and total number of granule neurons were still 
restored as was the number of pre- and postsynaptic terminals in the stratum lucidum of CA3 when 
mice reached 45-days of age. Accordingly, patch-clamp recording from field CA3 showed functional 
normalization of the input to CA3. Unlike in field CA3, the number of pre-and postsynaptic terminals 
in the dentate gyrus of treated Ts65Dn mice was no longer fully restored. The finding that many of 
the positive effects of neonatal treatment were retained after treatment cessation provides proof of 
principle demonstration of the efficacy of early inhibition of -secretase for the improvement of brain 
development in DS. 
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3.1.2 Introduction 
 
Generalized neurogenesis impairment during critical developmental stages and impaired dendritic 
maturation are the major determinants of intellectual disability in individuals with DS. Alterations of 
various signaling pathways due to gene triplication are likely to be involved in these 
neurodevelopmental alterations. Accumulating evidence in the Ts65Dn mouse model of DS suggests 
that alteration of the Sonic Hedgehog (SHH) pathway may be one important factor involved in 
neurogenesis impairment in DS (Roper and Reeves, 2006, Trazzi et al., 2011, Trazzi et al., 2013). In 
particular, defective functioning of the SHH pathway appears to cause reduced proliferation of neural 
precursor cells (NPCs) of the cerebellum, the subventricular zone (SVZ) of the lateral ventricle and 
the subgranular zone (SGZ) of the hippocampal dentate gyrus. Regarding the causes of SHH signaling 
impairment in DS, recent data suggest that the triplicated gene APP (amyloid precursor protein), a 
gene that is important for cell cycle progression and neuron migration (Nalivaeva and Turner, 2013), 
may be a key candidate underlying trisomy-linked alteration of SHH signaling (Trazzi et al., 2013). 
APP undergoes complex proteolytic processing, giving rise to several fragments. Cleavage of APP 
by α- and β-secretases gives origin to the carboxy-terminal fragments (CTFs) αCTF and βCTF, 
respectively. Cleavage of βCTF by the enzyme -secretase gives origin to the amyloid precursor 
protein intracellular domain (AICD) and p3, and cleavage of βCTF gives origin to β-amyloid (Aβ) 
and AICD. Previous evidence showed that excessive AICD levels in trisomic NPCs caused over-
expression of Patched 1 (PTCH1), the inhibitor of the SHH pathway (Trazzi et al., 2011, Trazzi et 
al., 2013). The outcome of this over-inhibition was impairment of neurogenesis and neurite 
development. Treatments that restored SHH signaling reverted both these defects. In agreement with 
a key role played by AICD in neurogenesis alterations in the Ts65Dn model, it has been shown that 
AICD transgenic mice exhibit impaired neurogenesis, similarly to trisomic mice (Ghosal et al., 2010). 
The evidence reported above suggests that impairment of the SHH pathway due to AICD-dependent 
PTCH1 over-expression may be a key mechanism that underlies reduced proliferation and impaired 
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maturation of neuronal precursors in the trisomic brain. Since PTCH1 over-expression keeps the 
pathway under repression, therapies have been attempted with SAG, a drug that activates the SHH 
pathway by acting downstream of PTCH1 (Roper et al., 2009, Das et al., 2013). Although this strategy 
is effective, the use of activators of the SHH pathway may pose some caveats because the SHH 
pathway is implicated in the development of cancers (Katoh and Katoh, 2009). Since PTCH1 over-
expression in the DS brain is due to excessive AICD levels, an ideal approach to restore PTCH1 levels 
and, hence, SHH signaling, would be to reduce AICD formation through inhibitors of γ-secretase. 
During the last few years, various selective APP γ-secretase inhibitors have been developed by ELAN 
Inc (Fleisher et al., 2008, Basi et al., 2010) as strategic tools to reduce Aβ levels in Alzheimer's 
disease. So far, no study has explored the possibility to exploit γ-secretase inhibitors as a 
pharmacological tool to reduce the excessive levels of AICD that characterize the DS brain. Based 
on this rationale, the goal of the current study was to establish whether early treatment with a selective 
γ-secretase inhibitor, ELND006, positively impacts neurogenesis in the Ts65Dn model, and, if so, 
whether this effect is followed by a long-lasting improvement in the organization of the hippocampal 
circuits.  
 
3.1.3 Materials and methods 
 
Colony 
Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (Reeves, 1995) were obtained 
from Jackson Laboratories (Bar Harbour, ME, USA) and the original genetic background was 
maintained by mating them with C57BL/6JEi x C3SnHeSnJ (B6EiC3) F1 males. Animals were 
genotyped as previously described (Reinholdt et al., 2011). The day of birth was designated postnatal 
day zero (P0). A total of 98 mice were used. The animals’ health and comfort were controlled by the 
veterinary service. The animals had access to water and food ad libitum and lived in a room with a 
12:12 h dark/light cycle. Experiments were performed in accordance with the Italian and European 
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Community law for the use of experimental animals and were approved by Bologna University 
Bioethical Committee. In this study, all efforts were made to minimize animal suffering and to keep 
the number of animals used to a minimum. 
 
Experimental protocol. 
During the last few years, various selective APP γ-secretase inhibitors have been developed by ELAN 
Inc (Basi et al., 2010), as strategic tools to reduce Aβ levels in Alzheimer's disease. Among these, 
ELND006 is a γ-secretase inhibitor which retains selectivity and incorporates improved drug-like 
properties (Basi et al., 2010). In order to test the efficacy of ELND006 in DS, euploid and Ts65Dn 
mice received a daily subcutaneous injection of ELND006 (ELN; gift by ELAN Inc, USA) dissolved 
in 25% PEG300, 25% ethylen glycol, 25% cremophor, 15% ethanol, 10% propanol from postnatal 
day 3 (P3) to postnatal day 15 (P15). We evaluated the outcome of the treatment immediately after 
its cessation (Experiment 1, P15 mice) and one month later (Experiment 2, P45 mice). 
Experiment 1. Based on previous evidence, Euploid (n=11) and Ts65Dn (n=11) mice were daily 
treated with ELN at a dose of 30.0 mg/kg (Fig. 3.1.1A) (Basi et al., 2010). Age-matched euploid 
(n=8) and Ts65Dn (n=8) mice were injected with the vehicle. These mice will be called here untreated 
mice. Each treatment group had approximately the same composition of males and females. Animals 
(4-7 animals for each condition) received a subcutaneous injection (150 g/g body weight) of BrdU 
(5-bromo-2-deoxyuridine; Sigma), a marker of proliferating cells (Nowakowski et al., 1989) in Tris 
HCl 50 mM (at 11-12am) 2 h before being killed. The brain of the other animals (4 animals for each 
condition) was quickly removed, the hippocampal formation was dissected, kept at –80°C and used 
for western blot experiments.  
Experiment 2. We found that the dose (30.0 mg/kg) of ELN used in the first part of the study 
(Experiment 1) had no acute effect on mice viability. However, euploid and Ts65Dn mice treated 
with this dose exhibited a higher mortality rate (death rate=30-40%) after weaning. For this reason, 
we decided to reduce the dose of ELN. In a pilot experiment we found that a 20.0 mg/kg dose did not 
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increase the mortality rate and was able to reinstate cell proliferation in the DG of Ts65Dn mice (n=4-
5 mice for each experimental group; data not shown), similarly to the dose of 30.0 mg/kg. Therefore, 
in this part of the study (Experiment 2) we treated mice with a dose of 20.0 mg/kg. Euploid (n=20) 
and Ts65Dn (n=11) mice received a daily subcutaneous injection of ELN (dose 20.0 mg/kg) dissolved 
in the vehicle from P3 to P15 (Fig.3.1.1B). Age-matched euploid (n=19) and Ts65Dn (n=10) mice 
were injected with the vehicle. Each treatment group had approximately the same composition of 
males and females. On P45-P50 mice were weighed, sacrificed, the brain was quickly removed and 
weighed. These mice will be called here P45 mice (Fig. 3.1.1B). The left hemisphere was fixed by 
immersion in PFA 4%, frozen and used for immunohistochemistry. The right hemisphere was kept at 
–80°C and used for western blotting. The number of animals used for each of the experimental 
procedures described below is specified in the figure legends. Other groups of mice were treated from 
P3 to P15 with either ELN (20.0 mg/kg) (euploid: n=8; Ts65Dn: n=4) or vehicle (euploid: n=9; 
Ts65Dn: n=7) and at 30-45 days of age were used for electrophysiological recordings from field CA3. 
 
Histological procedures 
P15 mice. Mice that had received BrdU were deeply anesthetized, the brain was removed cut along 
the midline. The left hemisphere was fixed by immersion in Glyo-Fixx as previously described 
(Bianchi et al., 2010b) and the right hemisphere was fixed in 4% PFA and frozen. The left hemisphere 
was embedded in paraffin and cut in series of 8-µm-thick coronal sections that were attached to poly-
lysine coated slides and used for BrdU, Ki-67, and cleaved caspase-3 immunohistochemistry and for 
hematoxylin staning. The right hemisphere was cut with a freezing microtome in 30-m-thick coronal 
sections that were serially collected in PBS and used for synaptophysin (SYN) and postsynaptic 
density protein-95 (PSD-95) immunohistochemistry.  
P45 mice. The left hemisphere was cut with a freezing microtome in 30-m-thick coronal sections 
that were serially collected in anti-freezing solution (30% glycerol; 30% ethylen-glycol; 10% 
PBS10X; 0.02% sodium azide; MilliQ to volume) and used for immunohistochemistry for Ki-67, 
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Figure 3.1.1. Experimental protocols. A: Euploid and Ts65Dn mice received a daily injection of either 
vehicle (Euploid + Vehicle; Ts65Dn + Vehicle) or ELND006 (30.0 mg/kg; Euploid + ELN; Ts65Dn + ELN) 
from postnatal (P) day 3 to P15. At P15, mice received one injection of BrdU, and were killed after 2 h in order 
to evaluate the number of cells in the S-phase of the cell cycle. The brains of these mice were used for 
immunohistochemistry and western blotting. B: Euploid and Ts65Dn mice received a daily injection of either 
vehicle (Euploid + Vehicle; Ts65Dn + Vehicle) or ELND006 (20.0 mg/kg; Euploid + ELN; Ts65Dn + ELN) 
from P3 to P15. Mice were killed on P45-P50. The brains of these mice were used for immunohistochemistry 
and western blotting. Abbreviations: BrdU, bromodeoxyuridine; ELN, ELND006; P, postnatal.
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SYN and PSD-95. 
BrdU immunohistochemistry in P15 mice. One out of 20 sections was taken from the beginning of 
the lateral ventricle to the end of the hippocampal formation (n=16-20 sections). After inactivation of 
endogenous peroxidases, sections were blocked for 1 h in PBS containing 1% bovine serum albumin 
and 0.1% Triton X-100. Sections were treated prior to blocking with 2 N HCl for 45 min at 37°C, 
washed in borate buffer 0.1 M pH 8.5 and then incubated overnight at 4°C in blocking buffer 
containing the primary antibody anti-BrdU (mouse monoclonal 1:100, Roche Applied Science, 
Mannheim, Germany). Detection was performed with an HRP-conjugated anti-mouse secondary 
antibody (dilution 1:200; Jackson Immunoresearch, West Grove, PE, USA) and DAB kit (Vector 
Laboratories, Burlingame, CA, USA). 
Ki-67 immunohistochemistry in P15 mice. One out of 20 sections were taken starting from the 
beginning of the lateral ventricle up to the end of the hippocampal formation. Sections were incubated 
overnight at 4°C with a rabbit monoclonal anti-Ki67 antibody (1:100; Thermo Scientific). Detection 
was performed with a HRP-conjugated anti-rabbit secondary antibody (1:200; Jackson 
Immunoresearch) and DAB kit (Vector Laboratories).  
Ki-67 immunohistochemistry in P45 mice. One out of 6 sections were taken starting from the 
beginning to the end of the hippocampal formation (n=16-20 sections). Sections were incubated 
overnight at 4°C with rabbit monoclonal anti-Ki67 antibody (1:100; Thermo Scientific). Section were 
then incubated for 2 h with a Cy3 conjugated anti-rabbit IgG (1:200; Jackson Immunoresearch). 
Sections were counterstained with Hoechst 33342 in order to label cell nuclei.  
Cleaved caspase–3 immunohistochemistry in P15 mice. One out of 20 sections from the beginning of 
the lateral ventricle to the end of the hippocampal formation (n=16-20 sections) were processed for 
cleaved caspase-3 immunohistochemistry, as previously described. Deparaffinized sections were 
permeabilized with 0.1% Triton X-100 in PBS for 30 min, blocked for 1 h in 3% BSA in 0.1% Triton 
X-100 and PBS, incubated overnight at 4°C with a primary antibody [rabbit cleaved caspase-3 (Asp 
175) antibody (Cell Signaling Technology)], and diluted 1:200 in 3% BSA in 0.1% Triton X-100 and 
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PBS. Sections were washed in 0.1% Triton X-100 in PBS for 40 min and incubated for 2 h with a 
secondary antibody, Cy3-conjugated anti-rabbit IgG (1:200; Jackson Immunoresearch) diluted in 
0.1% Triton X-100 in PBS and 3% BSA, and rinsed in 0.1% Triton X-100 in PBS for 30 min. 
Fluorescent images were taken with an Eclipse TE 2000-S microscope. 
SYN and PSD-95 immunohistochemistry in P15 and P45 mice. Free-floating sections (n=4-6 per 
animal) taken at the level of the hippocampal formation were submitted to fluorescence 
immunohistochemistry for SYN and PSD-95. Sections were counterstained with Hoechst dye in order 
to label cell nuclei. Sections were incubated for 48 h at 4°C with a mouse monoclonal anti-SYN 
(SY38) antibody (Millipore-Biomanufacturing and Life Science Research, Billerica, MA, USA) and 
rabbit polyclonal anti-PSD-95 antibody (Abcam) both diluted 1:1000. Sections were then incubated 
overnight at 4°C with a FITC-conjugated goat anti-mouse antibody or with a CY3-conjugated anti-
rabbit (Jackson Laboratory) antibody both diluted 1: 200.  
Hematoxylin-staining in P15 mice. One out of 20 sections, taken from the beginning to the end of the 
hippocampal formation (n=9-12) were stained with hematoxylin. 
 
Measurements 
Image acquisition. A light microscope (Leitz) equipped with a motorized stage and focus control 
system and a color digital camera (Coolsnap-Pro; Media Cybernetics, Silver Spring, MD, USA) were 
used to take bright field images of section processed for BrdU (P15) and Ki67 (P15) 
immunohistochemisty. Immunofluorescence images of sections processed for cleaved caspase-3 
(P15) and Ki-67 (P45) were taken with a Nikon Eclipse TE 2000-S inverted microscope (Nikon Corp., 
Kawasaki, Japan), equipped with a Nikon digital camera DS 2MBWc. Immunofluorescence images 
of sections processed for SYN and PSD-95 immunohistochemistry were taken with a LEICA TCS 
SL confocal microscope. Measurements were carried out using Image Pro Plus software (Media 
Cybernetics, Silver Spring, MD 20910, USA). 
Number of BrdU-positive cells. Cells were sampled from the dentate gyrus (DG) and the rostral 
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subventricular zone (SVZ). BrdU-positive cells in the DG and SVZ of P15 mice were detected using 
a light microscope (Eclipse; objective: x 40, 0.75 NA; final magnification: x 400). Quantification of 
BrdU-labeled nuclei was conducted in every 20th section using a modified unbiased stereology 
protocol that has previously been reported as successfully quantifying BrdU labeling (Malberg et al., 
2000, Kempermann and Gage, 2002, Tozuka et al., 2005). All BrdU labeled cells located in the 
granule cell and subgranular layers were counted in their entire z axis (1 µm steps) in each section. 
To avoid oversampling errors, nuclei intersecting the uppermost focal plane were excluded. The total 
number of BrdU labeled cells per animal was determined and multiplied by 20 to obtain the total 
estimated number of cells per DG. 
Number of Ki-67-positive cells. In P15 mice, cells were sampled from the rostral SVZ. The total 
number of positive cells in the DG and SVZ was estimated by multiplying the total number counted 
in the series of sampled sections by the inverse of the section sampling fraction (ssf = 1/20). 
Quantification of Ki-67-labeled nuclei in the DG of P45 mice was conducted in every 6th section 
throughout the whole extent of the DG using a Nikon Eclipse TE 2000-S microscope (objective x 40, 
NA 0.75; final magnification x 400). A modified unbiased stereology protocol for quantification of 
proliferating cells (Malberg et al., 2000, Kempermann and Gage, 2002, Tozuka et al., 2005) was used. 
All Ki-67-labeled cells located in the granule cell and subgranular layers were counted along the 
entire z axis (1 µm steps) of each section. To avoid oversampling errors, the nuclei intersecting the 
uppermost focal plane were excluded. The total number of Ki-67-labeled cells per animal was 
determined and multiplied by six to obtain the total estimated number of cells per DG. We 
additionally evaluated, in P45 mice, the mean number of Ki-67-positive cells per section by dividing 
the number of counted cells by the number of sampled sections. 
Number of cleaved caspase-3 positive cells. In the series of sections processed for cleaved caspase-3 
IHC, cleaved caspase-3-positive cells were counted in the SVZ and DG of P15 mice. Images were 
taken using a fluorescence microscope (Eclipse; objective x 40, 0.75 NA; final magnification: x 400). 
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Total cell count was obtained from the sum of counts across all sections counted. 
Synaptic terminals. The intensity of SYN and PSD-95 immunoreactivity in the molecular layer of the 
DG and in the stratum lucidum of field CA3 of P15 mice was determined by the optical densitometry 
of immunohistochemically-stained sections. Fluorescence images were captured using a Nikon 
Eclipse E600 microscope equipped with a Nikon Digital Camera DXM1200 (ATI system). 
Densitometric analysis of SYN and PSD95 was carried out using the Nis-Elements Software 3.21.03 
(Nikon, Melville, NY, USA). A box of 490 µm2 was placed in the inner, middle and outer third of 
the molecular layer of the upper blade of the DG. Six measurements were taken for each region. For 
each image, the intensity threshold was estimated by analyzing the distribution of pixel intensities in 
the image areas that did not contain IR. This value was then subtracted to calculate IR of each sampled 
area. 
Images of sections immunoprocessed for SYN or PSD-95 of P15 and P45 mice were acquired with a 
confocal microscope (Nikon Ti-E fluorescence microscope coupled with an A1R confocal system, 
Nikon). In each section three images from the molecular layer of the DG and the stratum lucidum of 
field CA3 were captured and the density of individual puncta exhibiting SYN or PSD-95 
immunoreactivity was evaluated as previously described (Guidi et al., 2013). 
Stereology of the DG. Unbiased stereology was performed on Hoechst-stained sections. The optical 
disector method was used to obtain cell density, and the Cavalieri principle was used to estimate 
volume of the granule cell layer of the DG (West and Gundersen, 1990). In P45 mice, one DG is 
represented in 90-110 30-m-thick sections. To include 16-18 sections, every 6th section was 
selected, beginning at a random position within the first 6 sections. For determination of the granule 
cell number, granule cell nuclei were counted with an x 63 oil objective (NA 1.32). In order to obtain 
granule cell numerical density, cells were counted in 30 x 30 counting frames spaced in a 100 m 
square grid superimposed over each section. Cells that intersected the uppermost focal (exclusion) 
plane and those that intersected the exclusion boundaries of the unbiased sampling frame were 
excluded from counting. Cells that met the counting criteria through a 30 µm axial distance were 
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counted according to the optical disector principle. 
The neuron density (Nv) is given by 
NV = (Q/dis)/Vdis 
where Q is the number of particles counted in the disectors, dis is the number of disectors and Vdis 
is the volume of the disector. For volume (Vref) estimation with the Cavalieri principle, in each 
sampled section, the area of the granule cell layer was measured by tracing its contours. The volume 
of the granule cell layer (Vref) was estimated (West and Gundersen, 1990) by multiplying the sum of 
the cross sectional areas by the spacing T between sampled sections (180 m). The total number (N) 
of granule cells was estimated as the product of Vref  and the numerical density (Nv). 
N= NV x Vref 
 
Western blotting  
Total proteins were obtained from hippocampi of P15 and P45 mice. Briefly, hippocampi were 
homogenized in ice-cold RIPA buffer (1% Triton-X100, 150 mM NaCl, 1 mM EDTA and 20 mM 
Tris pH 8) supplemented with 1mM phenyl-methanesulphonylfluoride (PMSF) and 1% proteases and 
phosphatases inhibitors cocktail (Sigma). Samples were then incubated in ice for 30 minutes, 
sonicated for 15 minutes and clarified by centrifugation at 14 000 ¥ g for 20 minutes at 4°C. Protein 
concentration was determined by the Lowry method. Proteins (50 μg) extracted from P15 mice were 
subjected to electrophoresis on a 4-12% Mini-PROTEAN® TGX™Gel (Bio-Rad) and transferred to 
a Hybond ECL nitrocellulose membrane (Amersham Life Science). The following primary antibodies 
were used: anti-Amyloid Precursor Protein, C-Terminal (anti-APP; 1:5000; Sigma-Aldrich); anti-
PTCH1 (1:50; R&D systems), anti-GSK3β (anti-GSK3β; 1:1000; Cell Signaling Technology); anti-
Phospho-GSK3β (Ser9) XP® (anti-pGSK3β Cell Signaling Technology); anti-GAPDH (anti-
GAPDH; 1:10000; Sigma-Aldrich). Proteins (50-80 μg) extracted from P45 mice were subjected to 
electrophoresis on a 4-12% NuPAGE Bis-Tris Precast Gel (Novex, Life Technologies, Ltd, Paisley, 
UK) and transferred to a Hybond ECL nitrocellulose membrane (Amersham Life Science). The 
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following primary antibodies were used: anti-PTCH1 (1:1000; Abcam), anti-p21 (1:500; Santa Cruz 
Biotechnology), anti-APP C-Terminal (1:2000; Sigma-Aldrich) and anti-GAPDH (1:5000; Sigma-
Aldrich). Densitometric analysis of images digitized with ChemiDoc XRS+ was performed with 
Image Lab software (Bio-Rad Laboratories, Hercules, CA, USA) and intensity for each band was 
normalized to the intensity of the corresponding GAPDH band. 
 
Patch-clamp experiments 
Preparation of slices. Mice (P30-P45) were anesthetised by inhalation of isoflurane (Merial Italia, 
Milan, Italy) and transcardially perfused with a cutting solution. The brain was quickly extracted 
under hypothermic conditions and submerged in ice-cold cutting solution. For the preparation of 
slices for the voltage-clamp recordings. Two coronal cuts were made, in order to remove the anterior 
half and the occipital pole of the brain, and the piece thus obtained was laid on the posterior section 
plane. The tissue was blocked on the stage of a Microslicer DTK-1000 vibratome (Dosaka, Kyoto, 
Japan) using cyanoacrilate glue. Coronal slices of the hippocampus, 350-μm thick, were cut 
maintaining the tissue submerged in an ice-cold solution composed of (in mmol/l): 130 K gluconate, 
15 KCl, 20 HEPES, 0.2 EGTA, 11 glucose. The use of this high-K+ solution was found to improve 
neuron viability (Stephane Dieudonné, unpublished results). The slices were then transferred to a 
recovery chamber filled with a maintaining solution continuously bubbled with 95% O2, 5% CO2, at 
room temperature (21-22°C) for at least one hour before starting the recording.  
Voltage-clamp recordings, drugs, and data analysis. Whole-cell, patch-clamp recordings from CA3 
pyramidal neurons were carried out on acute slices of the dorsal hippocampus obtained as described 
above. The experimental set-up employed and the basic procedures followed were the same as 
described elsewhere. Briefly, cells were visualized by means of an upright microscope (Axioskop 2 
FS; Zeiss, Oberkochen, FRG) equipped with a x 60 water-immersion objective lens, differential-
contrast optics, and a near-infrared charge-coupled device (CCD) camera. Slices were perfused with 
ACSF (continuously bubbled with 95% O2, 5% CO2) at a rate of about 1.5 ml/min. Patch pipettes 
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were fabricated from thick-wall borosilicate glass capillaries (CEI GC 150-7.5; Harvard Apparatus, 
Edenbridge, UK) by means of a Sutter P-87 horizontal puller (Sutter Instruments, Novato, CA, USA). 
The pipette solution contained (in mmol/l): 150 CsF, 4 CsCl, 2 MgCl2, 10 N-2-hydroxyethyl 
piperazine-N-2-ethanesulphonic acid (HEPES), 10 ethylene glycol-bis (-aminoethyl ether) 
N,N,N´,N´-tetraacetic acid (EGTA), 2 adenosine 5-triphosphate (ATP)-Na2, 0.2 guanosine 5-
triphosphate (GTP)-Na, 2.5 lidocaine N-ethyl bromide (QX-314) (pH adjusted to 7.2 with CsOH). 
The patch pipettes had a resistance of 3-5 M when filled with the above solution. Tight seals (> 5 
G) and the whole-cell configuration were obtained by suction according to the standard technique 
(Hamill et al., 1981). Excitatory postsynaptic currents (EPSCs) were recorded at room temperature 
(21-22 °C) by means of an Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster City, 
CA, USA). Series resistance (Rs) was evaluated on line by canceling the whole-cell capacitive 
transients evoked by –5-mV voltage square pulses with the amplifier built-in compensation section, 
and reading out the corresponding values. Rs was normally 5-12 M and always < 20 M, and was 
compensated by ~90%. Current signals were acquired in gap-free modality with a personal computer 
interfaced to a Digidata 1322A interface (Axon Instr.) using the Clampex program of the pClamp 8.2 
software package (Axon Instr.). Current signals were low-pass filtered at 5 kHz and digitized at 20 
kHz. Miniature synaptic currents were recorded in the presence of tetrodotoxin (used to block voltage-
gated Na+ channels, and therefore the discharge of Na+-dependent action potentials) in the perfusing 
solution, so as to prevent spontaneous synaptic events due to presynaptic action potential firing. 
Tetrodotoxin (TTx) was purchased from Alomone Labs (Jerusalem, Israel). D-(-)-2-amino-5-
phosphonopentanoic acid (APV; NMDA-receptor antagonist) and (2,3-dihydroxy-6-nitro-7-
sulfamoyl-benzo[f]quinoxaline-2,3-dione) (NBQX; AMPA receptor antagonist) were purchased 
from Tocris (Bristol, UK). Drugs were preliminarily dissolved in H2O and stored in concentrated 
aliquots at -20 °C. At the time of recording, the small aliquots were dissolved to the final 
concentrations (TTx: 1μM; APV 50 μM; NBQX: 10 μM). 
Data analysis. Results were off-line detected using an automated threshold routine in the LabView 
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environment. All detected events were also visually inspected one-by-one for confirmation or 
rejection. To be considered a synaptic event the amplitude of the EPSC was required to be at least 
twice the noise amplitude: the events that showed a lower amplitude were ignored. Accepted events 
were then used to construct frequency distribution diagrams of mEPSC amplitude. The EPSCs 
amplitude from whole-cell recordings were analyzed by means of the program Clampfit of pClamp 
8.2 (Axon Instr.). Peak amplitude values of postsynaptic currents were analyzed with Origin 6.0 
(MicroCal Software, Northampton, MA, USA) in order to build up frequency-distribution diagrams 
of the current recorded. 
 
Statistical analysis 
Data from single animals represented the unity of analysis. Results are presented as mean ± standard 
error of the mean (SE). Distribution of data and the homogeneity of variances were evaluated with 
Shapiro-Wilk test and Levene’s test respectively. Statistical analysis of all examined variables was 
carried out using a two-way ANOVA with genotype (euploid and Ts65Dn) and treatment (vehicle 
and ELN) as factors. Post hoc multiple comparisons were carried out using the Fisher least signiﬁcant 
difference (LSD) test. Data were analyzed with IBM SPSS 22.0 software. For the overall mEPSC 
frequency, a linear mixed model was used. The model has been fit using the Restricted or Residual 
Maximum Likelihood (REML). It calculated the average frequency keeping memory of the number 
of cells recorded in each animal of the same experimental group (95% confidence interval). Data 
were analysed with the software R (The R Project for Statistical Computing; version 3.2.3). For the 
analysis of the decay time constant (dec) of mEPSC as a function of mEPSCs amplitude a linear 
regression analysis was used (y=A+B*X). The relative weight of each data point in the fitting 
procedure was made proportional to the number of events from which the corresponding average 
current had been obtained. Data were analysed with the software Origin 6.0 using the Fit Linear 
function. For all analyses, a probability level of p < 0.05 was considered to be statistically significant.  
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3.1.4 Results 
 
Short-term effect of neonatal treatment with ELN on neurogenesis in the SVZ and SGZ of Ts65Dn 
mice 
We treated euploid and Ts65Dn mice with ELN from P3 to P15, in order to establish whether 
treatment was able to restore neurogenesis in this model. At P15 mice were injected with BrdU and 
were killed after 2h. Evaluation of the number of proliferating cells in SGZ of the dentate gyrus (DG) 
and in the subventricular zone (SVZ) of the lateral ventricle showed that Ts65Dn mice had fewer 
BrdU-positive cells in comparison with euploid mice (Fig. 3.1.2A-D). Treatment with ELN increased 
the number of BrdU-positive cells in Ts65Dn mice, so that treated mice had a similar number of 
BrdU-positive cells as untreated euploid mice both in the DG (Fig. 3.1.2C) and SVZ (Fig. 3.1.2D). 
Treatment had no effects in euploid mice when compared with their untreated counterparts (Fig. 
3.1.2C,D). To establish whether treatment with ELN restores the overall size of the population of 
neural precursors in the DG and SVZ of Ts65Dn mice, we evaluated the number of cells 
immunopositive for Ki-67, an endogenous marker expressed during all the phases of the cell cycle 
(Scholzen and Gerdes, 2000). We found that in the DG of untreated Ts65Dn mice there were fewer 
Ki-67-positive cells in comparison with euploid mice (Fig. 3.1.2E). In treated Ts65Dn mice the 
number of cycling cells underwent a large increase and became similar to that of euploid mice (Fig. 
3.1.2E). Similar findings were obtained in the SVZ (Fig. 3.1.2F). The protein cleaved caspase-3 is 
one of the hallmarks of apoptotic death (Blomgren et al., 2007). The number of apoptotic cells was 
not different between untreated euploid and Ts65Dn mice in both DG and SVZ and treatment did not 
alter cleaved caspase-3- positive cells (Fig. 3.1.2G,H). Taken together, these results indicate that 
treatment with ELN during the first two postnatal weeks restores the number of neural precursor cells 
in the DG and SVZ of Ts65Dn mice and suggest that this effect is due to an increase in 
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Figure 3.1.2. Effect of APP γ-secretase inhibition on proliferation potency in the dentate gyrus and 
subventricular zone of Ts65Dn and euploid mice aged 15 days. Animals received a daily injection of 
ELND006 or vehicle in the period P3-P15. On P15 they received one injection of BrdU and were sacrificed 
after 2 h. A-B: Sections immunostained for BrdU from the DG (A) and SVZ (B) of untreated and treated 
euploid and Ts65Dn mice. Scale bar: 100 µm (A); 50 µm (B). C, D: Total number of BrdU-positive cells in 
the DG (C) and SVZ (D) of untreated euploid (n= 5) and Ts65Dn (n=4) mice and euploid (n=4) and Ts65Dn 
(n=5) mice treated with ELN. E, F: Number of Ki-67-positive cells in the dentate gyrus (E) and SVZ (F) of 
untreated euploid (n= 5) and Ts65Dn (n=4) mice and euploid (n=4) and Ts65Dn (n=5) mice treated with ELN. 
G,H: Number of cleaved caspase-3-positive cells in the DG (G) and SVZ (H) of untreated euploid (n= 5) and 
Ts65Dn (n=4) mice and euploid (n=4) and Ts65Dn (n=5) mice treated with ELN. Values (mean  SE) in (C-
H) represent totals for one hemisphere. * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: DG, dentate 
gyrus; ELN, ELND006; Eu, euploid; LV, lateral ventricle; SVZ, subventricular zone.
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proliferation potency and not to a decrease in cell death. 
In mice, the SGZ produces most of the granule cells that populate the granule cell layer of the DG in 
the first two postnatal weeks (Altman and Bayer, 1975). In order to establish whether the increase in 
the number of neural cell precursors in the DG of treated Ts65Dn mice translated into restoration of 
total granule cell number we evaluated the number of granule cells. In euploid mice, treatment did 
not change the volume of the granule cell layer, granule cell density and total granule cell number 
(Fig. 3.1.3). In contrast, in Ts65Dn mice, treatment significantly increased the volume of the granule 
cell layer, granule cell density and total granule cell number (Fig. 3.1.3). Treated Ts65Dn and 
untreated euploid mice had the same volume of the granule cell layer, granule cell density and total 
granule cell number (Fig. 3.1.3), indicating a treatment-induced rescue in the morphogenesis of the 
granule cell layer. 
 
Short-term effect of neonatal treatment with ELN on hippocampal synapse development 
Since treatment with ELN restored total granule cell number in Ts65Dn mice we wondered whether 
there  were also positive effects on synapse development, a process that is impaired in the trisomic 
brain (Kurt et al., 2004, Belichenko et al., 2007, Chakrabarti et al., 2007, Guidi et al., 2013). To 
answer this question, we evaluated the immunoreactivity for synaptophysin (SYN), a marker of 
presynaptic terminals, and the postsynaptic density protein-95 (PSD-95), a marker of postsynaptic 
terminals, in hippocampal sections from treated and untreated euploid and Ts65Dn mice. We focused 
on two regions of the hippocampal formation, the molecular layer of the DG because this layer 
receives inputs from the perforant pathway (the major input to the hippocampus), and the stratum 
lucidum of field CA3, the site of termination of the axons of the granule cells (Amaral and Witter, 
1995).  
Results showed that the levels of SYN immunoreactivity in untreated Ts65Dn mice was significantly 
lower than in untreated euploid mice in the inner (-21%), middle (-16%) and outer (-15%) molecular 
layer of the DG (Fig. 3.1.4B) and in the stratum lucidum (-13%) of CA3 (Fig. 3.1.4C). In parallel 
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Figure 3.1.3. Effect of APP γ-secretase inhibition on total granule cell number in the dentate gyrus of 
P15 mice. A: Hoechst-stained coronal section across the dentate gyrus of an animal of each experimental 
group. The higher magnification images in the lower row correspond to the region enclosed in the dotted box 
in the upper row. Scale bar = 50 µm (upper row); 10 µm (lower row). B: Volume of the granule cell layer, 
density of granule cells (number per mm3) and total number of granule cells of the DG. Values are mean  SE. 
Volume and granule cell number refer to one hemisphere. * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: 
ELN, ELND006; Eu, euploid; GR, granule cell layer; MOL, molecular layer. 
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with the low levels of SYN immunoreactivity, in Ts65Dn mice there was fewer immunoreactivity for 
PSD-95 in the inner (-10%), middle (-15%) and outer (-8%) molecular layer of the DG (Fig. 3.1.4E) 
and in the stratum lucidum (-10%) of CA3 (Fig. 3.1.4F). Treatment with ELN increased the 
immunoreactivity for SYN (Fig. 3.1.4B,C) and PSD-95 (Fig. 3.1.4E,F) in all zones of the molecular 
layer and in the stratum lucidum of CA3 in Ts65Dn mice, that became similar to that of untreated 
euploid mice. In euploid mice, treatment did not affect the immunoreactivity for SYN (Fig. 3.1.4B,C) 
and PSD-95 (Fig. 3.1.4E,F) both in the DG and CA3. In order to establish whether the effects of 
genotype and treatment on protein levels were attributable to different levels of synaptic proteins per 
synapse or to differences in the number of synapses, we evaluated the density of individual puncta 
exhibiting either SYN or PSD-95 immunoreactivity. While untreated Ts65Dn mice had fewer SYN- 
(Fig. 3.1.5B,C) and PSD-95- (Fig. 3.1.5E,F) positive puncta both in the DG and CA3, neonatal 
treatment with ELN increased the number of SYN (Fig. 3.1.5B,C) and PSD-95- positive puncta (Fig. 
3.1.5E,F) in Ts65Dn mice, that became similar to that of euploid mice in both regions. Together, 
these evidence suggests that treatment had restored hippocampal synapse development.  
 
Short-term effect of treatment with ELN on AICD levels 
An important issue regards the effects of ELN on the activity of γ-secretase and hence, AICD levels 
after treatment cessation. Unfortunately, unlike in cultures of NPCs, it was extremely difficult to 
detect AICD in brain samples processed for western blotting (we detected AICD band in 3% of all 
examined cases only). This small peptide has a very short half-life (about 5 min) (Cupers et al., 2001). 
Thus, its degradation in the phase of brain excision may render it undetectable. Since AICD derives 
from the cleavage of the CTFs, inhibition of the activity of γ-secretase should reduce the levels of 
AICD and, consequently, increase the levels of CTFs. This suggests that an estimate of AICD levels 
can be obtained indirectly by quantifying the levels of the CTFs. Thus, in order to obtain information 
regarding the short-term effect of treatment on AICD levels we evaluated the levels of the CTFs in 
111 
 
Figure 3.1.4. Effect of APP γ-secretase inhibition on synapse development in the hippocampal formation. 
A, D: Sections processed for SYN (A) and PSD-95 (D) immunofluorescence from the DG (upper row) and 
CA3 (lower row) of an animal from each experimental group. Scale bar = 100 m. B, C, E, F: Optical density 
of SYN (B, C) and PSD-95 (E, F) immunoreactivity in the inner, middle and outer third of the molecular layer 
of the DG (B, E) and the stratum lucidum of CA3 (C, F) of untreated euploid (n= 6) and Ts65Dn (n=5) mice 
and euploid (n=6) and Ts65Dn (n=5) mice treated with ELN. For each region, data of SYN and PSD-95 
immunoreactivity are given as fold difference vs. untreated euploid mice. Values in B, C, E, F represent mean 
 SE. * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: ELN, ELND006; Eu, euploid; GR, granule cell 
layer; i, inner; LUC, stratum lucidum; m, middle; MOL, molecular layer; o, outer; PYR, pyramidal layer. 
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Figure 3.1.5. Effect of APP γ-secretase inhibition on the number of puncta in the hippocampal 
formation. A,D: Images, taken with the confocal microscope, of sections processed for SYN (A) and PSD-95 
(D) immunofluorescence from the DG of an animal of each experimental group. Scale bar = 3 m. B, C, E, F: 
Number of puncta per m2 exhibiting SYN (B, C) and PSD-95 (E, F) immunoreactivity in the inner, middle 
and outer third of the molecular layer of the DG (B, E) and the stratum lucidum of CA3 (C, F) of untreated 
euploid (n=6), untreated Ts65Dn (n=5), and euploid (n=6) and Ts65Dn (n=5) mice treated with ELND006. 
Values in B, C, E, F represent mean  SE. * p < 0.05; ** p < 0.01; *** p < 0.001. Abbreviations: ELN, 
ELND006; Eu, euploid; LUC, stratum lucidum.
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P15 euploid and Ts65Dn mice.Results showed that in the hippocampus of untreated Ts65Dn mice 
there were higher levels of CTFs in comparison to euploid mice (Fig. 3.1.6A,B). Treatment with ELN 
in Ts65Dn mice provoked an increase in the levels of CTFs in comparison with their untreated 
counterparts (Fig. 3.1.6A,B), which is consistent with the inhibitory action exerted by ELN on the 
activity of γ-secretase. This indicates that probably levels of AICD underwent a reduction after 
treatment with ELN. 
 
Short-term effect of treatment with ELN on AICD targets 
AICD is a transcription factor that up-regulates various genes, including PTCH1, BACE1, APP and 
GSK3 (Cao and Sudhof, 2001, von Rotz et al., 2004, Nalivaeva and Turner, 2013). In light of this, 
we decided to examine the expression levels of these genes in the hippocampus of treated and 
untreated euploid and Ts65Dn mice. Untreated Ts65Dn mice had higher Ptch1 levels in comparison 
with euploid mice, and treatment with ELN decreased the levels of this protein. As in Ts65Dn mice, 
a reduction in PTCH1 levels also took place in treated euploid mice (Fig. 3.1.7A). BACE1 is an 
enzyme of the beta amyloidogenic pathway that cleaves APP, producing CTF. Ts65Dn mice had 
higher BACE1 levels in comparison with euploid mice. Treatment with ELN reduced treated BACE1 
levels in Ts65Dn mice, that became similar to those of untreated euploid mice, and in euploid mice 
(Fig. 3.1.7B). Untreated Ts65Dn mice had notably higher levels of APP in comparison with euploid 
mice (Fig. 3.1.7C). In Ts65Dn mice APP levels largely decreased after neonatal treatment with ELN 
in comparison with their untreated counterparts, though they remained larger in comparison with 
untreated euploid mice (Fig. 3.1.7C). In euploid mice treatment had no effect on APP levels (Fig. 
3.1.7C). Another protein presents at high levels in Ts65Dn mice in comparison with euploid mice is 
GSK3 a kinase involved in neurogenesis and neuron maturation (Kim and Snider, 2011). Treated 
Ts65Dn mice showed a large reduction in GSK3levels (Fig. 3.1.7D). A reduction in GSK3 levels 
also took place in treated in comparison with untreated euploid mice (Fig. 3.1.7D). In addition to 
regulate GSK3 transcription, AICD has been shown to reduce GSK3 phosphorylation at ser9 
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Figure 3.1.6. Short-term effect of treatment with ELN on CTFs levels. Western blot analysis of CTFs in 
the hippocampus of treated and untreated Ts65Dn and euploid mice (n=8 for each experimental group). Mice 
were treated with ELN in the period P3-P15 and sacrificed at P15. A: Examples of western blot images. B: 
Quantification of CTFs levels in untreated euploid (n = 4) and Ts65Dn (n = 4) and treated euploid (n = 4) and 
Ts65Dn (n = 5) mice normalized to GAPDH. Values (mean  SE) are expressed as fold difference in 
comparison with untreated euploid mice. ** p < 0.01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). 
Abbreviations: ELN, ELND006; Eu, Euploid.
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(Zhou et al., 2012).This kinase becomes active when dephosphorylated at ser9, thereby negatively 
influencing proliferation and differentiation of neural precursor cells. Evaluation of the hippocampal 
levels of the phosphorylated form of GSK3 showed that in untreated Ts65Dn mice the levels of the 
phosphorylated form were reduced in comparison with euploid mice (Fig. 3.1.7E), while after 
treatment there was an increase in the levels of p-GSK3in Ts65Dn mice, becoming higher than 
those of untreated euploid mice. An increase in p-GSK3 levels also took place in treated in 
comparison with untreated euploid mice (Fig. 3.1.7E).  
 
Long-term effect of treatment with ELN on body and brain weight 
We examined the effects of treatment on the body and brain weight in order to obtain information on 
the general effect of neonatal treatment with ELN when mice reached 45 days of age. A two-way 
ANOVA on body weight showed no genotype x treatment interaction; an effect of genotype [F(1,56) 
= 25.704, p ≤ 0.001] was shown, but no effect of treatment emerged. A post hoc Fisher LSD test 
showed that, as previously described, untreated Ts65Dn mice had a reduced body weight in 
comparison with their euploid counterparts (Fig. 3.1.8A). Treatment with ELN did not affect the body 
weight of either Ts65Dn or euploid mice (Fig. 3.1.8A).  
A two-way ANOVA on brain weight revealed no genotype x treatment interaction; a significant effect 
of genotype [F(1,56) = 33.463, p ≤ 0.001] but no effect of treatment. A post hoc Fisher LSD test 
showed that the brain of untreated Ts65Dn mice had a reduced weight in comparison with their 
euploid counterparts (Fig. 3.1.8B). As for the body weight, treatment did not influence the brain 
weight on either Ts65Dn or euploid mice (Fig. 3.1.8B). These results suggest that neonatal treatment 
with ELN has no patent long-term adverse effects on animals’ general conditions.  
 
Long-term effect of treatment with ELN on cell proliferation and cellularity in the dentate gyrus 
We had demonstrated that immediately after neonatal treatment with ELN there was a restoration of 
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Figure 3.1.7. Effect of APP γ-secretase inhibition on AICD targets in P15 mice. A: Western blot analysis 
of PTCH1, APP, phosphorylated GSK3β and total GSK3β in the hippocampus of untreated Ts65Dn (n = 4) 
and euploid (n = 4) mice and treated Ts65Dn (n = 5) and euploid (n = 4) mice. B-E: PTCH1 (B), APP (C), p-
GSK3β (D) and total GSK3β (E) levels. Data in (B, C and E) were normalized to GAPDH and data in (D) 
were normalized to total GSK3β. Values in (B-E) (mean  SE) are expressed as fold difference in comparison 
with untreated euploid mice. All western blot images are explicative reconstructions. * p < 0.05; ** p < 0.01; 
*** p < 0.001. Abbreviations: ELN, ELND006; Eu, euploid.
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Figure 3.1.8. Body and brain weight of P45 euploid and Ts65Dn mice treated with either vehicle or 
ELND006. Untreated euploid mice: n=19; untreated Ts65Dn mice: n=10; treated euploid mice: n=20; treated 
Ts65Dn mice: n=11. ** p < 0,01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in 
the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice; white asterisks in 
the black bar indicate a difference between treated Ts65Dn mice and treated euploid mice. Abbreviations: 
ELN, ELND006; Eu, Euploid.
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the pool size of actively dividing granule cell precursors. Thus, we wondered whether this positive 
effect was retained after treatment cessation. To this purpose, we evaluated the number of Ki-67-
positive cells in the DG of P45 mice. A two-way ANOVA showed a genotype x treatment interaction 
[F(1,20) =23.164, p ≤ 0.001] on total Ki-67-positive cells counted and a genotype x treatment 
interaction [F(1,20) =16.652, p = 0.001] on Ki-67-positive cells per section. Fisher LSD test showed 
that untreated Ts65Dn mice had fewer number of Ki-67-positive cells per section (Fig. 3.1.9B) and 
fewer total number of Ki-67-positive cells (Fig. 3.1.9C) than untreated euploid mice. In contrast, 
Ts65Dn mice that had been neonatally-treated with ELN had a similar number of Ki-67-positive cells 
per section (Fig. 3.1.9B) and a similar total cell number (Fig. 3.1.9C) as untreated euploid mice, 
indicating that the positive effect of treatment on precursor proliferation was retained with time. In 
euploid mice treated with ELN there was a reduction in the number of Ki-67-positive cells per section 
(Fig. 3.1.9B) and total number of Ki-67-positive cells (Fig. 3.1.9C) in comparison with untreated 
euploid mice.  
Then we asked whether the positive impact of treatment on the cellularity of the DG observed in 
neonates in Ts65Dn mice was retained after treatment cessation. To investigate this, we 
stereologically examined the granule cell layer of the DG. 
A two-way ANOVA on total number of granule cells showed a genotype x treatment interaction 
[F(1.20) = 16.070, p ≤ 0.001] but not significant effect of genotype or treatment. As in P15 mice, a 
post hoc Fisher LSD test showed that untreated Ts65Dn mice had fewer granule cells than untreated 
euploid mice (Fig. 3.1.10B), while ELN neonatally-treated Ts65Dn mice had a similar number of 
granule cells as untreated euploid mice (Fig. 3.1.10B), indicating that the positive effect of treatment 
on total granule cell number was retained with time. Unlike in Ts65Dn mice, in euploid mice 
neonatally-treated with ELN there was a reduction in the total number of granule cells in comparison 
with untreated euploid mice (Fig. 3.1.10B).  
  
119 
 
Figure 3.1.9. Long-term effect of treatment with ELN on the size of the population of neural precursor 
cells in the dentate gyrus. A: Examples of sections processed for fluorescence immunostaining for Ki-67 
from the dentate gyrus of untreated euploid and Ts65Dn mice and euploid and Ts65Dn mice treated with ELN. 
Examples of Ki-67-positive cells are indicated in the enlarged boxed area. Calibrations = 200 m (lower 
magnification) and 40 m (higher magnification). B, C: Mean number of Ki-67-positive cells per section (B) 
and total number of Ki-67-positive cells (C) in the DG of treated and untreated Ts65Dn and euploid mice (n=6 
for each experimental group). Values represent mean  SE. * p < 0.05; *** p < 0.001 (Fisher LSD test after 
two-way ANOVA). White asterisks in the black bar indicate a difference between treated Ts65Dn mice and 
treated euploid mice. Abbreviations: ELN, ELND006; Eu, Euploid; Gr, granule cell layer; SGZ, subgranular 
zone. 
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Figure 3.1.10. Long-term effect of treatment with ELN on the number of granule neurons of the dentate 
gyrus. A: Representative images of Hoechst-stained sections of the granule cell layer of an animal from each 
experimental group. The sides of the superimposed optical disector are 30 m in length. The stars indicate 
individual nuclei. Note that nuclei intersecting the exclusion sides (thick lines) were not counted. B: Total 
number of granule cells in untreated and treated euploid and Ts65Dn mice (n=6 for each experimental group). 
Values (mean  SE) refer to one hemisphere. * p < 0.05; ** p < 0.01 (Fisher LSD test after two-way ANOVA). 
Abbreviations: ELN, ELND006; Eu, Euploid. 
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Long-term effects of neonatal treatment with ELN on CTFs levels 
The increased levels of CTFs in P15 mice provided indirect evidence that treatment with ELN had 
caused a reduction in AICD levels. In order to establish whether this effect was retained after 
treatment cessation, we evaluated hippocampal CTFs levels in P45 mice. A two-way ANOVA did 
not reveal a genotype x treatment interaction, no significant effect of treatment but a main effect of 
genotype [F(1,28) = 30.081, p ≤ 0.001]. A post hoc Fisher LSD test showed that CTFs levels in the 
hippocampus of untreated Ts65Dn mice were higher in comparison with euploid mice (Fig. 3.1.11B). 
P45 Ts65Dn mice treated with ELN, however, had similar levels of CTFs as their untreated 
counterparts (Fig. 3.1.11B), indicating that the inhibition exerted by ELN on the activity of γ-
secretase did not outlast treatment cessation. 
 
Long-term effects of neonatal treatment with ELN on PTCH1 levels 
As reported above, P15 Ts65Dn mice show high levels of PTCH1 in the hippocampus, supporting 
our idea that neurogenesis impairment may be attributable to over-inhibition of the Shh pathway. In 
order to establish whether neonatal treatment with ELN caused an enduring effect on PTCH1 levels 
in Ts65Dn mice, we evaluated the expression of this protein in hippocampal homogenates of P45 
mice, i.e. one month after treatment cessation. A two-way ANOVA on hippocampal PTCH1 levels 
did not highlight a genotype x treatment interaction and no significant effects of both genotype and 
treatment were emerged. A post hoc Fisher LSD test showed no statistical differences among the four 
experimental groups (Fig. 3.1.12A,B). These results indicate an age-related normalization of PTCH1 
expression and suggest that the neurogenesis impairment still present in P45 Ts65Dn mice (Fig. 3.1.9) 
cannot be attributed to over-inhibition of the Shh pathway. Unlike in P15 mice, in P45 mice ELN did 
not cause a reduction in PTCH1 hippocampal levels neither in euploid nor in Ts65Dn (Fig. 3.1.12A). 
These findings suggest that neurogenesis defects in P45 Ts65Dn cannot be attributable the alterations 
of the SHH pathway. p21 is a cyclin-dependent kinase inhibitor that inhibits cell cycle progression 
and is expressed at high levels in embryos and infants with Down syndrome and in Ts65Dn mice.  
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Figure 3.1.11. Long-term effect of treatment with ELN on CTFs levels. Western blot analysis of CTFs in 
the hippocampus of treated and untreated Ts65Dn and euploid mice (n=8 for each experimental group). Mice 
were treated with ELN in the period P3-P15 and were sacrificed at P45. A: Examples of western blot images 
of CTFs. B: Quantification of CTFs levels normalized to GAPDH. Values (mean  SE) are expressed as fold 
difference in comparison with untreated euploid mice. *** p < 0.001 (Fisher LSD test after two-way ANOVA). 
Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 
White asterisks in the black bar indicate a difference between treated Ts65Dn mice and treated euploid mice. 
Abbreviations: ELN, ELND006; Eu, Euploid. 
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Figure 3.1.12. Long-term effect of treatment with ELN on protein levels. Western blot analysis of PTCH1 
and p21 in the hippocampus of treated and untreated Ts65Dn and euploid mice (n=8 for each experimental 
group). Mice were treated with ELN in the period P3-P15 and were sacrificed at P45. A-D: Examples of 
western blot images of PTCH1 (B) and p21 (D) and quantification of PTCH1 (A) and p21 (C) levels 
normalized to GAPDH. Values (mean  SE) are expressed as fold difference in comparison with untreated 
euploid mice. (*) p < 0.06; * p < 0.05; ** p < 0.01 (Fisher LSD test after two-way ANOVA). Abbreviations: 
ELN, ELND006; Eu, Euploid. 
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Thus, p21 may be one of the factors that contribute to neurogenesis impairment in DS. For this reason, 
we examined p21 protein levels in the hippocampus of P45 euploid and Ts65Dn mice. A two-way 
ANOVA on p21 levels showed a genotype x treatment interaction [F(1, 28) = 8.354, p = 0.007], but 
no effects of genotype or treatment were revealed. A post hoc Fisher LSD showed that untreated 
Ts65Dn mice had higher levels of p21 than euploid mice. Treatment caused a reduction in p21 levels 
in Ts65Dn mice although this effect was only marginally significant (Fig. 3.1.12C). In contrast, in 
treated euploid mice p21 levels underwent an increase in comparison with untreated euploid mice 
(Fig. 3.1.12C). This evidence provides a mechanistic link between the long-term restoration of 
precursor proliferation found in P45 treated Ts65Dn mice and the reduction in the number of neural 
precursors in treated euploid mice (Fig. 3.1.9).  
 
Long-term effects of neonatal treatment with ELN on hippocampal synapses 
We counted the number of SYN and PSD-95 immunoreactive puncta in the middle molecular layer 
of the DG and the stratum lucidum of field CA3, in order to establish whether neonatal treatment with 
ELN has a long-term effect on hippocampal synapses. 
A two-way ANOVA on the number of SYN puncta in the molecular layer of the DG showed no 
genotype x treatment interaction; a main effect of genotype [F(1,20) = 14.330 p ≤ 0.001] emerged, 
but there was no effect of treatment. A two-way ANOVA on the number of PSD-95 puncta in the 
molecular layer of the DG showed no genotype x treatment interaction; there was an effect of 
genotype [F(1,20) = 46.893, p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed 
that in the molecular layer of the DG, untreated Ts65Dn mice had fewer SYN (Fig. 3.1.13A) and 
PSD-95 (Fig. 3.1.13B) immunoreactive puncta in comparison with untreated euploid mice. Even 
though in treated Ts65Dn mice the number of puncta was slightly larger in comparison with their 
untreated counterparts, this difference was not statistically significant. In the DG of treated Ts65Dn 
mice SYN and PSD-95 immunoreactive puncta were lower in comparison with untreated euploid 
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mice. 
A two-way ANOVA on the number of SYN puncta in the stratum lucidum of field CA3 showed no 
genotype x treatment interaction but did show a significant effect of both genotype [F(1,20) = 13.046, 
p ≤ 0.002] and treatment [F(1,20) = 60.003, p ≤ 0.001]. A two-way ANOVA on the number of PSD-
95 puncta in field CA3 showed a genotype x treatment interaction [F(1,20) = 8.181, p ≤0.010] and a 
main effect of both genotype [F(1,20) = 22.792, p ≤ 0.001] and treatment [F(1,20) =9.432, p ≤ 0.006]. 
A post hoc Fisher LSD test showed that in the field CA3 untreated Ts65Dn mice had fewer SYN 
(Fig. 3.1.13C) and PSD-95 (Fig. 3.1.13D) immunoractive puncta in comparison with untreated 
euploid mice. However, treated Ts65Dn mice showed a larger number of SYN and PSD-95 
immunoreactive puncta in comparison with their untreated counterparts and their number of puncta 
became than that of untreated euploid mice (Fig. 3.1.13C,D), indicating a long-term positive effect 
on the DG-CA3 connections.  
 
Long-term effect of ELN on basal synaptic input to CA3 neurons 
“Miniature” synaptic events reflect the spontaneous release of neurotransmitters from all presynaptic 
terminals converging on the recorded neuron. The frequency of these events is related to the total 
number of presynaptic terminals and the probability of release at each terminal. In order to 
functionally evaluate the basal excitatory synaptic input to CA3 pyramidal neurons, we recorded 
spontaneous miniature excitatory postsynaptic currents (mEPSCs) from individual CA3 pyramidal 
neurons by performing whole-cell, patch-clamp experiments in the voltage-clamp mode. Miniature 
events were recorded in the presence of tetrodotoxin (TTx, 1 M) in the perfusing solution, in order 
to prevent spontaneous synaptic events due to presynaptic action-potential firing.  
Fig. 3.1.14C shows examples of mEPSCs recorded, under the above conditions, in representative 
cells from untreated and ELN-treated euploid and Ts65Dn mice. No spontaneous synaptic events 
were observable any longer after application of the glutamatergic inhibitors NBQX (10 M) + APV 
(50 M) (n=4 cells; not shown). Due to baseline noise levels normally observed at –70 mV, events 
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Figure 3.1.13. Long-term effect of treatment with ELN on hippocampal synapses in Ts65Dn and euploid 
mice. A-D: Images in the panels at the top represent confocal microscope images of sections processed for 
SYN (A, C) and PSD-95 (B,D) immunofluorescence from the molecular layer of the DG (A, B) and the stratum 
lucidum of field CA3 (C, D) of an animal from each experimental group. Calibration=5 m. The histograms 
represent the number of puncta per m2 exhibiting SYN (A, C) and PSD-95 (B, D) immunoreactivity in the 
molecular layer of the DG (A, B) and the stratum lucidum of CA3 (C, D) of treated and untreated Ts65Dn and 
euploid mice (n=6 for each experimental group). Values represent mean  SE. * p < 0.05; ** p < 0.01; *** p 
< 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a difference between 
untreated Ts65Dn mice and treated euploid mice; white asterisks in the black bar indicate a difference between 
treated Ts65Dn mice and treated euploid mice. Abbreviations: ELN, ELND006; Eu, Euploid. 
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Figure 3.1.14. Long-term effect of treatment with ELN on mEPSC frequency in CA3 pyramidal neurons. 
A: Schematic drawing of a section across the hippocampal formation showing the major intrinsic connections. 
Patch clamp recording (rec) of miniature synaptic potentials were carried out from pyramidal neurons of field 
CA3. The area occupied by the mossy fiber terminals in the stratum lucidum of field CA3 is indicated in gray. 
B: Mossy fiber circuitry in CA3. Mossy fibers establish excitatory synapses (+) with pyramidal neurons in the 
stratum lucidum of CA3. C: Exemplary current tracings recorded in the gap-free mode in four representative 
cells from untreated euploid and Ts65Dn mice and euploid and Ts65Dn mice treated with ELN, showing 
mEPSC activity. Holding potential was –70 mV. Recordings were made in the presence of 1-μM TTx in the 
superfusing solution. D: Average frequency-distribution diagrams of mEPSC amplitude for untreated euploid 
and Ts65Dn mice and euploid and Ts65Dn mice treated with ELN. E: Average, overall mEPSC frequency in 
the four animal groups. Data derive from 9 untreated euploid mice (13 cells), 7 untreated Ts65Dn mice (18 
cells), 8 ELN-treated euploid, mice (15 cells), and 4 ELN-treated Ts65Dn mice (12 cells). Values in D-E 
represent mean  SE. ** p < 0.01 (Linear mixed model analysis). Abbreviations: CA1-3, hippocampal fields; 
DG, dentate gyrus; ELN, ELND006; Eu, Euploid; GR, granule cell layer; MF, mossy fivers; PN, pyramidal 
neuron; PP, perforant pathway; PYR, pyramidal layer; SCH, Shaffer collaterals; SL, stratum lucidum. 
128 
of less than 10 pA in peak amplitude were ignored. Accepted events were then used to construct 
frequency-distribution diagrams of mEPSC amplitude. Data were averaged among the cells (n=2 to 
4), from each animal and then among the animals pertaining to the same experimental group. The 
plots obtained are reported in Fig. 3.1.14D. As previously shown (Stagni et al., 2013), in untreated 
Ts65Dn mice there was a reduction in mEPSC frequency for all amplitude classes, with a prominent 
reduction for amplitudes higher than 35 pA (Fig. 3.1.14D). An evaluation of the overall mEPSC 
frequency showed that in untreated Ts65Dn mice it was reduced by ~53% in comparison with 
untreated euploid mice (DF=29; WALD t=-2.670283; p = 0.0123) (Fig. 3.1.14E). In Ts65Dn mice 
treated with ELN there was a global increase in mEPSC frequency. This increase was particularly 
prominent for synaptic events of amplitude greater than 35 pA (Fig. 3.1.14E). The overall mEPSC 
frequency in treated Ts65Dn mice it was increased by ~156% in comparison with untreated Ts65Dn 
mice (DF=28; WALD t=-3.186090; p = 0.0035) and became similar to that of untreated euploid mice 
(Fig. 3.1.14E). In treated euploid mice there was little reduction in the mEPSC frequency in 
comparison with untreated euploid mice (Fig. 3.1.14E).  
Results reported in Fig. 3.1.14D show that genotype and treatment had differential effects on the 
frequency of mEPSCs of different magnitude. According to the theory of electrotonic decay of locally 
generated electric signals, it can be predicted that postsynaptic currents of low magnitude recorded 
from the soma correspond to the activation of synapses with a distal dendritic location, while mEPSCs 
with larger magnitude should mainly correspond to synaptic activation of synapses with a location 
proximal to the soma. Thus, assuming that mEPSCs kinetics are similar among different synaptic 
contacts, the mEPSCs of smaller magnitude should display a slower onset and decay kinetics in 
comparison with mEPSCs of larger amplitude. In order to clarify this issue, we carried out a 
systematic analysis aimed at correlating mEPSC amplitude and decay kinetics. To this purpose, 
mEPSCs recorded in each cell and belonging to the same class of amplitude were used to create a 
single average mEPSC. The decay phase of this average mEPSC was fitted with a single exponential 
function of the first order, which allowed us to obtain a single value for the decay time constant 
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(dec). The dec values obtained for each mEPSCs amplitude class were plotted as a function of the 
corresponding average amplitude. In all experimental groups, save for the group of untreated Ts65Dn 
mice, there was a significant inverse relationship between amplitude of the mEPSCs and their dec 
(untreated euploid mice: R=-0.54975, SD=1.6319, n=24, p = 0.00539; treated euploid mice: R=-
0.40739, SD=0.50525, n=65, p = 7.56715x10-4; treated Ts65Dn mice: R=-0.25085, SD=0.77471, 
n=148, p = 0.0021). The finding that this was not the case for untreated Ts65Dn mice (R=0.03051, 
SD=3.3066, n=51, p=0.83168) suggests that the amplitude heterogeneity of their mEPSCs may be 
due to additional factors, independent from the distance from the soma. For instance, the shape and 
size of the dendritic spines may affect the number of postsynaptic receptors and, thus, the magnitude 
of the mEPSCs. 
 
3.1.5 Discussion 
 
Neonatal treatment with a γ-secretase inhibitor restores neurogenesis in the major postnatal 
neurogenic niches 
Since the hippocampal DG mainly develops in the first two postnatal weeks in mice, we decided to 
treat neonate mice with ELN in this period in order to impact on hippocampal development. We found 
that the reduced number of NPCs in the DG of Ts65Dn mice was fully normalized after 13 days of 
treatment. Similar results were observed in the SVZ, indicating that ELN has a positive impact on 
neurogenic niches throughout the brain. Treatment had no effect on cell death, suggesting that there 
was no effect on cell survival. In agreement with the treatment-induced restoration of neurogenesis 
in Ts65Dn mice, the volume of the granule cell layer and total granule cell number became similar to 
those of euploid mice. In euploid mice, although treatment reduced the levels of PTCH1, there was 
no increase in the proliferation rate either in the SVZ or the SGZ (see Fig. 3.1.8A,B). This suggests 
that in the euploid brain the SHH pathway is normally regulated and that a strong disinhibition does 
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not influence its efficacy. 
 
Neonatal treatment with a -secretase inhibitor has long-term positive effects on neurogenesis in 
Ts65Dn mice 
We found here that inhibition of the activity of the APP γ-secretase by ELN in the neonatal period 
restores PTCH1 levels, the number of hippocampal granule cell precursors and total number of 
granule neurons in P15 mice(Giacomini et al., 2015)(Giacomini et al., 2015)(Giacomini et al., 2015). 
Since it seemed of relevance to establish the duration of these effects, we examined the long-term 
effects of treatment on the pool of neural precursor cells in the DG. We found that at one month after 
treatment cessation the pool of neural precursor cells was still normalized. Consistently with the long-
term restoration of neurogenesis, in treated Ts65Dn mice total number of granule cells was also 
normalized.  
In contrast with P15 Ts65Dn mice, P45 untreated Ts65Dn mice had normal levels of PTCH1. Since 
Ptch1 transcription in addition of being enhanced by AICD is positively and negatively modulated 
by other factors (He et al., 2011, Huang et al., 2012, Memmi et al., 2015), the normalization of its 
expression in P45 Ts65Dn mice suggests age-related changes in the mechanisms that regulate its 
transcription. The finding that untreated P45 Ts65Dn mice still had a reduced pool of neural precursor 
cells in the DG in spite of normal PTCH1 levels suggests that other perturbed mechanisms, such as 
enhanced levels of p21 (Fig. 3.1.12D) may contribute to neurogenesis impairment. This idea is 
strengthened by the observation that in treated P45 Ts65Dn mice there was a reduction in p21 levels 
and a parallel increase of neurogenesis and that in treated euploid mice there was an increase in p21 
levels with a reduction of neurogenesis. These findings suggest that inhibition of γ-secretase in the 
neonatal period leads to changes in p21 levels that outlast the period of treatment. Further studies are 
needed to elucidate the mechanism of p21 regulation mediated by ELN. Taken together, results in 
P15 and P45 mice suggest that the proliferation impairment of trisomic NPCs is due to alteration of 
various pathways and that deregulation of the SHH pathway plays a prominent role during early life 
131 
stages. The finding that in treated euploid mice there was a reduction in the number of NPCs in the 
DG and in total granule cell number indicates that inhibition of γ-secretase activity in the normal 
brain negatively affects the process of neurogenesis.  
 
Neonatal treatment with a -secretase inhibitor reduces the production of AICD, disinhibits the 
SHH pathway and reduces the levels of AICD targets. 
Among the triplicated genes, some located inside and outside the Down syndrome critical region have 
been reported as likely candidates involved in the neurogenesis impairment that characterizes this 
genetic condition (Dierssen, 2012, Costa and Scott-McKean, 2013). Previous (Trazzi et al., 2011, 
Trazzi et al., 2013) and current results highlight the contribution of the triplicated gene APP in 
neurogenesis impairment in DS. App triplication causes excessive formation of AICD which, in turn, 
causes excessive transcription of various genes, including Ptch1, the SHH receptor that inhibits the 
SHH pathway. This pathway is strongly involved in neural precursor cell proliferation, migration and 
differentiation (Machold et al., 2003, Angot et al., 2008). We found that treatment with ELN largely 
increase CTFs levels both in euploid and Ts65Dn mice when compared with their untreated 
counterparts, suggesting a reduction of the AICD levels. Accordingly, we observed a reduction of the 
levels of some AICD target as PTCH1. PTCH1 downregulation and, consequently, SHH pathway 
disinhibition, explains the effects of treatment with ELN on hippocampal proliferation rate restoration 
in the Ts65Dn hippocampus.  
Reduction of AICD levels is probably the cause of the reduction of APP and GSK3two AICD 
targets levels in mice treated with ELN and inhibition of GSK3 activity. Since these proteins may 
affect proliferation potency, their reduction/inhibition could concur to the positive effects of treatment 
in Ts65Dn mice. 
The reduction of PTCH1 levels seen in P15 mice was no longer present in P45 mice, indicating that 
treatment with ELN had no long-term effects on the SHH pathway. This evidence is consistent with 
the observation that CTFs levels in P45 treated Ts65Dn mice were similar to those of untreated 
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Ts65Dn mice, indicating that the inhibitory effect on γ-secretase mediated by ELN disappears with 
time. This implies that ELN should be administered continuously in order to maintain the inhibition 
of γ-secretase. 
 
Neonatal treatment with a -secretase inhibitor restores connectivity the molecular layer of the DG 
and in the CA3 field of the hippocampus. 
A reduced number of synaptic terminals in the Ts65Dn mice has been evidenced in various brain 
regions, including the molecular layer of the DG (Kurt et al., 2004, Belichenko et al., 2007, 
Chakrabarti et al., 2007, Guidi et al., 2013). Therefore, the trisomy-dependent defective functioning 
of hippocampal circuits appears to be also due to input-output alterations. The major hippocampal 
input derives from the entorhinal cortex; then, these signals progress to the DG and are transferred by 
the latter to fields CA3 and then CA1. These signals are essential for hippocampus-dependent long-
term memory functions. We observed that ELN restored the number of pre- and postsynaptic 
terminals in the molecular layer of the DG, suggesting restoration of the major input to the DG. In 
view of the increase in total granule cell number and the number of pre- and postsynaptic terminals 
in the molecular layer of the DG, we wondered whether the counterpart of this effect was an increase 
in the number of terminals in the stratum lucidum of CA3, where the axons of the granule cells end. 
Treated Ts65Dn mice exhibited full restoration of pre- and postsynaptic terminals, suggesting 
restoration of signal transfer to CA3. Neuron maturation is finely regulated by various molecular 
mechanisms, among which the kinase GSK3 appears to play a key role. Activation (de-
phosphorylation) of GSK3 leads to marked shrinkage of dendrites, whereas its inhibition 
(phosphorylation) enhances dendritic growth. Furthermore, there are evidence that GSK3 inhibition 
is required for proper synapse development (Kim and Snider, 2011, Jin et al., 2012, Rui et al., 2013). 
Treatment with ELN increased GSK3 phosphorylation at ser9 in Ts65Dn mice and this could 
explain the observed restoration of synapse development. 
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Neonatal treatment with a -secretase inhibitor has long-term positive effects on connectivity in 
field CA3 of Ts65Dn mice 
As we have discussed above, immediately after treatment cessation Ts65Dn mice had a significantly 
larger number of both SYN and PSD-95 immunoreactive puncta in the hippocampus. Evaluation of 
the pre- and postsynaptic terminals in the molecular layer of the DG in P45 mice showed that one 
month after treatment cessation Ts65Dn mice had still a slight larger number of SYN and PSD-95 
immunoreactive puncta in comparison with their untreated counterparts but this difference was not 
statistically significant. These results show that the restoration of connectivity observed in the DG of 
P15 mice at the end of treatment is not maintained one month after treatment cessation, suggesting 
that continuous treatment may be necessary in order to maintain this effect. Unlike in the molecular 
layer of the DG, in the stratum lucidum of field CA3 of treated Ts65Dn mice there was still a larger 
number of pre- and postsynaptic terminals in comparison with their untreated counterparts. The 
persistence of the effects of treatment on the connectivity in field CA3 can be accounted for by the 
fact that treatment induces long-term restoration of total granule cell number and, hence, of the axons 
sent by the granule neurons to CA3. The number of puncta in CA3 field in the different experimental 
groups is in agreement with patch-clamp recordings from the pyramidal neurons of CA3. In untreated 
Ts65Dn mice there was an overall reduction in the mEPSCs, indicating impairment in the functional 
connectivity of field CA3. The prominent reduction in the frequency of mEPSCs of large amplitude 
in untreated Ts65Dn mice (Fig. 3.1.14D) is thus consistent with loss of synapses proximal to the 
soma. These synapses derive from the mossy fibers, the axons of the granule cells. This conclusion 
is in agreement with the reduction of PSD-95 immunoreactive puncta observed here. The finding that 
in Ts65Dn mice treated with ELN there was a global increase in mEPSC frequency and that this 
increase was particularly prominent for synaptic events of large amplitude (Fig. 3.1.14D) suggests 
that treatment had a positive impact on the mossy fiber input to the proximal dendrites of CA3 
pyramidal neurons. This is fully in agreement with the restoration of the number of SYN and PSD-
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95 immunoreactive puncta in the stratum lucidum of field CA3 and indicates that the restored 
connections are functionally effective.  
 
Side effects of ELND006 
ELND006 is a drug that was created in order to reduce Aβ formation in AD (Basi et al., 2010). Our 
results suggest that inhibitors of APP γ-secretase may be exploited in order to improve neurogenesis 
defects in DS through a reduction in AICD formation. Indeed, we found that early treatment with 
ELN in Ts65Dn mice restored neurogenesis in the two major neurogenic niches of the postnatal brain 
and development of the hippocampal dentate gyrus. Furthermore, we observed that ELN had positive 
long-lasting effects on hippocampal circuitry. Studies have shown that ELN has no toxic effects on 
wild-type mice and primates (Basi et al., 2010), but a clinical trial with ELN for the cure of AD was 
interrupted due to adverse side effects (Hopkins, 2011). In this short article, Hopkins reported that 
ELN, although it is more selective than other γ-secretase inhibitors [such as Semagacestat, Eli Lilly, 
(Hopkins, 2010)], had liver side effects that are thought to be unrelated to ELN mechanism of action. 
In our studies, we observed that a dose of 30.0 mg/kg of ELN from postnatal day 3 (P3) to postnatal 
day 15 (P15) had no acute effect on mice viability, but mice treated with this dose exhibited a higher 
mortality rate (death rate=30-40%) after weaning. For this reason, we decided to reduce the dose of 
ELN to 20.0 mg/kg and we observed that this those was safe for our mice. Yet, though ELN by itself 
may not be a suitable drug for DS (or AD), our studies provides novel demonstration that inhibitors 
of γ-secretase can completely reinstate neurogenesis in the trisomic brain, and that some of the 
positive effects observed in pups were retained with time. Intense research is being carried out in 
order to devise safe inhibitors of γ-secretase for the cure of AD. Moreover, a direct inhibitor of AICD 
activity has recently been developed (Branca et al., 2014). All this evidence prospects that there will 
soon be the possibility to exploit safe drugs in order to reduce AICD levels/activity and correct the 
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neurogenesis defects of DS.  
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3.2 Section 2 
 
”Short- and long-term effects of the green tea extract 
epigallo-catechin-3-gallate in the Ts65Dn mouse model 
of Down syndrome” 
 
Information reported in this section refers to:  
“Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on 
hippocampal development in the Ts65Dn mouse model of Down syndrome”. Stagni F, Giacomini 
A, Emili M, Trazzi S, Guidi S, Sassi M, Ciani E, Rimondini R, Bartesaghi R. Stagni, Giacomini and 
Emili contributed equally to the article. Neuroscience 333 (2016) 277–301. 
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3.2.1 Abstract 
 
Down syndrome (DS) is associated with alterations of neurogenesis, neuron maturation and 
connectivity that are already present at prenatal life stages. Many triplicated genes may be involved 
in the neurodevelopmental alterations that characterize DS. Recent evidence suggests that DYRK1A, 
a kinase that is over-expressed in the DS brain starting from early developmental stages, may play a 
prominent role in the brain phenotype of DS. Epigallocatechin-3-gallate (EGCG), the major 
polyphenol of green tea, performs many actions in the brain, including inhibition of DYRK1A 
activity. A pilot study in young adults with DS has shown that treatment with green tea extracts exerts 
some behavioral benefit, although these effects disappear after treatment cessation. Considering that 
the bulk of neurogenesis takes place very early during development, we deemed it extremely 
important to establish whether treatment with EGCG at the initial stages of brain development leads 
to plastic changes that outlast treatment cessation. In the current study, we treated the Ts65Dn mouse 
model of DS with EGCG from postnatal day 3 (P3) to P15, i.e. during the peak of neurogenesis in the 
hippocampal dentate gyrus and examined the short- and long-term term effects of treatment in P15 
and P45 mice, respectively. We found that at P15, treated Ts65Dn pups exhibited restoration of 
neurogenesis, total hippocampal granule cell number and levels of pre- and postsynaptic proteins in 
the dentate gyrus, hippocampus and neocortex. However, at P45 none of these effects were still 
present, nor did treated Ts65Dn mice exhibit any improvement in hippocampus-dependent tasks. 
These findings show that treatment with EGCG carried out in the neonatal period rescues numerous 
trisomy-linked brain alterations. However, even during this, the most critical time window for 
hippocampal development, EGCG does not elicit enduring effects on the hippocampal physiology. 
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3.2.2 Introduction 
 
DYRK1A is located on HSA 21 and its ortholog, Dyrk1A, is ttriplicated in the Ts65Dn model of DS 
(Gardiner, 2015). DYRK1A over-expression has been linked to neurogenesis deficits (Garcia-Cerro 
et al., 2014, Najas et al., 2015) and connectivity alterations (Benavides-Piccione et al., 2005, 
Murakami et al., 2009). In mice that over-express DYRK1A there are brain and behavioral alterations 
resembling those seen in DS (Dierssen, 2012). 
Epigallocatechin-3-Gallate (EGCG) is a phytochemical found in green tea. Green tea consumption 
appears to be inversely correlated with dementia, Alzheimer’s disease and Parkinson’s disease (Hu 
et al., 2007, Mandel et al., 2008). EGCG appears to have many actions on the brain, including 
inhibition of DYRK1A (Schroeter et al., 2007, Spencer, 2009, Kelsey et al., 2010, Wang et al., 2012, 
Kim et al., 2014), and treatment with green tea extracts has been demonstrated to correct brain 
developmental alterations in transgenic mice that over-express DYRK1A (Guedj et al., 2009, De la 
Torre et al., 2014). There is evidence that after one month of treatment with green tea extracts there 
is an improvement in learning deﬁcits in adult Ts65Dn mice (Guedj et al., 2009, De la Torre et al., 
2014). A pilot study in young adult with DS showed that treatment with green tea extractcs exerts 
some behavioral benefits but that the effects decline after treatment cessation (De la Torre et al., 
2014). It must be observed that neurogenesis, and the overall organization of the brain circuits, is 
determined at early life stages (Stiles and Jernigan, 2010), with the exception of the hippocampal 
dentate gyrus (DG), where neurogenesis continues during the whole life span (Seress et al., 2001, 
Rice and Barone, 2010, Stiles and Jernigan, 2010). In mice, most of the granule cells of the 
hippocampal DG are generated during the first two postnatal weeks (Altman and Bayer, 1975, Altman 
and Bayer, 1990a, b, Workman et al., 2013). Therefore, it is conceivable that treatment with EGCG 
during the most important neurodevelopmental period of the hippocampus may restore  neurogenesis 
and neuron maturation and, possibly, engender permanent effects on behavior. Based on these 
premises, the current study was aimed at establishing whether neonatal therapy with EGCG restores 
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development of the hippocampal DG in the Ts65Dn mouse model and, if so, whether this effect is 
followed by an improvement in cognitive performance. 
 
3.2.3 Materials and Methods 
 
Colony 
In order to obtain Ts65Dn mice, B6EiC3Sn a/ATs(17<16>)65Dn females were mated with 
C57BL/6JEiJ x C3H/HeSnJ (B6EiC3Sn) F1 hybrid males provided by Jackson Laboratories (Bar 
Harbor, ME, USA). We used the first generation of this breeding. The genotyping of the animals was 
carried out as previously described (Reinholdt et al., 2011). The day of birth was designated postnatal 
day zero (P0). A total of 143 mice were used. The mice were kept in a room with a 12:12 h light/dark 
cycle and had free access to water and food. Experiments were performed in accordance with the 
European Communities Council Directive of 24 November 1986 (86/609/EEC) for the use of 
experimental animals and were approved by Bologna University Bioethical Committee (Prot. N.28-
IX/9). All efforts were made to minimize animal suffering and to keep the number of animals used to 
a minimum. 
 
Experimental protocol 
Euploid (n=40) and Ts65Dn (n=25) mice received a daily subcutaneous injection (at 9-10 am) of 
EGCG (Sigma-Aldrich) in 0.9% NaCl solution from postnatal day 3 (P3) to P15 (25.0 mg/kg) (Fig. 
3.2.1A,B). Age-matched euploid (n=53) and Ts65Dn (n=25) mice were injected with the vehicle 
(hereafter referred to as “untreated mice”). Each group was composed of approximately the same 
number of males and females.  
Experiment 1. A group of mice (euploid mice: n=15 untreated; n=15 treated; Ts65Dn mice: n=15 
untreated; and n=15 treated) was killed at the age of 15 days (P15 mice). Before being killed, six mice 
from each of these groups were i.p. injected with BrdU (5-bromo-2-deoxyuridine; Sigma; 150 g/g 
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body weight) in TrisHCl 50 mM 2h, in order to label proliferating cells (Fig. 3.2.1A) (Nowakowski 
et al., 1989). The brains of some P15 mice were fixed by immersion in Glyo-Fixx (as previously 
described (Bianchi et al., 2010b) and embedded in paraffin and the brains of the other P15 mice were 
fixed by immersion in PFA 4% and frozen (left hemisphere) or kept at –80°C for western blotting 
(right hemisphere). Mice were weighed before being sacrificed. After sacrifice, the brain was excised 
and weighed. The body and brain weights of the mice used are reported in Table 3.2.2. The number 
of animals used for each experimental procedure is specified in the figure legends. 
Experiment 2. A second group of mice (euploid mice: n=38 untreated; n= 25 treated; Ts65Dn mice: 
n=10 untreated; and n=10 treated), was treated with EGCG from P3 to P15 h. On P15, mice received 
an i.p. injection (150 g/g body weight) of BrdU in TrisHCl 50 mM and were killed after 30-35 days, 
i.e. at the age of 45-50 days (Fig. 3.2.1B). These mice will be called hereafter P45 mice. Because 
C3H/HeSnJ mice carry a recessive mutation that leads to retinal degeneration, animals were 
genotyped by standard PCR to screen out mice carrying this gene. Mice that did not carry a recessive 
mutation that leads to retinal degeneration entered the behavioral study. Behavioral testing started 9 
days before mice reached 45-50 days of age. The brains of P45 mice were fixed by immersion in PFA 
4% and frozen (left hemisphere) or kept at –80°C for western blotting (right hemisphere). Mice were 
weighed before being sacrificed. After sacrifice, the brain was excised and weighed. The body and 
brain weights of the mice used are reported in Table 3.2.2. The number of animals used for each 
experimental procedure is specified in the figure legends. 
 
Histological procedures 
P15 mice. The brains of P15 mice embedded in paraffin were cut into 8-m-thick coronal sections. 
Slices were processed for Ki-67 and cleaved caspase-3 immunohistochemistry. The frozen brains of 
P15 mice were cut with a freezing microtome into 30-m-thick coronal sections that were serially 
collected in anti-freezing solution (30% glycerol; 30% ethylen-glycol; 10% PBS10X; sodium azide 
0.02%; MilliQ to volume) (free-floating sections). Slices were used for BrdU and SYN/PSD95 double 
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Figure 3.2.1. Experimental protocols. A: Euploid and Ts65Dn mice received a daily injection of 
either vehicle (Euploid + Vehicle; Ts65Dn + Vehicle) or EGCG (25.0 mg/kg; Euploid + EGCG; 
Ts65Dn + EGCG) from postnatal (P) day 3 to P15. At P15, mice received one injection of BrdU, and 
were killed after 2 h in order to evaluate the number of cells in the S-phase of the cell cycle. The brains 
of these mice were used for immunohistochemistry and western blotting. B: Euploid and Ts65Dn mice 
received a daily injection of either vehicle (Euploid + Vehicle; Ts65Dn + Vehicle) or EGCG (25.0 
mg/kg; Euploid + EGCG; Ts65Dn + EGCG) from P3 to P15. Mice were killed on P45-P50 after 9 
days of behavioral tests. The brains of these mice were used for immunohistochemistry and western 
blotting. Abbreviations: BrdU, bromodeoxyuridine; P, postannatal.
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immunofluorescence. 
P45 mice. The frozen brains of P45 mice were cut with a freezing microtome into 30-m-thick 
coronal sections that were serially collected in anti-freezing solution (free-floating sections).  Slices 
were used for BrdU/NeuN, BrdU/GFAP, and SYN/PSD-95 double immunofluorescence. 
 
Immunohistochemistry 
The antibodies for immunohistochemistry, with their dilution and purpose are summarized in Table 
3.2.1. 
Ki-67 immunohistochemistry in P15 and P45 mice. One out of 20 sections (n=14-18 sections) of 
paraffin-embedded brains taken from the rostral pole of the lateral ventricle to the end of the 
hippocampal formation of P15 mice, and one out of six free-floating sections (n=14-17 sections) from 
the hippocampal formation of P45 mice, was processed for Ki-67 immunohistochemistry. The 
secondary antibodies used for detection are reported in Table 3.2.1. 
Cleaved caspase-3 immunohistochemistry in P15 and P45 mice. One out of 20 sections (n=14-18 
sections) of paraffin-embedded brains taken from the rostral pole of the lateral ventricle to the end of 
the hippocampal formation of P15 mice, and one out of six free-floating sections (n=14-17 sections) 
from the hippocampal formation of P45 mice, was processed for cleaved caspase-3 
immunohistochemistry. The secondary antibodies used for detection are reported in Table 3.2.1.  
BrdU immunohistochemistry in P15. One out of six free-floating sections (n=13-16 sections) from 
the hippocampal formation of P15 mice was processed for BrdU immunohistochemistry as described 
in Section 3.1. Slices were incubated with a rat anti-BrdU antibody (mouse monoclonal 1:100, Roche 
Applied Science, Mannheim, Germany). Detection was performed with a CY3-conjugated anti rat-
secondary antibody as indicated in Table 3.2.1.  
Double-fluorescence IHC for BrdU/NeuN and BrdU/GFAP in P45 mice. One out of six free-floating 
sections (n=14-17 sections) from the hippocampal formation of P45 mice was incubated with a 
primary anti-BrdU antibody and either a NeuN or GFAP primary antibody as indicated in 
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Table 3.2.1 Antibodies used for immunohistochemistry and western blotting. 
 
IHC, immunohistochemistry; DFIHC, Double-fluorescence immunohistochemistry; FIH, fluorescence 
immunohistochemistry; WB, Western blotting.
Antigen Application Antibody – Dilution- Manufactures  Purpose 
5-bromo-2-
deoxyuridine 
(BrdU) 
FIH 
DFIHC 
Primary: rat monoclonal 1:200 (Roche 
Applied Science) 
Secondary: Cy3-conjugated anti-rat IgG 
1:200 (Jackson Immunoresearch) 
To detect BrdU positive cells 
(surviving cells)  
Cleaved 
caspase-3 
IHC Primary: rabbit monoclonal 1:100 (Cell 
Signaling Technology 
Secondary: Cy3-conjugated anti-rabbit 
IgG 1:200 (Jackson Immunoresearch) 
To label apoptotic cells  
GAPDH 
WB Primary: rabbit polyclonal 1:5000 
(Sigma-Aldrich) 
Secondary: HRP-conjugated anti-rabbit 
1:10000 (Jackson Immunoresearch) 
To examine the levels of the 
housekeeping protein GAPDH 
Glial fibrillary 
acidic protein 
(GFAP) 
DFIHC Primary: rabbit polyclonal 1:400 
(Abcam) 
Secondary: FITC-conjugated anti-rabbit 
IgG 1:200 (Jackson Immunoresearch) 
To detect surviving cells 
differentiated into astrocytes  
GSK3 
WB Primary: mouse monoclonal 1:1000 
(Cell Signaling Technology) 
Secondary: HRP-conjugated anti-mouse 
1:10000 (Jackson Immunoresearch) 
To examine the expression of 
the dephosphorylated form  
(active) of the kinase GSK3 
Phospho-
GSK3(Ser9) 
WB Primary: rabbit monoclonal 1:1000 
(Cell Signaling Technology) 
Secondary: HRP-conjugated anti-rabbit 
1:10000 (Jackson Immunoresearch) 
To examine the expression of 
the phosphorylated form 
(inactive) of the kinase GSK3 
Ki-67 
IHC Primary: rabbit monoclonal 1:100 
(Thermo Scientific) 
Secondary: HRP-conjugated anti-rabbit 
dilution 1:200 (Jackson 
Immunoresearch) and DAB kit (Vector 
Laboratories) 
To label cycling cells (Ki-67 is 
expressed in all phases of the 
cell cycle except early G1) 
Neuronal-
specific 
nuclear protein 
(NeuN) 
DFIHC Primary: mouse monoclonal 1:400 
(Millipore) 
Secondary: FITC-conjugated anti-
mouse IgG 1:200 (Jackson 
Immunoresearch) 
To detect surviving cells that 
have differentiated into neurons 
p21 
WB Primary: mouse monoclonal 1:500 
(Santa Cruz Biotechnology) 
Secondary: HRP-conjugated anti-mouse 
1:10000 (Jackson Immunoresearch) 
To examine the expression p21, 
an inhibitor of cell cycle 
progression  
Postsynaptic 
density 
protein-95 
(PSD-95) 
IHC Primary: rabbit polyclonal 1:1000 
(Abcam) 
Secondary: CY3-conjugated anti-rabbit 
1:200 (Jackson Immunoresearch) 
To label postsynaptic regions 
Synaptophysin 
(SYN) 
IHC Primary: mouse monoclonal 1:1000 
(Millipore-Biomanufacturing and Life 
Science Research) 
Secondary: FITC-conjugated anti-
mouse 1:200 (Jackson Immunoresearch) 
To label presynaptic terminals 
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Table 3.2.1. The secondary antibodies used for detection are reported in Table 3.2.1.  
Double-fluorescence IHC for SYN and PSD-95 in P15 and P45 mice. One out of six free-floating 
sections from the rostral two-thirds of the hippocampal formation of P15 and P45 mice (n=4-6 
sections) was incubated with the antibodies indicated in Table 3.2.1.  
 
Nissl-staining 
One out of six free-floating sections taken from the beginning to the end of the hippocampal formation 
of P15 (n=13-16 sections) and P45 (n=14-17 sections) mice was stained with toluidine blue according 
to the Nissl method. 
 
Measurements 
Image acquisition. A light microscope (Leitz) equipped with a motorized stage and focus control 
system and a color digital camera (Coolsnap-Pro; Media Cybernetics, Silver Spring, MD, USA) were  
used to take bright field images. Immunofluorescence images were taken with a Nikon Eclipse TE 
2000-S inverted microscope (Nikon Corp., Kawasaki, Japan), equipped with a Nikon digital camera 
DS 2MBWc. Immunofluorescence images of sections processed for i) SYN and PSD-95 
immunohistochemistry of P15 and P45 animals, and ii) BrdU/NeuN or BrdU/GFAP of P45 animals 
were taken with a LEICA TCS SL confocal microscope. Measurements were carried out using Image 
Pro Plus software (Media Cybernetics, Silver Spring, MD 20910, USA) or ImageJ v1.51a. 
Ki-67 positive cells in P15 and P45 mice. Images of the series of sections processed for Ki-67 IHC 
from the subventricular zone (SVZ) and dentate gyrus (DG) of P15 mice and from the DG of P45 
mice were taken using a light microscope (Leitz; objective: x 40, 0.70 NA; final magnification: x 
500). Images were taken at the focal plane at which the largest number of cells was recognizable. In 
this study, the SVZ corresponds to the region comprised between the beginning of the lateral ventricle 
and the beginning of the hippocampal formation. In the SVZ, an area enclosing the dorso-lateral and 
medial wall of the lateral ventricle was manually traced and all Ki-67-positive cells within this area 
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were counted. In the DG, an area enclosing the granule cell layer + subgranular zone + hilus was 
manually traced and all Ki-67-positive cells within this area were counted. Cells were counted in the 
series of sections processed for Ki-67 immunohistochemistry from the SVZ and DG. The counted 
cells are expressed here as “total cell count”, obtained from the sum of counts across all sections 
counted, and as “cells per unit area”, obtained by dividing the number of counted cells by the traced 
area and expressed as cells/mm2. The number of cells per unit area in individual sections was averaged 
in order to obtain the mean number of cells per unit area in each mouse.  
Cleaved caspase-3 positive cells in P15 and P45 mice. In the series of sections processed for cleaved 
caspase-3 immunohistochemistry, cleaved caspase-3-positive cells were counted in the SVZ and DG 
of P15 mice and in the DG of P45 mice. Images were taken using a fluorescence microscope (Eclipse; 
objective x 40, 0.75 NA; final magnification: x 400). Total cell count was obtained from the sum of 
counts across all sections counted. 
BrdU-positive cells in P15 mice. Images of the series of sections processed for BrdU 
immunohistochemistry from the DG were taken using a fluorescence microscope (Eclipse; objective: 
x 40, 0.75 NA; final magnification: x 400). Images were taken at the focal plane at which the largest 
number of cells was recognizable. Cells were counted in the series of sections processed for BrdU 
immunohistochemistry from the DG, within a manually-traced area enclosing the granule cell layer 
+ subgranular zone + hilus. Total cell count and the number of cells per unit area were obtained as 
indicated above for Ki-67-positive cells.  
Number of BrdU-positive cells and cell phenotypes in the DG of P45 mice. Quantification of BrdU-
labeled nuclei in the DG was conducted in every 6th section using a confocal microscope (objective 
x 40, NA 0.75; final magnification x 400). In order to quantify BrdU labeling, we used a modified 
unbiased stereology protocol (Malberg et al., 2000, Kempermann and Gage, 2002, Tozuka et al., 
2005). All BrdU-labeled cells located in the granule cell and subgranular layers were counted along 
the entire z axis (1 µm steps) of each section. To avoid oversampling errors, the nuclei intersecting 
the uppermost focal plane were excluded. The total number of BrdU-labeled cells per animal was 
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determined and multiplied by six to obtain the total estimated number of cells per DG. For double-
labeling, we randomly selected 100 BrdU-labeled nuclei across the DG and counted the number of 
BrdU-positive nuclei that co-expressed either NeuN or GFAP. BrdU-positive nuclei were analyzed 
(oil objective x 63, NA 1.32) along the entire z-axis (0.5 µm steps) and were rotated onto orthogonal 
planes (x–y) to verify double-labeling and to exclude false double-labeling caused by the overlay of 
signals from different cells. The percentage of BrdU-labeled nuclei that co-expressed either NeuN or 
GFAP, or neither of these two markers, was calculated. The total number of cells with a neuronal 
(BrdU+/NeuN+ cells) phenotype, an astrocytic (BrdU+/GFAP+ cells) phenotype, or an undetermined 
phenotype (i.e. BrdU+ cells that did not express either of the two markers) was estimated by 
multiplying the absolute numbers of BrdU-positive cells by the percentage of co-localisation for each 
of those two markers, or by no co-localization for either marker.  
Synaptic terminals in P15 and P45 mice. Optical densitometry was used to evaluate the intensity of 
SYN and PSD-95 immunoreactivity in the DG, hippocampal fields CA3 and CA1, and neocortex 
overlying the hippocampus in fluorescence images captured with an Eclipse microscope (objective x 
20, 0.50 NA; final magnification x 200). Densitometric analysis was carried out using Image Pro Plus 
software, as described in Section 3.1. For evaluation of puncta exhibiting SYN or PSD-95 
immunoreactivity in the DG, hippocampal fields CA3 and CA1, and neocortex overlying the 
hippocampus, images were acquired using a confocal microscope (objective x 63, NA 1.32; zoom 
factor=8). Three images from the regions of interest were captured in each section and the density of 
SYN or PSD-95 immunoreactive puncta was evaluated as previously described (Guidi et al., 2013).  
Stereology of the DG. Unbiased stereology was performed on Nissl-stained sections of the brain of 
P15 and P45 mice, as previously described (Severi et al., 2005, Bianchi et al., 2010b). The protocol 
used for the stereology of the DG is the same as the one used in Section 3.1. 
 
Western blotting 
Total proteins were obtained from hippocampal homogenates of P15 and P45 as described in Section 
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3.1. Equivalent amount of proteins (50 μg) were subjected to electrophoresis on a 4-12% NuPAGE 
Bis-Tris Precast Gel (Novex, Life Technologies, Ltd, Paisley, UK) and transferred to a Hybond ECL 
nitrocellulose membrane (Amersham Life Science). The levels of p21, ser9 phosphorylated GSK3β, 
and total GSK3β were examined using the antibodies reported in Table 3.2.2. Images were digitized 
with ChemiDoc XRS+ and densitometric analysis was carried out with Image Lab software (Bio-Rad 
Laboratories, Hercules, CA, USA). Intensity of each band was normalized to the intensity of the 
corresponding GAPDH band. 
 
Behavioral testing 
Ts65Dn (untreated n=10, treated n=10) and euploid (untreated n=38, treated n=25) mice were 
behaviorally tested using the Y-maze (YM) tests and the Morris Water Maze (MWM). All 
behavioural tests were conducted on P45 mice, i.e. 30-35 days after treatment cessation. 
YM. YM testing was performed using an apparatus with three equal arms (35 cm long, 5 cm wide, 10 
cm high) made of gray solid plastic and set at angles of 120°. Each mouse was placed at the center of 
the maze and allowed to move freely for a 10-min session. Data were collected during the first 6-min 
period of each session. Mice with fewer than 10 arm entries during the 6-min observation period were 
not included in the analysis. All four limbs were required to enter an arm for the entry to be considered 
valid. A series of three entries into three different arms is defined as a triad. The percentage of 
alternations was calculated as 100 x (number of correct alternations)/(total number of arm entries - 
2).  
MWM. Mice were trained in the MWM task to locate a hidden escape platform in a circular pool, 
using a previously a protocol based on a published protocol (Vorhees and Williams, 2006). The 
apparatus consisted of a large circular water tank (1.00 m diameter, 50 cm height) with a transparent 
round escape platform (10 cm2). The pool was virtually divided into four equal quadrants identified 
as northeast, northwest, southeast, and southwest. The tank was filled with tap water at a temperature 
of 22±1.0ºC. The tank was filled with water up to 0.5 cm above the top of the platform and the water 
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was made opaque with milk. The platform was placed in the tank in a fixed position (in the middle 
of the south-west quadrant). The pool was placed in a large room with various intra- (squares, 
triangles, circles and stars) and extra-maze visual cues. Each mouse was tested in one session of 4 
trial on the first day and in two sessions of 4 trials in the following 4 days with an inter-session interval 
of 45 min. A video camera was placed above the center of the pool and connected to a videotracking 
system (Ethovision 3.1; Noldus Information Technology B.V., Wageningen, Netherlands). Mice were 
randomely released facing the wall of the pool from one of the following starting points: North, East, 
South, or West and allowed to search for up to 60 s for the platform. If a mouse did not find the 
platform, it was gently guided to it and allowed to remain there for 15 s. During the inter-trail time 
(10 s) mice were placed in an empty cage. For the learning phase, we evaluated the latency to find 
the hidden platform. Retention of memory was assessed with one trial (probe trial), on the sixth day, 
24 h after the last acquisition trial, using the same starting point for all mice. The platform was 
removed from the tank and mice were allowed to search for up to 60 s for the platform. For the probe 
trial, the latency of the first entrance in the trained platform zone, the frequency of entrances in the 
platform quadrant, and the percentage of time spent in the trained platform quadrant were employed 
as measures of retention of acquired spatial preference. All experimental sessions were carried out 
between 9.00am and 5.00pm.  
 
Statistical analysis 
Data from single animals represented the unity of analysis. Results are presented as mean ± standard 
error of the mean (SE). Data were analyzed with IBM SPSS 22.0 software. Distribution of data and 
the homogeneity of variances were evaluated with Shapiro-Wilk test and Levene’s test respectively. 
Statistical analysis was carried out using a two-way ANOVA with genotype (euploid and Ts65Dn) 
and treatment (vehicle, EGCG) as factors. Post hoc multiple comparisons were carried out using the 
Fisher least signiﬁcant difference (LSD) test. For the learning phase of MWM, statistical analyses 
was performed using a three-way mixed ANOVA, with genotype and treatment as grouping factors 
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and days as a repeated measure. For the probe test of MWM and for the YM, we used a two-way 
ANOVA with genotype and treatment as factors followed by the Fisher LSD post hoc test. A 
probability level of p ≤ 0.05 was considered to be statistically significant.  
 
3.2.4 Results 
 
General results of P15 mice 
The Ts65Dn strain is characterized by a high mortality rate during gestation and before weaning 
(Roper and Reeves, 2006). In the current study, treatment with either EGCG or vehicle began on 
postnatal day 3 (P3). All mice of the litters used in this study that survived in the P0 to P3 period 
entered the study, with no specific selection criteria. Six vehicle-treated (7%) and five EGCG-treated 
(7%) mice died before weaning, in the P6-P22 period. The similarity in the mortality rate across 
groups suggests that treatment has no adverse effects on the health of mice. We evaluated the body 
and brain weight of P15 mice in order to establish the short-term effect of treatment. A two-way 
ANOVA on the body weight of P15 mice showed no genotype x treatment interaction, a main effect 
of genotype in males [F(1,26) = 12.81, p ≤ 0.001] and females [F(1,26) = 6.29, p ≤ 0.05] and no 
effects of treatment. Two-way ANOVA on brain weight did not show genotype x treatment 
interaction and no significant effects of both genotype and treatment. Post hoc Fisher LSD test 
showed no statistical differences among the four experimental groups. The finding that the body and 
brain weight were not reduced by treatment (Table 3.2.2) suggests that treatment has no adverse 
effects. 
 
Short-term effects of neonatal treatment with EGCG on the proliferation potency of neural 
precursor cells 
The subventricular zone (SVZ) and the hippocampal dentate gyrus (DG) represent the major 
neurogenic regions of the postnatal brain. We made Ki-67 immunohistohemistry in P15 mice in order 
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Table 3.2.2. Body and brain weights of treated and untreated mice. 
 
Body and brain weight (mean  SE) in grams of P15 and P45 euploid and Ts65Dn mice that received either 
vehicle or EGCG in the period P3-P15, measured on postnatal days 15 (P15) or P45. The number of mice of 
each group is reported in the n column. The p values in the row below the body and brain weight refer to the 
comparison between euploid and Ts65Dn mice. The p values in the column on the right refer to the comparison 
between untreated and treated mice of the same genotype. n.s. not significant (Fisher LSD test after two-way 
ANOVA with genotype and treatment as factors).  
  Vehicle   EGCG    
  Mean  SE n  Mean  SE n p  
P15             
Body              
Males Euploid 7.67  0.60 (7)  7.53  0.36 (8) n.s.  
 Ts65Dn  5.68  0.41 (8)  6.60  0.44 (7) n.s.  
 p 0.01     n.s.      
Females Euploid 6.40  0.57 (8)  7.71  0.48 (7) n.s  
 Ts65Dn  5.77  0.45 (7)  5.64  0.58 (8) n.s  
 p n.s.     0.01      
Brain             
Males Euploid 0.396  0.003 (7)  0.399  0.008 (8) n.s.  
 Ts65Dn  0.389  0.009 (8)  0.386  0.010 (7) n.s.  
 p n.s     n.s      
Females Euploid 0.390  0.007 (8)  0.405  0.007 (7) n.s  
 Ts65Dn  0.397  0.008 (7)  0.396  0.011 (8) n.s  
 p n.s     n.s.      
             
P45             
Body              
Males Euploid 21.62  0.60 (17)  21.10  0.72 (12) n.s.  
 Ts65Dn  17.86  1.16 (5)  17.74  1.46 (5) n.s.  
 p 0.05     n.s.      
Females Euploid 17.58  0.40 (21)  20.61  1.69 (13) 0.05  
 Ts65Dn  16.23  1.43 (5)  15.34  1.08 (5) n.s.  
 p n.s     n.s.      
Brain             
Males Euploid 0.474  0.006 (17)  0.460  0.006 (12) n.s.  
 Ts65Dn  0.437  0.017 (5)  0.443  0.010 (5) n.s.  
 p 0.01     n.s.      
Females Euploid 0.456  0.009 (21)  0.452  0.004 (13) n.s.  
 Ts65Dn  0.428  0.015 (5)  0.442  0.013 (5) n.s.  
 p 0.05     n.s.      
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to evaluate the number of NPCs in both these regions.  
We evaluated the total number of Ki-67-positive cells counted in the series of sampled sections and 
their number per unit area.  
A two-way ANOVA on total Ki-67-positive cells counted in the SVZ showed a genotype x treatment 
interaction [F(1,20) = 5.93, p ≤ 0.05] and a significant effect of treatment [F(1,20) = 24.49, p ≤ 0.001], 
but no effect of genotype. A post hoc Fisher LSD test showed that the number of Ki-67-positive cells 
in untreated Ts65Dn mice was reduced in comparison with untreated euploid mice. This difference 
disappeared in neonatally-treated Ts65Dn mice (Fig. 3.2.2B). A two-way ANOVA on the density of 
Ki-67-positive cells in the SVZ showed no genotype x treatment interaction, but there was a 
significant effect of both genotype [F(1,20) = 6.35, p ≤ 0.05] and treatment [F(1,20) = 29.67, p ≤ 
0.001]. A post hoc Fisher LSD test showed that in untreated Ts65Dn mice the density of Ki-67-
positive cells was reduced in comparison with untreated euploid mice. This difference disappeared in 
neonatally-treated Ts65Dn mice (Fig. 3.2.2C).  
A two-way ANOVA on total Ki-67-positive cells counted in the DG showed a genotype x treatment 
interaction [F(1,20) = 25.42, p ≤ 0.001] and a significant effect of both genotype [F(1,20) = 21.11, p 
≤ 0.001] and treatment [F(1,20) = 26.68, p ≤ 0.001]. A post hoc Fisher LSD test showed that the total 
number of Ki-67-positive cells in untreated Ts65Dn mice was lower than that found in untreated 
euploid mice. Ts65Dn mice neonatally-treated with EGCG showed a similar number of Ki-67-
positive cells in comparison with untreated euploid mice (Fig. 3.2.3B). A two-way ANOVA on the 
density of Ki-67-positive cells in the DG showed a genotype x treatment interaction [F(1,20) = 5.51, 
p ≤ 0.05], with no effect of genotype, but a significant effect of treatment [F(1,20) = 38.62, p ≤ 0.001]. 
A post hoc Fisher LSD test showed that in untreated Ts65Dn mice the density of Ki-67-positive cells 
was reduced in comparison with untreated euploid mice and that treatment with EGCG restored this 
defect (Fig. 3.2.3C). 
In order to establish whether treatment affects apoptotic cell death, brain sections comprising the SVZ 
and the DG were subjected to immunohistochemistry for cleaved caspase-3. No genotype x treatment 
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Figure 3.2.2. Effects of neonatal treatment with EGCG on neural precursor number in the 
subventricular zone of P15 mice. A: Examples of sections immunostained for Ki-67 from the 
subventricular zone of an animal from each experimental group. Calibration bar=200 m. The insets 
show zoomed images with examples of individual Ki-67-positive cells. Calibration bar=10 m. B-E: 
Ki-67 positive cells expressed as total cell count (B), as cells/mm3 (C), as cells per section (D) and 
number of cleaved caspase-3-positive cells expressed as total cell count (E) in the SVZ of untreated 
and treated euploid and Ts65Dn mice (n=6: 3 males and 3 females for each of the four experimental 
groups). Values (mean  SE) refer to one hemisphere. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher 
LSD test after two-way ANOVA). Asterisks over the brackets indicate a difference between the two 
indicated groups. Abbreviations: Casp, Caspase-3; d, dorsal; l, lateral; LV, lateral ventricle; m, medial; 
SVZ, subventricular zone; v, ventral. 
 
153 
interaction was found; nor there were any main effects of genotype or treatment for the total number 
of cleaved caspase-3-positive cells counted in the SVZ and DG. A post hoc Fisher LSD test showed 
no differences between untreated euploid and Ts65Dn mice in the number of cleaved caspase-3-
positive cells and that treatment did not affect this parameter in both the SVZ (Fig. 3.2.2E) and DG 
(Fig. 3.2.3D). 
In view of its role on cell cycle progression, we analyzed the levels p21 (cip1/WAF1), a cyclin-
dependent kinase that inhibits cell cycle progression and is overexpressed in brains of DS people. A 
two-way ANOVA on p21 protein levels in hippocampal homogenates of mice aged 15 days showed 
a genotype x treatment interaction [F(1,20) = 6.86, p ≤ 0.05], no main effect of genotype, but a main 
effect of treatment [F(1,20) = 17.07, p ≤ 0.001]. A post hoc Fisher LSD test showed that untreated 
mice had higher levels of p21 in comparison with untreated euploid mice (Fig. 3.2.3E) and that 
treatment with EGCG normalized p21 levels (Fig. 3.2.3E). No effect of treatment on p21 levels was 
found in euploid mice (Fig. 3.2.3E).  
We then evaluated the effect of treatment on the population of cells in the S-phase of the cell cycle. 
To this purpose, we administered to Ts65Dn and euploid mice BrdU on P15 and the number of BrdU-
positive cells in the DG was evaluated 2h after the injection. A two-way ANOVA on the total number 
of BrdU-positive cells showed no genotype x treatment interaction, but a main effects of both 
genotype [F(1,20) = 16.74, p ≤ 0.001] and treatment [F(1,20) = 5.00, p ≤ 0.05] emerged. A post hoc 
analysis with Fisher LSD test showed that in untreated Ts65Dn mice there were fewer BrdU-positive 
cells than that of untreated euploid mice; this difference disappeared in treated Ts65Dn mice (Fig. 
3.2.4B). A two-way ANOVA on the density of BrdU-positive cells showed a genotype x treatment 
interaction [F(1,20) = 6.19, p ≤ 0.05], no effect of genotype, but a main effect of treatment [F(1,20) 
= 4.48, p ≤ 0.05]. A post hoc Fisher LSD test showed that untreated Ts65Dn mice had a number of 
BrdU positive cells/mm2 lower than that of untreated euploid mice and that treatment restored this 
defect (Fig. 3.2.4C). 
Taken together these results show that neonatal treatment with EGCG restores the population of the 
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Figure 3.2.3. Effects of neonatal treatment with EGCG on neural precursor number in the dentate gyrus 
of P15 mice. A: Examples of sections immunostained for Ki-67 from the dentate gyrus of an animal from each 
experimental group. Calibration bar=100 m. Calibration bar=10 m. B-E: Ki-67-positive cells expressed as 
total cell count (B), as cells/mm3 (C), as cells per section (D) and number of cleaved caspase-3-positive cells 
expressed as total cell count (E) in the dentate gyrus of untreated and treated euploid and Ts65Dn mice (n=6: 
3 males and 3 females for each of the four experimental groups). Values (mean  SE) refer to one hemisphere. 
F: Western blot analysis of p21 levels in the hippocampal formation of untreated and treated euploid and 
Ts65Dn mice. Western immunoblots (left panel) are examples from animals of each experimental group. The 
histograms on the right show p21 levels normalized to GAPDH and expressed as a fold difference in 
comparison with untreated euploid mice (n=6: 3 males and 3 females for each experimental group). Values in 
(B-E) are mean  SE. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black 
asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 
Abbreviations: Casp, caspase-3; Eu, euploid; GR, granule cell layer; H, hilum; MOL, molecular layer.
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Figure 3.2.4. Effects of neonatal treatment with EGCG on the size of the population of cells in 
the S-phase of the cell cycle of P15 mice. A: Representative images of sections immunostained for 
BrdU from the dentate gyrus of an animal for each experimental group. Calibration bar=100 m. The 
insets show zoomed images of the boxed area with examples of individual BrdU-positive cells. 
Calibration bar=20 m. B, C: BrdU-positive cells, expressed as total cell count (B) and cells/mm2 (C), 
in the dentate gyrus of untreated and treated euploid and Ts65Dn mice (n=6: 3 males and 3 females 
for each of the four experimental groups). Values (mean  SE) refer to one hemisphere. ** p < 0.01; 
*** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a 
difference between untreated Ts65Dn mice and treated euploid mice. Abbreviations: BrdU, 
bromodeoxyuridine; Eu, euploid. 
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actively dividing cells in both the DG and SVZ and suggest that this effect is linked to a restoration 
of the proliferation potency and not to a decrease in apoptotic cell death.  
 
Short-term effects of neonatal treatment with EGCG on total number of hippocampal granule cells 
Neurogenesis in the hippocampal DG starts embryonically in both humans and mice, but in mice 
most of the granule cells are born in the first two postnatal weeks (Altman and Bayer, 1975, Altman 
and Bayer, 1990a, c, Seress et al., 2001, Rice and Barone, 2010, Stiles and Jernigan, 2010). In order 
to establish whether treatment restores the defective cellularity that characterizes the DG of Ts65Dn 
mice, we stereologically analyzed the volume of the granule cell layer, the density of the granule cells 
and the total number of granule cells. A two-way ANOVA on the volume of the granule cell layer 
showed a genotype x treatment interaction [F(1,20) = 8.37, p ≤ 0.01], a main effect of genotype 
[F(1,20) = 17.88, p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed that the 
volume of the granule cell layer was reduced in untreated Ts65Dn mice in comparison with untreated 
euploid mice (Fig. 3.2.5B), which is in agreement with previous evidence (Bianchi et al., 2010b) and 
that its size was normalized by treatment. A two-way ANOVA on granule cell density showed a 
genotype x treatment interaction [F(1,20) = 9.05, p ≤ 0.01] and a main effect of both genotype [F(1,20) 
= 10.32, p ≤ 0.001] and treatment [F(1,20) = 18.69, p ≤ 0.001]. A post hoc Fisher LSD test revealed 
that untreated Ts65Dn mice had a reduced granule cell density in comparison with untreated euploid. 
Treated Ts65Dn mice underwent a restoration of this defect (Fig. 3.2.5B). A two-way ANOVA on 
total number of granule cells showed a genotype x treatment interaction [F(1,20) = 11.10, p ≤ 0.005] 
and a main effect of both genotype [F(1,20) = 17.02, p ≤ 0.001] and treatment [F(1,20) = 6.99, p ≤ 
0.05]. A post hoc Fisher LSD test showed that untreated Ts65Dn mice had fewer granule neurons in 
comparison with euploid mice and that this defect was restored by treatment (Fig. 3.2.4B).  
 
Short-term effects of neonatal treatment with EGCG on cortical and hippocampal synapses 
The altered functionality of  the trisomic brain is mainly due to neurogenesis defects (Chakrabarti et 
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al., 2007, Contestabile et al., 2007, Guidi et al., 2008, Bianchi et al., 2010a, Bianchi et al., 2010b, 
Guidi et al., 2011a, Trazzi et al., 2011) and to altered synaptic connectivity (Takashima et al., 1989, 
Becker, 1991, Belichenko et al., 2004, Benavides-Piccione et al., 2004, Guidi et al., 2013). Circuit 
formation critically takes place in the early postnatal period when the newborn neurons establish 
synaptic contacts with other neurons. To establish whether treatment with EGCG had an effect on 
brain circuitry, in P15 mice we examined the levels of immunoractivity for (optical density; OD) 
SYN (synaptophysin) PSD-95 (postsynaptic density protein-95). We took into account the superficial 
(II-III) and deep (IV-VI) layers of the somatosensory cortex, the molecular layer of the DG, the 
stratum lucidum of field CA3, and the stratum radiatum of field CA1. Additionally, we also evaluated 
the number of SYN and PSD-95 immunoreactive puncta using confocal microscopy, in order to 
establish whether possible differences in SYN and PSD-95 OD reflected differences in the number 
of pre- and post-synaptic terminals.  
A two-way ANOVA on the OD of SYN and PSD-95 and on the number of SYN- and PSD-95-
immunoreactive puncta revealed numerous interactive effects and main effects of genotype and 
treatment (summarized in Table 3.2.3). A post hoc Fisher LSD test showed that in untreated Ts65Dn 
mice the OD of SYN and PSD-95 was significantly lower than in untreated euploid mice in all regions 
analyzed (Fig. 3.2.6C-F). Furthermore, an evaluation of the number of puncta revealed that untreated 
Ts65Dn mice had fewer SYN- and PSD-95 immunoreactive puncta in all the examined regions. This 
suggests that Ts65Dn mice have a reduced number of pre- and postsynaptic terminals. Importantly, 
in Ts65Dn mice that had been neonatally-treated with EGCG there was a total restoration of the OD 
of SYN and PSD-95 and the number of SYN- and PSD-95-immunoreactive puncta (Fig. 3.2.7C-F) 
in comparison with untreated euploid mice. Treatment also had an effect on SYN and PSD-95 OD 
and number of puncta in some of the examined regions of euploid mice (Fig. 3.2.7C-F). 
 
General results of P45 mice 
We evaluated the body and brain weight of P45 mice in order to establish the long-term effect of 
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Figure 3.2.5. Effects of neonatal treatment with EGCG on granule cell number in the dentate 
gyrus of P15 mice. A: Representative images of Nissl-stained sections in the granule cell layer of an 
animal from each experimental group. The sides of the superimposed optical disector are 30 m in 
length. The stars indicate individual nuclei. Note that nuclei intersecting the exclusion sides (thick 
lines) were not counted. B: Volume of the granule cell layer, density of granule cells (cells/mm3) and 
total number of granule cells of untreated and treated euploid and Ts65Dn mice (n=6: 3 males and 3 
females for each of the four experimental groups). Values (mean  SE) refer to one dentate gyrus. ** 
p < 0.01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar 
indicate a difference between untreated Ts65Dn mice and treated euploid mice. Abbreviation: Eu, 
euploid.
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Figure 3.2.6. Effects of neonatal treatment with EGCG on synapse development in P15 mice. A, B: Sections 
processed for SYN (A) and PSD-95 (B) immunofluorescence from the neocortex overlying the hippocampus, 
hippocampal field CA1 and DG of an animal from each experimental group. Calibration bar=200 m. C-F: Optical 
density of SYN and PSD-95 immunoreactivity in layers II-III and IV-VI of the neocortex (C: SYN; D: PSD-95), 
molecular layer of the dentate gyrus, stratum radiatum of field CA1 and stratum lucidum of field CA3 (E: SYN; F: 
PSD-95) of untreated and treated euploid and Ts65Dn mice (n=6: 3 males and 3 females for each of the four 
experimental groups). For each region, data of SYN and PSD-95 optical density are given as fold difference in 
comparison with untreated euploid mice. Values in (C-F) represent mean  SE. * p < 0.05; ** p < 0.01; *** p < 
0.001 (Fisher LSD after two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated 
Ts65Dn mice and treated euploid mice; white asterisks in the black bar indicate a difference between treated 
Ts65Dn mice and treated euploid mice. Abbreviations: CA1 and CA3, hippocampal fields; DG, dentate gyrus; GR, 
granule cell layer; LM, stratum lacunosum-moleculare; LUC, stratum lucidum; MOL, molecular layer; OR, stratum 
oriens; PYR, pyramidal layer; RAD, stratum radiatum.  
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Figure 3.2.7. Effects of neonatal treatment with EGCG on number of synaptic puncta in P15 
mice. A, B: Representative confocal microscope images of sections processed for SYN (A) and PSD95 
(B) immunofluorescence from the neocortex of an animal of each experimental group. Calibration 
bar=3 m. C-F: Number of puncta per m2 exhibiting SYN and PSD-95 immunoreactivity in layers 
II-III and IV-VI of the neocortex (C: SYN; D: PSD-95), molecular layer of the dentate gyrus, stratum 
lucidum of field CA3, and stratum radiatum of field CA1 (E: SYN; F: PSD-95) of untreated and treated 
euploid and Ts65Dn mice (n=6: 3 males and 3 females for each of the four experimental groups). 
Values in C-F represent mean  SE. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD after two-way 
ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and 
treated euploid mice; white asterisks in the black bar indicate a difference between treated Ts65Dn 
mice and treated euploid mice. Abbreviations: Eu, euploid; DG, dentate gyrus; CA1 and CA3, 
hippocampal fields.
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treatment. A two-way ANOVA (genotype x treatment) showed a main effect of genotype on body 
weight [F(1,35) = 8.67, p ≤ 0.01] and brain weight [F(1,35) = 4.98, p ≤ 0.05] in males with 
nointeraction between genotype x treatment. A main effect of treatment on body weight [F(1,40) = 
4.09, p ≤ 0.05] was found in females with no interaction between genotype x treatment (and no effect 
of treatment). These results suggest that neonatal treatment has no long-term adverse effects on body 
and brain weight in P45 mice (Table 3.2.1).  
 
Long-term effects of neonatal treatment with EGCG on cell survival, cell phenotype and 
proliferation potency 
We evaluated the number and phenotype of BrdU-positive cells present in the DG of P45 mice that 
had been injected with BrdU at P15 (i.e. at the end of treatment). A two-way ANOVA on the total 
number of BrdU-positive cells showed no genotype x treatment interaction, a main effect of genotype 
[F(1,20) = 24.88, p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed that the 
total number of BrdU-positive cells in untreated Ts65Dn mice was reduced in comparison with 
euploid mice (Fig. 3.2.8C). Unexpectedly, even though neonatal treatment with EGCG had restored 
the number of BrdU-positive cells in Ts65Dn mice at P15 (Fig. 3.2.4B), one month after treatment 
cessation these positive effects disappeared and the number of their BrdU-positive cells was 
againreduced in comparison with that of euploid mice (Fig. 3.2.8C).  
One peculiar characteristic of a trisomic brain is the higher astrocyte/neuron ratio (Guidi et al., 2008, 
Lu et al., 2012). In order to establish whether neonatal treatment with EGCG had an effect on 
phenotype acquisition, we evaluated the percentage and number of BrdU/NeuN (a marker of mature 
neurons), BrdU/GFAP (a marker of astrocytes) double-labeled cells. Additionally, we evaluated the 
percentage and number of not double-labeled cells (i.e. only marked with BrdU).  
A two-way ANOVA on the percentage of BrdU/NeuN cells showed no genotype x treatment 
interaction, a main effect of genotype [F(1,20) = 21.62, p ≤ 0.001], and no effect of treatment. A post 
hoc Fisher LSD test showed that untreated Ts65Dn mice had a reduced percentage of new neurons in 
comparison with untreated euploid mice and that treatment did not affect this condition (Fig. 3.2.8D: 
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upper panel). A two-way ANOVA on the number of BrdU/NeuN-positive cells showed no genotype 
x treatment interaction, a main effect of genotype [F(1,20) = 37.13, p ≤ 0.001], but no effect of 
treatment. A post hoc Fisher LSD test showed that untreated Ts65Dn mice had a reduced number of 
new neurons in comparison with untreated euploid mice and that this defect was not rescued by 
treatment (Fig. 3.2.8D: lower panel). In euploid mice, no effect of treatment was found on both the 
percentage and total number of BrdU/NeuN positive cells (Fig. 3.2.8D). 
A two-way ANOVA on the percentage of BrdU/GFAP-positive cells revealed no genotype x 
treatment interaction, a main effect of genotype [F(1,20) = 21.63, p ≤ 0.001] and no effect of 
treatment. A post hoc Fisher LSD test showed that untreated Ts65Dn mice had an increased 
percentage of new astrocytes in comparison with untreated euploid mice and that this defect was not 
corrected after neonatal treatment with EGCG (Fig. 3.2.8E: upper panel). In agreement with results 
obtained for the percentage of BrdU/GFAP-positive cells, two-way ANOVA analysis on the number 
of cells with an astrocytic phenotype showed no genotype x treatment interaction and no significant 
effect of either genotype or treatment. A post hoc Fisher LSD test showed no differences between 
groups (Fig. 3.2.8E: lower panel). In euploid mice, no effect of treatment was found either in the 
percentage or number of new astrocytes (Fig. 3.2.8E). 
From these results it emerges that early treatment with EGCG has no long-term effect on the abnormal 
phenotype acquisition that characterizes the trisomic brain.  
 
Long-term effects of neonatal treatment with EGCG on hippocampal proliferation potency and 
total number of granule cells 
We evaluated the number of Ki67-positive cells in the DG of P45 mice in order to evaluate the long-
term effects of neonatal treatment with EGCG on the size of the population of NPCs one month after 
treatment cessation. A two-way ANOVA on the total number of Ki-67-positive cells counted showed 
no genotype x treatment interaction, a main effect of genotype [F(1,20) = 26.13, p ≤ 0.001], but there 
was no effect of treatment. A post hoc Fisher LSD test showed that treatment was ineffective in P45 
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Figure 3.2.8. Long-term effects of neonatal treatment with EGCG on the fate of neural precursor cells 
of P45 euploid and Ts65Dn mice. A: Representative confocal images of sections processed for fluorescence 
immunostaining for BrdU/NeuN from the dentate gyrus of an animal from each experimental group. 
Calibration bar=100 mm. The inset shows a zoomed image of the boxed area with examples of individual 
BrdU/NeuN-positive cells. Calibration bar=10 mm. B: Confocal laser scanning microscope stack image at 
higher magnification showing a cell double-labeled for BrdU (red) and NeuN (green) in the dentate gyrus. The 
BrdU/NeuN-double-labeled cell is shown in x–y orthogonal planes and z-sectioning at 0.5 mm intervals to 
confirm overlap of the two immunoreactions. Calibration bar=5 µm. C: Total number of BrdU-positive cells 
in the dentate gyrus of untreated and treated euploid and Ts65Dn mice (n=6: 3 males and 3 females for each 
of the four experimental groups). Values refer to one hemisphere. These animals were injected with BrdU at 
P15 and killed at P45. D: Percentage (upper panel) and number (lower panel) of surviving cells with a neuronal 
phenotype (BrdU/NeuN). E: Percentage (upper panel) and number (lower panel) of surviving cells with an 
astrocytic phenotype (BrdU/GFAP). F: percentage (upper panel) and number (lower panel) of surviving cells 
with an undetermined phenotype (Neither) in the DG of untreated and treated euploid and Ts65Dn mice. Same 
animals as in (C). Values in (C-F) are mean  SE. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test after 
two-way ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and 
treated euploid mice; white asterisks in the black bar indicate a difference between treated Ts65Dn mice and 
treated euploid mice. Abbreviations: BrdU, bromodeoxyuridine; Eu, euploid.
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Ts65Dn mice since the number of Ki-67-positive cells was not increased (Fig. 3.2.9A). Neither was 
there any effect of treatment in euploid mice (Fig. 3.2.9A). A two-way ANOVA on the density of Ki-
67-positive cells showed no genotype x treatment interaction, a main effect of genotype [F(1,20) = 
21.33, p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed that in P45 Ts65Dn 
and euploid mice the density of Ki-67-positive was not increased by treatment (Fig. 3.2.9B). In P45 
mice, similarly to P15 mice, a two-way ANOVA analysis on the number of caspase-3-positive cells 
in the DG showed that there were no genotype x treatment interactions and no effects of either 
genotype or treatment (Fig. 3.2.9C). A two-way ANOVA on p21 protein levels in in the hippocampus 
of P45 mice showed no genotype x treatment interaction; a main effect of genotype [F(1,20) = 7.00, 
p ≤ 0.05], but no effect of treatment. A post hoc Fisher LSD test showed that in P45 treated Ts65Dn 
mice p21 levels did not undergo a reduction and were still higher in comparison with euploid mice 
(Fig. 3.2.9D). In treated P45 euploid mice, p21 levels were unaffected by treatment (Fig 3.2.9D).  
We then stereologically examined the DG of P45 mice in order to establish whether the restoration 
of cellularity observed in P15 mice was retained with time. A two-way ANOVA on the volume of 
the granule cell layer showed no genotype x treatment interaction; a main effect of genotype [F(1,20) 
= 17.80, p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed that in Ts65Dn 
mice the volume of the granule cell layer was not increased by treatment and remained reduced in 
comparison with that of euploid mice (Fig. 3.2.9E), indicating no retention of short-term effects. A 
two-way ANOVA on granule cell density showed a genotype x treatment interaction [F(1,20) = 4.39, 
p ≤ 0.05] and a main effect of both genotype [F(1,20) = 26.76, p ≤ 0.001] and treatment [F(1,20) = 
5.85, p ≤ 0.05]. A post hoc Fisher LSD test showed that treated Ts65Dn mice had no improvement 
when compared with untreated euploid mice. Surprisingly, in euploid mice treatment caused a small 
but significant reduction in granule cell density (Fig. 3.2.9F). A two-way ANOVA on total granule 
cell number showed no genotype x treatment interaction, a main effect of genotype [F(1,20) = 32.15, 
p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed that untreated Ts65Dn mice 
had a reduced number of granule neurons in comparison with euploid mice and that this defect was 
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Figure 3.2.9. Long-term effects of neonatal treatment with EGCG on neural precursor cell 
number and granule cell number in the dentate gyrus of P45 Ts65Dn and euploid mice. A-C: Ki-
67 positive cells, expressed as total cell count (A) and cells/mm2 (B), and cleaved caspase-3 positive 
cells, expressed as total cell count (C), in the dentate gyrus of untreated and treated euploid and Ts65Dn 
mice (n=6: 3 males and 3 females for each of the four experimental groups). D: Western blot analysis 
of p21 levels in the hippocampal formation of untreated and treated euploid and Ts65Dn mice (n=6: 3 
males and 3 females for each of the four experimental groups). Western blots (left) are examples taken 
from one animal from each experimental group. Histograms (right) show p21 levels normalized to 
GAPDH and expressed as a fold difference in comparison with untreated euploid mice. E-G: Volume 
of the granule cell layer (E), density of granule cells (F) and total number of granule cells (G) in 
untreated and treated euploid and Ts65Dn mice (n=6: 3 males and 3 females for each of the four 
experimental groups). Values (mean  SE) in (A-G) refer to one hemisphere. * p < 0.05; ** p < 0.01; 
*** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a 
difference between untreated Ts65Dn mice and treated euploid mice; white asterisks in the black bar 
indicate a difference between treated Ts65Dn mice and treated euploid mice. Abbreviations: Casp, 
caspase-3; Eu, euploid.
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not rescued by treatment (Fig. 3.2.9G).  
 
Long-term effects of neonatal treatment with EGCG on cortical and hippocampal synapses 
In P45 mice, we evaluated the long-term effects of neonatal EGCG treatment on the expression of 
SYN and PSD-95 in the same regions examined in P15 mice, in order to compare the outcomes. A 
two-way ANOVA on the OD of SYN and PSD-95 and revealed no genotype x treatment interactions, 
a main effect of genotype in most of the examined regions and a main effect of treatment in a few 
regions (summarized in Table 3.2.3). Similar results were obtained after two-way ANOVA on the 
number of SYN and PSD-95 immunoreactive puncta (Table 3.2.3). A post hoc Fisher LSD test 
showed that untreated Ts65Dn mice had OD levels of SYN and PSD-95 and a number of puncta 
smaller than in untreated euploid mice in the neocortex, DG, field CA3 and field CA1 (Fig. 
3.2.10C,D; Fig. 3.2.11C,D). This evidence indicates that trisomy-linked defects in synapse 
development do not ameliorate in mice aged P45. In addition, similarly to the other morphological 
parameters analyzed in this study, the positive effects of neonatal treatment with EGCG on synaptic 
proteins seen in Ts65Dn mice did not outlast treatment cessation. Rather, in the DG and field CA1 
the immunoreactivity for SYN was reduced in comparison with untreated Ts65Dn mice (Fig. 
3.2.10E). Some negative effects of treatment took place in the hippocampal region of treated euploid 
mice, in which a reduction in the OD of both SYN and PSD-95 was observed (Fig. 3.2.10D,F). 
 
Effects of treatment with EGCG on GSK3β protein levels and phosphorylation 
The main activity of EGCG is to inhibit DYRK1A, but there is evidence that this catechin has also 
antioxidant properties (Kim et al., 2014), acts on the Shh pathway (Wang et al., 2012), activates a 
pro-survival PKC pathway (Kelsey et al., 2010), activates the MEK-ERK pathway (Spencer, 2009), 
and stimulates the activity of ERK-dependent cyclic AMP response element (Schroeter et al., 2007). 
Thus, various mechanisms may take part in the positive effects induced by treatment with EGCG. 
Recent evidence shows that EGCG is able to increase the phosphorylation levels of GSK3β at ser9 
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Table 3.2.3. Two-way ANOVA of SYN and PSD-95 measurements in P15 and P45 mice.  
 
The F and p values of two-way ANOVA with genotype (euploid, Ts65Dn) and treatment (vehicle, EGCG) as 
factors are reported for the optical density of SYN and PSD-95, and number of SYN and PSD-95 
immunoreactive puncta. The p values are reported as: p < 0.05, 0.01, 0.005, 0.001, 0.0005. n.s.: not significant. 
Abbreviations: Cx, cortex; DG, dentate gyrus; GEN, genotype; Luc, stratum lucidum; Mol stratum moleculare; 
OD, optical density, PSD-95, postsynaptic density protein-95; Rad, stratum radiatum; SYN, synaptophysin; 
TREAT, treatment. 
Measurement Region Variable  Main effect  
Two-way 
interaction 
   GEN  TREAT  GEN x TREAT 
   F(1,20) p F(1,20) p F(1,20) p 
P15 mice         
SYN Cx (II-III) OD 1.09 n.s. 24.40 0.0005 9.02 0.01 
  Puncta 4.93 0.05 10.45 0.005 4.27 0.05 
 Cx (IV-VI) OD 2.48 n.s. 31.22 0.0005 6.27 0.05 
  Puncta 14.14 0.001 47.44 0.0005 7.58 0.01 
 DG (Mol) OD 24.35 0.0005 7.84 0.01 2.29 n.s. 
  Puncta 12.26 0.01 12.09 0.005 6.47 0.05 
 CA3 (Luc) OD 0.39 n.s. 31.16 0.0005 12.48 0.005 
  Puncta 8.37 0.01 24.64 0.0005 0.07 n.s. 
 CA1 (Rad) OD 3.28 n.s. 28.87 0.0005 1.68 n.s. 
  Puncta 8.09 0.01 20.57 0.0005 2.71 n.s. 
PSD-95  Cx (II-III) OD 0.71 n.s. 31.43 0.0005 2.28 n.s. 
  Puncta 5.68 0.05 13.87 0.001 14.19 0.001 
 Cx (IV-VI) OD 0.00 n.s. 26.22 0.0005 5.77 0.05 
  Puncta 0.43 n.s. 28.79 0.0005 1.17 n.s. 
 DG (Mol) OD 0.31 n.s. 28.74 0.0005 3.38 n.s. 
  Puncta 1.35 n.s. 7.65 0.05 3.25 n.s. 
 CA3 (Luc) OD 0.70 n.s. 29.07 0.0005 11.71 0.005 
  Puncta 10.02 0.005 5.14 0.05 9.41 0.01 
 CA1 (Rad) OD 0.08 n.s. 30.14 0.0005 4.83 0.05 
  Puncta 6.90 0.05 32.17 0.0005 0.23 n.s. 
P45 mice         
SYN Cx (II-III) OD 14.50 0.001 1.21 n.s. 0.79 n.s. 
  Puncta 10.60 0.01 0.02 n.s. 0.07 n.s. 
 Cx (IV-VI) OD 21.83 0.0005 0.30 n.s. 3.23 n.s. 
  Puncta 8.20 0.01 0.00 n.s. 0.14 n.s. 
 DG (Mol) OD 20.07 0.0005 7.72 0.05 0.38 n.s. 
  Puncta 11.19 0.005 0.61 n.s. 0.05 n.s. 
 CA3 (Luc) OD 3.37 n.s. 15.58 0.001 3.93 n.s. 
  Puncta 21.01 0.0005 2.06 n.s. 0.87 n.s. 
 CA1 (Rad) OD 17.08 0.001 11.86 0.005 0.78 n.s. 
  Puncta 20.64 0.0005 0.55 n.s. 0.01 n.s. 
PSD-95  Cx (II-III) OD 26.11 0.0005 0.01 n.s. 2.18 n.s. 
  Puncta 12.96 0.005 2.99 n.s. 0.11 n.s. 
 Cx (IV-VI) OD 17.23 0.0005 1.84 n.s. 0.90 n.s. 
  Puncta 14.98 0.001 0.04 n.s. 0.03 n.s. 
 DG (Mol) OD 25.27 0.0005 2.90 n.s. 0.42 n.s. 
  Puncta 22.70 0.0005 0.36 n.s. 0.00 n.s. 
 CA3 (Luc) OD 6.15 0.01 1.60 n.s. 4.26 0.05 
  Puncta 18.18 0.0005 0.01 n.s. 0.43 n.s. 
 CA1 (Rad) OD 13.92 0.001 7.18 0.05 4.01 n.s. 
  Puncta 14.63 0.001 1.99 n.s 0.01 n.s. 
 
168 
 
Figure 3.2.10. Long-term effects of neonatal treatment with EGCG on synapse development in P45 Ts65Dn 
and euploid mice. A, B: Sections processed for SYN (A) and PSD-95 (B) immunofluorescence from the neocortex 
overlying the hippocampus, hippocampal field CA1, and DG of an animal from each experimental group. 
Calibration bar=200 m. C-F: Optical density of SYN and PSD-95 immunoreactivity in layers II-III and IV-VI of 
the neocortex (C: SYN; D: PSD-95), molecular layer of the dentate gyrus, stratum lucidum of field CA3, and 
stratum radiatum of field CA1 (E: SYN; F: PSD-95) of untreated and treated euploid and Ts65Dn mice (n=6: 3 
males and 3 females for each of the four experimental groups). For each region, data of SYN and PSD-95 optical 
density are given as a fold difference compared to untreated euploid mice. Values in C-F represent mean  SE. * p 
< 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate 
a difference between untreated Ts65Dn mice and treated euploid mice; white asterisks in the black bar indicate a 
difference between treated Ts65Dn mice and treated euploid mice. Abbreviations: CA1 and CA3, hippocampal 
fields; DG, dentate gyrus; Eu, euploid; GR, granule cell layer; LM, stratum lacunosum-moleculare; LUC, stratum 
lucidum; MOL, molecular layer; OR, stratum oriens; PYR, pyramidal layer; RAD, stratum radiatum. 
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Figure 3.2.11. Effects of neonatal treatment with EGCG on number of synaptic puncta in P45 
mice. A, B: Representative confocal microscope images of sections processed for SYN (A) and PSD-
95 (B) immunofluorescence from the neocortex of an animal of each experimental group. Calibration 
bar=3 m. C-F: Number of puncta per m2 exhibiting SYN and PSD-95 immunoreactivity in layers 
II-III and IV-VI of the neocortex (C: SYN; D: PSD-95), molecular layer of the dentate gyrus, stratum 
lucidum of field CA3, and stratum radiatum of field CA1 (E: SYN; F: PSD-95) of untreated and treated 
euploid and Ts65Dn mice (n=6: 3 males and 3 females for each of the four experimental groups). 
Values in C-F represent mean  SE. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD after two-way 
ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and 
treated euploid mice; white asterisks in the black bar indicate a difference between treated Ts65Dn 
mice and treated euploid mice. Abbreviations: Eu, euploid; DG, dentate gyrus; CA1 and CA3, 
hippocampal fields.
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in neurons (Lin et al., 2009, Ruan et al., 2009), thereby inhibiting its activity. GSK3β is a 
serine/threonine kinase that plays a fundamental role in various biological processes (Jope and 
Johnson, 2004) at physiological levels. Altered GSK3β activity appears to be involved in 
neurodegenerative and neurological disturbances (Eldar-Finkelman and Martinez, 2011). In fact, 
when GSK3β is over-activated, it causes reduction in neurogenesis and impairment of synapse 
development (Eldar-Finkelman and Martinez, 2011, Kim and Snider, 2011). As previously shown in 
this thesis (see Section 3.1), in the hippocampus of P15 Ts65Dn mice GSK3β is dephosphorylated at 
ser9.  
Based on these premises, we wondered whether treatment with EGCG affects the GSK3β 
phosphorylation state. Thus, we examined the levels of ser9 phosphorylated GSK3β (pGSK3β) and 
total GSK3β levels in hippocampal homogenates of P15 and P45 mice. In P15 mice, a two-way 
ANOVA on pGSK3β levels showed no genotype x treatment interaction, no significant effect of 
genotype, but a main effect of treatment [F(1,20) = 33.75, p ≤ 0.001]. A post hoc Fisher LSD test 
confirmed (see Section 3.1 of the thesis) that in the hippocampus of untreated Ts65Dn mice there 
were reduced levels of pGSK3β in comparison with euploid mice. Treatment with EGCG increased 
pGSK3β levels, that reached those of untreated euploid mice (Fig. 3.2.12A,B). A similar effect of 
EGCG treatment was also seen in euploid mice (Fig. 3.2.12A,B). A two-way ANOVA on total levels 
of GSK3β showed no genotype x treatment interaction, but did show a main effect of both genotype 
[F(1,20) = 5.04, p ≤ 0.05] and treatment [F(1,20) = 18.83, p ≤ 0.001]. A post hoc Fisher LSD test 
showed that while in untreated Ts65Dn mice there were higher total levels of GSK3β, in treated 
Ts65Dn mice levels of GSK3β underwent a large reduction (Fig. 3.2.12A,C). In P45 mice, a two-
way ANOVA on pGSK3β levels showed no genotype x treatment interaction, a main effect of 
genotype [F(1,20) = 12.90, p ≤ 0.001], but no effect of treatment. A post hoc Fisher LSD test showed 
that Ts65Dn mice exhibited reduced hippocampal levels of pGSK3β (Fig. 3.2.12D,E) in comparison 
with euploid mice also at P45. However, treated Ts65Dn mice aged 45 days did not exhibit any 
change in pGSK3β (Fig. 3.2.12D,E). A two-way ANOVA on total levels of GSK3β showed no 
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Figure 3.2.12. Short- and long-term effects of neonatal treatment with EGCG on GSK3β protein 
expression in P15 and P45 Ts65Dn and euploid mice. Western blot analysis of p-GSK3β, total 
GSK3β and GAPDH in the hippocampus of untreated and treated euploid and Ts65Dn mice at P15 
(A-C) and P45 (D-F). At each age: n=6 (3 males and 3 females) for each experimental group. Western 
blots in (A, D) are examples from P15 (A) and P45 (D) animals from each experimental group. 
Histograms in (B, E) show p-GSK3β levels normalized to total GSK3β in P15 (B) and P45 (E) mice. 
Histograms in (C, F) show total GSK3β normalized to GAPDH in P15 (C) and P45 (F) mice. Values 
in (B, C, E, F) are expressed as fold difference in comparison with untreated euploid mice. Values in 
(B, C, E, F) are mean  SE. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test after two-way 
ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and 
treated euploid mice; white asterisks in the black bar indicate a difference between treated Ts65Dn 
mice and treated euploid mice. Abbreviation: Eu, euploid.
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genotype x treatment interaction, a main effect of genotype [F(1,20) = 9.10, p ≤ 0.01], but no effect 
of treatment. A post hoc Fisher LSD test showed that Ts65Dn mice aged 45 days exhibited increased 
levels of total GSK3β (Fig. 3.2.12D,F) in comparison with euploid mice and that treatment had no 
effects in total levels of GSK3β in both euploid and Ts65Dn mice (Fig. 3.2.12D,F). 
 
Effects of neonatal treatment with EGCG on hippocampus-dependent learning and memory  
In order to explore the effects of a neonatal treatment with EGCG on hippocampus-dependent spatial 
learning and memory (Crawley, 2007), animals were subjected to behavioral tasks starting at P45, 
i.e. 25-30 days after treatment cessation. We used the Y-maze (YM) test and the Morris Water Maze 
(MWM) test.  
Regarding the YM test, we compared the rate of spontaneous alternations and the number of arm 
entries for Ts65Dn and euploid mice. A two-way ANOVA revealed no genotype x treatment 
interaction, a main effect of genotype [F(1,77) = 18.60, p ≤ 0.0001], but there was no significant 
effect of treatment. A post hoc Fisher LSD test showed that untreated Ts65Dn mice had a lower 
alternation rate in comparison with euploid mice (Fig. 3.2.13A). This defect was not improved by 
neonatal treatment with EGCG (Fig. 3.2.13A). The YM also provides estimation of spontaneous 
locomotor activity. A two-way ANOVA revealed no genotype x treatment interaction; a main effect 
of genotype [F(1,77) = 5.50, p ≤ 0.05], but no effect of treatment. A post hoc Fisher LSD test showed 
that untreated and treated Ts65Dn had a larger number of entries in comparison with untreated euploid 
mice, although the difference was statistically significant only for treated mice (Fig. 3.2.13B). This 
evidence indicates that treatment did not improve either impaired working memory or enhanced 
spontaneous locomotor activity in Ts65Dn mice (Faizi et al., 2011).  
A three-way mixed ANOVA, with genotype and treatment as grouping factors and day as a repeated 
measure revealed a genotype x day interaction [F(4,316) = 5.73, p ≤ 0.001], a main effect of genotype 
[F(1,79) = 104.99, p ≤ 0.0001] and day [F(4,316) = 22.22, p ≤ 0.0001]. We found no genotype x 
treatment x day, genotype x treatment, treatment x day interactions or a main effect of treatment. A 
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post hoc Fisher LSD analysis showed that, on all of the examined days, untreated and treated Ts65Dn 
mice exhibited a poorer performance compared to untreated euploid mice (Fig. 3.2.13C). Similarly 
to Ts65Dn mice, in euploid mice treatment had no effect on the learning curve. A comparison of 
treated and untreated Ts65Dn mice showed no latency difference on days 1-4 but on day 5 treated 
Ts65Dn exhibited a latency reduction compared to untreated Ts65Dn mice (p ≤ 0.05). Considering 
the absence of any genotype x treatment x day interaction (see above), it is possible that this difference 
is related to an "experiment-wise" error due to multiple comparisons across days rather than a learning 
improvement. Regarding the probe test, a two-way ANOVA revealed i) no genotype x treatment 
interaction, a main effect of genotype [F(1,79) = 14.38, p ≤ 0.001], but no effect of treatment on 
latency; ii) no genotype x treatment interaction, a main effect of genotype [F(1,79) = 15.78, p ≤ 
0.001], but no effect of treatment on the percentage of time; and iii) no genotype x treatment 
interaction, a main effect of genotype  [F(1,79) = 17.00 p ≤ 0.0001] but no effect of treatment on the 
frequency. A post hoc Fisher LSD test revealed that untreated Ts65Dn mice performed worse than 
untreated euploid mice in all parameters analyzed in the probe test. In fact, they showed an increase 
in latency to enter the trained platform quadrant (Fig. 3.2.13D), a reduction in the time spent there 
(Fig. 3.2.13E), and a decrease in the frequency of entrances (Fig. 3.2.13F). In neonatally-treated 
euploid and Ts65Dn mice none of these parameters underwent an improvement in comparison with 
their untreated counterparts (Fig. 3.2.13D-F).  
 
3.2.5 Discussion 
 
In this study, we examined the effects of neonatal treatment with EGCG on hippocampal development 
in the Ts65Dn model of DS. The results show that pharmacotherapy with EGCG in the first two 
postnatal weeks fully rescues neural precursor cell proliferation and cellularity, as well as synapse 
development in Ts65Dn pups. However, these effects vanish with time and do not lead to an 
improvement in hippocampus-dependent long-term memory in young adult mice. Thus, therapy with 
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Figure 3.2.13. Long-term effects of neonatal treatment with EGCG on spatial learning in Ts65Dn 
and euploid mice. These mice received either saline or EGCG in the period P3-P15 and were 
behaviorally tested starting from 9 days before reaching 45-50 days of age (i.e. from 36-41 days old, 
for 9 days). A, B: Working memory performance in the Y-maze. Percentage of spontaneous 
alternations (A) and number of arm entries (B) in the Y-maze test in untreated euploid mice (n=37: 17 
males and 20 females), untreated Ts65Dn mice (n=9: 5 males and 4 females), treated euploid mice 
(n=25: 12 males and 13 females), and treated Ts65Dn mice (n=10: 5 males and 5 females). C-F: Spatial 
learning and memory assessed with the Morris Water Maze in untreated euploid mice (n=38: 17 males 
and 21 females), untreated Ts65Dn mice (n=10: 5 males and 5 females), treated euploid mice (n=25: 
12 males and 13 females), and treated Ts65Dn mice (n=10: 5 males and 5 females). The learning 
curves (C) reports data of euploid mice that received either saline (empty circle) or EGCG (filled 
circle) and Ts65Dn mice that received either saline (empty square) or EGCG (filled square). The 
symbols * and # indicate a difference between untreated euploid and untreated Ts65Dn mice, and 
between untreated euploid and treated Ts65Dn mice, respectively. Values represent mean  SE. * p < 
0.05; ** p< 0.01; *** p < 0.001; ## p < 0.01; ### p < 0.001 (Fisher LSD test after ANOVA). Black 
asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid 
mice; white asterisks in the black bar indicate a difference between treated Ts65Dn mice and treated 
euploid mice. Abbreviation: Eu, euploid; sec, seconds.
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EGCG even during a particularly critical period for development of the hippocampus has no enduring 
effects on trisomic brain physiology. 
 
Early treatment with EGCG restores hippocampal development in Ts65Dn pups 
Neurogenesis failure and neuronal maturation are the major neurodevelopmental defects of the 
trisomic brain (reviewed by (Bartesaghi et al., 2011, Dierssen, 2012)). Among the triplicated genes, 
Dyrk1A is likely to play a key role in disrupting neurodevelopment. Some studies have already shown 
that treatment with EGCG, an inhibitor of DYRK1A and other kinases (see (Aranda et al., 2011)), 
restores hippocampus-dependent learning in adult Ts65Dn mice (De la Torre et al., 2014), even 
though there is no evidence regarding the neuroanatomical substrate of the positive effects of EGCG 
in the Ts65Dn mouse. Moreover, no study has investigated the effect of early treatment with EGCG 
in the Ts65Dn mouse. We found that neonatal treatment with EGCG restores i) the pool of 
proliferating NPCs (Ki-67-positive cells) in the SVZ and SGZ, with no effect on cell death (caspase-
3-positive cells); ii) the number of cells in the S-phase of the cell cycle (BrdU-positive cells) in the 
DG; iii) the number of granule neurons in the hippocampal DG; iv) development of hippocampal as 
well as of neocortical synapses in trisomic pups.  
In Ts65Dn mice aged 15 and 45 days p21 hippocampal levels were higher in comparison with euploid 
mice. In P15 Ts65Dn mice, treatment largely reduced p21 levels, suggesting that this effect may play 
a role in the restoration of neurogenesis. In contrast, in treated P45 Ts65Dn mice p21 protein levels 
returned to be high. This may explain the disappearance of the improvement in proliferation potency 
seen in P15 Ts65Dn mice. Since expression of p21 is regulated in a p53-dependent and independent 
manner (Macleod et al., 1995, Jung et al., 2010), EGCG may modulate p21 levels by inhibiting the 
DYRK1A-p53 pathway (Park et al., 2010). Importantly, restoration of NPCs proliferation in P15 mice 
translated into an increase in total granule cell number, indicating that an early treatment with EGCG 
may is able to restore the typical hypotrophy of the DG of the trisomic brain.  
There is a number of evidence that green tea catechins up-regulates synaptic plasticity-related proteins 
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(Li et al., 2007, Rodrigues et al., 2013). Consistently with these effects of catechins, EGCG treatment 
in Ts65Dn pups increased the number of SYN and PSD-95 immunoreactive puncta, indicating an 
effect on maturation of pre- and post-synaptic terminals. Importantly, we observed these effects not 
only in the hippocampus but also in the neocortex, indicating that EGCG has a widespread effect on 
synapse development. As reported in Section 3.1, altered GSK3 signaling may underlie connectivity 
alterations in DS. We found that in trisomic pups EGCG restored the levels of GSK3 as well as its 
phosphorylation status, suggesting that this effect may contribute to the positive effect of EGCG on 
synapse plasticity. GSK3 can be phosphorylated (inactivated) at ser9 by several kinases, including 
Akt, protein kinase A, and protein kinase C (Jope and Johnson, 2004), that are in turn activated by 
EGCG (Levites et al., 2003, Mandel et al., 2004, Schroeter et al., 2007, Kelsey et al., 2010). This may 
explain the increased phosphorylation of GSK3 following EGCG treatment. 
 
EGCG only transiently restores the developmental alterations of the trisomic brain 
The reduced neurogenesis of the trisomic brain has been shown to be due to both cell cycle elongation 
and precocious exit from the cell cycle (Chakrabarti et al., 2007, Contestabile et al., 2007, 
Contestabile et al., 2009, Dierssen, 2012). We found here that neonatal treatment with EGCG restores 
the number of cells in the S-phase of the cell cycle (BrdU-positive cells) and the total pool of 
proliferating NPCs (Ki-67-positive cells). It remains to be established whether treatment with EGCG 
impacts on both cell cycle kinetics and cell cycle exit. Whatever the mechanisms, it may be expected 
that treatments that are able to expand the reduced pool of NPCs during the critical windows of 
maximum neurogenesis, could lead to an enduring neurogenesis rescue. For this reason, we envisaged 
that the positive impact of EGCG on neurogenesis could outlast treatment cessation. Unfortunately, 
in Ts65Dn mice, the proliferation potency of granule cell precursors was reverted to untreated 
trisomic mice levels. The lack of enduring effects was also observed for phenotype acquisition, 
number of granule neurons and density of synaptic terminals in the hippocampal region and 
neocortex. Consistently with the lack of long-term effects of EGCG on brain neuroanatomy, treated 
177 
Ts65Dn mice exhibited poorer memory in comparison with untreated euploid mice one month after 
treatment cessation. This finding is consistent with the observation that EGCG improves cognitive 
performance in adolescents with DS but that this effect decreases with time (De la Torre et al., 2014). 
The disappearance with time of the beneficial effects on neurogenesis and connectivity following 
treatment with EGCG suggests that continuous administration of EGCG may be necessary in order 
to prevent the disappearance of its effects.  
In both euploid and Ts65Dn mice, following treatment discontinuation there was a reduction in the 
levels of synaptic proteins in some of the examined brain regions when mice were 45 days old (Fig. 
3.2.10-11). In addition, in treated Ts65Dn mice there was a reduction in the number of Ki-67-positive 
cells per unit area in comparison with their untreated counterparts (Fig. 3.2.9B), and in treated euploid 
mice there was a reduction in granule cell numerical density (Fig. 3.2.9F). Taken together, these 
findings suggest that treatment may leave a negative trace in the brain after its discontinuation.  
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3.3 Section 3 
 
“Pharmacotherapy with 7,8-dihydroxiflavone, a BDNF 
mimetic, in the Ts65Dn mouse model of Down 
syndrome” 
 
Information reported in this section refers to:  
“A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and 
hippocampus-dependent memory in the Ts65Dn mouse model of DS”. Stagni F, Giacomini A, Guidi 
S, Emili M, Uguagliati B, Salvalai ME, Bortolotto V, Grilli M, Rimondini R, Bartesaghi R. (Stagni 
and Giacomini contributed equally to the article). Experimental Neurology (2017) 298 (Pt A):79-96. 
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3.3.1 Abstract 
 
Reduced neurogenesis and impaired neuron maturation are considered major determinants of altered 
brain function in DS. Since the DS brain is impaired starting from the earliest fetal life stages, attempts 
to rescue neurogenesis and neuron maturation should take place as soon as possible. The brain-
derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in brain development by 
specifically binding to the TRKB receptor. Systemic BDNF administration is impracticable because 
BDNF has a poor blood-brain barrier penetration. 7,8-dihydroxyflavone (7,8-DHF), a flavone present 
in plants, is a recently found small-molecule that crosses the blood-brain barrier and mimics the 
BDNF activity by binding the TRKB receptor. The goal of this study was to establish whether it is 
possible to restore brain development in the Ts65Dn mouse model of DS by targeting the TRKB 
receptor with 7,8-DHF. Ts65Dn mice, treated with 7,8-DHF in the neonatal period P3-P15, exhibited 
a large increase in the number of neural precursor cells in the dentate gyrus, restoration of granule 
cell number, and restoration of spine density. In order to establish the functional outcome of 
treatment, mice were treated with 7,8-DHF from P3 to adolescence (P45-50) and were tested with the 
Morris Water Maze test, in order to examine hippocampus-dependent learning and memory. Treated 
Ts65Dn mice exhibited restoration of learning and memory, indicating that the recovery of the 
hippocampal anatomy translated into a functional rescue. Ts65Dn mice aged 4 months, treated with 
7,8-DHF for one month, exhibited no restoration of neurogenesis, but they showed an improvement 
in hippocampus-dependent learning and memory, indicating that treatment at advanced life stages, 
unlike at early life stages, is unable to completely rescue the trisomy-linked brain defects. Our study 
provides novel evidence that treatment with 7,8-DHF during the early postnatal period restores 
trisomy-linked neurodevelopmental defects, suggesting that targeting BDNF/TRKB pathway may 
represent a possible breakthrough for DS.  
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3.3.2 Introduction 
 
Most of the brain neurons are produced in the prenatal period, with the notable exception of those 
involved in the formation of the hippocampus, where neurogenesis continues postnatally and 
throughout life (Seress et al., 2001, Rice and Barone, 2010, Stiles and Jernigan, 2010). After the 
critical periods of neurogenesis and synaptogenesis the brain can undergo relatively limited plastic 
changes. Thus, the perinatal period represents a window of opportunity for therapies aimed at 
improving the neurodevelopmental alterations of DS. Since the DS brain starts at a disadvantage, 
attempts to rescue neurogenesis and neuron maturation should take place as soon as possible.  
The brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in brain 
plasticity by specifically binding to the tropomyosin-related kinase receptor B (TRKB) (Haniu et al., 
1997). This binding causes dimerization and autophosphorylation of the TRKB receptor, which 
triggers the activity of several intracellular pathways, thereby favoring neurogenesis, neuritogenesis 
and spine growth (see (Vilar and Mira, 2016)). In the DS brain, BDNF levels are already reduced at 
fetal life stages (Guedj et al., 2009, Toiber et al., 2010) and reduced BDNF levels have been shown 
in various brain regions of the Ts65Dn mouse (Bimonte-Nelson et al., 2003, Bianchi et al., 2010b, 
Fukuda et al., 2010, Begenisic et al., 2015).  
In view of the role of the BDNF-TRKB system in neurogenesis and dendritic morphogenesis, it is 
conceivable that interventions targeted to the BDNF-TRKB system may be exploited in order to 
improve the trisomy-linked neurodevelopmental defects. Systemic administration of BDNF is 
impracticable because BDNF has a poor blood-brain barrier penetration. This obstacle could be 
circumvented by using TRKB agonists that can enter the brain. Recent screening of a chemical library 
has identified a flavone derivative, 7,8-dihydroxyflavone (7,8-DHF), as the first small-molecule 
compound that binds with high affinity and specificity to the TRKB receptor, activates its downstream 
signaling cascade (Liu et al., 2010), and penetrates the blood brain barrier (Liu et al., 2013). 
Administration of  7,8-DHF enhances the activation of phosphorylated TRKB and increases spine 
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density in several brain regions (Zeng et al., 2012), promotes neurogenesis in the dentate gyrus (Liu 
et al., 2010), fosters neurite outgrowth (Tsai et al., 2013) and exerts therapeutic efficacy in various 
animal disease models that are related to deficient BDNF signaling (Liu et al., 2016). 
Various pharmacotherapies have been attempted in DS mouse models (Bartesaghi et al., 2011, Costa 
and Scott-McKean, 2013, Gardiner, 2015). A comparison of the effects of different therapies in 
mouse models shows that many of them were effective (Stagni et al., 2015a). It should be noted, 
however, that some of the used drugs may be not devoid of side effects, and/or have ephemeral effects, 
which diminishes their translational impact. The therapeutic potential of TRKB agonists for 
neurogenesis improvement in DS has never been examined. Considering the important role of the 
BDNF-TRKB receptor system on neurogenesis, we expect that by acting upon this system by 
exploiting the flavonoid 7,8-DHF it may be possible to positively impact the DS brain. Moreover, 
considering that flavonoids are natural substances, it seems likely that their administration at 
appropriate doses may be devoid of side effects. Based on these premises, we deemed it important to 
investigate whether treatment with 7,8-DHF is able to restore hippocampal development and 
hippocampus-dependent memory in the Ts65Dn mouse model of DS. 
 
3.3.3 Materials and Methods 
 
Colony 
Ts65Dn mice were generated by mating B6EiC3Sn a/A-Ts(17^16)65Dn females with C57BL/6JEiJ 
x C3H/HeSnJ (B6EiC3Sn) F1 hybrid males. This parental generation was provided by Jackson 
Laboratories (Bar Harbor, ME, USA). To maintain the original genetic background, the mice used 
were of the first generation of this breeding. Animals were genotyped as previously described 
(Reinholdt et al., 2011). The day of birth was designated postnatal day zero (P0). The animals’ health 
and comfort were controlled by the veterinary service. The animals had access to water and food ad 
libitum and lived in a room with a 12:12 h light/dark cycle. Experiments were performed in 
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accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) 
for the use of experimental animals and were approved by Italian Ministry of Public Health 
(813/2016-PR). In this study, all efforts were made to minimize animal suffering and to keep the 
number of animals used to a minimum. 
In the current study, treatment with either 7,8-DHF or vehicle began on postnatal day 3 (P3). All mice 
that survived in the P0 to P3 period entered this study, with no specific selection criteria. A total of 
185 mice entered the study (96 males and 89 females). The number of vehicle-treated and 7,8-DHF 
treated mice was 96 and 89, respectively. Seven vehicle-treated (7.3%) and five 7,8-DHF-treated 
(5.6%) mice died before weaning, in the P6-P22 period. The similarity in the mortality rate across 
groups suggests that treatment has no adverse effects on the health of mice.  
 
Experimental protocol 
Pilot experiment. In a pilot study we tested the effects of different doses of 7,8-DHF on the 
proliferation rate in the subgranular zone (SGZ) of the dentate gyrus (DG) of Ts65Dn mice. Mice 
received a daily subcutaneous injection of 7,8-DHF (2.5, 5.0, or 10.0 mg/kg in PBS with 1% DMSO) 
from postnatal day 3 (P3) to P15. On P15, mice received an intraperitoneal injection (150 g/g body 
weight) of BrdU (5-bromo-2-deoxyuridine; Sigma) in TrisHCl 50 mM 2h before being killed and the 
number of BrdU-positive cells in the SGZ was evaluated. We found that the optimum dose was 5.0 
mg/kg (see Fig. 3.3.4A). Therefore, this study (Experiment 1, Experiment 2, and Experiment 3) was 
carried out using a 5.0 mg/kg dose.  
Experiment 1. Euploid and Ts65Dn mice received a daily subcutaneous injection (at 9-10am) of 7,8-
DHF (5.0 mg/kg in vehicle: PBS with 1% DMSO) or vehicle from postnatal day 3 (P3) to postnatal 
day 15 (Fig. 3.3.1A). Mice that received 7,8-DHF will be called “treated mice” (treated euploid mice: 
n=25; treated Ts65Dn mice: n=15). Mice that received the vehicle will be called “untreated mice” 
(untreated euploid mice: n=35; untreated Ts65Dn mice: n=21). On P15, mice received an 
intraperitoneal injection (150 g/g body weight) of BrdU in TrisHCl 50 mM 2h before being killed 
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(Fig. 3.3.1A). The brains were excised and cut along the midline. The left hemisphere of a group of 
mice was fixed by immersion in PFA 4% and frozen, and the left hemisphere of another group of 
mice was used for Golgi staining. The right hemispheres of all mice was kept at –80°C and used for 
western blotting.  
Experiment 2. Euploid and Ts65Dn mice received a daily subcutaneous injection (at 9-10am) of 7,8-
DHF (5.0 mg/kg in vehicle) or vehicle from postnatal day 3 (P3) to postnatal day P45-P50 (Fig. 
3.3.2A). At the end of treatment, mice were subjected to behavioural experiments (MWM), using the 
same protocol as that used in Section 3.2. Because C3H/HeSnJ mice carry a recessive mutation that 
leads to retinal degeneration, animals used for the behavioral study were genotyped by standard PCR 
to screen out all mice carrying this gene. Mice that did not carry a recessive mutation that leads to 
retinal degeneration entered the behavioral study (untreated euploid mice: n=19; untreated Ts65Dn 
mice: n=14; treated euploid mice: n=17; treated Ts65Dn mice: n=16). These mice will be called here 
P45 mice. Mice were behaviorally tested in the 6 days that preceded the day of sacrifice (Fig. 3.3.2A). 
The body weight of mice of all groups was recorded prior to sacrifice and the brain weight was 
recorded immediately after its removal. The number of animals used for each experimental procedure 
is specified in the figure legends and in Table 3.3.1. 
Experiment 3. A total of 38 adult male mice were used. Mice aged 4 months received a daily i.p. 
injection of i) vehicle (0.9% NaCl; n=13 euploid and n=11 Ts65Dn mice) or ii) 7,8-DHF (5.0 mg/kg) 
dissolved in the vehicle (n=7 euploid and n=7 Ts65Dn mice) for 41 days (Fig. 3.3.3A). During the 
last 11 days of treatment mice were behaviorally tested with the Morris Water Maze (MWM) test. 
Adult mice underwent a longer MWM in order to detect, if present, age-dependent cognitive decline. 
These mice will be called here 5 month-old mice. At the end of behavioral testing mice were killed, 
the brain was removed, fixed by immersion in PFA 4% and frozen.  
 
Histological procedures 
The frozen brains of P15 and 5 month-old mice were cut with a freezing microtome into 30-m-thick 
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Figure 3.3.1. Experimental protocols. A: Euploid and Ts65Dn pups received one daily injection of either 
vehicle or 7,8-DHF (5.0 mg/kg) from postnatal day 3 (P3) to P15. At P15, mice received one injection of BrdU, 
and were killed after 2 h in order to evaluate the number of cells in the S-phase of the cell cycle. B: Euploid 
and Ts65Dn mice received one daily injection of either vehicle or 7,8-DHF (5.0 mg/kg) from postnatal day P3 
to P45-50. These mice were tested with the Morris Water Maze test 6 days before being killed. C: Euploid and 
Ts65Dn mice received one daily injection of either vehicle or 7,8-DHF (5.0 mg/kg) from 4 months to 5 months 
+ 9 days of age. These mice were tested with the Morris Water Maze test 9 days before being killed. 
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; BrdU, bromodeoxyuridine; d, days; Eu, euploid; MWM, 
Morris Water Maze, P, postnatal.
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Table 3.3.1 Number of mice included and excluded from the analyses. 
 
 
 
 
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; DG, dentate gyrus; ML, molecular layer of the dentate gyrus; 
N., number; P, post-natal day
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coronal sections that were serially collected in anti-freezing solution (30% glycerol; 30% ethylen-
glycol; 10% PBS10X; sodium azide 0.02%; MilliQ to volume). Slices from P15 brains were used for 
BrdU immunofluorescence; slices from 5 month-old brains were used for doublecortin (DCX) 
immunofluorescence. 
 
Immunohistochemistry 
The antibodies for immunohistochemistry, with their dilution and purpose are summarized in Table 
3.3.2. 
BrdU immunohistochemistry in P15 mice. One out of six free-floating sections (n=15-18 sections) 
from the hippocampal formation of P15 mice was processed for BrdU immunohistochemistry as 
described in Section 3.1. Slices were incubated with a rat anti-BrdU antibody (mouse monoclonal 
1:100, Roche Applied Science, Mannheim, Germany). Detection was performed with a Cy3-
conjugated anti rat-secondary antibody as indicated in Table 3.3.2.  
DCX Immunohistochemistry in 5 month-old mice. One out of six free-floating sections from the 
hippocampal formation (n=10 sections) of 5 months old mice were processed for DCX 
immunohistochemistry, using the methods described in (Guidi et al., 2013). Quantification of DCX-
positive cells in the DG was conducted in every 6th section using a fluorescence microscope (Nikon 
Eclipse TE 2000-S inverted microscope; Nikon Corp., Kawasaki, Japan; objective: x 20, 0.50 NA; 
final magnification: x 200), equipped with a Nikon digital camera DS 2MBWc. DCX positive-cells 
were counted along the whole length of the granule cell layer and their number was expressed as 
number of cells for 100 µm of linear length. 
 
Golgi staining  
Brains of P15 mice were Golgi stained using the FD Rapid Golgi Stain TM Kit (FD 
NeuroTechnologies, Inc.). Brains were immersed in the impregnation solution containing mercuric 
chloride, potassium dichromate and potassium chromate and stored at room temperature in darkness 
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Table 3.3.2. Antibodies used for immunohistochemistry and western blot. 
Antigen Application Antibody Dilution- Manufactures  
α-Tubulin 
WB Primary: mouse monoclonal 1:1000 (Clone B-5-1-2) (Sigma-
Aldrich, T5168) 
Secondary: HRP-conjugated anti-mouse 1:20000 (Jackson 
Immunoresearch, 115-035-003) 
BDNF 
WB Primary: rabbit polyclonal 1:500 (N-20) (Santa Cruz 
Biotechnology, cs-546) 
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson 
Immunoresearch, 111-035-003) 
5-bromo-2-
deoxyuridine (BrdU) 
IHC 
 
Primary: rat monoclonal 1:200 (BioRad, OBT0030) 
Secondary: Cy3-conjugated anti-rat IgG 1:200 (Jackson 
Immunoresearch, 112-165-143) 
Extracellular signal-
regulated kinase 
(ERK1/2)  
WB Primary: mouse monoclonal 1:1000 (3A7) (Cell Signaling, 9107) 
Technology 
Secondary: HRP-conjugated anti-mouse 1:10000(Jackson 
Immunoresearch, 115-035-003) 
phosphorylated ERK 
(p-ERK1/2) 
WB Primary: rabbit polyclonal 1:1000 (Cell Signaling Technology, 
9101) 
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson 
Immunoresearch, 111-035-003) 
GAPDH 
WB Primary: rabbit polyclonal 1:5000 (Sigma-Aldrich, G9545) 
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson 
Immunoresearch, 111-035-003) 
Synaptophysin (SYN) 
WB Primary: rabbit polyclonal 1:1000(Abcam, ab 14692) 
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson 
Immunoresearch, 111-035-003) 
Tropomyosin receptor 
kinase (Trk) B Full 
Length (FL) and TrkB 
truncated (T1) 
WB Primary: rabbit monoclonal 1:1000 (Cell Signaling Technology, 
80E3) 
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson 
Immunoresearch, 111-035-003) 
phosphorylated TrkB-
FL (p-TrkB-FL) 
WB Primary: rabbit polyclonal 1:1000 (Millipore, ABN1381) 
Secondary: HRP-conjugated anti-rabbit 1:10000 (Jackson 
Immunoresearch, 111-035-003) 
Abbreviations: IHC, immunohistochemistry; WB, Western blotting.  
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for 3 weeks. Hemispheres were cut with a microtome in 90-μm-thick coronal sections that were 
mounted on gelatin-coated slides and were air dried at room temperature in the dark for one day. 
After drying, sections were rinsed with distilled water and subsequently stained in a developing 
solution (FD Rapid Golgi Stain Kit).  
 
Measurements  
Image acquisition. Immunofluorescence images were taken with a Nikon Eclipse TE 2000-S inverted 
microscope (Nikon Corp., Kawasaki, Japan), equipped with a Nikon digital camera DS 2MBWc. 
Measurements were carried out using the software Image Pro Plus (Media Cybernetics, Silver Spring, 
MD 20910, USA). Bright field images were taken on a light microscope (Leitz) equipped with a 
motorized stage and focus control system and a Coolsnap-Pro color digital camera (Media 
Cybernetics, Silver Spring, MD, USA).  
BrdU-positive cells in P15 mice. BrdU-positive cells in the DG of P15 mice were detected using a 
fluorescence microscope (Eclipse; objective: x 40, 0.75 NA; final magnification: x 400). 
Quantification of BrdU-labeled nuclei was conducted in every 6th section using a modified unbiased 
stereology protocol that has previously been reported as successfully quantifying BrdU labeling 
(Malberg et al., 2000, Kempermann and Gage, 2002, Tozuka et al., 2005). All BrdU-labeled cells 
located in the granule cell and subgranular layers were counted in their entire z axis (1 µm steps) in 
each section. To avoid oversampling errors, nuclei intersecting the uppermost focal plane were 
excluded. The total number of BrdU-labeled cells per animal was determined and multiplied by six 
to obtain the total estimated number of cells per DG. 
Spine density in P15 mice. In Golgi-stained sections from the DG of P15 mice, spines of granule cells 
were counted using a 100x oil immersion objective lens (1.4 NA). Spines were counted in dendritic 
segments in the inner and outer half of the molecular layer. For each neuron, 2-3 segments were 
analyzed in the outer and inner half of the molecular layer, respectively. For each animal, spines were 
counted in at least 8 neurons. The length of each sampled dendritic segment was determined by 
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tracing its profile and the number of spines was counted manually. The linear spine density was 
calculated by dividing the total number of spines by the length of the dendritic segment. Spine density 
was expressed as number of spines per 100 m dendrite. 
Stereology of the DG in P15 mice. Unbiased stereology was performed on Hoechst-stained sections 
from P15 mice. The protocol used for stereology of the DG is the same as that used in Section 3.1. 
Number of DCX positive cells in 5 month-old mice. Quantification of DCX positive cells in the DG 
was conducted in every 6th section using a fluorescence microscope (Nikon Eclipse TE 2000-S 
inverted microscope; Nikon Corp., Kawasaki, Japan; objective: x 20, 0.50 NA; final magnification: 
x 200), equipped with a Nikon digital camera DS 2MBWc. DCX positive cells were counted along 
the whole length of the granule cell layer and their number was expressed as number of cells for 100 
µm of linear length. 
 
Western blotting 
In homogenates of the hippocampal formation of P15 mice, total proteins were obtained as described 
in Section 3.1 of this thesis. Equivalent amount of proteins (50 μg) were subjected to electrophoresis 
on a Bolt 4-12% NuPAGE Bis-Tris Precast Gel (Novex, Life Technologies, Ltd, Paisley, UK) and 
transferred to a Hybond ECL nitrocellulose membrane (Amersham Life Science). The levels of the 
following proteins were evaluated: BDNF, TrkB full length (TrkB-FL), phosphorylated TRKB (p-
TRKB), the truncated form 1 of the TRKB receptor (TRKB-T1), phosphorylated ERK1 (p-ERK1), 
phosphorylated ERK2 (p-ERK2), ERK1, ERK2, SYN, GAPDH and α-Tubulin using the antibodies 
reported in Table 3.3.2. Densitometric analysis of digitized images with ChemiDoc XRS+ was 
performed with Image Lab software (Bio-Rad Laboratories, Hercules, CA, USA) and intensity for 
each band was normalized to the intensity of the corresponding GAPDH or α-Tubulin band.  
 
Behaviorioral testing 
Morris Water Maze (MWM). The MWM protocol and apparatus used for P45 mice were the same as 
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those used in Section 3.2. Since we have not made YM in this study, we evaluated more parameters 
for MWM because in comparison with those analysed in Section 3.2. For the learning phase, we 
evaluated the latency to find the hidden platform, time in periphery, percentage of time in periphery, 
path length, proximity to the platform, and swimming speed. Retention was assessed with one trial 
(probe trial), on the sixth day, 24 h after the last acquisition trial, using the same starting point for all 
mice. For the probe trial, the latency of the first entrance in the trained platform zone, the frequency 
of entrances in the trained quadrant, the proximity to the trained platform position (Gallagher’s test), 
the percentage of time spent at the periphery (thigmotaxis), the swimming speed and the percentage 
of time spent in each quadrant were employed as measures of retention of acquired spatial preference. 
The following number of mice were tested. Untreated euploid mice: n=19; untreated Ts65Dn mice: 
n=14; 7,8-DHF-treated euploid mice: n=17; 7,8-DHF-treated Ts65Dn mice: n=16. Three untreated 
euploid mice (yielding n=16), one 7,8-DHF-treated euploid mouse (yielding n=16) and one 7,8-DHF-
treated Ts65Dn mouse (yielding n=15) were excluded from MWM analysis due to thigmotaxis for a 
whole recording session.  
For adult (5-month-old) mice, the apparatus and the experimental condition of the MWM test was the 
same as those for P45 mice, with the exception of the learning phase duration. Learning phase was 
organized as follows. Days 1-8: learning sessions; day 9: probe test. During the learning phase mice 
were subjected to 4 trials on day one and to two blocks of 4 trials separated by an interval of 45 
minutes on days 2-8. Mice were tested longer than in the other MWM protocols reported in the 
dissertation because we sought to establish whether Ts65Dn mice have cognitive decline at five 
months of age and whether treatment could prevent this condition. 
 
Statistical analysis 
Results are presented as mean ± standard error of the mean (SE). Data were analyzed with the IBM 
SPSS 22.0 software. Distribution of data and the homogeneity of variances were evaluated with 
Shapiro-Wilk test and Levene’s test respectively. Statistical analysis was carried out using either a 
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one-way ANOVA or a two-way ANOVA with genotype (euploid, Ts65Dn) and treatment (vehicle, 
7,8-DHF), as factors. Post hoc multiple comparisons were carried out using the Fisher least signiﬁcant 
difference (LSD) test. For the learning phase of the MWM test, statistical analysis was performed 
using a three-way mixed ANOVA, with genotype and treatment as grouping factors and days as a 
repeated measure. For the probe test of MWM, we used a two-way ANOVA with genotype and 
treatment as factors followed by the Fisher LSD post hoc test for the latency of the first entrance in 
the trained platform zone, the frequency of entrances in the trained quadrant, the proximity to the 
trained platform position, the percentage of time spent in the periphery, and the swimming speed. For 
the percentage of time spent in quadrants, the percentage of time spent in the NW, NE and SE 
quadrants was compared to the percentage of time spent in the trained platform quadrant (SW), 
respectively, with a paired-samples t-test. Based on the “Box plot” tool available in SPSS Descriptive 
Statistics we excluded from each analysis the extremes, i.e. values that were larger than 3 times the 
IQ range [x ≥ Q3 + 3 * (IQ); x ≤ Q1 – 3 * (IQ)]. Figure legends report the number of mice used for 
statistical analysis. A probability level of p ≤ 0.05 was considered to be statistically significant.  
 
3.3.4 Results 
 
Effect of treatment with 7,8-DHF in P15 mice: general results 
The Ts65Dn strain is characterized by a high mortality rate during gestation and before weaning 
(Roper and Reeves, 2006). In view of the fragility of this strain, we sought to establish whether 
treatment with 7,8-DHF has adverse effects on the outliving of Ts65Dn mice. In the current study, 
treatment with either 7,8-DHF or vehicle began on postnatal day 3 (P3). All mice that survived in the 
P0 to P3 period entered this study. A total of 185 mice entered the study (96 males and 89 females). 
The number of vehicle- and 7,8-DHF-treated mice was 96 and 89, respectively. Seven vehicle-treated 
(7.3%) and five 7,8-DHF-treated (5.6%) mice died before weaning, in the first two postnatal weeks. 
The mortality rate is similar between groups treated with either vehicle or 7,8-DHF, suggesting that 
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the treatment has no adverse effects on the health of mice.  
We evaluated the body and brain weight of P15 mice in order to establish the effect of treatment on 
gross growth parameters. A two-way ANOVA on the body weight of P15 mice showed no genotype 
x treatment interaction [F(1,92) = 0.63, p = 0.431], no main effect of treatment but a main effect of 
genotype [F(1,92) = 14.78, p < 0.001]. A post hoc Fisher LSD test confirmed well-established 
evidence that Ts65Dn mice have a reduced body weight in comparison with euploid mice. Multiple 
comparisons revealed that treatment did not negatively affect the body weight of Ts65Dn mice (Fig. 
3.3.2A). A two-way ANOVA on the brain weight of P15 mice showed no genotype x treatment 
interaction [F(1,92) = 1.09, p = 0.300], a main effect of genotype [F(1,92) = 7.73, p = 0.007] and a 
main effect of treatment [F(1,92) = 6.18,  p = 0.015]. A post hoc Fisher LSD test showed that Ts65Dn 
mice had a reduced brain weight in comparison with euploid mice and that treatment did not cause a 
further brain weight reduction (Fig. 3.3.2B). Surprisingly, treated euploid mice showed a little but 
significant brain weight reduction in comparison with their untreated counterparts (Fig. 3.3.2B).  
 
Effect of neonatal treatment with 7,8-DHF on neural precursor proliferation in the hippocampal 
dentate gyrus of Ts65Dn mice 
Recent work has evaluated the effect of 7,8-DHF in mouse models of Alzheimer disease. A dose of 
5.0 mg/kg has been shown to have no toxic effects, to restore cognitive performance, and to increase 
the proliferation rate of neural precursor cells of the DG (Liu et al., 2010). In order to establish 
whether this is the optimal dose for proliferation enhancement in our model, we treated pups with 
vehicle, 2.5 mg/kg, 5.0 mg/kg or 10.0 mg/kg of 7,8-DHF in the period P3-P15. Two hours after the 
last treatment, mice received one injection of BrdU (150 mg/Kg) and were killed after 2 h in order to 
examine the outcome of a thirteen days treatment on proliferation rate. A one-way ANOVA on the 
number of BrdU-positive cells in the dentate gyrus (DG) of Ts65Dn pups showed a significant effect 
of treatment [F(3,20) = 4.15, p = 0.019]. A post hoc Fisher LSD test showed that the 2.5 mg/kg was 
not effective on proliferation rate in comparison with vehicle-treated mice, while both the 5.0 mg/kg 
193 
 
 
Figure 3.3.2. Body and brain weight of euploid and Ts65Dn mice treated with either vehicle or 7,8-DHF. 
A,B: Body (A) and brain (B) weight (mean  SE) in grams of P15 euploid (n=35) and Ts65Dn (n=21) mice 
that received vehicle and euploid (n=25) and Ts65Dn (n=15) mice that received 7,8-DHF (5.0 mg/kg) in the 
period P3-P15. C,D: Body (C) and brain (D) weight (mean  SE) in grams of P45 euploid (n=19) and Ts65Dn 
(n=14) mice that received vehicle and euploid (n=17) and Ts65Dn (n=16) mice that received 7,8-DHF (5.0 
mg/kg) in the period P3-P45. E,F: Body (E) and brain (F) weight (mean  SE) in grams of 5 month-old euploid 
(n=13) and Ts65Dn (n=11) mice that received vehicle and euploid (n=7) and Ts65Dn (n=7) mice that received 
7,8-DHF (5.0 mg/kg) in the period 4M-5M+9d. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test after 
two-way ANOVA). Black asterisk in the gray bar indicate a difference between untreated Ts65Dn mice and 
treated euploid mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; BrdU, bromodeoxyuridine; Eu, euploid; 
MWM, Morris Water Maze, P, postnatal.
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and the 10.0 mg/kg doses increased the number of BrdU-positive cells in Ts65Dn mice. In absolute 
terms, the 5.0 mg/kg dose had a higher pro-proliferative effect than the 10.0 mg/kg dose (Fig. 3.3.3A).  
Based on the preliminary experiments reported above, we chose a dose of 5.0 mg/kg dose for the 
experiments of this study. In order to establish the effects of 7,8-DHF on proliferation rate of neural 
progenitor cells (NPCs) of the DG, Ts65Dn mice and their euploid littermates were daily injected 
with 5.0 mg/kg of 7,8-DHF in the period P3-P15. At the end of treatment, mice were injected with 
BrdU and the number of BrdU-positive cells in the subgranular zone (SGZ) of the DG was evaluated. 
A two-way ANOVA on the total number of BrdU-positive cells showed a genotype x treatment 
interaction [F(1,19) = 8.53, p = 0.009], a main effect of genotype [F(1,19) = 21.25, p < 0.001], but no 
effect of treatment. A post hoc Fisher LSD test showed that untreated Ts65Dn mice had fewer 
proliferating cells in comparison with untreated euploid mice (total number per DG in Ts65Dn mice: 
n=7166±337, in euploid mice: n=10281±111). The number of proliferating cells after treatment in 
Ts65Dn mice underwent an increase (n=8963±449), becoming greater than that of their untreated 
counterparts, but already slightly lower in comparison with untreated euploid mice (Fig. 3.3.3B,C). 
BrdU-positive cells did not change in treated euploid mice (Fig. 3.3.3B,C). These results show that 
treatment greatly enhances cell proliferation in trisomic mice, although the number of proliferating 
cells does not reach the levels of euploid mice.  
 
Effect of 7,8-DHF on the number of granule neurons in the dentate gyrus of Ts65Dn mice 
Since treatment induced an increase in the proliferation potency of neural precursor cells in the DG 
of Ts65Dn mice, we expected this effect to lead to improvement of the defective cellularity proper of 
the DG of trisomic mice (Bianchi et al., 2010b). In order to answer this question, we stereologically 
counted the total number of granule cells in treated and untreated mice. A two-way ANOVA on total 
number of granule cells showed a genotype x treatment interaction [F(1,13) = 6.71, p = 0.022], but 
no main effect of either genotype or treatment. A post hoc Fisher LSD test showed that untreated 
Ts65Dn mice had fewer granule neurons in comparison with euploid mice. In treated Ts65Dn mice 
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Figure 3.3.3. Effects of neonatal treatment with 7,8-DHF on the size of the population of cells in the S-
phase of the cell cycle in the dentate gyrus of P15 Ts65Dn and euploid mice. A: In pilot experiments 
Ts65Dn mice received a daily injection of vehicle (n=8) or 7,8-DHF (2.5 mg/kg, n=4; 5.0 mg/kg, n=5; 10.0 
mg/kg, n=7) in the period P3-P15. At P15, they were injected with BrdU and killed after 2 h. The histograms 
show the number of BrdU-positive cells in the DG of Ts65Dn mice treated with either vehicle or the indicated 
doses of 7,8-DHF. The number of BrdU-positive cells in euploid mice reported in (C) that received the vehicle 
is shown for comparison. B: Representative images of sections immunostained for BrdU from the DG of 
untreated euploid and Ts65Dn mice and euploid and Ts65Dn mice that were daily treated with 5.0 mg/kg of 
7,8-DHF in the period P3-P15. Calibration bar=200 m. The insets show zoomed images of the boxed area 
with examples of individual BrdU-positive cells. Calibration bar=20 m. C: Total number of BrdU-positive 
cells in the DG of untreated euploid (n=7) and Ts65Dn (n=8) mice and euploid (n=3) and Ts65Dn (n=5) mice 
treated with 5.0 mg/kg of 7,8-DHF. Values (mean  SE) in (A) and (C) refer to one hemisphere. * p < 0.05; 
** p < 0.01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate 
a difference between untreated Ts65Dn mice and treated euploid mice. Abbreviation: 7,8-DHF, 7,8-
dihydroxyflavone; Eu, euploid.
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Figure 3.3.4. Effects of neonatal treatment with 7,8-DHF on granule cell number in the dentate gyrus of 
P15 Ts65Dn and euploid mice. A: Representative images of Hoechst-stained sections showing the granule 
cell layer of an animal from each experimental group. Calibration bar=100 m. B: Total number of granule 
cells of untreated euploid (n=4) and Ts65Dn (n=4) mice and euploid (n=4) and Ts65Dn mice (n=5) treated 
with 5.0 mg/kg 7,8-DHF. Values (mean  SE) refer to one DG. * p < 0.05 (Fisher LSD test after two-way 
ANOVA). Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; GR, granule cell layer; SGZ, 
subgranular zone; Veh, vehicle.
197 
 
the number of granule cells became similar to that of untreated euploid mice (Fig. 3.3.4A,B). In 
euploid mice treatment had no effect on total number of granule cells (Fig. 3.3.4A,B). 
 
Effect of 7,8-DHF on dendritic spine density in the dentate gyrus of Ts65Dn mice 
Spine density reduction is a typical feature of the trisomic brain (Benavides-Piccione et al., 2004, 
Guidi et al., 2013) that, in conjunction with hypocellularity, is probably a critical determinant of 
intellectual disability. In order to establish whether 7,8-DHF improves this defects, in Golgi-stained 
brains we evaluated dendritic spine density of DG granule neurons. A two-way ANOVA on spine 
density showed a genotype x treatment interaction [F(1,12) = 13.23, p = 0.003], a main effect of 
genotype [F(1,12) = 19.93, p = 0.001] and a main effect of treatment [F(1,12) = 42.30, p < 0.001]. A 
post hoc Fisher LSD test showed that untreated Ts65Dn had a considerably reduced spine density in 
comparison with untreated euploid mice (Fig. 3.3.5C). Treatment with 7,8-DHF restored the number 
of spines of Ts65Dn mice (Fig. 3.3.5C), indicating that treatment fully rescues spine development. 
No effect of treatment were observed on spine density in euploid mice (Fig. 3.3.5C). 
 
Effect of 7,8-DHF on synaptophysin levels in the hippocampal formation of Ts65Dn mice 
The trisomic brain is characterized by altered synaptic circuitry that, in conjunction with reduced 
neurogenesis and dendritic pathology, largely contributes to impairment of signal processing 
(Bartesaghi et al., 2011). Since circuit formation is critically shaped in the early postnatal period 
throughout the brain we tried to establish whether neonatal treatment with 7,8-DHF had an effect on 
synapse development, examining the expression levels of SYN in the hippocampus of P15 mice.  
A two-way ANOVA on the levels of SYN showed no genotype x treatment interaction [F(1,27) = 
0.82, p = 0.372], no main effect of genotype, but a main effect of treatment [F(1,27) = 6.62, p = 
0.016]. Confirming previous evidence (Stagni et al., 2013), a post hoc Fisher LSD test showed that 
untreated Ts65Dn mice had reduced SYN levels in comparison with untreated euploid mice, although 
the difference was marginally significant. Treatment with 7,8-DHF increased SYN levels in Ts65Dn 
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Figure 3.3.5. Effects of neonatal treatment with 7,8-DHF on dendritic spine density and synaptophysin 
levels in the dentate gyrus of P15 Ts65Dn and euploid mice. A: The photomicrograph shows a Golgi-stained 
granule cell. Dendritic spines were counted in the inner and outer half of the dendritic arbor of the granule 
cells. Calibration bar=10 m. B: Photomicrograph of Golgi-stained granule cell dendrites showing spines on 
distal dendritic branches in an animal from each experimental groups. Calibration bar=5 m. C: Spine density 
on the dendritic arbor of the granule cells of untreated euploid (n=4) and Ts65Dn mice (n=4) and euploid (n=4) 
and Ts65Dn (n=4) mice treated with 7,8-DHF. D: Western blot analysis of the expression levels of 
synaptophysin (SYN) in hippocampal homogenates of untreated euploid (n=10) and Ts65Dn (n=10) mice and 
treated euploid (n=5) and Ts65Dn (n=6) mice. SYN levels were normalized to α-Tubulin and expressed as fold 
difference in comparison with untreated euploid mice. Representative western blots are shown on the right. 
Values in (C,D) are mean  SE. (*) p < 0.06; * p < 0.05; *** p < 0.001 (Fisher LSD test after two-way 
ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated 
euploid mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; SYN, synaptophysin; Veh, 
Vehicle.
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 (similar levels to those of untreated euploid mice) and in euploid mice (Fig. 3.3.5D). These findings 
suggest that treatment with 7,8-DHF restores development of hippocampal synapses in Ts65Dn mice 
and enhances synaptic development in euploid mice. 
 
Effect of 7,8-DHF on the BDNF-TrkB receptor system in the hippocampal formation of Ts65Dn 
mice 
BDNF signaling is elicited when it binds to TRKB, resulting in the receptor dimerization and 
autophosphorylation. The BDNF/TRKB signaling pathway is essential for normal brain function 
(Bibel et al., 1999). The TRKB full-length receptor (TRKB-FL) possesses an intracellular tyrosine 
kinase domain that mediates the crucial effects of BDNF. By contrast, the truncated form 1 of the 
TRKB receptor (TRKB-T1) lacks tyrosine kinase domain and, hence, the normal BDNF-mediated 
activity. However, TRKB-T1 appears to mediate inositol-1,4,5-trisphosphate-dependent calcium 
release (Rose et al., 2003). In order to establish the effect of genotype and treatment on the 
BDNF/TRKB system, we examined the protein levels of BDNF and TRKB receptors in the 
hippocampus of P15 euploid and Ts65Dn mice. 
A two-way ANOVA on the BDNF levels showed no genotype x treatment interaction [F(1,48) = 
0.86, p = 0.359], no main effect of genotype, but a main effect of treatment [F(1,48) = 8.76, p = 
0.005]. A post hoc Fisher LSD test showed that Ts65Dn mice had similar BDNF protein levels as 
euploid mice (Fig. 3.3.6B). Treatment with 7,8-DHF caused a reduction in BDNF levels both in 
euploid and Ts65Dn mice although the difference was statistically significant for the latter only (Fig. 
3.3.6B). A two-way ANOVA on the levels of TRKB-FL receptor showed no genotype x treatment 
interaction [F(1,45) = 2.17, p = 0.148] , a main effect of genotype [F(1,45) = 5.71, p = 0.021], and no 
effect of treatment. A post hoc Fisher LSD test showed no difference between untreated euploid and 
Ts65Dn mice in the levels of TRKB-FL (Fig. 3.3.6A,C). In Ts65Dn, but not in euploid mice, 
treatment with 7,8-DHF caused a reduction in the levels of TRKB-FL (Fig. 3.3.6A,C). A two-way 
ANOVA on the levels of the phosphorylated (active) form of the TRKB receptor (p-TRKB-FL) 
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showed no genotype x treatment interaction [F(1,39) = 0.03, p = 0.865], no main effect of genotype, 
but a main effect of treatment [F(1,39) = 10.88, p = 0.002]. A post hoc Fisher LSD test showed that 
in untreated Ts65Dn mice the levels of p-TRKB-FL were similar to those of euploid mice. In both 
genotypes, treatment with 7,8-DHF caused an increase in the levels of p-TRKB-FL (Fig. 3.3.6A,D). 
A two-way ANOVA on the levels of the TRKB-T1 receptor showed a genotype x treatment 
interaction [F(1,47) = 6.04, p = 0.018], but no main effect of either genotype or treatment. A post hoc 
Fisher LSD test showed that untreated Ts65Dn mice has similar levels of TRKB-T1 as untreated 
euploid mice. Treated Ts65Dn mice underwent a reduction in the levels of TRKB-T1 in comparison 
with their untreated counterparts and untreated euploid mice (Fig. 3.3.6A,E). These data suggest that 
treatment with 7,8-DHF stimulates the BDNF-signaling pathway. When the TRKB-FL receptor is 
activated, it interacts and activates a number of proteins that, in turn, trigger a signaling cascade to 
gene transcription. One of the main target of the BDNF/TRKB system is the RAS/ERK signaling 
pathway. Since RAS/ERK signaling is involved in cell proliferation and differentiation, we examined 
the effects of treatment on the activation of ERK1/2 in the hippocampus of Ts65Dn and euploid mice. 
A two-way ANOVA on p-ERK1 levels showed no genotype x treatment interaction [F(1,29) = 0.78, 
p = 0.385], but a main effect of both genotype [F(1,29) = 7.21, p = 0.012] and treatment [F(1,29) = 
4.64, p = 0.040]. A post hoc Fisher LSD test showed no differences between untreated Ts65Dn and 
euploid mice and that treatment increased p-ERK1 levels of Ts65Dn mice in comparison with 
untreated Ts65Dn mice as well as untreated euploid mice (Fig. 3.3.7A,C). A two-way ANOVA on 
p-ERK2 levels showed no genotype x treatment interaction [F(1,29) = 1.73, p = 0.199], a main effect 
of genotype [F(1,29) = 8.92, p = 0.006] but no main effect of treatment. A post hoc Fisher LSD test 
showed that treated Ts65Dn mice underwent an increase in p-ERK2 levels in comparison with 
untreated euploid mice (Fig. 3.3.87A,C), but not with Ts65Dn mice. A two-way ANOVA on the 
levels of total ERK1 showed no genotype x treatment interaction [F(1,28) = 0.815, p = 0.374] and no 
main effect of either genotype or treatment. A post hoc Fisher LSD test showed that treated Ts65Dn 
mice underwent an increase in total ERK1 levels in comparison with untreated Ts65Dn mice (Fig. 
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3.3.7B,C). A two-way ANOVA on the levels of total ERK2 showed no genotype x treatment 
interaction [F(1,30) = 0.065, p = 0.801], no main effect of genotype, but a main effect of treatment 
[F(1,30) = 13.76, p = 0.001]. A post hoc Fisher LSD test showed that Ts65Dn mice treated with 7,8-
DHF underwent an increase in total ERK2 levels in comparison with untreated euploid and Ts65Dn 
mice (Fig. 3.3.7B,C). An increase in total ERK2 levels also took place in treated euploid mice in 
comparison with their untreated counterparts (Fig. 3.3.7B,C). There is evidence that ERK2 is 
approximately four time more abundant than ERK1 in various brain regions and that alteration of the 
stoichiometry of the two isoform of ERK may have adverse effects (Lefloch et al., 2008). Therefore, 
we examined the relative abundance of ERK2/ERK1 and p-ERK2/p-ERK1 in treated and untreated 
mice. We found that in the hippocampal region of untreated euploid and Ts65Dn mice the ratio 
between ERK2 and ERK1 was approximately 3:1 and the ratio between p-ERK2 and p-ERK1 was 
approximately 2:1. Although in absolute terms treatment increased the levels of ERK1/2 and p-
ERK1/2 in Ts65Dn mice (Fig. 3.3.7A-C), it did not affect their stoichiometry.  
 
Effect of treatment with 7,8-DHF in P45 mice: general results 
A two-way ANOVA on the body weight of P45 mice showed no genotype x treatment interaction 
[F(1,62) = 1.57, p = 0.215], a main effect of genotype [F(1,62) = 4.98, p = 0.029], but no main effect 
of treatment. A post hoc Fisher LSD test showed that Ts65Dn mice retained a reduced body weight 
in comparison with euploid mice and that treatment did not affect their body weight (Fig. 3.3.2C). In 
contrast, treated euploid mice underwent a body weight reduction in comparison with their untreated 
counterparts (Fig. 3.3.2C). A two-way ANOVA on the brain weight of P45 mice showed no genotype 
x treatment interaction [F(1,62) = 2.06, p = 0.156], and no main effect of both genotype and treatment. 
A post hoc Fisher LSD test showed that untreated Ts65Dn mice had a reduced brain weight in 
comparison with untreated euploid mice and that treatment restored this defect (Fig. 3.3.2D).  
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Figure 3.3.6. Effects of neonatal treatment with 7,8-DHF on the BDNF/TRKB receptor system in the 
hippocampal formation of P15 Ts65Dn and euploid mice. Western blot analysis of the BDNF/TRKB 
receptor system in the hippocampal formation of P15 Ts65Dn and euploid mice that received either vehicle or 
7,8-DHF in the postnatal period P3-P15. A: representative western blots showing immunoreactivity for the 
phosphorylated TRKB receptor (p-TRKB), the full length TRKB receptor (TRKB-FL), the truncated TRKB 
receptor (TRKB-T1), and the housekeeping gene GAPDH. B: Levels of BDNF (untreated euploid mice: n=20; 
untreated Ts65Dn mice: n=21; treated euploid mice: n=5; treated Ts65Dn mice: n=6) and representative 
western blots showing immunoreactivity for BDNF and the housekeeping gene GAPDH. C: Levels of TRKB-
FL (untreated euploid mice: n=19; untreated Ts65Dn mice: n=19; treated euploid mice: n=5; treated Ts65Dn 
mice: n=6). D: Levels of p-TRKB-FL (untreated euploid mice: n=15; untreated Ts65Dn mice: n=16; treated 
euploid mice: n=5; treated Ts65Dn mice: n=6). E: levels of TRKB-T1 (untreated euploid mice: n=19; untreated 
Ts65Dn mice: n=21; treated euploid mice: n=5; treated Ts65Dn mice: n=6). Data in (B, C, E) were normalized 
to GAPDH; data in (D) were normalized to TRKB-FL. Protein levels (mean  SE) are expressed as fold 
difference in comparison with untreated euploid mice. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test 
after two-way ANOVA). White asterisks in the black bar indicate a difference between treated Ts65Dn mice 
and treated euploid mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle.
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Figure 3.3.7. Effects of neonatal treatment with 7,8-DHF on the BDNF/TRKB receptor targets ERK1/2 
in the hippocampal formation of P15 Ts65Dn and euploid mice. Data refer to P15 Ts65Dn and euploid 
mice that received either vehicle or 7,8-DHF in the postnatal period P3-P15. A,B: Western blot analysis of p-
ERK1/p-ERK2 (untreated euploid mice: n=10; untreated Ts65Dn mice: n=12; treated euploid mice: n=5; 
treated Ts65Dn mice: n=6) (A) and total ERK1/ERK2 levels (untreated euploid mice: n=11; untreated Ts65Dn 
mice: n=11; treated euploid mice: n=5; treated Ts65Dn mice: n=6) (B) and representative western blots (C) 
showing immunoreactivity for p-ERK1, p-ERK2, ERK1, ERK2 and for the housekeeping protein α-Tubulin. 
Data in (B) were normalized to α-Tubulin; data in (A) were normalized to total ERK1 and total ERK2, 
respectively. Protein levels (mean  SE) are expressed as fold difference in comparison with untreated euploid 
mice. * p < 0.05; ** p < 0.01; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black asterisks in the 
gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. White asterisks in the 
black bar indicate a difference between treated Ts65Dn mice and treated euploid mice. Abbreviations: 7,8-
DHF, 7,8-dihydroxyflavone; Eu, euploid; Veh, vehicle. 
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Effect of 7,8-DHF on hippocampus-dependent learning and memory in P45 mice 
At the age of P45, mice can be behaviorally tested with tasks that explore hippocampus-dependent 
learning and memory (Guidi et al., 2014). In order to establish whether positive effects of treatment 
on brain morphology translates in a functional amelioration, we treated euploid and Ts65Dn mice 
from P3 to P45-50 and examined their behavior with the Morris Water Maze (MWM) test. The 
learning phase of the test lasted 5 days and on day six mice were subjected to the probe test in order 
to evaluate spatial memory. For the learning phase, the following variables were evaluated: escape 
latency, time in periphery, percentage of time in periphery, path length, proximity, and swimming 
speed. We carried out a three-way mixed ANOVA for all variables followed by post hoc Fisher LSD 
test. Results of ANOVA are reported hereafter and results of the post hoc test are summarized in 
Table 3.3.3. 
A three-way mixed ANOVA on escape latency, with genotype and treatment as grouping factors and 
day as a repeated measure revealed no effect of genotype x treatment x day [F(4,228) = 1.52, p = 
0.196]. We found a genotype x day interaction [F(4,228) = 3.10, p = 0.016], a treatment x day 
interaction [F(4,228) = 2.77, p = 0.028], no genotype x treatment interaction [F(1,57) = 0.03, p = 
0.874], a main effect of genotype [F(1,57) = 42.58, p < 0.001], a main effect of treatment [F(1,57) = 
10.14, p = 0.002], and a main effect of day [F(4,228) = 21.75, p < 0.001]. In accordance with previous 
findings, euploid mice exhibited a fast learning improvement with time, while untreated Ts65Dn mice 
exhibited a very scarce learning improvement and the latency to reach the platform did not decrease 
throughout the test (Fig. 3.3.8A, Table 3.3.3). In contrast, treatment improved learning in Ts65Dn 
mice and, save for day 3, their performance was similar to that of untreated euploid mice (Fig. 3.3.8A, 
Table 3.3.3). Treatment with 7,8-DHF induced an improvement in the latency of euploid mice in 
comparison with their untreated counterpart (Fig. 3.3.8A), although the difference was statistically 
significant on day 2 only (Table 3.3.3).  
A three-way mixed ANOVA on the time spent in the periphery zone (thigmotaxis) revealed an effect 
of genotype x treatment x day [F(4,228) = 2.88, p = 0.023]. We found no genotype x day interaction 
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[F(4,228) = 0.99, p = 0.412], a treatment x day interaction [F(4,228) = 3.31, p = 0.012], no genotype 
x treatment interaction [F(1,57) = 0.001, p = 0.992], a main effect of genotype [F(1,57) = 19.63, p < 
0.001], a main effect of treatment [F(1,57) = 8.07, p = 0.006], and a main effect of day [F(4,228) = 
27.72, p < 0.001]. A post hoc Fisher LSD test showed that while untreated Ts65Dn mice spent more 
time in the periphery than untreated euploid mice, Ts65Dn mice treated with 7,8-DHF spent a similar 
time as euploid mice (Fig. 3.3.8B, Table 3.3.3), suggesting an improvement in the searching strategy. 
A reduction in thigmotaxis was also shown by euploid mice treated with 7,8-DHF. 
A three-way mixed ANOVA on the percentage of time spent in the periphery showed an effect of 
genotype x treatment x day [F(4,228) = 3.01, p = 0.019]. We found a genotype x day interaction 
[F(4,228) = 2.47, p = 0.045], a treatment x day interaction [F(4,228) = 7.76, p < 0.001], no genotype 
x treatment interaction [F(1,57) = 1.48, p = 0.229], a main effect of genotype [F(1,57) = 11.71, p = 
0.001], a main effect of treatment [F(1,57) = 8.04, p = 0.006], and a main effect of day [F(4,228) = 
23.88, p < 0.001]. A post hoc Fisher LSD test showed that the time spent in the periphery by untreated 
Ts65Dn mice, expressed as percentage of the total latency, was similar to that of untreated euploid 
mice (Fig. 3.3.8C, Table 3.3.3). This means that the proportion of time spent in the periphery and 
outside the periphery was similar in euploid and Ts65Dn mice. Since in Ts65Dn mice the total latency 
to reach the platform was longer than in euploid mice, this means that Ts65Dn mice spent more time 
swimming in the periphery as well as outside the periphery. This implies that their longer escape 
latency can be attributable to both higher thigmotaxis levels and poorer spatial learning. In treated 
Ts65Dn mice the percentage of time in thigmotaxis underwent a reduction in comparison with their 
untreated counterparts (Fig. 3.3.8C, Table 3.3.3), suggesting an improvement in spatial learning. 
A three-way mixed ANOVA on path length revealed no effect of genotype x treatment x day 
[F(4,228) = 2.09, p = 0.082]. We found a genotype x day interaction [F(4,228) = 7.80, p < 0.001], no 
treatment x day interaction [F(4,228) = 0.54 p = 0.707], no genotype x treatment interaction [F(1,57) 
= 0.05, p = 0.819], no main effect of genotype, no main effect of treatment but a main effect of day 
[F(4,228) = 43.74, p < 0.001]. In all groups, the path length decreased from day 1 to day 5 (Fig. 
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3.3.8D, Table 3.3.3). Until day 4, all four groups the path length was similar, even though in untreated 
Ts65Dn mice, the reduction was smaller than in untreated euploid mice. On day 5, the path length of 
untreated Ts65Dn mice was significantly larger in comparison with untreated euploid mice (Fig. 
3.3.8D, Table 3.3.3). In contrast, on day 5 the path length of treated Ts65Dn mice was equal to that 
of treated and untreated euploid mice, suggesting an improvement in the searching strategy.  
A three-way mixed ANOVA on the mean distance to the trained platform position (Gallagher’s test; 
proximity) revealed an effect of genotype x treatment x day [F(4,228) = 2.59, p = 0.038]. We found 
a genotype x day interaction [F(4,228) = 3.93, p = 0.004], a treatment x day interaction [F(4,228) = 
4.79, p < 0.001], no genotype x treatment interaction [F(1,57) = 1.12, p = 0.295], a main effect of 
genotype [F(1,57) = 9.66, p = 0.003], a main effect of treatment [F(1,57) = 12.91, p = 0.001], and a 
main effect of day [F(4,228) = 13.39, p < 0.001]. Fig. 3.3.8E shows that while in untreated euploid 
mice the proximity to the platform position increased from day 1 to day 5, untreated Ts65Dn mice 
underwent no improvement. Treated Ts65Dn mice underwent an improvement and on day 5 their 
proximity was significantly larger than their untreated counterparts and similar to that of untreated 
and treated euploid mice (Fig. 3.3.8E, Table 3.3.3), indicating a better swimming strategy to locate 
the platform.  
A three-way mixed ANOVA on swimming speed revealed an effect of genotype x treatment x day 
[F(4,228) = 3.20, p = 0.014]. We found no genotype x day interaction [F(4,228) = 0.71, p = 0.584] , 
no treatment x day interaction [F(4,228) = 1.98, p = 0.098], no genotype x treatment interaction 
[F(1,57) = 0.09, p = 0.760], a main effect of genotype [F(1,57) = 5.27, p = 0.025], no main effect of 
treatment, but a main effect of day [F(4,228) = 20.05, p < 0.001]. A post hoc Fisher LSD test showed 
that in untreated Ts65Dn mice the swimming speed was similar to that the others three experimental 
groups throughout the learning phase (Fig. 3.3.8F, Table 3.3.3), suggesting that their longer escape 
latency was not due to speed reduction. Treated Ts65Dn mice had a reduced speed in comparison 
with untreated euploid mice on day 1, 2, and 3 but this condition disappeared in days 4 and 5, 
suggesting that their reduced escape latency was not due to an improvement in swimming speed. 
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Treated euploid mice had a reduced speed in comparison with untreated euploid mice on day 1, but a 
similar speed on days 2-5 (Fig. 3.3.8F, Table 3.3.3).  
In the probe test, we considered the following parameters as an index of spatial memory: i) latency 
to enter the trained platform zone (latency), ii) frequency of entrances in the trained quadrant 
(frequency), iii) proximity to the trained platform position (Gallagher’s test; proximity), iv) 
percentage of time spent at the periphery (thigmotaxis); v) swimming speed; vi) percentage of time 
spent in each quadrant. For all the parameters analyzed in the probe test, with the exclusion of the 
percentage of time spent in each quadrant, we conducted a two-way ANOVA, with genotype and 
treatment as independent variables, followed by a post hoc Fisher LSD test. A two-way ANOVA on 
the latency showed no genotype x treatment interaction [F(1,57) = 0.87, p = 0.356], but a main effect 
of genotype [F(1,57) = 10.24, p = 0.002] and a main effect of treatment [F(1,57) = 4.60, p = 0.036]. 
A post hoc Fisher LSD test showed that untreated Ts65Dn mice exhibited a larger latency than euploid 
mice. Treatment with 7,8-DHF caused a notable reduction in the latency of Ts65Dn mice that became 
similar to that of untreated euploid mice (Fig. 3.3.9A). A two-way ANOVA on the frequency showed 
no genotype x treatment interaction [F(1,57) = 0.001, p = 0.992], but a main effect of genotype 
[F(1,57) = 10.06, p = 0.002] and a main effect of treatment [F(1,57) = 7.46, p = 0.008]. A post hoc 
Fisher LSD test showed that untreated Ts65Dn mice exhibited a reduced frequency of entrances than 
euploid mice. In treated Ts65Dn mice, there was an increase in the frequency, that became similar to 
that of untreated euploid mice (Fig. 3.3.9B), although this effects was only marginally significant. A 
large increase in the frequency of entrances took place in treated euploid mice (Fig. 3.3.9B). This 
effect is in line with the reduction in the percentage of time they spent at the periphery (Fig. 3.3.9F). 
A two-way ANOVA on the proximity showed no genotype x treatment interaction [F(1,57) = 1.60, p 
= 0.211], but a main effect of genotype [F(1,57) = 4.81, p = 0.032] and a main effect of treatment 
[F(1,57) = 7.05, p = 0.010]. A post hoc Fisher LSD test showed that untreated Ts65Dn mice swam at 
a larger distance from the trained platform zone in comparison with untreated euploid mice (Fig. 
3.3.9C). Treated Ts65Dn mice swam closer to the trained platform zone and their performance 
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became similar to that of untreated euploid mice (Fig. 3.3.9C).   
A two-way ANOVA on the percentage of time spent in the periphery showed no genotype x treatment 
interaction [F(1,57) = 0.62, p = 0.436], no main effect of genotype but a main effect of treatment 
[F(1,57) = 12.03, p = 0.001]. A post hoc Fisher LSD test showed that in untreated Ts65Dn mice the 
percentage of time spent in the periphery was similar to that of untreated euploid mice (Fig. 3.3.9D). 
This indicates that Ts65Dn mice spent the same proportion of time in and outside the periphery as 
euploid mice. In treated Ts65Dn mice the percentage of time spent in the periphery was reduced in 
comparison with their untreated counterparts mice (Fig. 3.3.9D), suggesting that improvement in 
thigmotaxis contributes to the shorter latency to reach the trained platform zone. A reduction in the 
percentage of time in the periphery was also exhibited by treated vs. untreated euploid mice (Fig. 
3.3.9D). 
As during the learning phase, two-way ANOVA on the swimming speed showed no genotype x 
treatment interaction [F(1,57) = 0.44, p = 0.511], no main effect of genotype and no main effect of 
treatment and a post hoc Fisher LSD test showed no differences between groups (Fig. 3.3.9E). 
A paired samples t-test showed that untreated Ts65Dn mice exhibited no differences in the time spent 
in the trained platform quadrant in comparison with the other quadrants (Fig. 3.3.9F). In contrast, 
treated Ts65Dn mice spent significantly more time in the trained platform quadrant in comparison 
with the NE quadrant [t(14) = 2.49; p = 0.026] and with the SE quadrant  although the latter difference 
was only marginally significant [t(14) = 2.05; p = 0.059] (Fig. 3.3.9F). Untreated euploid mice spent 
significantly more time in the trained platform quadrant in comparison with the NE [t(15) = 3.09; p 
= 0.008] and SE quadrant [t(15) = 2.16; p = 0.047] quadrants (Fig. 3.3.9F). Likewise, treated euploid 
mice spent significantly more time in the trained platform quadrant in comparison with the NE [t(15) 
= 3.85; p = 0.002] and SE quadrant [t(15) = 6.02; p < 0.001] quadrants (Fig. 3.3.9F).  
Taken together, these results show that Ts65Dn mice are impaired in spatial learning and memory. 
Treatment with 7,8-DHF indices an amelioration in Ts65Dn mice day by day in all parameters of the 
learning phase, although not to a significant level. At day 5, however, the performance of Ts65Dn 
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mice underwent a significant improvement in comparison with their untreated counterparts and was 
similar to that of untreated euploid mice. Importantly, in the probe test the behavior of treated Ts65Dn 
mice was similar to that of untreated euploid mice. This evidence suggests a complete restoration of 
hippocampus dependent memory. 
 
Effect of treatment with 7,8-DHF in 5 month-old mice: general results 
A two-way ANOVA on the body weight of 5 month-old mice showed no genotype x treatment 
interaction [F(1,34) = 2.64, p = 0.114], and no main effect of either genotype or treatment. A post hoc 
Fisher LSD test showed that Ts65Dn mice retained a reduced body weight in comparison with euploid 
mice and that treatment slightly increased their body weight (Fig. 3.3.2E). No effects of treatment on 
body weight were detectable in euploid mice (Fig. 3.3.2E). A two-way ANOVA on the brain weight 
of P45 mice showed no genotype x treatment interaction [F(1,34) = 0.24, p = 0.626], and no main 
effect of both genotype and treatment. A post hoc Fisher LSD test showed no difference in brain 
weight among groups (Fig. 3.3.2F).  
 
Effect of 7,8-DHF on hippocampus-dependent learning and memory in 5 month-old mice 
We examined the behavior of mice that had received 7,8-DHF or vehicle starting from four months 
of age. Behavioral testing started when mice were 5 month-old and lasted 11 days. Treatment was 
continued during behavioral testing. For the learning phase, we evaluated: escape latency, percentage 
of time at the periphery, path length, and swimming speed. 
A three-way mixed ANOVA, with genotype and treatment as grouping factors and day as a repeated 
measure, on the escape latency revealed no effect of genotype x treatment x day. We found no 
genotype x day interaction, a treatment x day interaction [F(7,238) = 2.23, p = 0.032], no genotype x 
treatment interaction, a main effect of genotype [F(1,34) = 20.63, p < 0.001], no main effect of 
treatment but a main effect of day [F(7,238) = 24.67, p < 0.001]. While euploid mice exhibited a fast 
learning improvement with time, untreated Ts65Dn mice exhibited a very scarce learning 
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Figure 3.3.8. Effect of treatment with 7,8-DHF on spatial learning in young adult Ts65Dn and euploid 
mice. Mice received either vehicle or 7,8-DHF in the period P3-P45-50 and were behaviorally tested with the 
MWM starting from 6 days before reaching 45-50 days of age (untreated euploid mice: n=16; untreated 
Ts65Dn mice: n=14; treated euploid mice: n=16; treated Ts65Dn mice: n=15). The curves in (A-F) report data 
of euploid mice that received either vehicle (empty circle) or 7,8-DHF (filled circle) and Ts65Dn mice that 
received either vehicle (empty square) or 7,8-DHF (filled square). A-E: Learning phase of the MWM evaluated 
as latency to reach the platform (A), time spent in the periphery (thigmotaxis) (B), percentage of time spent in 
the periphery (C), path length (D), and proximity to the platform zone (E). F: Swimming speed. B-D: Values 
represent mean  SE. Statistical analyses for: untreated Ts65Dn vs Treated Ts65Dn, * p < 0.05; ** p < 0.01; 
*** p < 0.001; untreated euploid mice vs untreated Ts65Dn mice, # p < 0.05; ## p < 0.01; ### p < 0.001 (Fisher 
LSD test after two-way ANOVA). Detailed statistical analysis is reported in Table 3.3.3. Abbreviations: 7,8-
DHF, 7,8-dihydroxyflavone; cm, centimeters; Eu, euploid; sec, seconds.
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Table 3.3.3. P values of the Fisher LSD test for the indicated variables of P45 mice. 
 
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; sec, seconds; Ts, Ts65Dn; Veh, vehicle.  
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Figure 3.3.9. Effect of treatment with 7,8-DHF on spatial memory in young adult Ts65Dn and euploid 
mice. Spatial memory was assessed in the probe test after spatial learning (same mice as in Fig. 3.3.7). In the 
probe test, memory was assessed as latency to reach the trained platform zone (A), number of crossings 
(frequency) over the trained platform quadrant (B), proximity to the trained platform zone (C), percentage of 
time spent in the periphery (D), percentage of time spent in quadrants (F). E: Swimming speed during the 
probe test. Values represent mean  SE. (*) p < 0.06; * p < 0.05; ** p < 0.01; *** p < 0.001; (Fisher LSD test 
after ANOVA). Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and 
treated euploid mice; white asterisks in the black bar indicate a difference between treated Ts65Dn mice and 
treated euploid mice. The symbol § in (F) indicates a difference between each individual quadrant and the 
trained platform quadrant (see key on the left). for each experimental group. § p < 0.05; §§ p < 0.01; §§§ p < 
0.001; (two-sample paired t-test). Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; NE, north-east; 
NW, north-west; SE, south-east; SW, south-west; sec, seconds.
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improvement and the latency to reach the platform did not decrease throughout the test (Fig. 3.3.10A, 
Table 3.3.4). Likewise, Ts65Dn mice treated with 7,8-DHF showed a scarce learning improvement 
and their performance was not statistically different from that of untreated Ts65Dn mice (Fig. 
3.3.10A, Table 3.3.4). In euploid mice treated with 7,8-DHF the latency was reduced in comparison 
with that of untreated euploid mice starting from day 5 (Fig. 3.3.10A, Table 3.3.4), although the 
difference was not statistically significant.  
Three-way mixed ANOVA on the percentage of time spent in the periphery revealed an interaction 
of genotype x treatment x day [F(7,238) = 2.140, p = 0.04]. We found a genotype x day interaction 
[F(7,238) = 3.28, p = 0.003], no treatment x day interaction, no genotype x treatment interaction, and 
no main effects of genotype, treatment and day. A post hoc Fisher LSD test showed no differences 
among groups in the percentage of time spent in the periphery, with the exception of the first day, on 
which treated euploid mice explored more than the other groups (Fig. 3.3.10B, Table 3.3.4). 
Three-way mixed ANOVA on the path length showed no effect of genotype x treatment x day. We 
found a genotype x day interaction [F(7,238) = 2.21, p = 0.034], no treatment x day interaction, no 
genotype x treatment interaction, a main effect of genotype [F(1,34) = 4.22, p = 0.048], a main effect 
of treatment [F(1,34) = 14.11, p = 0.001], and a main effect of day [F(7,238) = 13.33, p < 0.001]. A 
post hoc Fisher LSD test showed that path length decreased throughout the test for all experimental 
groups. Untreated euploid and Ts65Dn mice made the same path length over the entire test, with 
slight but not significant differences (Fig. 3.3.10C, Table 3.3. 4). In treated euploid mice the path 
length decreased day by day faster than in their untreated counterpart, suggesting a positive effect on 
the search strategy (Fig. 3.3.10C, Table 3.3.4). The path length also decreased faster in treated 
Ts65Dn in comparison with untreated Ts65Dn mice, and on days 3, 6, and 7 this decrement reached 
statistical significance (Fig. 3.3.10D, Table 3.3.4). This indicates that treated Ts65Dn have a better 
strategy to reach the platform in comparison with their untreated counterpart. Three-way mixed 
ANOVA on the path length showed no effect of genotype x treatment x day. We found no genotype 
x day interaction, no treatment x day interaction, no genotype x treatment interaction, no main effects 
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of either genotype or treatment, but a main effect of day [F(7,238) = 8.49, p < 0.001]. A post hoc 
Fisher LSD test showed no differences among groups in swimming speed and this parameter 
decreased day by day for all experimental groups (Fig. 3.3.10D, Table 3.3. 4). Treated Ts65Dn had 
a reduced swimming speed in comparison with the other groups every day of the test, although this 
difference was not statistically significant (Fig. 3.3.10E, Table 3.3.4). 
In the probe test, we considered the following parameters as an index of spatial memory: i) latency 
to enter the trained platform zone (latency), ii) frequency of entrances in the trained platform zone 
(frequency), iii) proximity to the trained platform position (Gallagher’s test; proximity), iv) 
percentage of time spent in the periphery (thigmotaxis), v) swimming speed, vi) percentage of time 
spent in quadrants. A two-way ANOVA on the latency showed no genotype x treatment interaction, 
no main effect of treatment but a main effect of genotype [F(1,32) = 5,59, p = 0.024]. A post hoc 
Fisher LSD test showed that untreated Ts65Dn mice exhibited a longer latency than untreated and 
treated euploid mice, although this difference was statistically significant in comparison with 
untreated euploid mice only, and that treatment did not improve latency (Fig. 3.3.11A). A two-way 
ANOVA on the frequency showed no genotype x treatment interaction, no main effect of treatment 
but a main effect of genotype [F(1,32) = 6.44, p = 0.016]. A post hoc Fisher LSD test showed that 
untreated Ts65Dn mice exhibited a reduced frequency of entrances than untreated euploid mice and 
that treatment did not cause a frequency increase (Fig. 3.3.11B). A two-way ANOVA on the 
proximity showed no genotype x treatment interaction, but a main effect of genotype [F(1,32) = 5.08, 
p = 0.031] and a main effect of treatment [F(1,32) = 6.54, p = 0.016]. A post hoc Fisher LSD test 
showed that untreated Ts65Dn mice swam at a larger distance from the trained platform zone in 
comparison with untreated and treated euploid mice, although this difference was statistically 
significant vs. the latter only (Fig. 3.3.11C). In treated Ts65Dn mice, the distance from the trained 
platform zone was not different in comparison with that of untreated euploid mice, although it was 
not different also in comparison with Ts65Dn mice (Fig. 3.3.11C). This indicates an improvement in 
searching strategy of treated Ts65Dn mice, and this result is in agreement with that obtained on path 
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length during learning phase (see Fig. 3.3.10C). A two-way ANOVA on thigmotaxis showed no 
genotype x treatment interaction, no main effect of both genotype and treatment. In agreement with 
evidence for the learning phase, a post hoc Fisher LSD test showed that in the probe test there were 
no differences in thigmotaxis among experimental groups, even though treated and untreated euploid 
mice spent more time in the center of the pool in comparison with Ts65Dn mice (Fig. 3.3.11D). 
Two-way ANOVA on the swimming speed showed no genotype x treatment interaction, no main 
effect of both genotype and treatment. A post hoc Fisher LSD test no differences among groups, with 
the only exception of treated Ts65Dn mice that had a lower swimming speed in comparison with 
untreated euploid mice (Fig. 3.3.11E).  
A paired samples t-test showed that untreated Ts65Dn mice exhibited no differences in the time spent 
in the trained platform quadrant in comparison with the other quadrants (Fig. 3.3.11F). Like their 
untreated counterparts, treated Ts65Dn mice did not discern among quadrants (Fig. 3.3.11F). 
Untreated euploid mice spent significantly more time in the trained platform quadrant in comparison 
with the NE [t(11) = 2.98; p = 0.013], SE quadrant [t(11) = 3.43; p = 0.006] and NW [t(11) = 2.23; p 
= 0.047] quadrants (Fig. 3.3.11F). Likewise, treated euploid mice spent significantly more time in 
the trained platform quadrant in comparison with the SE [t(6) = 3.52; p = 0.013] quadrant but not 
with the other two (Fig. 3.3.11F).  
Taken together, data from learning phase and probe test show that treatment with 7,8-DHF 
administered from 4 to 5 months of age improves only partially spatial hippocampal skills in the 
Ts65Dn mouse. Indeed, in contrast to what we observed in P45 mice, there were no effects of 
treatment on latency to reach the platform neither in learning phase nor in the probe test, although 
Ts65Dn mice treated with 7,8-DHF had a reduced swim path and swam closer to the trained platform 
zone in comparison with untreated Ts65Dn mice. These discrepancies between P45 and 5 month-old 
mice suggest that there is an effect of age in Ts65Dn mice that changes their response to BDNF 
mimetics, such as 7,8-DHF. It remains to be established whether other doses of 7,8-DHF would be 
able to ameliorate more strongly hippocampus-dependent behavior in adult Ts65Dn mice. 
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Interestingly, 5 month-old euploid mice treated with 7,8-DHF showed an improvement in almost all 
parameters of the learning phase (but not of the probe test) analysed in this study in comparison with 
their untreated counterpart. Indeed, although there is no statistical differences (see Table 3.3.4), 
treated euploid mice had a reduced latency to reach the platform, spent less time at the periphery, and 
had a shorter swim path. These data indicates that a molecule that stimulate the BDNF/TRKB 
pathway increases learning abilities in adult healthy mice. 
 
Effect of 7,8-DHF on neurogenesis in 5 month-old Ts65Dn and euploid mice 
Immature granule neurons express doublecortin (DCX) during the period of neurite elongation (from 
one to four weeks after neuron birth) (Couillard-Despres et al., 2005), which allows evaluation of 
total number of new granule cells. In order to establish whether treatment with 7,8-DHF enhances 
hippocampal neurogenesis, brain sections of mice treated for one month with saline or 7,8-DHF were 
subjected to immunohistochemistry for DCX. A two-way ANOVA on the number of DCX-positive 
cells showed no genotype x treatment interaction but a significant effect of genotype [F(1,14) = 24.83, 
p < 0.001] and no effect of treatment. In agreement with previous evidence, untreated Ts65Dn mice 
had a reduced number of new granule cells in comparison with untreated euploid mice (Fig. 
3.3.12A,B). Treatment with 7,8-DHF did not increase the number of new granule cells that remained 
reduced in comparison with control euploid mice (Fig. 3.3.12A,B). In euploid mice treatment with 
either vehicle or 7,8-DHF did not affect the number of proliferating cells (Fig. 3.3.12A,B).  
 
Effect of 7,8-DHF on the phosphorylation levels of the TRKB receptor in 5 month- old Ts65Dn 
and euploid mice 
Binding of BDNF or its mimetic 7,8-DHF to the TRKB full length receptor (TRKB-FL), that 
possesses an intracellular tyrosine kinase domain, causes receptor dimerization and 
autophosphorylation. By contrasts, the truncated form of the TRKB receptor (TRKB-T1) lacks 
tyrosine kinase activity. In order to establish the effect of 7,8-DHF on the expression levels and 
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Figure 3.3.10. Effect of treatment with 7,8-DHF on spatial learning in 5 month-old Ts65Dn and euploid 
mice. Mice received either vehicle or 7,8-DHF in the period 4M-5M+9 days and were behaviorally tested with 
the MWM during the last 9 days of treatment (untreated euploid mice: n=13; untreated Ts65Dn mice: n=11; 
treated euploid mice: n=7; treated Ts65Dn mice: n=7). The curves in (A-D) report data of euploid mice that 
received either vehicle (empty circle) or 7,8-DHF (filled circle) and Ts65Dn mice that received either vehicle 
(empty square) or 7,8-DHF (filled square). A-C: Learning phase of the MWM evaluated as latency to reach 
the platform (A), percentage of time spent in the periphery (B), path length (C). D: Swimming speed. Values 
in (B-D) represent mean  SE. Statistical analyses for: untreated Ts65Dn vs Treated Ts65Dn, * p < 0.05; 
untreated euploid mice vs untreated Ts65Dn mice, # p < 0.05; ## p < 0.01; ### p < 0.001 (Fisher LSD test 
after two-way ANOVA). Detailed statistical analysis is reported Table 3.3.4. Abbreviations: 7,8-DHF, 7,8-
dihydroxyflavone; Eu, euploid; sec, seconds. 
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Table 3.3.4. P values of the Fisher LSD test for the indicated variables of 5 month-old mice. 
  Latency (s) 
   D1 D2 D3 D4 D5 D6 D7 D8 
Eu+Veh Eu+7,8-DHF 0.296 0.135 0.170 0.281 0.078 0.051 0.293 0.209 
  Ts65Dn+Veh 0.017 0.006 0.001 0.003 0.022 0.060 0.079 0.282 
  Ts65Dn+7,8-DHF 0.018 0.005 0.083 0.002 0.108 0.073 0.174 0.194 
Eu+7,8-DHF Ts65Dn+Veh 0.283 0.331  ≤ 0.001 0.001 0.001 0.001 0.015 0.037 
  Ts65Dn+7,8-DHF 0.217 0.204 0.008 ≤ 0.001 0.004 0.002 0.038 0.029 
Ts65Dn+Veh Ts65Dn+7,8-DHF 0.767 0.659 0.144 0.585 0.668 0.882 0.852 0.722 
  Time at the periphery (%) 
   D1 D2 D3 D4 D5 D6 D7 D8 
Eu+Veh Eu+7,8-DHF 0.016 0.215 0.159 0.559 0.293 0.414 0.459 0.096 
  Ts65Dn+Veh 0.617 0.907 0.980 0.234 0.490 0.405 0.516 0.917 
  Ts65Dn+7,8-DHF 0.975 0.805 0.312 0.093 0.359 0.237 0.225 0.357 
Eu+7,8-DHF Ts65Dn+Veh 0.007 0.269 0.178 0.119 0.113 0.139 0.209 0.125 
  Ts65Dn+7,8-DHF 0.032 0.194 0.038 0.050 0.088 0.084 0.091 0.026 
Ts65Dn+Veh Ts65Dn+7,8-DHF 0.693 0.735 0.317 0.519 0.758 0.653 0.525 0.328 
  Path Lenght (m) 
    D1 D2 D3 D4 D5 D6 D7 D8 
Eu+Veh Eu+7,8-DHF 0.531 0.739 0.030 0.166 0.107 0.067 0.259 0.085 
  Ts65Dn+Veh 0.620 0.447 0.033 0.082 0.070 0.175 0.105 0.361 
  Ts65Dn+7,8-DHF 0.018 0.979 0.627 0.773 0.725 0.206 0.441 0.420 
Eu+7,8-DHF Ts65Dn+Veh 0.850 0.746  ≤ 0.001 0.007 0.003 0.005 0.016 0.017 
  Ts65Dn+7,8-DHF 0.111 0.787 0.129 0.144 0.262 0.601 0.749 0.407 
Ts65Dn+Veh Ts65Dn+7,8-DHF 0.054 0.535 0.024 0.225 0.062 0.021 0.037 0.124 
  Swim speed (cm/s) 
   D1 D2 D3 D4 D5 D6 D7 D8 
Eu+Veh Eu+7,8-DHF 0.531 0.954 0.789 0.473 0.453 0.152 0.730 0.343 
 Ts65Dn+Veh 0.620 0.292 0.821 0.749 0.815 0.929 0.654 0.689 
  Ts65Dn+7,8-DHF 0.018 0.104 0.150 0.913 0.616 0.119 0.484 0.071 
Eu+7,8-DHF Ts65Dn+Veh 0.477 0.401 0.947 0.670 0.356 0.144 0.476 0.559 
  Ts65Dn+7,8-DHF 0.180 0.166 0.298 0.468 0.827 0.908 0.754 0.435 
Ts65Dn+Veh Ts65Dn+7,8-DHF 0.432 0.480 0.225 0.706 0.494 0.113 0.292 0.152 
 Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Ts, Ts65Dn; Veh, vehicle.  
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Figure 3.3.11. Effect of treatment with 7,8-DHF on spatial memory in 5 month-old Ts65Dn and euploid 
mice. Spatial memory was assessed in the probe test after spatial learning (same mice as in Fig. 3.3.10). In the 
probe test, memory was assessed as latency to reach the trained platform zone (A), number of crossings 
(frequency) over the trained platform zone (B), proximity to the trained platform zone (C), percentage of time 
spent in the periphery (D), percentage of time spent in quadrants (F). E: Swimming speed during the probe 
test. Values represent mean  SE. (*) p < 0.06; * p < 0.05; *** p < 0.001 (Fisher LSD test after ANOVA). 
Black asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice. 
The symbol § in (F) indicates a difference between each individual quadrant and the trained platform quadrant 
(see key below). for each experimental group. (§) p < 0.06; § p < 0.05; §§ p < 0.01 (two-sample paired t-test). 
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; NE, north-east; NW, north-west; SE, south-east 
sec, sec, seconds 
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activity of the TRKB receptor, hippocampal homogenates of treated and untreated mice were 
subjected to western blot analysis. A two-way ANOVA on the levels of BDNF showed no genotype 
x treatment interaction and no main effect of both genotype and treatment. Accordingly with data 
obtained in P15 mice, a post hoc Fisher LSD test did not reveal any difference in BDNF levels 
between untreated euploid and Ts65Dn mice aged 5 months (data not shown). Treatment with 7,8-
DHF did not affect the levels of BDNF in euploid as well as Ts65Dn mice (data not shown). 
A two-way ANOVA on the levels of TRKB-FL receptor showed no genotype x treatment interaction, 
no main effect of genotype but a main effect of treatment [F(1,26) = 16.51, p < 0.001]. A post hoc 
Fisher LSD test showed that untreated and Ts65Dn mice had reduced levels of the TRKB-FL receptor 
in comparison with untreated euploid mice (Fig. 3.3.13B). Treatment with 7,8-DHF caused an 
increase in the levels of the TRKB-FL receptor that became similar to those of untreated euploid 
mice. An increase in TRKB-FL receptor levels also took place in treated euploid mice in comparison 
with their untreated counterparts, although the difference was not statistically significant. A two-way 
ANOVA on the levels of the phosphorylated form of the TRKB receptor (p-TRKB) showed no 
genotype x treatment interaction, no main effect of genotype but a main effect of treatment [F(1,23) 
= 5.31, p = 0.03]. A post hoc Fisher LSD test showed that in untreated Ts65Dn mice the levels of p-
TRKB were similar to those of euploid mice (Fig. 3.3.13C). In Ts65Dn mice, treatment with 7,8-
DHF caused a reduction in the levels of p-TRKB in comparison with their untreated counterparts as 
well as in comparison with untreated euploid (Fig. 3.3.13C).  
A two-way ANOVA on the levels of the TRKB-T1 receptor showed no genotype x treatment 
interaction and no main effect of either genotype or treatment. A post hoc Fisher LSD test showed 
that untreated Ts65Dn mice has similar levels of TRKB-T1 as untreated euploid mice. Treated 
Ts65Dn and euploid mice underwent an increase in the levels of TRKB-T1 in comparison with their 
untreated counterparts but the difference was not statistically significant (Fig. 3.3.13D). 
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Figure 3.3.12. Effect of treatment with 7,8-DHF on the number of new granule cells in the dentate gyrus 
of 5 month-old mice. A: Examples of sections processed for fluorescence immunostaining for DCX from the 
DG of untreated and treated mice. Calibration bar: 50 µm. B: Number of DCX-positive cells in the DG of of 
untreated euploid (n=6) and Ts65Dn mice (n=6) and euploid (n=4) and Ts65Dn (n=4) mice treated with 7,8-
DHF. Values represent mean  SE. * p < 0.05; *** p < 0.001 (Fisher LSD test after two-way ANOVA). Black 
asterisks in the gray bar indicate a difference between untreated Ts65Dn mice and treated euploid mice; white 
asterisks in the black bar indicate a difference between treated euploid and treated Ts65Dn mice. 
Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid; Gr, granule cell layer; SGZ, subgranular zone.
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Figure 3.3.14. Effects of treatment with 7,8-DHF on the TRKB receptor. Western blot analysis of the 
TRKB receptor in hippocampal homogenates of treated and untreated mice. A: representative western blots 
showing immunoreactivity for the phosphorylated TRKB receptor (p-TRKB), the full length TRKB receptor 
(TRKB-FL), the truncated TRKB receptor (TRKB-T1), and the housekeeping gene GAPDH. B-D: Levels of 
TRKB-FL (B) p-TRKB (C) and TRKB-T1 (D) of untreated euploid (n=8) and Ts65Dn (n=9) and euploid (n=7) 
and Ts65Dn (n=7) mice treated with 7,8-DHF. Values represent mean  SE. * p < 0.05; p < 0.01 *** p < 0.001 
(Fisher LSD test after two-way ANOVA). Black asterisks in the gray bar indicate a difference between 
untreated Ts65Dn mice and treated euploid mice; white asterisks in the black bar indicate a difference between 
treated euploid and treated Ts65Dn mice. Abbreviations: 7,8-DHF, 7,8-dihydroxyflavone; Eu, euploid. 
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3.3.5 Discussion 
 
Results show that treatment with a BDNF mimetic restores hippocampal neurogenesis and dendritic 
spine density in pups and largely improves behavior in young adult mice. In contrast, 7,8-DHF 
administration in adult mice is ineffective on neurogenesis and only partially improves behavior, 
suggesting that the magnitude of treatment effects may change with age.  
 
Treatment with the BDNF mimetic 7,8-DHF positively impacts the major defects of hippocampal 
development in Ts65Dn mice 
In disagreement with data obtained in adult Ts65Dn mice (Bimonte-Nelson et al., 2003, Fukuda et 
al., 2010, Begenisic et al., 2015), we did not find any reduction in BDNF protein levels in the 
hippocampus of P15 Ts65Dn mice, suggesting that BDNF expression may be differently regulated 
during different life stages. Although there were no differences of BDNF expression levels in neonate 
Ts65Dn in comparison with euploid mice, treatment with 7,8-DHF resulted in the recovery of 
neurogenesis reduction and dendritic pathology, consistently with the pivotal role played by BDNF 
in brain development.  
We found that treatment with 7,8-DHF increased the number of proliferating cells in the SGZ of 
Ts65Dn mice. Indeed, while the number of dividing cells in untreated Ts65Dn mice was -30% in 
comparison with untreated euploid mice, in treated Ts65Dn mice their number was -13% (see Fig. 
3.3.3C), indicating that 7,8-DHF causes a large improvement in proliferation potency. Importantly, 
although the number of dividing cells in the SGZ of Ts65Dn mice was not fully rescued after 
treatment, total granule cell number was fully restored. This result may be explained by an effect of 
7,8-DHF on the process of phenotype acquisition, with a shift in the relative number of cells destined 
to become neurons. P15 Ts65Dn mice exhibited an impairment in the process of spinogenesis. The 
finding that their granule neurons had a reduced spine density indicates that this defect starts at early 
phases of hippocampal development. This spine defects implies a reduction in the number of 
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excitatory terminals and, consequently, reduced complexity of hippocampal circuitry. Consistently 
with this conclusion, an evaluation of the levels of the presynaptic protein SYN in Ts65Dn mice 
showed that the counterpart of the spine density reduction was a reduction in SYN levels. We showed 
that treatment with 7,8-DHF restored the number of dendritic spines of Ts65Dn mice as well as SYN 
levels, suggesting a treatment-induced restoration of the hippocampal circuitry.  
Conflicting results are reported in the literature regarding the pro-proliferative effect of the 
BDNF/TRKB system in different species and cellular systems (Foltran and Diaz, 2016, Vilar and 
Mira, 2016). Many studies suggest that BDNF fosters neurogenesis and neuron maturation but not 
proliferation of NPCs. Our results suggest that in Ts65Dn mice activation of the TRKB receptor 
enhances NPCs proliferation, in addition to neurogenesis and neuron maturation. Although the effect 
on proliferation was less prominent than the effect on neurogenesis and neuron maturation, the 
outcome was restoration of the defective cellularity in the granule layer of the DG. It is of interest to 
observe that some of the neurogenesis-enhancing therapies attempted so far in mouse models of DS 
may present caveats for human use due to the risk of uncontrolled proliferation in peripheral tissues 
and, thus, have a cancerogenic effect (Bartesaghi et al., 2011, Gardiner, 2015). The finding that 7,8-
DHF, in spite of its relatively moderate pro-proliferative activity, is able to restore the final number 
of granule neurons may render this molecule a good candidate for therapy in DS.  
 
Treatment with 7,8-DHF rescues hippocampus-dependent behavior in young adult Ts65Dn mice 
The granule cells of the DG are the first element of the hippocampal trisynaptic circuit, a circuit 
whose function is fundamental for long-term memory. The dendrites of the granule cells receive their 
major input from the entorhinal cortex that represents an interface between the hippocampal 
formation and the rest of the brain. Signals from polymodal association cortices sent by the entorhinal 
cortex to the DG are processed by the trisynaptic circuit and then sent back to the entorhinal cortex. 
Hippocampus-dependent learning and memory impairment is a consistent feature of DS and the 
Ts65Dn mouse model (Demas et al., 1996, Carlesimo et al., 1997, Vicari et al., 2000, Belichenko et 
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al., 2007, Salehi et al., 2009). We found here that in Ts65Dn mice treated with 7,8-DHF there was an 
improvement in hippocampus-dependent learning and a rescue in spatial memory, as assessed in the 
probe test, indicating that the effects of treatment on the hippocampal defects that characterize the 
trisomic condition translate into a behavioral benefit. It remains to be established whether after 
treatment cessation these effects are retained at further life stages.  
 
Activation of the TRKB receptor by 7,8-DHF enhances the activity of TRKB receptor-dependent 
signaling 
In the hippocampus of P15 Ts65Dn mice we found normal levels of BDNF, TRKB-FL, and TRKB-
T1 receptors. Results showed a reduction in the levels of BDNF and TRKB-FL receptor in Ts65Dn 
mice after thirteen days of treatment with 7,8-DHF, suggesting a compensatory reduction of their 
transcription and/or an increase in their degradation. The absence of a similar reduction in treated 
euploid mice suggests that the mechanisms underlying degradation of the TRKB receptor may be 
more powerful in the trisomic brain. It must be noted that, although treatment induced an overall 
reduction in TRKB receptor levels, its phosphorylation increased, indicating that treatment activates 
TRKB receptor, and, hence, TRKB-dependent pathways. Accordingly, we found here that in treated 
Ts65Dn mice there was an increase in the levels of p-ERK1 and p-ERK2, which is consistent with 
the treatment-induced phosphorylation increase of the TRKB receptor. ERK activity is required for 
cell proliferation (Lefloch et al., 2008), and there is evidence that the BDNF/TRKB signaling-induced 
increase in spine density of hippocampal pyramidal neurons is ERK1/2 dependent (Alonso et al., 
2004). Thus, we hypothesize that the increased activity of ERK1/2 after 7,8-DHF treatment may 
represent a key contributor to the rescue of hippocampal development in Ts65Dn mice.  
Although much is now known regarding the role of ERK1/2, the mechanisms underlying their 
expression still need to be elucidated (Busca et al., 2016). We found here that treatment with 7,8-
DHF increased both ERK1 and ERK2 levels. A recent study shows that the ratio between total ERK1 
and ERK2 protein levels in different mouse brain regions is about 1:4, that the same ratio holds for 
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p-ERK1/2 and that derangement of these ratios has adverse effects on the brain (Lefloch et al., 2008). 
Importantly, in Ts65Dn mice, treatment caused an increase in ERK1/2 and p-ERK1/2 but their ratios 
remained similar to those of their untreated counterparts. This indicates that treatment enhances the 
activity of ERK1/2 without disrupting the important balance between the two ERK isoforms. 
 
Treatment with 7,8-DHF has no adverse effects on viability and growth of Ts65Dn mice  
In order to evaluate whether 7,8-DHF as adverse effects in Ts65Dn mice, we considered mice 
viability, body weight, and brain wheight. We found no effect of treatment on mice viability. There 
is evidence that in rodents treatment with BDNF causes a reduction in food intake and that activation 
of muscular TRKB by 7,8-DHF regulates energy metabolism in muscles (Gray et al., 2006, Chan et 
al., 2015). Conversely, rodent models with a reduction in BDNF/TRKB signaling exhibit hyperphagia 
and obesity (Chan et al., 2015). We found that a relatively short treatment with 7,8-DHF (13 days: 
from P3 to P15) as well as a more prolonged treatment (42-47 days: from P3 to P45-50) did not cause 
a body weight reduction in Ts65Dn mice. In addition, we did not found an adverse effect of treatment 
on the brain weight of Ts65Dn mice, but rather, a positive effect on brain growth. From these findings 
it appears that a chronic treatment with 7,8-DHF has a safe profile on the general health of Ts65Dn 
mice, suggestig a high translational impact  of treatment with 7,8-DHF.  
 
Treatment with 7,8-DHF does not rescue neurogenesis but leads to an improvement of behavior 
in adult Ts65Dn mice 
In contrast with the positive effects of a treatment with 7,8-DHF seen in Ts65Dn pups, we found that 
41 days of treatment with 7,8-DHF in adult Ts65Dn mice did not enhance hippocampal neurogenesis. 
Although with a different magnitude, treatment amelliorated hippocampus-dependent learning 
abilities as in young-adult as in adult Ts65Dn mice. There are evidence that treatment with 7,8-DHF 
in 5XFAD mice (a mouse model of familial AD) increases dendritic spine density in hippocampal 
neurons and rescues memory deficits (Zhang et al., 2014). Given that there was a lack of neurogenesis 
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enhancement in 5 month-old treated Ts65Dn mice, it would be reasonable that good effects of 7,8-
DHF observed in learning phase of MWM may be related to an improvement in neuronal maturation 
(dendritic arbour/dendritic spines) of pre-existent hippocamapal granule cells. This could lead to an 
amelioration of hippocampal circuitry and, thus, hippocampal dependent behavior. Further studies 
should be conducted to settle this issue. These results in the Ts65Dn mouse model of DS are consistent 
with evidence obtained in models of other brain disorders, showing that treatment with 7,8-DHF, 
administered at the same dose (5.0 mg/kg) used in this study, ameliorates cognition (Jang et al., 2010, 
Liu et al., 2010, Andero et al., 2011, Andero et al., 2012, Devi and Ohno, 2012, Zeng et al., 2012, 
Zhang et al., 2014). Treatment with 7,8-DHF ameliorates motor function in a mouse model of 
Hungtington’s disease (Jiang et al., 2013) and improves motor performance and neuronal survival in 
a mouse model of amyotrophic lateral sclerosis (Korkmaz et al., 2014). This is in contrast with our 
observation in Ts65Dn mice, where we observed a mild reduction in swimming speed during MWM 
in adult mice treated with 7,8-DHF.  
The schedule of treatment used in the studies mentioned above ranged from a few days to months, 
suggesting that the lack of an effect on neurogenesis in Ts65Dn mice observed here is unlikely to be 
related to an insufficient duration of treatment. Different disorders of the nervous system may show 
common molecular signatures but also widely different molecular alterations, suggesting that the 
outcome of a given therapeutic approach may not be necessarily shared by different brain disorders. 
It seems reasonable to conclude that the reduced effects of treatment with 7,8-DHF on neurogenesis 
observed here in the Ts65Dn model may be related to differences in the molecular pathways that are 
perturbed in this model and in the models in which 7,8 DHF resulted effective. In this connection, it 
is of importance to observe that 5XFAD mouse model of AD shows reduction in both TRKB-FL and 
p-TRKB receptors and that treatment with 7,8-DHF for 12 days restores both TRKB-FL and p-TRKB 
receptor levels (Devi and Ohno, 2012). In the same model, treatment for 4 months increases p-TRKB 
(although not total TRKB) levels (Zhang et al., 2014). Aged rats, exhibit significant decreases in 
TRKB and p-TRKB levels in the hippocampus compared to young controls and administration of 
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7,8-DHF for 34 days enhances p-TRKB (but not total TRKB) levels (Zeng et al., 2012). Finally, in a 
mouse model of Hungtington’s disease, treatment with 7,8-DHF from 6 to 20 weeks of age has been 
shown to increase p-TRKB levels (Jiang et al., 2013). 
We found here that Ts65Dn mice exhibit reduced levels of the TRKB receptor but normal levels of 
its active form (p-TRKB). This is at variance with the 5XFAD mouse model and with aged rats that 
exhibit reduced levels of both the TRKB and p-TRKB receptors. In Ts65Dn mice treatment with 7,8-
DHF largely increased the expression of the TRKB receptor that became twice as large as that of 
untreated Ts65Dn mice but, surprisingly, it reduced the relative levels of its active form (p-TRKB). 
The mechanisms underlying the treatment-induced increase in TRKB levels with a concomitant 
reduction in its relative phosphorylation form remain to be elucidated. It should be taken into account 
that, however, higher levels of TRKB-FL would lead to an increase in the number of receptors that 
can be phosphorylated and, in fact, we observed an increase of 32% in p-TRKB absolute levels 
(normalizing p-TRKB on GAPDH) in the hippocampus of Ts65Dn treated with 7,8-DHF (data not 
shown). Whatever the explanation, since the BDNF/TRKB receptor system plays an important role 
in the modulation of neurogenesis, deregulation of this pathway observed in Ts65Dn mice after 
treatment with 7,8-DHF may explain the lack of a beneficial effect on neurogenesis 
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4. GENERAL DISCUSSION AND CONCLUSIONS 
 
4.1 Goal 
In spite of the growing interest in the field of potential treatments for cognitive impairment in DS, 
there are no effective therapies for DS so far. The overall goal of my thesis work was to give a 
contribution to the discovery of effective pharmacotherapies for DS.  
 
4.2 Model 
To this purpose, I have used the Ts65Dn mouse model because, in spite of unavoidable limitations 
i) it is the model that most closely recapitulates the human condition and ii) most of the 
pharmacotherapies attempted so far have used this model, which allows a comparison across different 
interventions (see (Bartesaghi et al., 2011, Stagni et al., 2015a)). 
 
4.3 Timing  
Considering that neurogenesis and dendritogenesis defects occur at very early phases of brain 
development (Takashima et al., 1981, Becker, 1991, Vuksic et al., 2002, Contestabile et al., 2007, 
Guidi et al., 2008, Larsen et al., 2008, Guidi et al., 2011a, Lu et al., 2012), prenatal therapies should 
be the most appropriate choice in order to restore the trisomy-linked developmental defects of the 
brain. However, the prenatal period also represents a critical time for the development of the other 
organs forming the body. This aspect should be considered carefully and may raise concerns in the 
framework of potential treatments, unless their safety is granted. In rodents, the hippocampal dentate 
gyrus produces most of its neurons in the first two postnatal weeks (Brazel et al., 2003). Thus, the 
neonatal period appears to be an ideal time window in order to establish whether it is possible to 
correct neurogenesis and dendritogenesis defects with selected molecules and to establish the long-
term effect (if any) of treatment. Information gained with early postnatal treatments may provide an 
answer to various key questions. 1) Is the selected molecule effective in correcting neurogenesis? 2) 
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Does the same molecule also correct dendritogenesis defects? 3) Does treatment elicit long-term 
effects? 4) Does treatment elicit adverse effects during treatment or after treatment cessation? This 
information may have a powerful translational impact at least in two directions. 1) Molecules 
effective and without side effects may be exploited in children with DS in order to IMPROVE their 
brain and cognitive performance. If clinical trials in children with DS will show a clear efficacy 
without side effects this outcome may suggest that it could be worthwhile to test the effective 
molecule during pregnancy and to run the risk of possible unpredictable side effects in the face of a 
potential full RESCUE of brain development. 
 
4.4 Rationale for the chosen treatments and their effects 
With this idea in mind, in this study I have examined the effects of three different molecules on 
development of the hippocampus. Which was the idea that lead to the selection of these molecules? 
The general idea was to act on pathways important for neurogenesis and dendritogenesis and that are 
known to be perturbed in DS.  
APP is one of the triplicated genes that appears to be involved in several detrimental effects in the 
DS brain (see (Bartesaghi et al., 2011)). One of its cleavage products, AICD, strongly interferes with 
the SHH pathway, a pathway fundamental for morphogenesis and neurogenesis (Trazzi et al., 2011, 
Trazzi et al., 2013). In particular, AICD increases the transcription of PTCH1 which, in turn, keeps 
the SHH pathway in a repressed state. The outcome of this inhibition is a reduction in the proliferation 
rate of NPCs and a reduced propensity to acquire a neuronal phenotype. Since AICD derives from 
the cleavage of the carboxy-terminal fragments of APP that is operated by the enzyme γ-secretase, 
inhibition of the activity of γ-secretase should reduce the formation of AICD. This should translate 
into a reduction on PTCH1 levels and disinhibition of the SHH pathway. We used the γ-secretase 
inhibitor ELND006 (Basi et al., 2010) and found that neonatal treatment with this compound restored 
neurogenesis and neuron number in the DG and synaptic development in the hippocampal formation 
(DG and hippocampus) of Ts65Dn mice. Most of these effects were retained at one month after 
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treatment cessation and were accompanied by restoration of the synaptic function at the synapse 
between granule cells and field CA3 pyramidal neurons. 
DYRK1A belongs to the triplicated genes that are considered to be strongly involved in neurogenesis 
impairment in DS (Chen et al., 2013). Many of the downstream targets of DYRK1A are associated 
with the control of cell growth and survival, especially in the nervous system (Hindley and Philpott, 
2012, Chen et al., 2013). DYRK1A impairs cell cycle progression of embryonic progenitors through 
various mechanisms, suggesting that inhibition of its activity may restore neurogenesis in DS. Several 
small-molecule inhibitors of the protein kinase activity of DYRK1A are available. Many DYRK1A 
inhibitors also inhibit CDK-like kinase 1. EGCG (the major polyphenolic compound of green tea), 
however, has been identified as a specific DYRK1A inhibitor (Bain et al., 2003). Therefore, treatment 
with EGCG may be exploited in order to inhibit DYRK1A activity and, consequently, counteract the 
negative effects exerted by DIRK1A on neurogenesis in the DS brain. Indeed, green tea extracts 
appear to improve learning in the adult Ts65Dn mouse and exert some behavioral, although 
ephemeral, benefits in young adults with DS (De la Torre et al., 2014, de la Torre et al., 2016). It is 
possible that treatment with EGCG in the critical time window of hippocampal neurogenesis has more 
pronounced effects on hippocampal neurogenesis and that these effects are retained with time, which 
might lead to a long-lasting behavioral improvement. In order to clarify this issue, we have treated 
Ts65Dn mice in the neonatal period and examined the short- and long-term effects of treatment. We 
found that at the end of treatment there was full restoration of hippocampal neurogenesis, neuron 
number and synapse development. Unfortunately, at one month after treatment cessation, these effects 
had disappeared and there were no signs of behavioral improvement.  
BDNF is a neurotrophin that plays a key role in brain plasticity by specifically binding to the TRKB 
teceptor. This binding triggers the activity of several intracellular pathways, thereby favoring 
neurogenesis, neuritogenesis and spine growth (Haniu et al., 1997). In the DS brain, BDNF levels are 
already reduced at fetal life stages and reduced BDNF levels have been shown in various brain regions 
of the Ts65Dn mouse (Bimonte-Nelson et al., 2003, Guedj et al., 2009, Bianchi et al., 2010a, Fukuda 
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et al., 2010, Toiber et al., 2010, Begenisic et al., 2015, Stagni et al., 2015b, Kazim et al., 2017, 
Villarroya et al., 2017). In view of the role of the BDNF-TRKB system in neurogenesis and dendritic 
morphogenesis, interventions targeted to the BDNF-TRKB system may be exploited in order to 
improve the trisomy-linked neurodevelopmental defects. Systemic administration of BDNF is 
impracticable because BDNF has a poor blood-brain barrier penetration. 7,8-dihydroxyflavone (7,8-
DHF), however, is a flavone-derivative that penetrates the blood brain barrier, binds with high 
specificity to the TRKB receptor and activates its downstream signaling cascade (Liu et al., 2010, Liu 
et al., 2013, Liu et al., 2016). Administration of 7,8-DHF has been shown to exert therapeutic efficacy 
in various animal disease models that are related to deficient BDNF signaling. Based on these 
premises we sought to establish whether it is possible to restore neurogenesis in the Ts65Dn mouse 
by targeting the TRKB receptor with 7,8-DHF. We found that Ts65Dn mice, neonatally-treated with 
7,8-DHF, underwent restoration of neurogenesis, granule cell number, and dendritic spine density. 
Mice that were treated with 7,8-DHF from postnatal day 3 to adolescence exhibited restoration of 
learning and memory, indicating that the recovery of the hippocampal anatomy translated into a 
functional rescue. No adverse effects were observed on the general health and growth of mice. 
 
4.5 Potential translational impact of the study  
From the viewpoint of the magnitude and duration of the effects, the use of ELND006, a selective 
inhibitor of γ-secretase, seems to be a promising strategy. However, we also found some adverse 
effects, possibly due to the fact that so called “selective inhibitors” of γ-secretase are not completely 
selective. Indeed, a clinical trial with ELND006 in individuals with Alzheimer’s disease was 
interrupted due to toxicity. Therefore, the promising results of our study require that more selective 
inhibitors of γ-secretase and/or other means to prevent the transcriptional activity of AICD are 
created, in order to have a true translational impact for DS.  
While EGCG may represent a good strategy for the restoration of the major trisomy-due brain 
defects, the disappearance of its effects with time implies that a schedule of continuous treatment 
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should be used in order to maintain the brain in its restored state. The advantage of natural compounds 
is that they have a long tradition in the history of the humankind and, therefore their use is considered 
to be safe (at appropriate doses). Taken together, the results of this study suggest that neonatal 
treatment with EGCG represents a good strategy for DS. The timing however is not all, because even 
neonatal treatment must not be discontinued or, at least, followed by additional treatment according 
to a schedule that needs to be identified. However, potential adverse effects of a prolonged EGCG 
treatment on the bone should be carefully considered. 
Treatment with 7,8-DHF during the early postnatal period restored neurogenesis and spinogenesis in 
the hippocampus of Ts65Dn mice and treatment until adolescence lead to full recue of hippocampus-
dependent learning and memory.  It remains to be established whether these effects are retained after 
treatment cessation. If so, targeting the BDNF/TRKB pathway may represent a good treatment for 
DS. Even if the effects of 7,8-DHF will be proven to be ephemeral, since it is a natural compound 
present in plants and has been shown to have no adverse effects on vital organs, such as the kidney 
and the liver, it seems likely that repeated treatment may be feasible and have no drawbacks.  
A comparison of the three therapies used in this study indicates that although all are able to rescue 
neurogenesis, targeting the BDNF/TRKB pathway with 7,8-DHF may represent the treatment with 
the highest translational impact for children with DS because, it is effective and has the highest safety 
profile.  
 
4.6 Future directions and challenges 
In my study, I focused on the effects of treatments in the early postnatal period with the goal to 
identify molecules that can restore neurogenesis alterations in DS. I took advantage of the fact that in 
rodents hippocampal neurogenesis is very prominent in the early postnatal period. This makes it 
possible to treat mice and easily observe whether treatment is effective and has no patent adverse 
effects. Neurogenesis, however, is fundamentally a prenatal event. Therefore, the next step will be to 
establish whether prenatal treatments restore neurogenesis and cellularity throughout the brain. If so, 
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a generalized recovery of the functions that are impaired in DS may be expected. Preclinical 
demonstration that it is possible to pharmacologically prevent brain developmental alterations in a 
mouse model of DS with a variety of agents may stimulate the design of clinical trials during 
pregnancy with the molecule/s with the safest profile. Provided that the selected therapies elicit in 
fetuses with DS the same effects as in mice this would imply a drastic amelioration (restoration?) of 
intellectual disability. This is the challenge that faces the community of preclinical researchers 
interested in DS: to transform a dream into reality. 
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